Title,URL,Description,Details,ShortDetails,Resource,Type,Identifiers,Db,EntrezUID,Properties
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.,/pubmed/31803504,"Benavides M, Díaz-Rubio E, Carrato A, Abad A, Guillén C, Garcia-Alfonso P, Gil S, Cano MT, Safont MJ, Gravalos C, Manzano JL, Sánchez A, Alcaide J, López R, Massutí B, Sastre J, Martínez E, Escudero P, Méndez M, Aranda E.",ESMO Open. 2019 Dec 1;4(6):e000599. doi: 10.1136/esmoopen-2019-000599. eCollection 2019.,ESMO Open.  2019,PubMed,citation,PMID:31803504 | PMCID:PMC6890384,pubmed,31803504,create date:2019/12/06 | first author:Benavides M
The activating transcription factor 2: an influencer of cancer progression.,/pubmed/31799611,"Huebner K, Procházka J, Monteiro AC, Mahadevan V, Schneider-Stock R.",Mutagenesis. 2019 Dec 4. pii: gez041. doi: 10.1093/mutage/gez041. [Epub ahead of print],Mutagenesis.  2019,PubMed,citation,PMID:31799611,pubmed,31799611,create date:2019/12/05 | first author:Huebner K
Association of Polyps with Early-Onset Colorectal Cancer and Throughout Surveillance: Novel Clinical and Molecular Implications.,/pubmed/31795313,"Perea García J, Arribas J, Cañete Á, García JL, Álvaro E, Tapial S, Narváez C, Vivas A, Brandáriz L, Hernández-Villafranca S, Rueda D, Rodríguez Y, Pérez-García J, Olmedillas-López S, García-Olmo D, Cavestro GM, Urioste M, Goel A, González-Sarmiento R.",Cancers (Basel). 2019 Nov 29;11(12). pii: E1900. doi: 10.3390/cancers11121900.,Cancers (Basel).  2019,PubMed,citation,PMID:31795313,pubmed,31795313,create date:2019/12/05 | first author:Perea García J
Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis.,/pubmed/31783291,"Wu CC, Wang JH, Lin PC, Liang CA, Huang CY, Lien HC, Chen CY, Chou KJ, Su YC.",Crit Rev Oncol Hematol. 2019 Nov 15;145:102823. doi: 10.1016/j.critrevonc.2019.102823. [Epub ahead of print] Review.,Crit Rev Oncol Hematol.  2019,PubMed,citation,PMID:31783291,pubmed,31783291,create date:2019/11/30 | first author:Wu CC
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.,/pubmed/31781481,"Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, et al.",Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019.,Front Oncol.  2019,PubMed,citation,PMID:31781481 | PMCID:PMC6857002,pubmed,31781481,create date:2019/11/30 | first author:Caraglia M
Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study.,/pubmed/31769323,"Mezheyeuski A, Ponten F, Edqvist PH, Sundström M, Thunberg U, Qvortrup C, Pfeiffer P, Sorbye H, Glimelius B, Dragomir A.",Acta Oncol. 2019 Nov 26:1-7. doi: 10.1080/0284186X.2019.1691258. [Epub ahead of print],Acta Oncol.  2019,PubMed,citation,PMID:31769323,pubmed,31769323,create date:2019/11/27 | first author:Mezheyeuski A
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study.,/pubmed/31762802,"Grassadonia A, Di Marino P, Ficorella C, Cortellini A, Cannita K, Parisi A, Gamucci T, Zoratto F, Vici P, Barba M, Porreca E, Neri M, Veronese A, Natoli C, De Tursi M, Tinari N.",J Cancer. 2019 Oct 15;10(24):5926-5934. doi: 10.7150/jca.34550. eCollection 2019.,J Cancer.  2019,PubMed,citation,PMID:31762802 | PMCID:PMC6856567,pubmed,31762802,create date:2019/11/26 | first author:Grassadonia A
Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.,/pubmed/31720832,"Liu F, Ren C, Jin Y, Xi S, He C, Wang F, Wang Z, Xu RH, Wang F.",Virchows Arch. 2019 Nov 13. doi: 10.1007/s00428-019-02668-9. [Epub ahead of print],Virchows Arch.  2019,PubMed,citation,PMID:31720832,pubmed,31720832,create date:2019/11/14 | first author:Liu F
Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients.,/pubmed/31719050,"Datta J, Smith JJ, Chatila WK, McAuliffe JC, Kandoth C, Vakiani E, Frankel TL, Ganesh K, Wasserman I, Lipsyc-Sharf M, Guillem J, Nash GM, Paty PB, Weiser MR, Saltz LB, Berger MF, Jarnagin WR, Balachandran V, Kingham TP, Kemeny NE, Cercek A, Garcia-Aguilar J, et al.",Clin Cancer Res. 2019 Nov 12. pii: clincanres.2390.2019. doi: 10.1158/1078-0432.CCR-19-2390. [Epub ahead of print],Clin Cancer Res.  2019,PubMed,citation,PMID:31719050,pubmed,31719050,create date:2019/11/14 | first author:Datta J
[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.,/pubmed/31705176,"van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW.",Eur J Nucl Med Mol Imaging. 2019 Nov 9. doi: 10.1007/s00259-019-04555-6. [Epub ahead of print],Eur J Nucl Med Mol Imaging.  2019,PubMed,citation,PMID:31705176,pubmed,31705176,create date:2019/11/11 | first author:van Helden EJ
Use of perioperative chemotherapy in colorectal cancer metastatic to the liver.,/pubmed/31687149,"Symonds LK, Cohen SA.",Gastroenterol Rep (Oxf). 2019 Aug 21;7(5):301-311. doi: 10.1093/gastro/goz035. eCollection 2019 Oct. Review.,Gastroenterol Rep (Oxf).  2019,PubMed,citation,PMID:31687149 | PMCID:PMC6821343,pubmed,31687149,create date:2019/11/07 | first author:Symonds LK
Increased Incidence of Colon Tumors in AOM-Treated Apc (1638N/+) Mice Reveals Higher Frequency of Tumor Associated Neutrophils in Colon Than Small Intestine.,/pubmed/31681563,"Metzger R, Maruskova M, Krebs S, Janssen KP, Krug AB.",Front Oncol. 2019 Oct 2;9:1001. doi: 10.3389/fonc.2019.01001. eCollection 2019.,Front Oncol.  2019,PubMed,citation,PMID:31681563 | PMCID:PMC6797844,pubmed,31681563,create date:2019/11/05 | first author:Metzger R
Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.,/pubmed/31669704,"Siraj AK, Bu R, Iqbal K, Parvathareddy SK, Siraj N, Siraj S, Diaz MRF, Rala DR, Benito AD, Sabido MA, Al-Rasheed M, Al-Obaisi KAS, Al-Haqawi W, Victoria IG, Al Balawy W, Abedalthagafi M, Wakil SM, Ajarim D, Mohammed S, Alhussain T, Tulbah A, Al-Badawi IA, et al.",Genomics. 2019 Oct 30. pii: S0888-7543(19)30404-5. doi: 10.1016/j.ygeno.2019.09.017. [Epub ahead of print],Genomics.  2019,PubMed,citation,PMID:31669704,pubmed,31669704,create date:2019/11/02 | first author:Siraj AK
Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.,/pubmed/31646798,"Kucukoner M, Oztekin E, Akdeniz N, Morkuzu S, Yerlikaya H, Urakci Z, Kaplan MA, Isikdogan A.",J BUON. 2019 Jul-Aug;24(4):1501-1506.,J BUON.  2019,PubMed,citation,PMID:31646798,pubmed,31646798,create date:2019/10/28 | first author:Kucukoner M
Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.,/pubmed/31646797,"Demircan NC, Dane F, Ozturk MA, Babacan NA, Besiroglu M, Kaya S, Ercelep O, Tanrikulu E, Halil S, Koca S, Alan O, Hasanov R, Yumuk PF.",J BUON. 2019 Jul-Aug;24(4):1494-1500.,J BUON.  2019,PubMed,citation,PMID:31646797,pubmed,31646797,create date:2019/10/28 | first author:Demircan NC
Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread.,/pubmed/31641356,"Pretzsch E, Bösch F, Neumann J, Ganschow P, Bazhin A, Guba M, Werner J, Angele M.",J Oncol. 2019 Sep 19;2019:7407190. doi: 10.1155/2019/7407190. eCollection 2019. Review.,J Oncol.  2019,PubMed,citation,PMID:31641356 | PMCID:PMC6770301,pubmed,31641356,create date:2019/10/24 | first author:Pretzsch E
Understanding the Interplay between COX-2 and hTERT in Colorectal Cancer Using a Multi-Omics Analysis.,/pubmed/31614548,"Ayiomamitis GD, Notas G, Vasilakaki T, Tsavari A, Vederaki S, Theodosopoulos T, Kouroumalis E, Zaravinos A.",Cancers (Basel). 2019 Oct 11;11(10). pii: E1536. doi: 10.3390/cancers11101536.,Cancers (Basel).  2019,PubMed,citation,PMID:31614548 | PMCID:PMC6827032,pubmed,31614548,create date:2019/10/17 | first author:Ayiomamitis GD
Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report.,/pubmed/31612019,"Feng Y, Cao Y, Yuan M, Chen R, Ji X, Hu X.",Oncol Lett. 2019 Nov;18(5):5085-5090. doi: 10.3892/ol.2019.10909. Epub 2019 Sep 23.,Oncol Lett.  2019,PubMed,citation,PMID:31612019 | PMCID:PMC6781514,pubmed,31612019,create date:2019/10/16 | first author:Feng Y
Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status.,/pubmed/31602326,"Rasmy A, Fayed A, Omar A, Fahmy N.",J Gastrointest Oncol. 2019 Oct;10(5):886-895. doi: 10.21037/jgo.2019.05.04.,J Gastrointest Oncol.  2019,PubMed,citation,PMID:31602326 | PMCID:PMC6776817,pubmed,31602326,create date:2019/10/12 | first author:Rasmy A
Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research.,/pubmed/31601052,"Mullins CS, Micheel B, Matschos S, Leuchter M, Bürtin F, Krohn M, Hühns M, Klar E, Prall F, Linnebacher M.",Cancers (Basel). 2019 Oct 9;11(10). pii: E1520. doi: 10.3390/cancers11101520.,Cancers (Basel).  2019,PubMed,citation,PMID:31601052 | PMCID:PMC6826890,pubmed,31601052,create date:2019/10/12 | first author:Mullins CS
RAS mutation: site of disease and recurrence pattern in colorectal cancer.,/pubmed/31597436,"Bonnot PE, Passot G.",Chin Clin Oncol. 2019 Oct;8(5):55. doi: 10.21037/cco.2019.08.11.,Chin Clin Oncol.  2019,PubMed,citation,PMID:31597436,pubmed,31597436,create date:2019/10/11 | first author:Bonnot PE
Long-Term Outcome in Patients with a Solitary Peutz-Jeghers Polyp.,/pubmed/31582972,"Iwamuro M, Aoyama Y, Suzuki S, Kobayashi S, Toyokawa T, Moritou Y, Hori S, Matsueda K, Yoshioka M, Tanaka T, Okada H.",Gastroenterol Res Pract. 2019 Sep 8;2019:8159072. doi: 10.1155/2019/8159072. eCollection 2019.,Gastroenterol Res Pract.  2019,PubMed,citation,PMID:31582972 | PMCID:PMC6754916,pubmed,31582972,create date:2019/10/05 | first author:Iwamuro M
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).,/pubmed/31578276,"Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, et al.",Oncologist. 2019 Oct 2. pii: theoncologist.2019-0328. doi: 10.1634/theoncologist.2019-0328. [Epub ahead of print],Oncologist.  2019,PubMed,citation,PMID:31578276,pubmed,31578276,create date:2019/10/04 | first author:Palmieri LJ
Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.,/pubmed/31571151,"Liu R, Zhao X, Guo W, Huang M, Qiu L, Zhang W, Zhang Z, Li W, Zhu X, Chen Z.",Clin Transl Oncol. 2019 Sep 30. doi: 10.1007/s12094-019-02215-7. [Epub ahead of print],Clin Transl Oncol.  2019,PubMed,citation,PMID:31571151,pubmed,31571151,create date:2019/10/02 | first author:Liu R
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents.,/pubmed/31570462,"Fiala O, Ostasov P, Hosek P, Sorejs O, Liska V, Buchler T, Poprach A, Kucera R, Topolcan O, Sustr J, Sedivcova M, Finek J.",Anticancer Res. 2019 Oct;39(10):5645-5652. doi: 10.21873/anticanres.13761.,Anticancer Res.  2019,PubMed,citation,PMID:31570462,pubmed,31570462,create date:2019/10/02 | first author:Fiala O
Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.,/pubmed/31567189,"Lasota J, Chłopek M, Lamoureux J, Christiansen J, Kowalik A, Wasąg B, Felisiak-Gołąbek A, Agaimy A, Biernat W, Canzonieri V, Centonze G, Chmielik E, Daum O, Dubová M, Dziuba I, Goertz S, Góźdź S, Guttmejer-Nasierowska A, Haglund C, Hałoń A, Hartmann A, Inaguma S, et al.",Am J Surg Pathol. 2019 Sep 23. doi: 10.1097/PAS.0000000000001377. [Epub ahead of print],Am J Surg Pathol.  2019,PubMed,citation,PMID:31567189,pubmed,31567189,create date:2019/10/01 | first author:Lasota J
Microbiota Profile and Impact of Fusobacterium nucleatum in Colorectal Cancer Patients of Barretos Cancer Hospital.,/pubmed/31555583,"de Carvalho AC, de Mattos Pereira L, Datorre JG, Dos Santos W, Berardinelli GN, Matsushita MM, Oliveira MA, Durães RO, Guimarães DP, Reis RM.",Front Oncol. 2019 Aug 29;9:813. doi: 10.3389/fonc.2019.00813. eCollection 2019.,Front Oncol.  2019,PubMed,citation,PMID:31555583 | PMCID:PMC6727361,pubmed,31555583,create date:2019/09/27 | first author:de Carvalho AC
"KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.",/pubmed/31553708,"Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C.",Radiol Oncol. 2019 Sep 24;53(3):265-274. doi: 10.2478/raon-2019-0033.,Radiol Oncol.  2019,PubMed,citation,PMID:31553708 | PMCID:PMC6765160,pubmed,31553708,create date:2019/09/26 | first author:Afrăsânie VA
Mutation profiling of cancer drivers in Brazilian colorectal cancer.,/pubmed/31548566,"Dos Santos W, Sobanski T, de Carvalho AC, Evangelista AF, Matsushita M, Berardinelli GN, de Oliveira MA, Reis RM, Guimarães DP.",Sci Rep. 2019 Sep 23;9(1):13687. doi: 10.1038/s41598-019-49611-1.,Sci Rep.  2019,PubMed,citation,PMID:31548566 | PMCID:PMC6757044,pubmed,31548566,create date:2019/09/25 | first author:Dos Santos W
PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis.,/pubmed/31545109,"Jin J, Shi Y, Zhang S, Yang S.",Acta Oncol. 2019 Sep 23:1-9. doi: 10.1080/0284186X.2019.1664764. [Epub ahead of print],Acta Oncol.  2019,PubMed,citation,PMID:31545109,pubmed,31545109,create date:2019/09/24 | first author:Jin J
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.,/pubmed/31539295,"Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, et al.",J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.,J Clin Oncol.  2019,PubMed,citation,PMID:31539295 | PMCID:PMC6864846,pubmed,31539295,create date:2019/09/21 | first author:Morano F
E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors.,/pubmed/31534120,"Choi EH, Kim KP.",Exp Mol Med. 2019 Sep 18;51(9):106. doi: 10.1038/s12276-019-0307-2.,Exp Mol Med.  2019,PubMed,citation,PMID:31534120 | PMCID:PMC6802646,pubmed,31534120,create date:2019/09/20 | first author:Choi EH
Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRAS(G12C).,/pubmed/31531201,"Shin Y, Jeong JW, Wurz RP, Achanta P, Arvedson T, Bartberger MD, Campuzano IDG, Fucini R, Hansen SK, Ingersoll J, Iwig JS, Lipford JR, Ma V, Kopecky DJ, McCarter J, San Miguel T, Mohr C, Sabet S, Saiki AY, Sawayama A, Sethofer S, Tegley CM, et al.",ACS Med Chem Lett. 2019 Aug 20;10(9):1302-1308. doi: 10.1021/acsmedchemlett.9b00258. eCollection 2019 Sep 12.,ACS Med Chem Lett.  2019,PubMed,citation,PMID:31531201 | PMCID:PMC6746093,pubmed,31531201,create date:2019/09/19 | first author:Shin Y
Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal Cancer.,/pubmed/31519572,"Kuramochi H, Nakajima GO, Hayashi K, Araida T, Yamamoto M.",Anticancer Res. 2019 Sep;39(9):4729-4736. doi: 10.21873/anticanres.13655.,Anticancer Res.  2019,PubMed,citation,PMID:31519572,pubmed,31519572,create date:2019/09/15 | first author:Kuramochi H
The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.,/pubmed/31500429,"Allievi N, Goffredo P, Utria AF, Pisano M, Poiasina E, Lucianetti A, Zhou P, Hassan I.",Chin Clin Oncol. 2019 Oct;8(5):46. doi: 10.21037/cco.2019.08.10. Epub 2019 Sep 2.,Chin Clin Oncol.  2019,PubMed,citation,PMID:31500429,pubmed,31500429,create date:2019/09/11 | first author:Allievi N
Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients.,/pubmed/31475100,"You XH, Wen C, Xia ZJ, Sun F, Li Y, Wang W, Fang Z, Chen QG, Zhang L, Jiang YH, Wang XZ, Ying HQ, Zong Z.",Front Oncol. 2019 Aug 14;9:723. doi: 10.3389/fonc.2019.00723. eCollection 2019.,Front Oncol.  2019,PubMed,citation,PMID:31475100 | PMCID:PMC6702298,pubmed,31475100,create date:2019/09/03 | first author:You XH
"Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.",/pubmed/31475067,"Matsuhashi N, Takahashi T, Fujii H, Suetsugu T, Fukada M, Iwata Y, Tokumaru Y, Imai T, Mori R, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Futamura M, Yoshida K.",Mol Clin Oncol. 2019 Oct;11(4):390-396. doi: 10.3892/mco.2019.1899. Epub 2019 Jul 18.,Mol Clin Oncol.  2019,PubMed,citation,PMID:31475067 | PMCID:PMC6713946,pubmed,31475067,create date:2019/09/03 | first author:Matsuhashi N
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.,/pubmed/31456948,"Ottaiano A, Capozzi M, Tafuto S, De Stefano A, De Divitiis C, Romano C, Avallone A, Nasti G.",Front Oncol. 2019 Aug 13;9:766. doi: 10.3389/fonc.2019.00766. eCollection 2019.,Front Oncol.  2019,PubMed,citation,PMID:31456948 | PMCID:PMC6700318,pubmed,31456948,create date:2019/08/29 | first author:Ottaiano A
Timing of Perioperative Chemotherapy Does Not Influence Long-Term Outcome of Patients Undergoing Combined Laparoscopic Colorectal and Liver Resection in Selected Upfront Resectable Synchronous Liver Metastases.,/pubmed/31451846,"Ratti F, Fuks D, Cipriani F, Gayet B, Aldrighetti L.",World J Surg. 2019 Dec;43(12):3110-3119. doi: 10.1007/s00268-019-05142-4.,World J Surg.  2019,PubMed,citation,PMID:31451846,pubmed,31451846,create date:2019/08/28 | first author:Ratti F
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis.,/pubmed/31443300,"Galvano A, Incorvaia L, Badalamenti G, Rizzo S, Guarini A, Cusenza S, Castellana L, Barraco N, Calò V, Cutaia S, Currò G, Silvestris N, Beretta GD, Bazan V, Russo A.",Cancers (Basel). 2019 Aug 15;11(8). pii: E1189. doi: 10.3390/cancers11081189. Review.,Cancers (Basel).  2019,PubMed,citation,PMID:31443300 | PMCID:PMC6721481,pubmed,31443300,create date:2019/08/25 | first author:Galvano A
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.,/pubmed/31433498,"Piawah S, Venook AP.",Cancer. 2019 Dec 1;125(23):4139-4147. doi: 10.1002/cncr.32163. Epub 2019 Aug 21. Review.,Cancer.  2019,PubMed,citation,PMID:31433498,pubmed,31433498,create date:2019/08/23 | first author:Piawah S
Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.,/pubmed/31426677,"O Connor JM, Sanchez Loria F, Ardiles V, Grondona J, Sanchez P, Andriani O, Fauda M, Brancato F, Huertas E, Alvarez F, de Santibañes E.",Future Oncol. 2019 Sep;15(27):3149-3157. doi: 10.2217/fon-2019-0196. Epub 2019 Aug 20.,Future Oncol.  2019,PubMed,citation,PMID:31426677,pubmed,31426677,create date:2019/08/21 | first author:O Connor JM
Cardiovascular complications of metastatic colorectal cancer treatment.,/pubmed/31392061,"Keramida K, Charalampopoulos G, Filippiadis D, Tsougos E, Farmakis D.",J Gastrointest Oncol. 2019 Aug;10(4):797-806. doi: 10.21037/jgo.2019.03.04. Review.,J Gastrointest Oncol.  2019,PubMed,citation,PMID:31392061 | PMCID:PMC6657319,pubmed,31392061,create date:2019/08/09 | first author:Keramida K
The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.,/pubmed/31389831,"Margonis GA, Amini N, Buettner S, Kim Y, Wang J, Andreatos N, Wagner D, Sasaki K, Beer A, Kamphues C, Morioka D, Løes IM, Imai K, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Burkhart R, Endo I, Baba H, Mischinger HJ, et al.",Ann Surg. 2019 Aug 5. doi: 10.1097/SLA.0000000000003504. [Epub ahead of print],Ann Surg.  2019,PubMed,citation,PMID:31389831,pubmed,31389831,create date:2019/08/08 | first author:Margonis GA
Missense mutations in the C-terminal portion of the B4GALNT2-encoded glycosyltransferase underlying the Sd(a-) phenotype.,/pubmed/31367682,"Stenfelt L, Hellberg Å, Möller M, Thornton N, Larson G, Olsson ML.",Biochem Biophys Rep. 2019 Jul 17;19:100659. doi: 10.1016/j.bbrep.2019.100659. eCollection 2019 Sep.,Biochem Biophys Rep.  2019,PubMed,citation,PMID:31367682 | PMCID:PMC6646742,pubmed,31367682,create date:2019/08/02 | first author:Stenfelt L
A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.,/pubmed/31340858,"Jia M, Zhang Y, Jansen L, Walter V, Edelmann D, Gündert M, Tagscherer KE, Roth W, Bewerunge-Hudler M, Herpel E, Kloor M, Ulrich A, Burwinkel B, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M.",Clin Epigenetics. 2019 Jul 24;11(1):109. doi: 10.1186/s13148-019-0703-4.,Clin Epigenetics.  2019,PubMed,citation,PMID:31340858 | PMCID:PMC6657180,pubmed,31340858,create date:2019/07/26 | first author:Jia M
Myofibroblasts Enhance Tumor Growth in a Novel Mouse Model of Colorectal Cancer.,/pubmed/31325658,"Plummer R, Papageorge M, Ciomek N, Liu T, Yoo J.",J Surg Res. 2019 Dec;244:374-381. doi: 10.1016/j.jss.2019.06.051. Epub 2019 Jul 17.,J Surg Res.  2019,PubMed,citation,PMID:31325658,pubmed,31325658,create date:2019/07/22 | first author:Plummer R
Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS.,/pubmed/31324478,"Margalit O, Shacham-Shmueli E, Lawrence YR, Yang YX, Reiss KA, Golan T, Mamtani R, Halpern N, Aderka D, Giantonio B, Boursi B.",Clin Colorectal Cancer. 2019 Sep;18(3):e300-e307. doi: 10.1016/j.clcc.2019.06.001. Epub 2019 Jun 26.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:31324478,pubmed,31324478,create date:2019/07/22 | first author:Margalit O
"Terminology, Molecular Features, Epidemiology, and Management of Serrated Colorectal Neoplasia.",/pubmed/31323292,"Crockett SD, Nagtegaal ID.",Gastroenterology. 2019 Oct;157(4):949-966.e4. doi: 10.1053/j.gastro.2019.06.041. Epub 2019 Jul 16. Review.,Gastroenterology.  2019,PubMed,citation,PMID:31323292,pubmed,31323292,create date:2019/07/20 | first author:Crockett SD
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.,/pubmed/31322322,"Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, et al.",Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.,Mol Oncol.  2019,PubMed,citation,PMID:31322322 | PMCID:PMC6717744,pubmed,31322322,create date:2019/07/20 | first author:Elez E
Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.,/pubmed/31319395,"Wang ZX, Wu HX, He MM, Wang YN, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH.",J Natl Compr Canc Netw. 2019 Jul 1;17(7):805-811. doi: 10.6004/jnccn.2018.7279.,J Natl Compr Canc Netw.  2019,PubMed,citation,PMID:31319395,pubmed,31319395,create date:2019/07/19 | first author:Wang ZX
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.,/pubmed/31309326,"Hayama T, Hashiguchi Y, Okamoto K, Okada Y, Ono K, Shimada R, Ozawa T, Toyoda T, Tsuchiya T, Iinuma H, Nozawa K, Matsuda K.",Int J Colorectal Dis. 2019 Aug;34(8):1491-1496. doi: 10.1007/s00384-019-03344-9. Epub 2019 Jul 15.,Int J Colorectal Dis.  2019,PubMed,citation,PMID:31309326,pubmed,31309326,create date:2019/07/17 | first author:Hayama T
Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.,/pubmed/31307428,"Bencsikova B, Budinska E, Selingerova I, Pilatova K, Fedorova L, Greplova K, Nenutil R, Valik D, Obermannova R, Sheard MA, Zdrazilova-Dubska L.",BMC Cancer. 2019 Jul 15;19(1):687. doi: 10.1186/s12885-019-5909-5.,BMC Cancer.  2019,PubMed,citation,PMID:31307428 | PMCID:PMC6631500,pubmed,31307428,create date:2019/07/17 | first author:Bencsikova B
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.,/pubmed/31300973,"Köhne CH, Karthaus M, Mineur L, Thaler J, Van den Eynde M, Gallego J, Koukakis R, Berkhout M, Hofheinz RD.",Drugs R D. 2019 Sep;19(3):267-275. doi: 10.1007/s40268-019-0278-8.,Drugs R D.  2019,PubMed,citation,PMID:31300973 | PMCID:PMC6738356,pubmed,31300973,create date:2019/07/14 | first author:Köhne CH
Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.,/pubmed/31292272,"Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y.",Oncologist. 2019 Jul 10. pii: theoncologist.2019-0171. doi: 10.1634/theoncologist.2019-0171. [Epub ahead of print],Oncologist.  2019,PubMed,citation,PMID:31292272,pubmed,31292272,create date:2019/07/12 | first author:Chen MH
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.,/pubmed/31285374,"Lee DW, Han SW, Bae JM, Jang H, Han H, Kim H, Bang D, Jeong SY, Park KJ, Kang GH, Kim TY.",Clin Cancer Res. 2019 Oct 15;25(20):6141-6147. doi: 10.1158/1078-0432.CCR-19-1105. Epub 2019 Jul 8.,Clin Cancer Res.  2019,PubMed,citation,PMID:31285374,pubmed,31285374,create date:2019/07/10 | first author:Lee DW
Prognostic and predictive markers in liver limited stage IV colorectal cancer.,/pubmed/31279594,"Rehman AH, Jones RP, Poston G.",Eur J Surg Oncol. 2019 Dec;45(12):2251-2256. doi: 10.1016/j.ejso.2019.06.038. Epub 2019 Jun 27. Review.,Eur J Surg Oncol.  2019,PubMed,citation,PMID:31279594,pubmed,31279594,create date:2019/07/08 | first author:Rehman AH
"Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?",/pubmed/31270570,"Eisterer W, Prager G.",Cardiovasc Intervent Radiol. 2019 Sep;42(9):1213-1220. doi: 10.1007/s00270-019-02278-7. Epub 2019 Jul 3.,Cardiovasc Intervent Radiol.  2019,PubMed,citation,PMID:31270570,pubmed,31270570,create date:2019/07/05 | first author:Eisterer W
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.,/pubmed/31268481,"Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, et al.",JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print],JAMA Oncol.  2019,PubMed,citation,PMID:31268481 | PMCID:PMC6613306,pubmed,31268481,create date:2019/07/04 | first author:Pietrantonio F
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.,/pubmed/31268130,"Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.",Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.,Ann Oncol.  2019,PubMed,citation,PMID:31268130,pubmed,31268130,create date:2019/07/04 | first author:Taieb J
Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis.,/pubmed/31258736,"Wang J, Shen J, Huang C, Cao M, Shen L.",J Cancer. 2019 May 26;10(10):2332-2341. doi: 10.7150/jca.30789. eCollection 2019.,J Cancer.  2019,PubMed,citation,PMID:31258736 | PMCID:PMC6584400,pubmed,31258736,create date:2019/07/02 | first author:Wang J
Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?,/pubmed/31238809,"Dogan E, Firat ST, Cosar R, Bozkurt O, Inanc M, Ozkan M.",J Oncol Pharm Pract. 2019 Jun 25:1078155219856682. doi: 10.1177/1078155219856682. [Epub ahead of print],J Oncol Pharm Pract.  2019,PubMed,citation,PMID:31238809,pubmed,31238809,create date:2019/06/27 | first author:Dogan E
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).,/pubmed/31235483,"García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J.",Oncologist. 2019 Nov;24(11):e1115-e1122. doi: 10.1634/theoncologist.2018-0728. Epub 2019 Jun 24.,Oncologist.  2019,PubMed,citation,PMID:31235483 | PMCID:PMC6853109,pubmed,31235483,create date:2019/06/27 | first author:García-Albéniz X
Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report.,/pubmed/31219972,"Stueger A, Winder T, Tinguely M, Petrausch U, Helbling D.",J Immunother. 2019 Sep;42(7):274-277. doi: 10.1097/CJI.0000000000000279.,J Immunother.  2019,PubMed,citation,PMID:31219972,pubmed,31219972,create date:2019/06/21 | first author:Stueger A
Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.,/pubmed/31209667,"Bruzzi M, Auclin E, Lo Dico R, Voron T, Karoui M, Espin E, Cianchi F, Weitz J, Buggenhout A, Malafosse R, Denimal F, Le Malicot K, Vernerey D, Douard R, Emile JF, Lepage C, Laurent-Puig P, Taieb J.",Ann Surg Oncol. 2019 Oct;26(11):3561-3567. doi: 10.1245/s10434-019-07513-6. Epub 2019 Jun 17.,Ann Surg Oncol.  2019,PubMed,citation,PMID:31209667,pubmed,31209667,create date:2019/06/19 | first author:Bruzzi M
Identification of a novel PRR15L-RSPO2 fusion transcript in a sigmoid colon cancer derived from superficially serrated adenoma.,/pubmed/31209633,"Mizuguchi Y, Sakamoto T, Hashimoto T, Tsukamoto S, Iwasa S, Saito Y, Sekine S.",Virchows Arch. 2019 Nov;475(5):659-663. doi: 10.1007/s00428-019-02604-x. Epub 2019 Jun 17.,Virchows Arch.  2019,PubMed,citation,PMID:31209633,pubmed,31209633,create date:2019/06/19 | first author:Mizuguchi Y
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.,/pubmed/31205516,"Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.",J Cancer. 2019 Mar 3;10(7):1611-1615. doi: 10.7150/jca.29106. eCollection 2019.,J Cancer.  2019,PubMed,citation,PMID:31205516 | PMCID:PMC6548008,pubmed,31205516,create date:2019/06/18 | first author:Yoon SE
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.,/pubmed/31205502,"Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, Calvisi G, Troncone G, Simmaco M, Ricevuto E.",Ther Adv Med Oncol. 2019 May 10;11:1758835919846421. doi: 10.1177/1758835919846421. eCollection 2019.,Ther Adv Med Oncol.  2019,PubMed,citation,PMID:31205502 | PMCID:PMC6535746,pubmed,31205502,create date:2019/06/18 | first author:Bruera G
NO(2) functionalized coumarin derivatives suppress cancer progression and facilitate apoptotic cell death in KRAS mutant colon cancer.,/pubmed/31199928,"Lin MH, Wang JS, Hsieh YC, Zheng JH, Cho EC.",Chem Biol Interact. 2019 Aug 25;309:108708. doi: 10.1016/j.cbi.2019.06.021. Epub 2019 Jun 11.,Chem Biol Interact.  2019,PubMed,citation,PMID:31199928,pubmed,31199928,create date:2019/06/15 | first author:Lin MH
Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting.,/pubmed/31199507,"Mardinian K, Okamura R, Kato S, Kurzrock R.",Int J Cancer. 2020 Jan 15;146(2):566-576. doi: 10.1002/ijc.32510. Epub 2019 Jul 1.,Int J Cancer.  2020,PubMed,citation,PMID:31199507 | PMCID:PMC6874714,pubmed,31199507,create date:2019/06/15 | first author:Mardinian K
Clinicopathological features and prognosis of AFP-producing colorectal cancer: a single-center analysis of 20 cases.,/pubmed/31191017,"Ren F, Weng W, Zhang Q, Tan C, Xu M, Zhang M, Wang L, Sheng W, Ni S, Huang D.",Cancer Manag Res. 2019 May 16;11:4557-4567. doi: 10.2147/CMAR.S196919. eCollection 2019.,Cancer Manag Res.  2019,PubMed,citation,PMID:31191017 | PMCID:PMC6529609,pubmed,31191017,create date:2019/06/14 | first author:Ren F
The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients.,/pubmed/31183193,"Aladhraei M, Al-Salami E, Poungvarin N, Suwannalert P.",J Gastrointest Oncol. 2019 Jun;10(3):437-444. doi: 10.21037/jgo.2019.01.17.,J Gastrointest Oncol.  2019,PubMed,citation,PMID:31183193 | PMCID:PMC6534720,pubmed,31183193,create date:2019/06/12 | first author:Aladhraei M
"Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.",/pubmed/31162857,"Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ, Cai SJ, Liu FQ, Xu Y.",Int J Cancer. 2019 Sep 15;145(6):1625-1634. doi: 10.1002/ijc.32489. Epub 2019 Jun 22.,Int J Cancer.  2019,PubMed,citation,PMID:31162857 | PMCID:PMC6771586,pubmed,31162857,create date:2019/06/05 | first author:Guo TA
"Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score.",/pubmed/31150437,"Gasser E, Braunwarth E, Riedmann M, Cardini B, Fadinger N, Presl J, Klieser E, Ellmerer P, Dupré A, Imai K, Malik H, Baba H, Ulmer H, Schneeberger S, Öfner D, Dinnewitzer A, Stättner S, Primavesi F.",PLoS One. 2019 May 31;14(5):e0217411. doi: 10.1371/journal.pone.0217411. eCollection 2019.,PLoS One.  2019,PubMed,citation,PMID:31150437 | PMCID:PMC6544347,pubmed,31150437,create date:2019/06/01 | first author:Gasser E
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.,/pubmed/31147489,"Fernández Montes A, López López C, Argilés Martínez G, Páez López D, López Muñoz AM, García Paredes B, Gutiérrez Abad D, Castañón López C, Jiménez Fonseca P, Gallego Plazas J, López Doldán MC, Martínez de Castro E, Sánchez Cánovas M, Tobeña Puyal M, Llorente Ayala B, Juez Martel I, López Flores M, Carmona-Bayonas A.",Oncologist. 2019 Aug;24(8):e687-e695. doi: 10.1634/theoncologist.2018-0824. Epub 2019 May 30.,Oncologist.  2019,PubMed,citation,PMID:31147489 | PMCID:PMC6693717,pubmed,31147489,create date:2019/05/31 | first author:Fernández Montes A
Reduced Frequency and Prognostic Significance of Ring Finger Protein 43 Nucleotide Polymorphisms in a Chinese Colorectal Cancer Cohort.,/pubmed/31140864,"Wen D, Wang G, Huang Z, Cui X, Song J, Zhu Z, Cui L.",DNA Cell Biol. 2019 Jun;38(6):541-548. doi: 10.1089/dna.2019.4645. Epub 2019 May 28.,DNA Cell Biol.  2019,PubMed,citation,PMID:31140864,pubmed,31140864,create date:2019/05/30 | first author:Wen D
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018.,/pubmed/31139561,"Shahjehan F, Kamatham S, Kasi PM.",Front Oncol. 2019 May 8;9:358. doi: 10.3389/fonc.2019.00358. eCollection 2019.,Front Oncol.  2019,PubMed,citation,PMID:31139561 | PMCID:PMC6519295,pubmed,31139561,create date:2019/05/30 | first author:Shahjehan F
The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.,/pubmed/31127994,"Sahin S, Karatas F.",J BUON. 2019 Mar-Apr;24(2):479-487.,J BUON.  2019,PubMed,citation,PMID:31127994,pubmed,31127994,create date:2019/05/28 | first author:Sahin S
Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer.,/pubmed/31099282,"Degirmencioglu S, Tanrıverdi O, Demiray AG, Senol H, Dogu GG, Yaren A.",J Int Med Res. 2019 Jun;47(6):2507-2515. doi: 10.1177/0300060519848258. Epub 2019 May 17.,J Int Med Res.  2019,PubMed,citation,PMID:31099282 | PMCID:PMC6567718,pubmed,31099282,create date:2019/05/18 | first author:Degirmencioglu S
Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion: A case report and systematic literature review.,/pubmed/31096446,"Xu L, Zhang M, Xu M.",Medicine (Baltimore). 2019 May;98(20):e15482. doi: 10.1097/MD.0000000000015482.,Medicine (Baltimore).  2019,PubMed,citation,PMID:31096446 | PMCID:PMC6531123,pubmed,31096446,create date:2019/05/18 | first author:Xu L
Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.,/pubmed/31090260,"Price T, Shen L, Ma B, Esser R, Chen W, Gibbs P, Lim R, Cheng AL.",Asia Pac J Clin Oncol. 2019 Aug;15(4):225-230. doi: 10.1111/ajco.13154. Epub 2019 May 15.,Asia Pac J Clin Oncol.  2019,PubMed,citation,PMID:31090260 | PMCID:PMC6852115,pubmed,31090260,create date:2019/05/16 | first author:Price T
Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations.,/pubmed/31070935,"Dinarvand P, Davaro EP, Doan JV, Ising ME, Evans NR, Phillips NJ, Lai J, Guzman MA.",Arch Pathol Lab Med. 2019 Nov;143(11):1382-1398. doi: 10.5858/arpa.2018-0570-RA. Epub 2019 May 9.,Arch Pathol Lab Med.  2019,PubMed,citation,PMID:31070935,pubmed,31070935,create date:2019/05/10 | first author:Dinarvand P
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.,/pubmed/31062389,"Barrow P, Richman SD, Wallace AJ, Handley K, Hutchins GGA, Kerr D, Magill L, Evans DG, Gray R, Quirke P, Hill J.",Histopathology. 2019 Aug;75(2):236-246. doi: 10.1111/his.13895. Epub 2019 Jul 5.,Histopathology.  2019,PubMed,citation,PMID:31062389 | PMCID:PMC6772160,pubmed,31062389,create date:2019/05/08 | first author:Barrow P
The primary tumor location impacts survival outcome of colorectal liver metastases after hepatic resection: A systematic review and meta-analysis.,/pubmed/31054852,"Liu W, Wang HW, Wang K, Xing BC.",Eur J Surg Oncol. 2019 Aug;45(8):1349-1356. doi: 10.1016/j.ejso.2019.04.017. Epub 2019 Apr 25. Review.,Eur J Surg Oncol.  2019,PubMed,citation,PMID:31054852,pubmed,31054852,create date:2019/05/06 | first author:Liu W
Radiogenomics: bridging imaging and genomics.,/pubmed/31049614,"Bodalal Z, Trebeschi S, Nguyen-Kim TDL, Schats W, Beets-Tan R.",Abdom Radiol (NY). 2019 Jun;44(6):1960-1984. doi: 10.1007/s00261-019-02028-w.,Abdom Radiol (NY).  2019,PubMed,citation,PMID:31049614,pubmed,31049614,create date:2019/05/03 | first author:Bodalal Z
Colorectal metastasis to the gallbladder mimicking a primary gallbladder malignancy: histopathological and molecular characteristics.,/pubmed/31044440,"de Bitter TJJ, van der Linden RLA, van Vliet S, Weren F, Sie D, Ylstra B, van der Linden HC, Knijn N, Ligtenberg MJL, van der Post RS, Simmer F, Nagtegaal ID.",Histopathology. 2019 Sep;75(3):394-404. doi: 10.1111/his.13892. Epub 2019 Jul 18.,Histopathology.  2019,PubMed,citation,PMID:31044440 | PMCID:PMC6794645,pubmed,31044440,create date:2019/05/03 | first author:de Bitter TJJ
"Dietary intake of fiber, whole grains and risk of colorectal cancer: An updated analysis according to food sources, tumor location and molecular subtypes in two large US cohorts.",/pubmed/31044426,"He X, Wu K, Zhang X, Nishihara R, Cao Y, Fuchs CS, Giovannucci EL, Ogino S, Chan AT, Song M.",Int J Cancer. 2019 Dec 1;145(11):3040-3051. doi: 10.1002/ijc.32382. Epub 2019 May 21.,Int J Cancer.  2019,PubMed,citation,PMID:31044426,pubmed,31044426,create date:2019/05/03 | first author:He X
A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients.,/pubmed/31036835,"Koster J, Plasterk RHA.",Sci Rep. 2019 Apr 29;9(1):6577. doi: 10.1038/s41598-019-42729-2.,Sci Rep.  2019,PubMed,citation,PMID:31036835 | PMCID:PMC6488612,pubmed,31036835,create date:2019/05/01 | first author:Koster J
"Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.",/pubmed/31036695,"Dcona MM, Damle PK, Zarate-Perez F, Morris BL, Nawaz Z, Dennis MJ, Deng X, Korwar S, Singh SJ, Ellis KC, Royer WE, Bandyopadhyay D, Escalante C, Grossman SR.",Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.,Mol Pharmacol.  2019,PubMed,citation,PMID:31036695 | PMCID:PMC6560337,pubmed,31036695,create date:2019/05/01 | first author:Dcona MM
Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.,/pubmed/31036005,"Isnaldi E, Garuti A, Cirmena G, Scabini S, Rimini E, Ferrando L, Lia M, Murialdo R, Tixi L, Carminati E, Panaro A, Gallo M, Grillo F, Mastracci L, Repetto L, Fiocca R, Romairone E, Zoppoli G, Ballestrero A.",J Transl Med. 2019 Apr 29;17(1):137. doi: 10.1186/s12967-019-1879-2.,J Transl Med.  2019,PubMed,citation,PMID:31036005 | PMCID:PMC6489172,pubmed,31036005,create date:2019/05/01 | first author:Isnaldi E
Partial response after treatment with Conversion chemotherapy: A case report of a patient with colon cancer and unresectable hepatic metastases.,/pubmed/31027071,"Bu Z, Lu C, Yang X, Lai H, Jiang Y, Li Y, Lin Y, Qin Y, Xiao M, Cheng C, Liu Q.",Medicine (Baltimore). 2019 Apr;98(17):e15239. doi: 10.1097/MD.0000000000015239.,Medicine (Baltimore).  2019,PubMed,citation,PMID:31027071 | PMCID:PMC6831392,pubmed,31027071,create date:2019/04/28 | first author:Bu Z
"Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.",/pubmed/30967421,"Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, et al.",Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9.,Clin Cancer Res.  2019,PubMed,citation,PMID:30967421,pubmed,30967421,create date:2019/04/11 | first author:Schirripa M
Efficacy of palliative chemotherapy in elderly patients with colorectal cancer.,/pubmed/30965378,"Bohle W, Pachlhofer A, Zoller WG.",Z Gastroenterol. 2019 Apr;57(4):484-490. doi: 10.1055/a-0851-6978. Epub 2019 Apr 9.,Z Gastroenterol.  2019,PubMed,citation,PMID:30965378,pubmed,30965378,create date:2019/04/10 | first author:Bohle W
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.,/pubmed/30963570,"Osumi H, Shinozaki E, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Takahari D, Ooki A, Suzuki T, Ota Y, Nakayama I, Chin K, Miki Y, Yamaguchi K.",Int J Cancer. 2019 Nov 1;145(9):2488-2495. doi: 10.1002/ijc.32320. Epub 2019 May 7.,Int J Cancer.  2019,PubMed,citation,PMID:30963570,pubmed,30963570,create date:2019/04/10 | first author:Osumi H
Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.,/pubmed/30963391,"Keum N, Liu L, Hamada T, Qian ZR, Nowak JA, Cao Y, da Silva A, Kosumi K, Song M, Nevo D, Wang M, Chan AT, Meyerhardt JA, Fuchs CS, Wu K, Ogino S, Nishihara R, Zhang X.",Cancer Causes Control. 2019 Jun;30(6):637-649. doi: 10.1007/s10552-019-01165-3. Epub 2019 Apr 8.,Cancer Causes Control.  2019,PubMed,citation,PMID:30963391 | PMCID:PMC6546870,pubmed,30963391,create date:2019/04/10 | first author:Keum N
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.,/pubmed/30962964,"Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F.",ESMO Open. 2019 Mar 8;4(2):e000489. doi: 10.1136/esmoopen-2019-000489. eCollection 2019.,ESMO Open.  2019,PubMed,citation,PMID:30962964 | PMCID:PMC6435314,pubmed,30962964,create date:2019/04/10 | first author:Cremolini C
Intussusception reveals MUTYH-associated polyposis syndrome and colorectal cancer: a case report.,/pubmed/30953464,"de Mesquita GHA, Carvalho BJ, de Almeida Medeiros KA, Nii F, Martines DR, Pipek LZ, Jardim YJ, Waisberg DR, Obara MT, Sitnik R, Meyer A, Mangueira CLP.",BMC Cancer. 2019 Apr 5;19(1):324. doi: 10.1186/s12885-019-5505-8.,BMC Cancer.  2019,PubMed,citation,PMID:30953464 | PMCID:PMC6451307,pubmed,30953464,create date:2019/04/07 | first author:de Mesquita GHA
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.,/pubmed/30952821,"Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, et al.",Oncologist. 2019 Oct;24(10):1395-1402. doi: 10.1634/theoncologist.2018-0785. Epub 2019 Apr 5.,Oncologist.  2019,PubMed,citation,PMID:30952821 | PMCID:PMC6795149,pubmed,30952821,create date:2019/04/07 | first author:Sartore-Bianchi A
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.,/pubmed/30952636,"Anandappa G, Lampis A, Cunningham D, Khan KH, Kouvelakis K, Vlachogiannis G, Hedayat S, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Darvish-Damavandi M, Lote H, Thomas J, Peckitt C, Kalaitzaki R, Khan N, Fotiadis N, Rugge M, Begum R, Rana I, et al.",Clin Cancer Res. 2019 Jul 1;25(13):3830-3838. doi: 10.1158/1078-0432.CCR-18-3769. Epub 2019 Apr 5.,Clin Cancer Res.  2019,PubMed,citation,PMID:30952636,pubmed,30952636,create date:2019/04/07 | first author:Anandappa G
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.,/pubmed/30952563,"Moretto R, Morano F, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, de Braud F, Falcone A, Cremolini C.",Clin Colorectal Cancer. 2019 Jun;18(2):116-124. doi: 10.1016/j.clcc.2019.02.007. Epub 2019 Mar 7.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:30952563,pubmed,30952563,create date:2019/04/07 | first author:Moretto R
"A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).",/pubmed/30941962,"Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E.",J BUON. 2019 Jan-Feb;24(1):136-142.,J BUON.  2019,PubMed,citation,PMID:30941962,pubmed,30941962,create date:2019/04/04 | first author:Degirmencioglu S
First-line treatment choices of Turkish medical oncologists in metastatic colorectal cancer: A survey study.,/pubmed/30941953,"Beypinar I, Araz M, Uysal M, Yalcin S.",J BUON. 2019 Jan-Feb;24(1):68-76.,J BUON.  2019,PubMed,citation,PMID:30941953,pubmed,30941953,create date:2019/04/04 | first author:Beypinar I
Clinical and Molecular Features of Post-Colonoscopy Colorectal Cancers.,/pubmed/30930275,"Samadder NJ, Neklason D, Snow A, Samowitz W, Cessna MH, Rowe K, Sandhu I, Boucher K, Pappas L, Smith KR, Wong J, Curtin K, Provenzale D, Burt RW.",Clin Gastroenterol Hepatol. 2019 Dec;17(13):2731-2739.e2. doi: 10.1016/j.cgh.2019.02.040. Epub 2019 Mar 29.,Clin Gastroenterol Hepatol.  2019,PubMed,citation,PMID:30930275,pubmed,30930275,create date:2019/04/02 | first author:Samadder NJ
RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer.,/pubmed/30928770,"Morgan Z, Chow BE, Strong EA, Tsai S, Christians K, Mogal H, Gamblin TC, Clarke CN.",J Surg Res. 2019 Aug;240:130-135. doi: 10.1016/j.jss.2019.02.050. Epub 2019 Mar 28.,J Surg Res.  2019,PubMed,citation,PMID:30928770,pubmed,30928770,create date:2019/04/01 | first author:Morgan Z
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options.,/pubmed/30922401,"Luo C, Cen S, Ding G, Wu W.",Cancer Commun (Lond). 2019 Mar 29;39(1):13. doi: 10.1186/s40880-019-0361-0. Review.,Cancer Commun (Lond).  2019,PubMed,citation,PMID:30922401 | PMCID:PMC6440160,pubmed,30922401,create date:2019/03/30 | first author:Luo C
Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.,/pubmed/30917791,"Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL.",BMC Gastroenterol. 2019 Mar 27;19(1):46. doi: 10.1186/s12876-019-0965-5.,BMC Gastroenterol.  2019,PubMed,citation,PMID:30917791 | PMCID:PMC6437985,pubmed,30917791,create date:2019/03/29 | first author:Xie MZ
[XELIRI plus Bmab Therapy as a Secondary Treatment for Recurrent Colorectal Cancer with Long-Term Survival].,/pubmed/30914563,"Yukimoto R, Fukunaga M, Konishi K, Matsuno Y, Nakai S, Takiguchi N, Honda S, Saito A, Takeoka T, Okada K, Ota H, Yokoyama S, Kobayashi K.",Gan To Kagaku Ryoho. 2019 Feb;46(2):369-371. Japanese. ,Gan To Kagaku Ryoho.  2019,PubMed,citation,PMID:30914563,pubmed,30914563,create date:2019/03/28 | first author:Yukimoto R
"Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer.",/pubmed/30913862,"Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, Mavroudis D, Georgoulias V, Souglakos J.",Cancer Res Treat. 2019 Oct;51(4):1518-1526. doi: 10.4143/crt.2019.008. Epub 2019 Mar 20.,Cancer Res Treat.  2019,PubMed,citation,PMID:30913862 | PMCID:PMC6790836,pubmed,30913862,create date:2019/03/28 | first author:Sfakianaki M
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.,/pubmed/30894685,"Oh HJ, Bae JM, Wen X, Jung S, Kim Y, Kim KJ, Cho NY, Kim JH, Han SW, Kim TY, Kang GH.",Br J Cancer. 2019 Apr;120(8):797-805. doi: 10.1038/s41416-019-0429-2. Epub 2019 Mar 21.,Br J Cancer.  2019,PubMed,citation,PMID:30894685 | PMCID:PMC6474280,pubmed,30894685,create date:2019/03/22 | first author:Oh HJ
"A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.",/pubmed/30877190,"Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, Shu Y, Chang L, Jiang H, Gu Y.",Oncologist. 2019 Jul;24(7):883-e407. doi: 10.1634/theoncologist.2019-0164. Epub 2019 Mar 15.,Oncologist.  2019,PubMed,citation,PMID:30877190 | PMCID:PMC6656475,pubmed,30877190,create date:2019/03/17 | first author:Chen X
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies.,/pubmed/30863179,"Chen D, Gu K, Wang H.",Cancer Manag Res. 2019 Feb 19;11:1705-1716. doi: 10.2147/CMAR.S196170. eCollection 2019. Review.,Cancer Manag Res.  2019,PubMed,citation,PMID:30863179 | PMCID:PMC6388996,pubmed,30863179,create date:2019/03/14 | first author:Chen D
Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study.,/pubmed/30857495,"Lonardi S, Nasti G, Fagnani D, Gemma D, Ciuffreda L, Granetto C, Lucchesi S, Ballestrero A, Biglietto M, Proserpio I, Bergamo F, Proietti E, Tonini G.",Tumori. 2019 Jun;105(3):243-252. doi: 10.1177/0300891619834126. Epub 2019 Mar 11.,Tumori.  2019,PubMed,citation,PMID:30857495,pubmed,30857495,create date:2019/03/13 | first author:Lonardi S
Clinicopathological and molecular differences in colorectal cancer according to location.,/pubmed/30854932,"Hsu YL, Lin CC, Jiang JK, Lin HH, Lan YT, Wang HS, Yang SH, Chen WS, Lin TC, Lin JK, Lin PC, Chang SC.",Int J Biol Markers. 2019 Mar;34(1):47-53. doi: 10.1177/1724600818807164. Epub 2019 Mar 10.,Int J Biol Markers.  2019,PubMed,citation,PMID:30854932,pubmed,30854932,create date:2019/03/12 | first author:Hsu YL
Colon Cancer Tumor Location Defined by Gene Expression May Disagree With Anatomic Tumor Location.,/pubmed/30853326,"Cannon E, Buechler S.",Clin Colorectal Cancer. 2019 Jun;18(2):149-158. doi: 10.1016/j.clcc.2019.02.002. Epub 2019 Feb 14.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:30853326,pubmed,30853326,create date:2019/03/12 | first author:Cannon E
CROCC-mutated rhabdoid colorectal carcinoma showing in intercellular spaces lamellipodia and cellular projections revealed by electron microscopy.,/pubmed/30852641,"Remo A, Cecchini MP, Benati D, Bernardi P, Manfrin E, Giordano G, Bonomi F, Parcesepe P, Fassan M, Colombari R, Sbarbati A, Pancione M.",Virchows Arch. 2019 Aug;475(2):245-249. doi: 10.1007/s00428-019-02554-4. Epub 2019 Mar 10.,Virchows Arch.  2019,PubMed,citation,PMID:30852641,pubmed,30852641,create date:2019/03/11 | first author:Remo A
"Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.",/pubmed/30851333,"Park HY, Kwon MJ, Kang HS, Kim YJ, Kim NY, Kim MJ, Min KW, Choi KC, Nam ES, Cho SJ, Park HR, Min SK, Seo J, Choe JY, Lee HK.",Hum Pathol. 2019 May;87:83-94. doi: 10.1016/j.humpath.2019.02.007. Epub 2019 Mar 6.,Hum Pathol.  2019,PubMed,citation,PMID:30851333,pubmed,30851333,create date:2019/03/10 | first author:Park HY
Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).,/pubmed/30834622,"Marschner N, Frank M, Vach W, Ladda E, Karcher A, Winter S, Jänicke M, Trarbach T.",Colorectal Dis. 2019 Jul;21(7):816-826. doi: 10.1111/codi.14600. Epub 2019 Mar 18.,Colorectal Dis.  2019,PubMed,citation,PMID:30834622 | PMCID:PMC6850201,pubmed,30834622,create date:2019/03/06 | first author:Marschner N
"Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center.",/pubmed/30826126,"Silva ACB, Vicentini MFB, Mendoza EZ, Fujiki FK, da Fonseca LG, Braghiroli MIFM, Hoff PM.",Curr Probl Cancer. 2019 Oct;43(5):477-486. doi: 10.1016/j.currproblcancer.2019.01.009. Epub 2019 Feb 20.,Curr Probl Cancer.  2019,PubMed,citation,PMID:30826126,pubmed,30826126,create date:2019/03/04 | first author:Silva ACB
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.,/pubmed/30824612,"Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, et al.",Mol Cancer Ther. 2019 Apr;18(4):845-855. doi: 10.1158/1535-7163.MCT-18-0539. Epub 2019 Mar 1.,Mol Cancer Ther.  2019,PubMed,citation,PMID:30824612,pubmed,30824612,create date:2019/03/03 | first author:Martini G
"MicroRNA‑92a promotes cell proliferation, migration and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells.",/pubmed/30816526,"Alcantara KMM, Garcia RL.",Oncol Rep. 2019 Apr;41(4):2103-2116. doi: 10.3892/or.2019.7020. Epub 2019 Feb 19.,Oncol Rep.  2019,PubMed,citation,PMID:30816526 | PMCID:PMC6412542,pubmed,30816526,create date:2019/03/01 | first author:Alcantara KMM
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.,/pubmed/30814645,"Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, et al.",Sci Rep. 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.,Sci Rep.  2019,PubMed,citation,PMID:30814645 | PMCID:PMC6393680,pubmed,30814645,create date:2019/03/01 | first author:Randon G
Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient.,/pubmed/30803558,"Kim K, Choi SH, Lee J, Lee WS.",Cancer Genet. 2019 Feb;231-232:54-61. doi: 10.1016/j.cancergen.2019.01.004. Epub 2019 Jan 11.,Cancer Genet.  2019,PubMed,citation,PMID:30803558,pubmed,30803558,create date:2019/02/26 | first author:Kim K
BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer.,/pubmed/30792536,"Shimada Y, Muneoka Y, Nagahashi M, Ichikawa H, Tajima Y, Hirose Y, Ando T, Nakano M, Sakata J, Kameyama H, Takii Y, Ling Y, Okuda S, Takabe K, Wakai T.",Sci Rep. 2019 Feb 21;9(1):2466. doi: 10.1038/s41598-019-39328-6.,Sci Rep.  2019,PubMed,citation,PMID:30792536 | PMCID:PMC6384937,pubmed,30792536,create date:2019/02/23 | first author:Shimada Y
MiR-451a suppressing BAP31 can inhibit proliferation and increase apoptosis through inducing ER stress in colorectal cancer.,/pubmed/30770794,"Xu K, Han B, Bai Y, Ma XY, Ji ZN, Xiong Y, Miao SK, Zhang YY, Zhou LM.",Cell Death Dis. 2019 Feb 15;10(3):152. doi: 10.1038/s41419-019-1403-x.,Cell Death Dis.  2019,PubMed,citation,PMID:30770794 | PMCID:PMC6377610,pubmed,30770794,create date:2019/02/17 | first author:Xu K
Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.,/pubmed/30761750,"Mendis S, Beck S, Lee B, Lee M, Wong R, Kosmider S, Shapiro J, Yip D, Steel S, Nott L, Jennens R, Lipton L, Burge M, Field K, Ananda S, Wong HL, Gibbs P.",Asia Pac J Clin Oncol. 2019 Jun;15(3):136-143. doi: 10.1111/ajco.13135. Epub 2019 Feb 13.,Asia Pac J Clin Oncol.  2019,PubMed,citation,PMID:30761750,pubmed,30761750,create date:2019/02/15 | first author:Mendis S
First-line therapy for metastatic colorectal cancer: Current perspectives and future directions.,/pubmed/30758881,"Burge M, Price T, Karapetis CS.",Asia Pac J Clin Oncol. 2019 Feb;15 Suppl 1:3-14. doi: 10.1111/ajco.13119. Review.,Asia Pac J Clin Oncol.  2019,PubMed,citation,PMID:30758881,pubmed,30758881,create date:2019/02/14 | first author:Burge M
Biomarker concordance between primary colorectal cancer and its metastases.,/pubmed/30733075,"Bhullar DS, Barriuso J, Mullamitha S, Saunders MP, O'Dwyer ST, Aziz O.",EBioMedicine. 2019 Feb;40:363-374. doi: 10.1016/j.ebiom.2019.01.050. Epub 2019 Feb 4.,EBioMedicine.  2019,PubMed,citation,PMID:30733075 | PMCID:PMC6413540,pubmed,30733075,create date:2019/02/09 | first author:Bhullar DS
Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study.,/pubmed/30730996,"Liao X, Hao Y, Zhang X, Ward S, Houldsworth J, Polydorides AD, Harpaz N.",PLoS One. 2019 Feb 7;14(2):e0212142. doi: 10.1371/journal.pone.0212142. eCollection 2019.,PLoS One.  2019,PubMed,citation,PMID:30730996 | PMCID:PMC6366887,pubmed,30730996,create date:2019/02/08 | first author:Liao X
[Li-Fraumeni syndrome].,/pubmed/30730202,"Sejben A, Tiszlavicz L, Polyák K, Kovács L, Maráz A, Török D, Leprán Á, Ottlakán A, Furák J.",Orv Hetil. 2019 Feb;160(6):228-234. doi: 10.1556/650.2019.31290. Hungarian. ,Orv Hetil.  2019,PubMed,citation,PMID:30730202,pubmed,30730202,create date:2019/02/08 | first author:Sejben A
Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.,/pubmed/30728734,"Aljubran A, Elshenawy MA, Kandil M, Zahir MN, Shaheen A, Gad A, Alshaer O, Alzahrani A, Eldali A, Bazarbashi S.",Clin Med Insights Oncol. 2019 Jan 30;13:1179554918825447. doi: 10.1177/1179554918825447. eCollection 2019.,Clin Med Insights Oncol.  2019,PubMed,citation,PMID:30728734 | PMCID:PMC6354297,pubmed,30728734,create date:2019/02/08 | first author:Aljubran A
Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial.,/pubmed/30713134,"Tapia Rico G, Price T, Tebbutt N, Hardingham J, Lee C, Buizen L, Wilson K, Gebski V, Townsend A.",Clin Colorectal Cancer. 2019 Jun;18(2):141-148. doi: 10.1016/j.clcc.2018.12.002. Epub 2019 Jan 3.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:30713134,pubmed,30713134,create date:2019/02/05 | first author:Tapia Rico G
Genetic Analysis Using a Gene Panel in 87 Caucasian Patients With Colorectal Cancer: Own Results and Review of Literature.,/pubmed/30711966,"Smolle MA, Kashofer K, Riedl JM, Stotz M, Gerger A.",Anticancer Res. 2019 Feb;39(2):847-852. doi: 10.21873/anticanres.13184. Review.,Anticancer Res.  2019,PubMed,citation,PMID:30711966,pubmed,30711966,create date:2019/02/04 | first author:Smolle MA
Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.,/pubmed/30692096,"Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ.",Clin Cancer Res. 2019 May 15;25(10):3096-3103. doi: 10.1158/1078-0432.CCR-18-3388. Epub 2019 Jan 28.,Clin Cancer Res.  2019,PubMed,citation,PMID:30692096 | PMCID:PMC6886223,pubmed,30692096,create date:2019/01/30 | first author:Tokunaga R
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.,/pubmed/30690930,"Fernández Montes A, Martínez Lago N, Covela Rúa M, de la Cámara Gómez J, González Villaroel P, Méndez Méndez JC, Jorge Fernández M, Salgado Fernández M, Reboredo López M, Quintero Aldana G, Luz Pellón Augusto M, Graña Suárez B, García Gómez J.",Cancer Med. 2019 Mar;8(3):882-889. doi: 10.1002/cam4.1903. Epub 2019 Jan 28.,Cancer Med.  2019,PubMed,citation,PMID:30690930 | PMCID:PMC6434192,pubmed,30690930,create date:2019/01/29 | first author:Fernández Montes A
"A case of autonomous cortisol secretion in a patient with subclinical Cushing's syndrome, GNAS mutation, and paradoxical cortisol response to dexamethasone.",/pubmed/30670014,"Sakaguchi C, Ashida K, Kohashi K, Ohe K, Fujii Y, Yano S, Matsuda Y, Sakamoto S, Sakamoto R, Oda Y, Nomura M, Ogawa Y.",BMC Endocr Disord. 2019 Jan 22;19(1):13. doi: 10.1186/s12902-019-0345-8.,BMC Endocr Disord.  2019,PubMed,citation,PMID:30670014 | PMCID:PMC6343241,pubmed,30670014,create date:2019/01/24 | first author:Sakaguchi C
Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report.,/pubmed/30662270,"Wang Z, Dai WP, Zang YS.",Onco Targets Ther. 2019 Jan 8;12:443-447. doi: 10.2147/OTT.S180845. eCollection 2019.,Onco Targets Ther.  2019,PubMed,citation,PMID:30662270 | PMCID:PMC6329477,pubmed,30662270,create date:2019/01/22 | first author:Wang Z
Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.,/pubmed/30659494,"Chong LC, Townsend AR, Young J, Roy A, Piantadosi C, Hardingham JE, Roder D, Karapetis C, Padbury R, Maddern G, Moore J, Price TJ.",Target Oncol. 2019 Feb;14(1):85-91. doi: 10.1007/s11523-018-0615-9.,Target Oncol.  2019,PubMed,citation,PMID:30659494,pubmed,30659494,create date:2019/01/20 | first author:Chong LC
Colorectal Cancer Biomarkers in the Era of Personalized Medicine.,/pubmed/30646508,"Patel JN, Fong MK, Jagosky M.",J Pers Med. 2019 Jan 14;9(1). pii: E3. doi: 10.3390/jpm9010003. Review.,J Pers Med.  2019,PubMed,citation,PMID:30646508 | PMCID:PMC6463111,pubmed,30646508,create date:2019/01/17 | first author:Patel JN
"Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.",/pubmed/30638691,"Digiacomo N, Bolzacchini E, Veronesi G, Cerutti R, Sahnane N, Pinotti G, Bregni M, Artale S, Verusio C, Crivelli F, Capella C, Sessa F, Furlan D.",Clin Colorectal Cancer. 2019 Jun;18(2):e251-e260. doi: 10.1016/j.clcc.2018.12.003. Epub 2018 Dec 20.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:30638691,pubmed,30638691,create date:2019/01/15 | first author:Digiacomo N
Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer.,/pubmed/30630301,"Kim K, Castro EJT, Shim H, Advincula JVG, Kim YW.",Ann Coloproctol. 2018 Dec;34(6):280-285. doi: 10.3393/ac.2018.12.17. Epub 2018 Dec 31.,Ann Coloproctol.  2018,PubMed,citation,PMID:30630301 | PMCID:PMC6347335,pubmed,30630301,create date:2019/01/12 | first author:Kim K
Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.,/pubmed/30617760,"Deli T, Orosz M, Jakab A.",Pathol Oncol Res. 2019 Jan 8. doi: 10.1007/s12253-018-00569-x. [Epub ahead of print] Review.,Pathol Oncol Res.  2019,PubMed,citation,PMID:30617760,pubmed,30617760,create date:2019/01/09 | first author:Deli T
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.,/pubmed/30616224,"Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A.",Cancer Treat Rev. 2019 Feb;73:41-53. doi: 10.1016/j.ctrv.2018.12.006. Epub 2018 Dec 27.,Cancer Treat Rev.  2019,PubMed,citation,PMID:30616224,pubmed,30616224,create date:2019/01/08 | first author:Mauri G
EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy.,/pubmed/30612313,"Uhlyarik A, Piurko V, Vizkeleti L, Pápai Z, Rásó E, Lahm E, Kiss E, Sikter M, Vachaja J, Kenessey I, Tímár J.",Pathol Oncol Res. 2019 Jan 5. doi: 10.1007/s12253-018-00572-2. [Epub ahead of print],Pathol Oncol Res.  2019,PubMed,citation,PMID:30612313,pubmed,30612313,create date:2019/01/07 | first author:Uhlyarik A
How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications.,/pubmed/30598662,"Bond CE, Whitehall VLJ.",Gastroenterol Res Pract. 2018 Nov 26;2018:9250757. doi: 10.1155/2018/9250757. eCollection 2018. Review.,Gastroenterol Res Pract.  2018,PubMed,citation,PMID:30598662 | PMCID:PMC6287148,pubmed,30598662,create date:2019/01/02 | first author:Bond CE
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.,/pubmed/30598357,"Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW.",Clin Colorectal Cancer. 2019 Mar;18(1):e117-e129. doi: 10.1016/j.clcc.2018.11.002. Epub 2018 Nov 16. Review.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:30598357,pubmed,30598357,create date:2019/01/02 | first author:Bekaii-Saab T
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.,/pubmed/30595807,"Sunakawa Y, Satake H, Ichikawa W.",World J Gastrointest Oncol. 2018 Dec 15;10(12):528-531. doi: 10.4251/wjgo.v10.i12.528.,World J Gastrointest Oncol.  2018,PubMed,citation,PMID:30595807 | PMCID:PMC6304303,pubmed,30595807,create date:2019/01/01 | first author:Sunakawa Y
Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.,/pubmed/30594039,"Ma CJ, Huang CW, Chang TK, Tsai HL, Su WC, Yeh YS, Chen PJ, Wang JY.",Transl Oncol. 2019 Mar;12(3):502-512. doi: 10.1016/j.tranon.2018.12.003. Epub 2018 Dec 27.,Transl Oncol.  2019,PubMed,citation,PMID:30594039 | PMCID:PMC6307535,pubmed,30594039,create date:2018/12/30 | first author:Ma CJ
"Systematic review: Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer.",/pubmed/30591863,"Christensen TD, Jensen SG, Larsen FO, Nielsen DL.",J Bone Oncol. 2018 Sep 22;13:97-105. doi: 10.1016/j.jbo.2018.09.009. eCollection 2018 Nov. Review.,J Bone Oncol.  2018,PubMed,citation,PMID:30591863 | PMCID:PMC6303484,pubmed,30591863,create date:2018/12/29 | first author:Christensen TD
"Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles.",/pubmed/30577807,"Imperial R, Ahmed Z, Toor OM, Erdoğan C, Khaliq A, Case P, Case J, Kennedy K, Cummings LS, Melton N, Raza S, Diri B, Mohammad R, El-Rayes B, Pluard T, Hussain A, Subramanian J, Masood A.",Mol Cancer. 2018 Dec 21;17(1):177. doi: 10.1186/s12943-018-0923-9.,Mol Cancer.  2018,PubMed,citation,PMID:30577807 | PMCID:PMC6303985,pubmed,30577807,create date:2018/12/24 | first author:Imperial R
Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer.,/pubmed/30570508,"Zhou Y, Zhang J, Dan Pu, Bi F, Chen Y, Liu J, Li Q, Gou H, Wu B, Qiu M.",Anticancer Drugs. 2019 Feb;30(2):195-200. doi: 10.1097/CAD.0000000000000726.,Anticancer Drugs.  2019,PubMed,citation,PMID:30570508 | PMCID:PMC6365256,pubmed,30570508,create date:2018/12/21 | first author:Zhou Y
"[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]",/pubmed/30565585,Pietrantonio F.,Recenti Prog Med. 2018 Nov;109(11):27e-29e. doi: 10.1701/3031.30304. Italian. ,Recenti Prog Med.  2018,PubMed,citation,PMID:30565585,pubmed,30565585,create date:2018/12/20 | first author:Pietrantonio F
"[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].",/pubmed/30565583,Pietrantonio F.,Recenti Prog Med. 2018 Nov;109(11):20e-23e. doi: 10.1701/3031.30302. Italian. ,Recenti Prog Med.  2018,PubMed,citation,PMID:30565583,pubmed,30565583,create date:2018/12/20 | first author:Pietrantonio F
Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment.,/pubmed/30555748,"Zheng P, Ren L, Feng Q, Zhu D, Chang W, He G, Ji M, Jian M, Lin Q, Yi T, Wei Y, Xu J.",Am J Cancer Res. 2018 Nov 1;8(11):2337-2345. eCollection 2018.,Am J Cancer Res.  2018,PubMed,citation,PMID:30555748 | PMCID:PMC6291650,pubmed,30555748,create date:2018/12/18 | first author:Zheng P
Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.,/pubmed/30554073,"Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ.",Eur J Cancer. 2019 Jan;107:100-114. doi: 10.1016/j.ejca.2018.11.019. Epub 2018 Dec 14.,Eur J Cancer.  2019,PubMed,citation,PMID:30554073 | PMCID:PMC6367121,pubmed,30554073,create date:2018/12/17 | first author:Suenaga M
Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?,/pubmed/30545999,Weinberg BA.,J Natl Compr Canc Netw. 2018 Dec;16(12):1547-1548. doi: 10.6004/jnccn.2018.7107. No abstract available. ,J Natl Compr Canc Netw.  2018,PubMed,citation,PMID:30545999,pubmed,30545999,create date:2018/12/14 | first author:Weinberg BA
Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.,/pubmed/30545991,"Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA.",J Natl Compr Canc Netw. 2018 Dec;16(12):1442-1450. doi: 10.6004/jnccn.2018.7074.,J Natl Compr Canc Netw.  2018,PubMed,citation,PMID:30545991,pubmed,30545991,create date:2018/12/14 | first author:Kratz JD
Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan.,/pubmed/30541038,"Kato S, Hayashi T, Suehara Y, Hamanoue H, Yamanaka S, Ichikawa Y, Higurashi T, Ohashi K, Yamaguchi S, Nozaki Y, Terao Y, Saito T.",Jpn J Clin Oncol. 2019 Feb 1;49(2):174-182. doi: 10.1093/jjco/hyy173.,Jpn J Clin Oncol.  2019,PubMed,citation,PMID:30541038,pubmed,30541038,create date:2018/12/13 | first author:Kato S
Multiple Gastrointestinal Cancers in a Single Patient-a Rare Clinical Entity.,/pubmed/30538406,"Sahni M, Goel A, Pande P, Kumar K.",Indian J Surg Oncol. 2018 Dec;9(4):633-635. doi: 10.1007/s13193-018-0770-6. Epub 2018 May 16.,Indian J Surg Oncol.  2018,PubMed,citation,PMID:30538406 | PMCID:PMC6265184,pubmed,30538406,create date:2018/12/13 | first author:Sahni M
Early-onset colorectal cancer in young individuals.,/pubmed/30520562,"Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S.",Mol Oncol. 2019 Feb;13(2):109-131. doi: 10.1002/1878-0261.12417. Epub 2018 Dec 22. Review.,Mol Oncol.  2019,PubMed,citation,PMID:30520562 | PMCID:PMC6360363,pubmed,30520562,create date:2018/12/07 | first author:Mauri G
Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma.,/pubmed/30505575,"Jensen CE, Villanueva JY, Loaiza-Bonilla A.",J Gastrointest Oncol. 2018 Oct;9(5):778-784. doi: 10.21037/jgo.2018.06.10.,J Gastrointest Oncol.  2018,PubMed,citation,PMID:30505575 | PMCID:PMC6219968,pubmed,30505575,create date:2018/12/07 | first author:Jensen CE
HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.,/pubmed/30513002,"La Salvia A, Lopez-Gomez V, Garcia-Carbonero R.",Expert Opin Investig Drugs. 2019 Jan;28(1):29-38. doi: 10.1080/13543784.2019.1555583. Epub 2018 Dec 9. Review.,Expert Opin Investig Drugs.  2019,PubMed,citation,PMID:30513002,pubmed,30513002,create date:2018/12/05 | first author:La Salvia A
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.,/pubmed/30499710,"Mozolevska V, Schwartz A, Cheung D, Goyal V, Shaikh B, Dingman B, Kim E, Mittal I, Asselin CY, Edel A, Ravandi A, Thliveris J, Singal PK, Czaykowski P, Jassal DS.",Am J Physiol Heart Circ Physiol. 2019 Mar 1;316(3):H446-H458. doi: 10.1152/ajpheart.00344.2018. Epub 2018 Nov 30.,Am J Physiol Heart Circ Physiol.  2019,PubMed,citation,PMID:30499710,pubmed,30499710,create date:2018/12/01 | first author:Mozolevska V
Clonality and heterogeneity of metachronous colorectal cancer.,/pubmed/30499617,"Di J, Yang H, Wang Z, Yang J, Gao P, Jiang B, Su X.",Mol Carcinog. 2019 Mar;58(3):447-457. doi: 10.1002/mc.22947. Epub 2018 Dec 16.,Mol Carcinog.  2019,PubMed,citation,PMID:30499617,pubmed,30499617,create date:2018/12/01 | first author:Di J
Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved.,/pubmed/30476540,"Afrin S, Giampieri F, Gasparrini M, Forbes-Hernández TY, Cianciosi D, Reboredo-Rodriguez P, Zhang J, Manna PP, Daglia M, Atanasov AG, Battino M.",Biotechnol Adv. 2018 Nov 23. pii: S0734-9750(18)30195-2. doi: 10.1016/j.biotechadv.2018.11.011. [Epub ahead of print] Review.,Biotechnol Adv.  2018,PubMed,citation,PMID:30476540,pubmed,30476540,create date:2018/11/27 | first author:Afrin S
Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.,/pubmed/30463788,"Shimada Y, Tajima Y, Nagahashi M, Ichikawa H, Oyanagi H, Okuda S, Takabe K, Wakai T.",J Surg Res. 2018 Dec;232:72-81. doi: 10.1016/j.jss.2018.06.020. Epub 2018 Jul 3.,J Surg Res.  2018,PubMed,citation,PMID:30463788,pubmed,30463788,create date:2018/11/23 | first author:Shimada Y
"Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.",/pubmed/30463680,"Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E.",Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:30463680,pubmed,30463680,create date:2018/11/23 | first author:Shapiro JD
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.,/pubmed/30454021,"Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V.",J Immunother Cancer. 2018 Nov 19;6(1):123. doi: 10.1186/s40425-018-0438-3.,J Immunother Cancer.  2018,PubMed,citation,PMID:30454021 | PMCID:PMC6245855,pubmed,30454021,create date:2018/11/21 | first author:Ledys F
[Diagnosis and Treatment of MSI-H Cancer in Gynecological Cancer].,/pubmed/30449841,"Yamamoto N, Tashiro H, Katabuchi H.",Gan To Kagaku Ryoho. 2018 Nov;45(11):1577-1581. Japanese. ,Gan To Kagaku Ryoho.  2018,PubMed,citation,PMID:30449841,pubmed,30449841,create date:2018/11/20 | first author:Yamamoto N
Small Molecules Targeting Mutant P53: A Promising Approach For Cancer Treatment.,/pubmed/30444195,"Lopes EA, Gomes S, Saraiva L, Santos M.",Curr Med Chem. 2018 Nov 16. doi: 10.2174/0929867325666181116124308. [Epub ahead of print],Curr Med Chem.  2018,PubMed,citation,PMID:30444195,pubmed,30444195,create date:2018/11/18 | first author:Lopes EA
Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors.,/pubmed/30443292,"Ottaiano A, Scotti V, De Divitiis C, Capozzi M, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Vicario V, De Stefano A, Tafuto S, Berretta M, Nasti G, Avallone A.",Oncotarget. 2018 Oct 16;9(81):35251-35265. doi: 10.18632/oncotarget.25834. eCollection 2018 Oct 16.,Oncotarget.  2018,PubMed,citation,PMID:30443292 | PMCID:PMC6219663,pubmed,30443292,create date:2018/11/18 | first author:Ottaiano A
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.,/pubmed/30422156,"Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C.",JAMA Oncol. 2019 Jan 1;5(1):83-90. doi: 10.1001/jamaoncol.2018.4465.,JAMA Oncol.  2019,PubMed,citation,PMID:30422156 | PMCID:PMC6440242,pubmed,30422156,create date:2018/11/14 | first author:Bennouna J
Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.,/pubmed/30415301,"Zhang J, Xiang C, Han Y, Teng H, Li X, Shao J, Zhu L, Han-Zhang H, Ye J, Yu K.",J Cancer Res Clin Oncol. 2019 Jan;145(1):269-279. doi: 10.1007/s00432-018-2788-0. Epub 2018 Nov 10.,J Cancer Res Clin Oncol.  2019,PubMed,citation,PMID:30415301,pubmed,30415301,create date:2018/11/12 | first author:Zhang J
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.,/pubmed/30412858,"Taniguchi H, Okamoto W, Muro K, Akagi K, Hara H, Nishina T, Kajiwara T, Denda T, Hironaka S, Kudo T, Satoh T, Yamanaka T, Abe Y, Fukushima Y, Yoshino T.",Neoplasia. 2018 Dec;20(12):1219-1226. doi: 10.1016/j.neo.2018.10.004. Epub 2018 Nov 6.,Neoplasia.  2018,PubMed,citation,PMID:30412858 | PMCID:PMC6226617,pubmed,30412858,create date:2018/11/10 | first author:Taniguchi H
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.,/pubmed/30412224,"Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E.",Ann Oncol. 2018 Oct 1;29(10):2061-2067. doi: 10.1093/annonc/mdy337.,Ann Oncol.  2018,PubMed,citation,PMID:30412224 | PMCID:PMC6225810,pubmed,30412224,create date:2018/11/10 | first author:Chang K
[Efficacy and Prognostic Factors of Cetuximab Therapy in Treating KRAS or All RAS Wild-type Metastatic Colorectal Cancer].,/pubmed/30404699,"Wu X, Deng BB, Bai CM, Zhao L, Cheng YJ, Li XY, Li NN, Zhou JF.",Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Oct 30;40(5):660-666. doi: 10.3881/j.issn.1000-503X.10125. Chinese. ,Zhongguo Yi Xue Ke Xue Yuan Xue Bao.  2018,PubMed,citation,PMID:30404699,pubmed,30404699,create date:2018/11/09 | first author:Wu X
A Changing Spectrum of Colorectal Cancer Biology With Age: Implications for the Young Patient.,/pubmed/30394984,"Chouhan H, Ferrandon S, DeVecchio J, Kalady MF, Church JM.",Dis Colon Rectum. 2019 Jan;62(1):21-26. doi: 10.1097/DCR.0000000000001188.,Dis Colon Rectum.  2019,PubMed,citation,PMID:30394984,pubmed,30394984,create date:2018/11/06 | first author:Chouhan H
The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.,/pubmed/30382908,"Cruz-Nova P, Schnoor M, Correa-Basurto J, Bello M, Briseño-Diaz P, Rojo-Domínguez A, Ortiz-Mendoza CM, Guerrero-Aguirre J, García-Vázquez FJ, Hernández-Rivas R, Thompson-Bonilla MDR, Vargas M.",BMC Cancer. 2018 Nov 1;18(1):1056. doi: 10.1186/s12885-018-4968-3.,BMC Cancer.  2018,PubMed,citation,PMID:30382908 | PMCID:PMC6211466,pubmed,30382908,create date:2018/11/02 | first author:Cruz-Nova P
[Analyses of Relapsed Cases after Oxaliplatin-Based Adjuvant Chemotherapy for Colorectal Cancer with Cur A Resection].,/pubmed/30382064,"Yoshimatsu K, Satake M, Sano M, Kodera A, Imaizumi R, Ito Y, Koike T, Yokomizo H, Yano Y, Okayama S, Yamada Y, Asaka S, Usui T, Yamaguchi K, Shiozawa S, Shimakawa T, Katsube T, Naritaka Y.",Gan To Kagaku Ryoho. 2018 Oct;45(10):1519-1520. Japanese. ,Gan To Kagaku Ryoho.  2018,PubMed,citation,PMID:30382064,pubmed,30382064,create date:2018/11/02 | first author:Yoshimatsu K
Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG).,/pubmed/30366852,"Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group..",J Geriatr Oncol. 2019 Jan;10(1):143-148. doi: 10.1016/j.jgo.2018.08.002. Epub 2018 Oct 23.,J Geriatr Oncol.  2019,PubMed,citation,PMID:30366852,pubmed,30366852,create date:2018/10/28 | first author:Asimakopoulou N
"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.",/pubmed/30361170,"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.",Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668.  Lancet Oncol. 2018 Nov;19(11):e581. ,Lancet Oncol.  2018,PubMed,citation,PMID:30361170,pubmed,30361170,create date:2018/10/27 | first author:Hodi FS
Novel targeting approaches and signaling pathways of colorectal cancer: An insight.,/pubmed/30357011,"Tiwari A, Saraf S, Verma A, Panda PK, Jain SK.",World J Gastroenterol. 2018 Oct 21;24(39):4428-4435. doi: 10.3748/wjg.v24.i39.4428.,World J Gastroenterol.  2018,PubMed,citation,PMID:30357011 | PMCID:PMC6196338,pubmed,30357011,create date:2018/10/26 | first author:Tiwari A
Aspects of the Natural History of Sessile Serrated Adenomas/Polyps: Risk Indicators for Carcinogenesis in the Colorectal Mucosa?,/pubmed/30346367,"Neary PM, Schwartzberg DM, Bora Cengiz T, Kalady MF, Church JM.",Dis Colon Rectum. 2018 Dec;61(12):1380-1385. doi: 10.1097/DCR.0000000000001208.,Dis Colon Rectum.  2018,PubMed,citation,PMID:30346367,pubmed,30346367,create date:2018/10/23 | first author:Neary PM
Recent advances in understanding colorectal cancer.,/pubmed/30345013,Stintzing S.,F1000Res. 2018 Sep 24;7. pii: F1000 Faculty Rev-1528. doi: 10.12688/f1000research.14604.1. eCollection 2018. Review.,F1000Res.  2018,PubMed,citation,PMID:30345013 | PMCID:PMC6173127,pubmed,30345013,create date:2018/10/23 | first author:Stintzing S
"Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.",/pubmed/30339194,"Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J.",Ann Oncol. 2019 Jan 1;30(1):124-131. doi: 10.1093/annonc/mdy461.,Ann Oncol.  2019,PubMed,citation,PMID:30339194 | PMCID:PMC6336001,pubmed,30339194,create date:2018/10/20 | first author:Yoshino T
Lysines residing in putative Small Ubiquitin-like MOdifier (SUMO) motifs regulate fate and function of 37 KDa laminin receptor.,/pubmed/30315854,"Umbaugh CS, Figueiredo ML.",Biochimie. 2019 Jan;156:92-99. doi: 10.1016/j.biochi.2018.10.003. Epub 2018 Oct 10.,Biochimie.  2019,PubMed,citation,PMID:30315854,pubmed,30315854,create date:2018/10/14 | first author:Umbaugh CS
ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature.,/pubmed/30314823,"Mokhtar A, Arnason T, Gaston D, Huang WY, MacKenzie H, Al-Hazmi R, Vaninetti N, Tugwell B, Rayson D.",Clin Colorectal Cancer. 2019 Mar;18(1):e163-e170. doi: 10.1016/j.clcc.2018.07.013. Epub 2018 Aug 11. Review.,Clin Colorectal Cancer.  2019,PubMed,citation,PMID:30314823,pubmed,30314823,create date:2018/10/14 | first author:Mokhtar A
Molecular and presymptomatic analysis of a Moroccan Lynch syndrome family revealed a novel frameshift MLH1 germline mutation.,/pubmed/30289396,"Moufid FZ, Bouguenouch L, El Bouchikhi I, Houssaini MI, Ouldim K.",Turk J Gastroenterol. 2018 Nov;29(6):701-704. doi: 10.5152/tjg.2018.17761.,Turk J Gastroenterol.  2018,PubMed,citation,PMID:30289396 | PMCID:PMC6284679,pubmed,30289396,create date:2018/10/06 | first author:Moufid FZ
The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.,/pubmed/30276588,"Goffredo P, Utria AF, Beck AC, Chun YS, Howe JR, Weigel RJ, Vauthey JN, Hassan I.",J Gastrointest Surg. 2019 Oct;23(10):1957-1963. doi: 10.1007/s11605-018-3978-4. Epub 2018 Oct 1.,J Gastrointest Surg.  2019,PubMed,citation,PMID:30276588,pubmed,30276588,create date:2018/10/03 | first author:Goffredo P
Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.,/pubmed/30275242,"Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.",Mol Cancer Ther. 2018 Dec;17(12):2788-2795. doi: 10.1158/1535-7163.MCT-18-0694. Epub 2018 Oct 1.,Mol Cancer Ther.  2018,PubMed,citation,PMID:30275242,pubmed,30275242,create date:2018/10/03 | first author:Sunakawa Y
Mitochondrial DNA D‑loop lesions with the enhancement of DNA repair contribute to gastrointestinal cancer progression.,/pubmed/30272316,"Wang B, Qiao L, Wang Y, Zeng J, Chen D, Guo H, Zhang Y.",Oncol Rep. 2018 Dec;40(6):3694-3704. doi: 10.3892/or.2018.6724. Epub 2018 Sep 21.,Oncol Rep.  2018,PubMed,citation,PMID:30272316,pubmed,30272316,create date:2018/10/03 | first author:Wang B
"Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer.",/pubmed/30271205,"Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu Y, Zhu D, Chang W, Ji M, Ren L, Wei Y, He G, Xu J.",Cancer Manag Res. 2018 Sep 17;10:3569-3577. doi: 10.2147/CMAR.S171855. eCollection 2018.,Cancer Manag Res.  2018,PubMed,citation,PMID:30271205 | PMCID:PMC6149864,pubmed,30271205,create date:2018/10/03 | first author:Mao Y
"Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.",/pubmed/30268921,"Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL.",Eur J Cancer. 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27.,Eur J Cancer.  2018,PubMed,citation,PMID:30268921,pubmed,30268921,create date:2018/10/01 | first author:Salem ME
Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis.,/pubmed/30241526,"Ma YS, Huang T, Zhong XM, Zhang HW, Cong XL, Xu H, Lu GX, Yu F, Xue SB, Lv ZW, Fu D.",Mol Cancer. 2018 Sep 21;17(1):139. doi: 10.1186/s12943-018-0890-1. Erratum in: Mol Cancer. 2019 Apr 2;18(1):72. ,Mol Cancer.  2018,PubMed,citation,PMID:30241526 | PMCID:PMC6148962,pubmed,30241526,create date:2018/09/23 | first author:Ma YS
Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans.,/pubmed/30239619,"Xicola RM, Manojlovic Z, Augustus GJ, Kupfer SS, Emmadi R, Alagiozian-Angelova V, Triche T Jr, Salhia B, Carpten J, Llor X, Ellis NA.",Carcinogenesis. 2018 Dec 13;39(11):1331-1341. doi: 10.1093/carcin/bgy122.,Carcinogenesis.  2018,PubMed,citation,PMID:30239619 | PMCID:PMC6292413,pubmed,30239619,create date:2018/09/22 | first author:Xicola RM
Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.,/pubmed/30237525,"Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM.",Mod Pathol. 2019 Feb;32(2):290-305. doi: 10.1038/s41379-018-0131-6. Epub 2018 Sep 20.,Mod Pathol.  2019,PubMed,citation,PMID:30237525,pubmed,30237525,create date:2018/09/22 | first author:Shamir ER
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?,/pubmed/30230679,"Semira C, Wong HL, Field K, Lee M, Lee B, Nott L, Shapiro J, Wong R, Tie J, Tran B, Richardson G, Zimet A, Lipton L, Tamjid B, Burge M, Ma B, Johns J, Harold M, Gibbs P.",Intern Med J. 2019 Apr;49(4):446-454. doi: 10.1111/imj.14115.,Intern Med J.  2019,PubMed,citation,PMID:30230679,pubmed,30230679,create date:2018/09/20 | first author:Semira C
Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.,/pubmed/30228942,"Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F.",Oncoimmunology. 2018 Aug 1;7(9):e1474319. doi: 10.1080/2162402X.2018.1474319. eCollection 2018.,Oncoimmunology.  2018,PubMed,citation,PMID:30228942 | PMCID:PMC6140586,pubmed,30228942,create date:2018/09/20 | first author:Isambert N
Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis.,/pubmed/30214286,"Chen D, Wu YS, Lin H, Wang Y, Li L, Zhang T.",Cancer Manag Res. 2018 Aug 28;10:2915-2924. doi: 10.2147/CMAR.S174584. eCollection 2018.,Cancer Manag Res.  2018,PubMed,citation,PMID:30214286 | PMCID:PMC6118256,pubmed,30214286,create date:2018/09/15 | first author:Chen D
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.,/pubmed/30205948,"Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S.",Clin Colorectal Cancer. 2018 Dec;17(4):e699-e709. doi: 10.1016/j.clcc.2018.07.005. Epub 2018 Jul 17.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:30205948 | PMCID:PMC6588353,pubmed,30205948,create date:2018/09/13 | first author:Khan M
The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis.,/pubmed/30197280,"Péron J, Mercier F, Tuech JJ, Younan R, Sideris L, Gelli M, Dumont F, Le Roy B, Sgarbura O, Lo Dico R, Bibeau F, Glehen O, Passot G; on behalf BIG-RENAPE working groups..",Surgery. 2019 Feb;165(2):476-484. doi: 10.1016/j.surg.2018.07.027. Epub 2018 Sep 7.,Surgery.  2019,PubMed,citation,PMID:30197280,pubmed,30197280,create date:2018/09/11 | first author:Péron J
Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.,/pubmed/30194214,"Jordan F, Grundmann N, Schenkirsch G, Märkl B, Messmann H, Anthuber M, Schmid C, Trepel M.",Anticancer Res. 2018 Sep;38(9):5539-5546. doi: 10.21873/anticanres.12889.,Anticancer Res.  2018,PubMed,citation,PMID:30194214,pubmed,30194214,create date:2018/09/09 | first author:Jordan F
Prevalence and clinicopathological characteristics of mismatch repair-deficient colorectal carcinoma in early onset cases as compared with late-onset cases: a retrospective cross-sectional study in Northeastern Iran.,/pubmed/30166308,"Goshayeshi L, Ghaffarzadegan K, Khooei A, Esmaeilzadeh A, Rahmani Khorram M, Mosannen Mozaffari H, Kiani B, Hoseini B.",BMJ Open. 2018 Aug 30;8(8):e023102. doi: 10.1136/bmjopen-2018-023102.,BMJ Open.  2018,PubMed,citation,PMID:30166308 | PMCID:PMC6119423,pubmed,30166308,create date:2018/09/01 | first author:Goshayeshi L
"Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.",/pubmed/30145148,"Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A.",Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007. Epub 2018 Jul 25.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:30145148,pubmed,30145148,create date:2018/08/27 | first author:Noepel-Duennebacke S
[Li-Fraumeni syndrome in a patient with multiple anaplastic oligodendrogliomas of the brain (a case report and literature review)].,/pubmed/30137042,"Potapov AA, Abdilatipov AA, Okhlopkov VA, Gavrilov AG, Zakharova NE, Goryaynov SA, Kobyakov GL, Absalyamova OV, Kravchuk AD, Kulikov AS, Shugay SV, Nikitin PV, Batalov AI, Shelygin YA, Lyubchenko LN, Aliev MD, Spallone A.",Zh Vopr Neirokhir Im N N Burdenko. 2018;82(4):87-96. doi: 10.17116/neiro201882487. Review. Russian. ,Zh Vopr Neirokhir Im N N Burdenko.  2018,PubMed,citation,PMID:30137042,pubmed,30137042,create date:2018/08/24 | first author:Potapov AA
"Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.",/pubmed/30123970,"Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J.",Cancer Med. 2018 Nov;7(11):5382-5393. doi: 10.1002/cam4.1703. Epub 2018 Aug 19.,Cancer Med.  2018,PubMed,citation,PMID:30123970 | PMCID:PMC6246927,pubmed,30123970,create date:2018/08/21 | first author:Fogelman D
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?,/pubmed/30120156,"Loupakis F, Schirripa M, Intini R, Bergamo F, Bertorelle R, Fassan M, Dadduzio V, Merigliano S, Pilati P, Urso ELD, Cillo U, Rugge M, Lonardi S, Zagonel V.",Oncologist. 2019 Feb;24(2):e77-e79. doi: 10.1634/theoncologist.2018-0180. Epub 2018 Aug 17.,Oncologist.  2019,PubMed,citation,PMID:30120156 | PMCID:PMC6369947,pubmed,30120156,create date:2018/08/19 | first author:Loupakis F
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.,/pubmed/30118796,Roskoski R Jr.,Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15. Review.,Pharmacol Res.  2018,PubMed,citation,PMID:30118796,pubmed,30118796,create date:2018/08/18 | first author:Roskoski R Jr
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature.,/pubmed/30116425,"Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y.",Gastroenterology Res. 2018 Aug;11(4):264-273. doi: 10.14740/gr1062w. Epub 2018 Feb 8. Review.,Gastroenterology Res.  2018,PubMed,citation,PMID:30116425 | PMCID:PMC6089587,pubmed,30116425,create date:2018/08/18 | first author:Baran B
Association of Clinicopathologic and Molecular Markers on Stage-specific Survival of Right Versus Left Colon Cancer.,/pubmed/30108021,"Narayanan S, Gabriel E, Attwood K, Boland P, Nurkin S.",Clin Colorectal Cancer. 2018 Dec;17(4):e671-e678. doi: 10.1016/j.clcc.2018.07.001. Epub 2018 Jul 5.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:30108021,pubmed,30108021,create date:2018/08/16 | first author:Narayanan S
Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis.,/pubmed/30100734,"Jiang W, Yu Q, Ning R, Zhao W, Wei C.",Onco Targets Ther. 2018 Jul 24;11:4271-4281. doi: 10.2147/OTT.S168695. eCollection 2018.,Onco Targets Ther.  2018,PubMed,citation,PMID:30100734 | PMCID:PMC6065471,pubmed,30100734,create date:2018/08/14 | first author:Jiang W
POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.,/pubmed/30086056,"Rosner G, Gluck N, Carmi S, Bercovich D, Fliss-Issakov N, Ben-Yehoyada M, Aharon-Caspi S, Kellerman E, Strul H, Shibolet O, Kariv R.",Dis Colon Rectum. 2018 Sep;61(9):1073-1079. doi: 10.1097/DCR.0000000000001150.,Dis Colon Rectum.  2018,PubMed,citation,PMID:30086056,pubmed,30086056,create date:2018/08/08 | first author:Rosner G
"Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival.",/pubmed/30084064,"Lillemoe HA, Kawaguchi Y, Passot G, Karagkounis G, Simoneau E, You YN, Mehran RJ, Chun YS, Tzeng CD, Aloia TA, Vauthey JN.",J Gastrointest Surg. 2019 Jan;23(1):84-92. doi: 10.1007/s11605-018-3890-y. Epub 2018 Aug 6.,J Gastrointest Surg.  2019,PubMed,citation,PMID:30084064 | PMCID:PMC6329635,pubmed,30084064,create date:2018/08/08 | first author:Lillemoe HA
Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.,/pubmed/30073926,"Włodarczyk M, Włodarczyk J, Siwiński P, Sobolewska-Włodarczyk A, Fichna J.",Curr Drug Targets. 2018;19(15):1731-1737. doi: 10.2174/1389450119666180803122744. Review.,Curr Drug Targets.  2018,PubMed,citation,PMID:30073926,pubmed,30073926,create date:2018/08/04 | first author:Włodarczyk M
Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy.,/pubmed/30072744,"Sugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, Eguchi H, Masuda T, Morita M, Toh Y, Maehara Y, Suzuki Y, Mimori K.",Br J Cancer. 2018 Aug;119(4):419-423. doi: 10.1038/s41416-018-0208-5. Epub 2018 Aug 3.,Br J Cancer.  2018,PubMed,citation,PMID:30072744 | PMCID:PMC6134007,pubmed,30072744,create date:2018/08/04 | first author:Sugimachi K
"Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.",/pubmed/30071442,"Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Mehrvarz Sarshekeh A, Bressler J, Lopez DS, Daniel CR, Swartz MD, Kopetz S.",Transl Oncol. 2018 Oct;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. Epub 2018 Jul 30.,Transl Oncol.  2018,PubMed,citation,PMID:30071442 | PMCID:PMC6080640,pubmed,30071442,create date:2018/08/03 | first author:Advani SM
Vemurafenib.,/pubmed/30069761,"Garbe C, Eigentler TK.",Recent Results Cancer Res. 2018;211:77-89. doi: 10.1007/978-3-319-91442-8_6. Review.,Recent Results Cancer Res.  2018,PubMed,citation,PMID:30069761,pubmed,30069761,create date:2018/08/03 | first author:Garbe C
Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.,/pubmed/30061258,"Liu W, Zhang D, Tan SA, Liu X, Lai J.",Anticancer Res. 2018 Aug;38(8):4847-4852. doi: 10.21873/anticanres.12796.,Anticancer Res.  2018,PubMed,citation,PMID:30061258,pubmed,30061258,create date:2018/08/01 | first author:Liu W
In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant KRAS antigens.,/pubmed/30042874,"Ng AWR, Tan PJ, Hoo WPY, Liew DS, Teo MYM, Siak PY, Ng SM, Tan EW, Abdul Rahim R, Lim RLH, Song AAL, In LLA.",PeerJ. 2018 Jul 20;6:e5056. doi: 10.7717/peerj.5056. eCollection 2018.,PeerJ.  2018,PubMed,citation,PMID:30042874 | PMCID:PMC6055689,pubmed,30042874,create date:2018/07/26 | first author:Ng AWR
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.,/pubmed/30036739,"Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, Tannapfel A, Arnold D.",Eur J Cancer. 2018 Sep;101:105-113. doi: 10.1016/j.ejca.2018.06.015. Epub 2018 Jul 20.,Eur J Cancer.  2018,PubMed,citation,PMID:30036739,pubmed,30036739,create date:2018/07/24 | first author:Hegewisch-Becker S
Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression.,/pubmed/30036518,"Jang BG, Kim HS, Chang WY, Bae JM, Kim WH, Kang GH.",Am J Pathol. 2018 Oct;188(10):2236-2250. doi: 10.1016/j.ajpath.2018.06.012. Epub 2018 Jul 21.,Am J Pathol.  2018,PubMed,citation,PMID:30036518,pubmed,30036518,create date:2018/07/24 | first author:Jang BG
The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.,/pubmed/30035653,"Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D.",Acta Oncol. 2018 Nov;57(11):1438-1444. doi: 10.1080/0284186X.2018.1487581. Epub 2018 Jul 23.,Acta Oncol.  2018,PubMed,citation,PMID:30035653,pubmed,30035653,create date:2018/07/24 | first author:Prasanna T
"Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.",/pubmed/30013091,"Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S.",Br J Cancer. 2018 Aug;119(3):303-312. doi: 10.1038/s41416-018-0165-z. Epub 2018 Jul 17.,Br J Cancer.  2018,PubMed,citation,PMID:30013091 | PMCID:PMC6068172,pubmed,30013091,create date:2018/07/18 | first author:Peeters M
Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer.,/pubmed/30003239,"Salvatore L, Lombardo F, Tortora G.",JAMA Oncol. 2018 Sep 1;4(9):1297-1298. doi: 10.1001/jamaoncol.2018.1692. No abstract available. ,JAMA Oncol.  2018,PubMed,citation,PMID:30003239,pubmed,30003239,create date:2018/07/14 | first author:Salvatore L
Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer-Reply.,/pubmed/30003228,Taieb J.,JAMA Oncol. 2018 Sep 1;4(9):1298. doi: 10.1001/jamaoncol.2018.1718. No abstract available. ,JAMA Oncol.  2018,PubMed,citation,PMID:30003228,pubmed,30003228,create date:2018/07/14 | first author:Taieb J
Differences in gene mutations according to gender among patients with colorectal cancer.,/pubmed/29976257,"Tsai YJ, Huang SC, Lin HH, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Lin JK, Chang SC.",World J Surg Oncol. 2018 Jul 5;16(1):128. doi: 10.1186/s12957-018-1431-5.,World J Surg Oncol.  2018,PubMed,citation,PMID:29976257 | PMCID:PMC6034318,pubmed,29976257,create date:2018/07/07 | first author:Tsai YJ
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.,/pubmed/29958812,"Burge M, Semira C, Lee B, Lee M, Kosmider S, Wong R, Shapiro J, Ma B, Dean AP, Zimet AS, Steel SA, Lok SW, Torres J, Eastgate M, Wong HL, Gibbs P.",Clin Colorectal Cancer. 2018 Sep;17(3):e593-e599. doi: 10.1016/j.clcc.2018.05.009. Epub 2018 Jun 1.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:29958812,pubmed,29958812,create date:2018/07/01 | first author:Burge M
Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers.,/pubmed/29950348,"Din S, Wong K, Mueller MF, Oniscu A, Hewinson J, Black CJ, Miller ML, Jiménez-Sánchez A, Rabbie R, Rashid M, Satsangi J, Adams DJ, Arends MJ.",Clin Cancer Res. 2018 Oct 15;24(20):5133-5142. doi: 10.1158/1078-0432.CCR-17-3713. Epub 2018 Jun 27.,Clin Cancer Res.  2018,PubMed,citation,PMID:29950348 | PMCID:PMC6193541,pubmed,29950348,create date:2018/06/29 | first author:Din S
Brain metastases in colorectal cancer: prognostic factors and survival analysis.,/pubmed/29943356,"Del Carpio Huerta L, Virgili Manrique AC, Szafranska J, Martin-Richard M, Paez Lopez-Bravo D, Sebio Garcia A, Espinosa Mariscal I, Gomila Pons P, Andres Granyo M, Barba Joaquin A, Barnadas Molins A, Tobeña Puyal M.",Int J Colorectal Dis. 2018 Nov;33(11):1517-1523. doi: 10.1007/s00384-018-3107-6. Epub 2018 Jun 25.,Int J Colorectal Dis.  2018,PubMed,citation,PMID:29943356,pubmed,29943356,create date:2018/06/27 | first author:Del Carpio Huerta L
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.,/pubmed/29936065,"Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, et al.",Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.,Eur J Cancer.  2018,PubMed,citation,PMID:29936065,pubmed,29936065,create date:2018/06/25 | first author:Goey KKH
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.,/pubmed/29921730,"Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators..",Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.,Clin Cancer Res.  2018,PubMed,citation,PMID:29921730,pubmed,29921730,create date:2018/06/21 | first author:Gallois C
Anatomy of the Right Anterior Sector of the Liver and Its Clinical Implications in Surgery.,/pubmed/29916108,"Cazauran JB, Pâris L, Rousset P, Mercier F, Kepenekian V, Viste A, Passot G.",J Gastrointest Surg. 2018 Oct;22(10):1819-1831. doi: 10.1007/s11605-018-3831-9. Epub 2018 Jun 18. Review.,J Gastrointest Surg.  2018,PubMed,citation,PMID:29916108,pubmed,29916108,create date:2018/06/20 | first author:Cazauran JB
Colorectal cancer genomics and designing rational trials.,/pubmed/29911107,"Mondaca S, Yaeger R.",Ann Transl Med. 2018 May;6(9):159. doi: 10.21037/atm.2018.03.27. Review.,Ann Transl Med.  2018,PubMed,citation,PMID:29911107 | PMCID:PMC5985274,pubmed,29911107,create date:2018/06/19 | first author:Mondaca S
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.,/pubmed/29897402,"Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.",Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print],Ann Oncol.  2018,PubMed,citation,PMID:29897402,pubmed,29897402,create date:2018/06/14 | first author:Cremolini C
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.,/pubmed/29873679,"Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.",Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print],Ann Oncol.  2018,PubMed,citation,PMID:29873679,pubmed,29873679,create date:2018/06/07 | first author:Cremolini C
Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer.,/pubmed/29869121,"Cheng HH, Lin JK, Chen WS, Jiang JK, Yang SH, Chang SC.",Int J Colorectal Dis. 2018 Sep;33(9):1173-1181. doi: 10.1007/s00384-018-3095-6. Epub 2018 Jun 4.,Int J Colorectal Dis.  2018,PubMed,citation,PMID:29869121,pubmed,29869121,create date:2018/06/06 | first author:Cheng HH
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.,/pubmed/29855806,"Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G.",Med Oncol. 2018 May 31;35(7):101. doi: 10.1007/s12032-018-1160-1.,Med Oncol.  2018,PubMed,citation,PMID:29855806,pubmed,29855806,create date:2018/06/02 | first author:Papaxoinis G
Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.,/pubmed/29844874,"Sayagués JM, Del Carmen S, Del Mar Abad M, Corchete LA, Bengoechea O, Anduaga MF, Baldeón MJ, Cruz JJ, Alcazar JA, Angoso M, González M, García J, Muñoz-Bellvis L, Orfao A, Sarasquete ME.",Oncotarget. 2018 May 8;9(35):24081-24096. doi: 10.18632/oncotarget.25300. eCollection 2018 May 8.,Oncotarget.  2018,PubMed,citation,PMID:29844874 | PMCID:PMC5963609,pubmed,29844874,create date:2018/05/31 | first author:Sayagués JM
Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing.,/pubmed/29844865,"Oliveira DM, Laudanna C, Migliozzi S, Zoppoli P, Santamaria G, Grillone K, Elia L, Mignogna C, Biamonte F, Sacco R, Corcione F, Viglietto G, Malanga D, Rizzuto A.",Oncotarget. 2018 May 8;9(35):23960-23974. doi: 10.18632/oncotarget.25251. eCollection 2018 May 8.,Oncotarget.  2018,PubMed,citation,PMID:29844865 | PMCID:PMC5963617,pubmed,29844865,create date:2018/05/31 | first author:Oliveira DM
Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.,/pubmed/29842994,"Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, Foekens JA, Sleijfer S, Martens JWM.",Neoplasia. 2018 Jul;20(7):687-696. doi: 10.1016/j.neo.2018.05.003. Epub 2018 May 26.,Neoplasia.  2018,PubMed,citation,PMID:29842994 | PMCID:PMC6030393,pubmed,29842994,create date:2018/05/31 | first author:Weerts MJA
The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.,/pubmed/29805705,"Kim ST, Kim HK, Lee J, Park SH, Lim HY, Park YS, Kang WK, Park JO.",J Cancer. 2018 Apr 19;9(10):1791-1796. doi: 10.7150/jca.25132. eCollection 2018.,J Cancer.  2018,PubMed,citation,PMID:29805705 | PMCID:PMC5968767,pubmed,29805705,create date:2018/05/29 | first author:Kim ST
Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.,/pubmed/29802524,"Gil-Raga M, Jantus-Lewintre E, Gallach S, Giner-Bosch V, Frangi-Caregnato A, Safont-Aguilera MJ, Garde-Noguera J, Zorraquino-Pina E, García-Martínez M, Camps-Herrero C.",Clin Transl Oncol. 2018 Nov;20(11):1422-1429. doi: 10.1007/s12094-018-1874-8. Epub 2018 May 25.,Clin Transl Oncol.  2018,PubMed,citation,PMID:29802524,pubmed,29802524,create date:2018/05/29 | first author:Gil-Raga M
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.,/pubmed/29799910,"Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, et al.",JAMA Surg. 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996. Epub 2018 Jul 18.,JAMA Surg.  2018,PubMed,citation,PMID:29799910 | PMCID:PMC6137519,pubmed,29799910,create date:2018/05/26 | first author:Margonis GA
Right Versus Left Colon Cancer: Resectable and Metastatic Disease.,/pubmed/29796712,"Ghidini M, Petrelli F, Tomasello G.",Curr Treat Options Oncol. 2018 May 23;19(6):31. doi: 10.1007/s11864-018-0544-y. Review.,Curr Treat Options Oncol.  2018,PubMed,citation,PMID:29796712,pubmed,29796712,create date:2018/05/26 | first author:Ghidini M
Colorectal Liver Metastases: A Pathologist's Guide to Creating an Informative Report and Improving Patient Care.,/pubmed/29790787,"Moreno Prats M, Sasatomi E, Stevenson HL.",Arch Pathol Lab Med. 2019 Feb;143(2):251-257. doi: 10.5858/arpa.2017-0505-RA. Epub 2018 May 23.,Arch Pathol Lab Med.  2019,PubMed,citation,PMID:29790787,pubmed,29790787,create date:2018/05/24 | first author:Moreno Prats M
Colorectal Cancer: Why Does Side Matter?,/pubmed/29790124,"Gallois C, Pernot S, Zaanan A, Taieb J.",Drugs. 2018 Jun;78(8):789-798. doi: 10.1007/s40265-018-0921-7. Review.,Drugs.  2018,PubMed,citation,PMID:29790124,pubmed,29790124,create date:2018/05/24 | first author:Gallois C
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.,/pubmed/29784738,"Grothey A, Venook AP.",J Natl Compr Canc Netw. 2018 May;16(5S):611-615. doi: 10.6004/jnccn.2018.0038.,J Natl Compr Canc Netw.  2018,PubMed,citation,PMID:29784738,pubmed,29784738,create date:2018/05/23 | first author:Grothey A
Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers.,/pubmed/29784668,"Remo A, Manfrin E, Parcesepe P, Ferrarini A, Han HS, Mickys U, Laudanna C, Simbolo M, Malanga D, Oliveira DM, Baritono E, Colangelo T, Sabatino L, Giuliani J, Molinari E, Garonzi M, Xumerle L, Delledonne M, Giordano G, Ghimenton C, Lonardo F, D'angelo F, et al.",Mol Cancer Res. 2018 Sep;16(9):1385-1395. doi: 10.1158/1541-7786.MCR-18-0062. Epub 2018 May 21.,Mol Cancer Res.  2018,PubMed,citation,PMID:29784668,pubmed,29784668,create date:2018/05/23 | first author:Remo A
First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.,/pubmed/29773991,"Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A.",Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.,Front Pharmacol.  2018,PubMed,citation,PMID:29773991 | PMCID:PMC5943532,pubmed,29773991,create date:2018/05/19 | first author:Ottaiano A
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.,/pubmed/29771009,"Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.",Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print],Cancer Med.  2018,PubMed,citation,PMID:29771009 | PMCID:PMC6051212,pubmed,29771009,create date:2018/05/18 | first author:Kamran SC
Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients.,/pubmed/29767751,"Natsume S, Yamaguchi T, Takao M, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Horiguchi SI, Koizumi K, Miyaki M.",Jpn J Clin Oncol. 2018 Jul 1;48(7):609-618. doi: 10.1093/jjco/hyy069.,Jpn J Clin Oncol.  2018,PubMed,citation,PMID:29767751,pubmed,29767751,create date:2018/05/17 | first author:Natsume S
Spatial mutation patterns as markers of early colorectal tumor cell mobility.,/pubmed/29760052,"Ryser MD, Min BH, Siegmund KD, Shibata D.",Proc Natl Acad Sci U S A. 2018 May 29;115(22):5774-5779. doi: 10.1073/pnas.1716552115. Epub 2018 May 14.,Proc Natl Acad Sci U S A.  2018,PubMed,citation,PMID:29760052 | PMCID:PMC5984490,pubmed,29760052,create date:2018/05/16 | first author:Ryser MD
Promising New Agents for Colorectal Cancer.,/pubmed/29752549,"Das S, Ciombor KK, Haraldsdottir S, Goldberg RM.",Curr Treat Options Oncol. 2018 May 11;19(6):29. doi: 10.1007/s11864-018-0543-z. Review.,Curr Treat Options Oncol.  2018,PubMed,citation,PMID:29752549 | PMCID:PMC6499928,pubmed,29752549,create date:2018/05/13 | first author:Das S
An unusual finding in a desmoid-type fibromatosis of the pancreas: a case report and review of the literature.,/pubmed/29751773,"Torres JC, Xin C.",J Med Case Rep. 2018 May 12;12(1):123. doi: 10.1186/s13256-018-1635-x. Review.,J Med Case Rep.  2018,PubMed,citation,PMID:29751773 | PMCID:PMC5948877,pubmed,29751773,create date:2018/05/13 | first author:Torres JC
Site-specific use of molecular markers could be a promising prognostic tool in colorectal cancer.,/pubmed/29745066,"Papagiorgis P, Zizi-Sermbetzoglou A, Chaniotis D, Thalassinos N, Tziakou P.",J BUON. 2018 Mar-Apr;23(2):286-289. Review.,J BUON.  2018,PubMed,citation,PMID:29745066,pubmed,29745066,create date:2018/05/11 | first author:Papagiorgis P
Predictive factors of synchronous colorectal peritoneal metastases: Development of a nomogram and study of its utilities using decision curve analysis.,/pubmed/29730071,"Mo S, Dai W, Xiang W, Li Q, Wang R, Cai G.",Int J Surg. 2018 Jun;54(Pt A):149-155. doi: 10.1016/j.ijsu.2018.04.051. Epub 2018 May 3.,Int J Surg.  2018,PubMed,citation,PMID:29730071,pubmed,29730071,create date:2018/05/08 | first author:Mo S
First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials.,/pubmed/31579770,"Vogel A, Kirstein MM.",Innov Surg Sci. 2018 May 7;3(2):85-86. doi: 10.1515/iss-2018-0012. eCollection 2018 Jun. Review.,Innov Surg Sci.  2018,PubMed,citation,PMID:31579770 | PMCID:PMC6604573,pubmed,31579770,create date:2018/05/07 | first author:Vogel A
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.,/pubmed/29721163,"Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.","Oncotarget. 2018 Apr 10;9(27):18811-18820. doi: 10.18632/oncotarget.24702. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 Jul 6;9(52):30023. Ichikawa, Wararu [corrected to Ichikawa, Wataru]. ",Oncotarget.  2018,PubMed,citation,PMID:29721163 | PMCID:PMC5922357,pubmed,29721163,create date:2018/05/04 | first author:Satake H
A20 regulates canonical wnt-signaling through an interaction with RIPK4.,/pubmed/29718933,"Nakamura BN, Glazier A, Kattah MG, Duong B, Jia Y, Campo D, Shao L.",PLoS One. 2018 May 2;13(5):e0195893. doi: 10.1371/journal.pone.0195893. eCollection 2018.,PLoS One.  2018,PubMed,citation,PMID:29718933 | PMCID:PMC5931457,pubmed,29718933,create date:2018/05/03 | first author:Nakamura BN
Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.,/pubmed/29706374,"Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A.",Lancet Oncol. 2018 Jun;19(6):758-767. doi: 10.1016/S1470-2045(18)30188-8. Epub 2018 Apr 26.,Lancet Oncol.  2018,PubMed,citation,PMID:29706374,pubmed,29706374,create date:2018/05/01 | first author:Yamada A
Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.,/pubmed/29705968,"Wang Y, Liu H, Hou Y, Zhou X, Liang L, Zhang Z, Shi H, Xu S, Hu P, Zheng Z, Liu R, Tang T, Ye F, Liang Z, Bu H.",Virchows Arch. 2018 Jun;472(6):959-968. doi: 10.1007/s00428-018-2359-4. Epub 2018 Apr 28.,Virchows Arch.  2018,PubMed,citation,PMID:29705968,pubmed,29705968,create date:2018/05/01 | first author:Wang Y
The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.,/pubmed/29675807,"Neumann J, Heinemann V, Engel J, Kirchner T, Stintzing S.",Virchows Arch. 2018 Aug;473(2):199-207. doi: 10.1007/s00428-018-2360-y. Epub 2018 Apr 19.,Virchows Arch.  2018,PubMed,citation,PMID:29675807,pubmed,29675807,create date:2018/04/21 | first author:Neumann J
Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles.,/pubmed/29662660,"Mori Y, Nyuya A, Yasui K, Toshima T, Kawai T, Taniguchi F, Kimura K, Inada R, Nishizaki M, Haraga J, Nakamura K, Umeda Y, Kishimoto H, Fujiwara T, Katata Y, Yamaguchi Y, Nagasaka T.",Oncotarget. 2018 Mar 27;9(23):16477-16488. doi: 10.18632/oncotarget.24735. eCollection 2018 Mar 27.,Oncotarget.  2018,PubMed,citation,PMID:29662660 | PMCID:PMC5893255,pubmed,29662660,create date:2018/04/18 | first author:Mori Y
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.,/pubmed/29650279,"Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P.",Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9. Review.,Crit Rev Oncol Hematol.  2018,PubMed,citation,PMID:29650279,pubmed,29650279,create date:2018/04/14 | first author:Ciliberto D
Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma.,/pubmed/29643917,"Liu J, Zeng W, Huang C, Wang J, Yang D, Ma D.",Gastroenterol Res Pract. 2018 Jan 31;2018:4585802. doi: 10.1155/2018/4585802. eCollection 2018.,Gastroenterol Res Pract.  2018,PubMed,citation,PMID:29643917 | PMCID:PMC5831938,pubmed,29643917,create date:2018/04/13 | first author:Liu J
Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.,/pubmed/29632645,"Brandariz L, Arriba M, García JL, Cano JM, Rueda D, Rubio E, Rodríguez Y, Pérez J, Vivas A, Sánchez C, Tapial S, Pena L, García-Arranz M, García-Olmo D, Urioste M, González-Sarmiento R, Perea J.",Oncotarget. 2018 Feb 15;9(20):15302-15311. doi: 10.18632/oncotarget.24502. eCollection 2018 Mar 16.,Oncotarget.  2018,PubMed,citation,PMID:29632645 | PMCID:PMC5880605,pubmed,29632645,create date:2018/04/11 | first author:Brandariz L
Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.,/pubmed/29627309,"Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M.",Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:29627309,pubmed,29627309,create date:2018/04/09 | first author:Boeckx N
Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/β-catenin signaling pathways.,/pubmed/29621572,"Jamwal G, Singh G, Dar MS, Singh P, Bano N, Syed SH, Sandhu P, Akhter Y, Monga SP, Dar MJ.",Biochim Biophys Acta Mol Cell Res. 2018 Jun;1865(6):920-931. doi: 10.1016/j.bbamcr.2018.03.013. Epub 2018 Apr 3.,Biochim Biophys Acta Mol Cell Res.  2018,PubMed,citation,PMID:29621572,pubmed,29621572,create date:2018/04/06 | first author:Jamwal G
Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?,/pubmed/29611198,"Marques MC, C Ribeiro HS, Costa WL Jr, de Jesus VHF, de Macedo MP, Diniz AL, Godoy AL, Farias IC, Aguiar S Jr, Riechelmann RSP, S Begnami MDF, Coimbra FJF.",J Surg Oncol. 2018 Apr;117(5):858-863. doi: 10.1002/jso.25048. Epub 2018 Apr 2.,J Surg Oncol.  2018,PubMed,citation,PMID:29611198,pubmed,29611198,create date:2018/04/04 | first author:Marques MC
Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.,/pubmed/29595113,"Snyder M, Bottiglieri S, Almhanna K.",Rev Recent Clin Trials. 2018;13(2):139-149. doi: 10.2174/1574887113666180328104109.,Rev Recent Clin Trials.  2018,PubMed,citation,PMID:29595113,pubmed,29595113,create date:2018/03/30 | first author:Snyder M
Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis.,/pubmed/29592868,"Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P, Vanoli A, Tagliabue G, Pisa E, Messerini L, Centonze G, Inzani F, Scarpa A, Papotti M, Volante M, Sessa F, Fazio N, Pruneri G, Rindi G, Solcia E, La Rosa S, Capella C.",Endocr Relat Cancer. 2018 May;25(5):583-593. doi: 10.1530/ERC-17-0557. Epub 2018 Mar 28.,Endocr Relat Cancer.  2018,PubMed,citation,PMID:29592868,pubmed,29592868,create date:2018/03/30 | first author:Milione M
The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis.,/pubmed/29580735,"Wang K, Xu D, Yan XL, Poston G, Xing BC.",Eur J Surg Oncol. 2018 Jun;44(6):771-777. doi: 10.1016/j.ejso.2018.02.210. Epub 2018 Mar 2.,Eur J Surg Oncol.  2018,PubMed,citation,PMID:29580735,pubmed,29580735,create date:2018/03/28 | first author:Wang K
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?,/pubmed/29580164,"Baretti M, Personeni N, Destro A, Santoro A, Rimassa L.",Cancer Biol Ther. 2018 Aug 3;19(8):659-663. doi: 10.1080/15384047.2018.1450117. Epub 2018 Apr 13.,Cancer Biol Ther.  2018,PubMed,citation,PMID:29580164 | PMCID:PMC6067891,pubmed,29580164,create date:2018/03/28 | first author:Baretti M
A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer.,/pubmed/29568913,"Matsuhashi N, Takahashi T, Matsui S, Tanahashi T, Imai H, Tanaka Y, Yamaguchi K, Yoshida K.",Int J Oncol. 2018 Mar 16. doi: 10.3892/ijo.2018.4322. [Epub ahead of print],Int J Oncol.  2018,PubMed,citation,PMID:29568913 | PMCID:PMC5873832,pubmed,29568913,create date:2018/03/24 | first author:Matsuhashi N
"Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.",/pubmed/29556349,"Li X, Yang T, Li CS, Song Y, Lou H, Guan D, Jin L.",Theranostics. 2018 Feb 12;8(6):1678-1689. doi: 10.7150/thno.22502. eCollection 2018.,Theranostics.  2018,PubMed,citation,PMID:29556349 | PMCID:PMC5858175,pubmed,29556349,create date:2018/03/21 | first author:Li X
GAEC1 mutations and copy number aberration is associated with biological aggressiveness of colorectal cancer.,/pubmed/29555101,"Lee KT, Gopalan V, Islam F, Wahab R, Mamoori A, Lu CT, Smith RA, Lam AK.",Eur J Cell Biol. 2018 Apr;97(3):230-241. doi: 10.1016/j.ejcb.2018.03.002. Epub 2018 Mar 13.,Eur J Cell Biol.  2018,PubMed,citation,PMID:29555101,pubmed,29555101,create date:2018/03/21 | first author:Lee KT
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.,/pubmed/29538669,"Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, et al.",Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090.,Ann Oncol.  2018,PubMed,citation,PMID:29538669,pubmed,29538669,create date:2018/03/15 | first author:Pietrantonio F
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.,/pubmed/29531837,"Peeters M, Forget F, Karthaus M, Valladares-Ayerbes M, Zaniboni A, Demonty G, Guan X, Rivera F.",ESMO Open. 2018 Feb 24;3(2):e000297. doi: 10.1136/esmoopen-2017-000297. eCollection 2018.,ESMO Open.  2018,PubMed,citation,PMID:29531837 | PMCID:PMC5844379,pubmed,29531837,create date:2018/03/14 | first author:Peeters M
Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.,/pubmed/29526493,"Wiesweg M, Reis H, Köster T, Goetz M, Worm K, Herold T, Paul A, Dechêne A, Schumacher B, Markus P, Virchow I, Kostbade K, Wolf N, Zaun G, Metzenmacher M, Schmid KW, Schuler M, Kasper S.",Clin Colorectal Cancer. 2018 Jun;17(2):e331-e352. doi: 10.1016/j.clcc.2018.02.003. Epub 2018 Feb 17.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:29526493,pubmed,29526493,create date:2018/03/13 | first author:Wiesweg M
"Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.",/pubmed/29523759,"Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ.",Mol Cancer Res. 2018 May;16(5):805-812. doi: 10.1158/1541-7786.MCR-17-0735. Epub 2018 Mar 9.,Mol Cancer Res.  2018,PubMed,citation,PMID:29523759 | PMCID:PMC6833953,pubmed,29523759,create date:2018/03/11 | first author:Salem ME
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.,/pubmed/29517682,"Chen D, Li L, Zhang X, Gao G, Shen L, Hu J, Yang M, Liu B, Qian X.",Medicine (Baltimore). 2018 Mar;97(10):e0097. doi: 10.1097/MD.0000000000010097. Review.,Medicine (Baltimore).  2018,PubMed,citation,PMID:29517682 | PMCID:PMC5882422,pubmed,29517682,create date:2018/03/09 | first author:Chen D
Do FHIT gene alterations play a role in human solid tumors?,/pubmed/29516675,"Silveira Zavalhia L, Weber Medeiros A, Oliveira Silva A, Vial Roehe A.",Asia Pac J Clin Oncol. 2018 Oct;14(5):e214-e223. doi: 10.1111/ajco.12868. Epub 2018 Mar 8. Review.,Asia Pac J Clin Oncol.  2018,PubMed,citation,PMID:29516675,pubmed,29516675,create date:2018/03/09 | first author:Silveira Zavalhia L
LRP1 expression in colon cancer predicts clinical outcome.,/pubmed/29507659,"Boulagnon-Rombi C, Schneider C, Leandri C, Jeanne A, Grybek V, Bressenot AM, Barbe C, Marquet B, Nasri S, Coquelet C, Fichel C, Bouland N, Bonnomet A, Kianmanesh R, Lebre AS, Bouché O, Diebold MD, Bellon G, Dedieu S.",Oncotarget. 2018 Jan 13;9(10):8849-8869. doi: 10.18632/oncotarget.24225. eCollection 2018 Feb 6.,Oncotarget.  2018,PubMed,citation,PMID:29507659 | PMCID:PMC5823651,pubmed,29507659,create date:2018/03/07 | first author:Boulagnon-Rombi C
Systemic Therapy for Colon Cancer.,/pubmed/29496087,Wu C.,Surg Oncol Clin N Am. 2018 Apr;27(2):235-242. doi: 10.1016/j.soc.2017.11.001. Epub 2017 Dec 16. Review.,Surg Oncol Clin N Am.  2018,PubMed,citation,PMID:29496087,pubmed,29496087,create date:2018/03/03 | first author:Wu C
[A Case of Surgery after Chemotherapy for Cecal Cancer with Onset of the Stenosis of the Colostomy].,/pubmed/29483445,"Kono T, Yokomizo H, Yano Y, Okayama S, Satake M, Yamada Y, Ida A, Usui T, Yamaguchi K, Shiozawa S, Yoshimatsu K, Shimakawa T, Katsube T, Kato H, Naritaka Y.",Gan To Kagaku Ryoho. 2018 Feb;45(2):353-355. Japanese. ,Gan To Kagaku Ryoho.  2018,PubMed,citation,PMID:29483445,pubmed,29483445,create date:2018/02/28 | first author:Kono T
Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer.,/pubmed/29435051,"Bai B, Shan L, Xie B, Huang X, Mao W, Wang X, Wang D, Zhu H.",Oncol Lett. 2018 Mar;15(3):3161-3166. doi: 10.3892/ol.2017.7709. Epub 2017 Dec 28.,Oncol Lett.  2018,PubMed,citation,PMID:29435051 | PMCID:PMC5778842,pubmed,29435051,create date:2018/02/13 | first author:Bai B
"Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study.",/pubmed/29433905,"Rosati G, Pinto C, Di Fabio F, Chiara S, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrara R, Antonuzzo L, Adua D, Racca P, Bilancia D, Benincasa E, Stroppolo ME, Di Costanzo F.",J Geriatr Oncol. 2018 May;9(3):243-248. doi: 10.1016/j.jgo.2018.01.009. Epub 2018 Feb 9.,J Geriatr Oncol.  2018,PubMed,citation,PMID:29433905,pubmed,29433905,create date:2018/02/13 | first author:Rosati G
Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China.,/pubmed/29423347,"Zhang X, Ran W, Wu J, Li H, Liu H, Wang L, Xiao Y, Wang X, Li Y, Xing X.",PeerJ. 2018 Feb 5;6:e4341. doi: 10.7717/peerj.4341. eCollection 2018.,PeerJ.  2018,PubMed,citation,PMID:29423347 | PMCID:PMC5804321,pubmed,29423347,create date:2018/02/10 | first author:Zhang X
[A Case of Locally Advanced Rectal Cancer with Abscess and Rectovesical Fistula Curatively Resected Following Preoperative Chemotherapy].,/pubmed/29394675,"Matsumoto T, Nakanishi M, Miyamae M, Takao K, Fukunaga T, Otsuji E.",Gan To Kagaku Ryoho. 2017 Nov;44(12):1482-1484. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:29394675,pubmed,29394675,create date:2018/02/06 | first author:Matsumoto T
[The Characteristics and Treatment Outcomes for Desmoid Tumors Associated with Familial Adenomatous Polyposis].,/pubmed/29394664,"Amano K, Chika N, Ito T, Yamamoto A, Hatano S, Ishiguro T, Fukuchi M, Kumagai Y, Ishibashi K, Mochiki E, Iwama T, Eguchi H, Okazaki K, Inokuma S, Ishida H.",Gan To Kagaku Ryoho. 2017 Nov;44(12):1449-1451. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:29394664,pubmed,29394664,create date:2018/02/06 | first author:Amano K
[Case Report of Long-Term Survival for Stage IV Advanced Sigmoid Colon Cancer with Para-Aortic Nodes by R0 Resection and Chemotherapy].,/pubmed/29394654,"Akai M, Otsuka S, Yasui Y, Isoda K, Hamano R, Tokunaga N, Takahashi K, Miyaso H, Tsunemitsu Y, Iwakawa K, Inagaki M, Iwagaki H.",Gan To Kagaku Ryoho. 2017 Nov;44(12):1420-1422. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:29394654,pubmed,29394654,create date:2018/02/06 | first author:Akai M
[A Case of Advanced Sigmoid Colon Cancer Successfully Resected via Laparoscopic Surgery after Preoperative Chemotherapy].,/pubmed/29394642,"Nonaka R, Adachi K, Moon JH, Fujie Y, Hashimoto K, Fujita S, Ohnishi T.",Gan To Kagaku Ryoho. 2017 Nov;44(12):1385-1387. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:29394642,pubmed,29394642,create date:2018/02/06 | first author:Nonaka R
[A Case of Sigmoid Colon Cancer with Distant Metastasis Successfully Treated with First-Line Cetuximab Monotherapy].,/pubmed/29394569,"Kuwahara R, Kagawa Y, Lshida T, Akiyama Y, Sakamoto T, Naito A, Murakami K, Katsura Y, Ohmura Y, Takeno A, Takeda Y, Kato T, Tamura S.",Gan To Kagaku Ryoho. 2017 Nov;44(12):1167-1169. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:29394569,pubmed,29394569,create date:2018/02/06 | first author:Kuwahara R
[A Case of Ascending Colon Cancer with Synchronous Liver Metastases and Peritoneal Dissemination].,/pubmed/29394555,"Mito M, Kameyama H, Shimada Y, Yamada S, Hotta S, Hirose Y, Yagi R, Tajima Y, Nakano M, Okamura T, Nakano M, Ichikawa H, Nagahashi M, Sakata J, Wakai T.",Gan To Kagaku Ryoho. 2017 Nov;44(12):1126-1128. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:29394555,pubmed,29394555,create date:2018/02/06 | first author:Mito M
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.,/pubmed/29391418,"Hsieh MC, Wu CF, Chen CW, Shi CS, Huang WS, Kuan FC.",Sci Rep. 2018 Feb 1;8(1):2047. doi: 10.1038/s41598-018-19835-8. Review.,Sci Rep.  2018,PubMed,citation,PMID:29391418 | PMCID:PMC5794997,pubmed,29391418,create date:2018/02/03 | first author:Hsieh MC
"Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.",/pubmed/29380640,"Christensen TD, Palshof JA, Larsen FO, Poulsen TS, Høgdall E, Pfeiffer P, Jensen BV, Yilmaz MK, Nielsen D.",Acta Oncol. 2018 Aug;57(8):1057-1062. doi: 10.1080/0284186X.2018.1433322. Epub 2018 Jan 30.,Acta Oncol.  2018,PubMed,citation,PMID:29380640,pubmed,29380640,create date:2018/01/31 | first author:Christensen TD
DPYD genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from Slovakia.,/pubmed/29372689,"Matáková T, Halašová E, Škovierová H, Dzian A, Dobrota D, Škereňová M.",Gen Physiol Biophys. 2017 Dec;36(5):557-563. doi: 10.4149/gpb_2017046.,Gen Physiol Biophys.  2017,PubMed,citation,PMID:29372689,pubmed,29372689,create date:2018/01/27 | first author:Matáková T
"ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.",/pubmed/29370427,"Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, et al.",J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.,J Natl Cancer Inst.  2017,PubMed,citation,PMID:29370427,pubmed,29370427,create date:2018/01/26 | first author:Pietrantonio F
The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel.,/pubmed/29366338,"Zheng J, Huang B, Nie X, Zhu Y, Han N, Li Y.",Future Oncol. 2018 Jun;14(14):1355-1364. doi: 10.2217/fon-2017-0662. Epub 2018 Jan 25.,Future Oncol.  2018,PubMed,citation,PMID:29366338,pubmed,29366338,create date:2018/01/26 | first author:Zheng J
Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry.,/pubmed/29336605,"Alpert L, Pai RK, Srivastava A, McKinnon W, Wilcox R, Yantiss RK, Arcega R, Wang HL, Robert ME, Liu X, Pai RK, Zhao L, Westerhoff M, Hampel H, Kupfer S, Setia N, Xiao SY, Hart J, Frankel WL.",Arch Pathol Lab Med. 2018 Apr;142(4):523-528. doi: 10.5858/arpa.2017-0156-OA. Epub 2018 Jan 16.,Arch Pathol Lab Med.  2018,PubMed,citation,PMID:29336605,pubmed,29336605,create date:2018/01/18 | first author:Alpert L
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.,/pubmed/29316426,"Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, You D, Viale A, Kemeny N, Segal NH, Stadler ZK, Varghese AM, Kundra R, Gao J, Syed A, Hyman DM, Vakiani E, Rosen N, et al.",Cancer Cell. 2018 Jan 8;33(1):125-136.e3. doi: 10.1016/j.ccell.2017.12.004.,Cancer Cell.  2018,PubMed,citation,PMID:29316426 | PMCID:PMC5765991,pubmed,29316426,create date:2018/01/10 | first author:Yaeger R
Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.,/pubmed/29302856,"Artaç M, Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS.",J Gastrointest Cancer. 2019 Jun;50(2):214-220. doi: 10.1007/s12029-017-0047-2.,J Gastrointest Cancer.  2019,PubMed,citation,PMID:29302856,pubmed,29302856,create date:2018/01/06 | first author:Artaç M
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).,/pubmed/29298682,"Huemer F, Thaler J, Piringer G, Hackl H, Pleyer L, Hufnagl C, Weiss L, Greil R.",BMC Cancer. 2018 Jan 3;18(1):11. doi: 10.1186/s12885-017-3955-4.,BMC Cancer.  2018,PubMed,citation,PMID:29298682 | PMCID:PMC5753540,pubmed,29298682,create date:2018/01/05 | first author:Huemer F
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).,/pubmed/29285289,"Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Holch JW, von Einem JC, Held S, Heinemann V.",Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.,Oncotarget.  2017,PubMed,citation,PMID:29285289 | PMCID:PMC5739676,pubmed,29285289,create date:2017/12/30 | first author:Modest DP
Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer.,/pubmed/29282362,"Riera P, Virgili AC, Salazar J, Sebio A, Tobeña M, Sullivan I, Páez D.",Pharmacogenomics J. 2018 Jul;18(4):556-564. doi: 10.1038/s41397-017-0009-x. Epub 2017 Dec 27.,Pharmacogenomics J.  2018,PubMed,citation,PMID:29282362,pubmed,29282362,create date:2017/12/29 | first author:Riera P
The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement.,/pubmed/29270051,"Abrahao ABK, Karim S, Colwell B, Berry S, Biagi J.",Curr Oncol. 2017 Dec;24(6):390-400. doi: 10.3747/co.24.3757. Epub 2017 Dec 20.,Curr Oncol.  2017,PubMed,citation,PMID:29270051 | PMCID:PMC5736481,pubmed,29270051,create date:2017/12/23 | first author:Abrahao ABK
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.,/pubmed/29267900,"Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, et al.",J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.,J Natl Cancer Inst.  2018,PubMed,citation,PMID:29267900 | PMCID:PMC6005015,pubmed,29267900,create date:2017/12/22 | first author:Sjoquist KM
"Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.",/pubmed/29254887,"Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T; FOCUS4 Trial Investigators..",Lancet Gastroenterol Hepatol. 2018 Mar;3(3):162-171. doi: 10.1016/S2468-1253(17)30394-1. Epub 2017 Dec 16.,Lancet Gastroenterol Hepatol.  2018,PubMed,citation,PMID:29254887 | PMCID:PMC6125825,pubmed,29254887,create date:2017/12/20 | first author:Adams R
Distinctive DNA mismatch repair and APC rare variants in African Americans with colorectal neoplasia.,/pubmed/29245953,"Ashktorab H, Azimi H, Varma S, Tavakoli P, Nickerson ML, Brim H.",Oncotarget. 2017 Oct 7;8(59):99966-99977. doi: 10.18632/oncotarget.21557. eCollection 2017 Nov 21.,Oncotarget.  2017,PubMed,citation,PMID:29245953 | PMCID:PMC5725144,pubmed,29245953,create date:2017/12/17 | first author:Ashktorab H
Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma.,/pubmed/29240583,"Landau MA, Zhu B, Akwuole FN, Pai RK.",Am J Surg Pathol. 2018 Mar;42(3):351-358. doi: 10.1097/PAS.0000000000001004.,Am J Surg Pathol.  2018,PubMed,citation,PMID:29240583,pubmed,29240583,create date:2017/12/15 | first author:Landau MA
"KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013.",/pubmed/29223986,"Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, Chen VW.",J Natl Compr Canc Netw. 2017 Dec;15(12):1484-1493. doi: 10.6004/jnccn.2017.7011.,J Natl Compr Canc Netw.  2017,PubMed,citation,PMID:29223986,pubmed,29223986,create date:2017/12/11 | first author:Charlton ME
"Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.",/pubmed/29215955,"Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J.",J Clin Oncol. 2018 Feb 1;36(4):350-358. doi: 10.1200/JCO.2017.74.3245. Epub 2017 Dec 7.,J Clin Oncol.  2018,PubMed,citation,PMID:29215955,pubmed,29215955,create date:2017/12/08 | first author:Xu J
Reactive oxygen species and colorectal cancer.,/pubmed/29215746,"Lin S, Li Y, Zamyatnin AA Jr, Werner J, Bazhin AV.",J Cell Physiol. 2018 Jul;233(7):5119-5132. doi: 10.1002/jcp.26356. Epub 2018 Jan 25. Review.,J Cell Physiol.  2018,PubMed,citation,PMID:29215746,pubmed,29215746,create date:2017/12/08 | first author:Lin S
Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer.,/pubmed/29212173,"Shimada Y, Kameyama H, Nagahashi M, Ichikawa H, Muneoka Y, Yagi R, Tajima Y, Okamura T, Nakano M, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Hayashida T, Takaishi H, Kitagawa Y, Oki E, Konishi T, Ishida F, Kudo SE, Ring JE, et al.",Oncotarget. 2017 Aug 24;8(55):93567-93579. doi: 10.18632/oncotarget.20510. eCollection 2017 Nov 7.,Oncotarget.  2017,PubMed,citation,PMID:29212173 | PMCID:PMC5706819,pubmed,29212173,create date:2017/12/08 | first author:Shimada Y
Implications of the tumor immune microenvironment for staging and therapeutics.,/pubmed/29192647,"Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.",Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.,Mod Pathol.  2018,PubMed,citation,PMID:29192647 | PMCID:PMC6132263,pubmed,29192647,create date:2017/12/02 | first author:Taube JM
Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer.,/pubmed/29187560,"Hu W, Yang Y, Li X, Huang M, Xu F, Ge W, Zhang S, Zheng S.",Mol Cancer Res. 2018 Mar;16(3):476-485. doi: 10.1158/1541-7786.MCR-17-0483. Epub 2017 Nov 29.,Mol Cancer Res.  2018,PubMed,citation,PMID:29187560,pubmed,29187560,create date:2017/12/01 | first author:Hu W
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.,/pubmed/29180604,"Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.",Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.,Clin Cancer Res.  2018,PubMed,citation,PMID:29180604 | PMCID:PMC5844818,pubmed,29180604,create date:2017/11/29 | first author:Loree JM
The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer.,/pubmed/29179247,"Ursem C, Venook AP.","Oncology (Williston Park). 2017 Nov 15;31(11):785-8, 802.",Oncology (Williston Park).  2017,PubMed,citation,PMID:29179247 | PMCID:PMC5752316,pubmed,29179247,create date:2017/11/28 | first author:Ursem C
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer.,/pubmed/29169325,"Kim D, Kim SY, Lee JS, Hong YS, Kim JE, Kim KP, Kim J, Jang SJ, Yoon YK, Kim TW.",BMC Gastroenterol. 2017 Nov 23;17(1):121. doi: 10.1186/s12876-017-0694-6.,BMC Gastroenterol.  2017,PubMed,citation,PMID:29169325 | PMCID:PMC5701369,pubmed,29169325,create date:2017/11/25 | first author:Kim D
Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.,/pubmed/29168112,"Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS.",J Gastrointest Cancer. 2019 Mar;50(1):69-77. doi: 10.1007/s12029-017-0027-6.,J Gastrointest Cancer.  2019,PubMed,citation,PMID:29168112,pubmed,29168112,create date:2017/11/24 | first author:Houts AC
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.,/pubmed/29167892,"Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators..",JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12.,JAMA Oncol.  2018,PubMed,citation,PMID:29167892 | PMCID:PMC6145739,pubmed,29167892,create date:2017/11/24 | first author:Taieb J
"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.",/pubmed/29156800,"Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL.",Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.,Oncotarget.  2017,PubMed,citation,PMID:29156800 | PMCID:PMC5689690,pubmed,29156800,create date:2017/11/22 | first author:Salem ME
Efficacy of proximal colectomy for surgical management of right-sided first colorectal cancer in Lynch Syndrome mutation carriers.,/pubmed/29153248,"Hiatt MJ, Casey MJ, Lynch HT, Snyder CL, Stacey M, Walters RW.",Am J Surg. 2018 Jul;216(1):99-105. doi: 10.1016/j.amjsurg.2017.11.003. Epub 2017 Nov 8.,Am J Surg.  2018,PubMed,citation,PMID:29153248,pubmed,29153248,create date:2017/11/21 | first author:Hiatt MJ
Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.,/pubmed/29137623,"Thiebault Q, Defossez G, Karayan-Tapon L, Ingrand P, Silvain C, Tougeron D.",BMC Cancer. 2017 Nov 14;17(1):765. doi: 10.1186/s12885-017-3759-6.,BMC Cancer.  2017,PubMed,citation,PMID:29137623 | PMCID:PMC5686889,pubmed,29137623,create date:2017/11/16 | first author:Thiebault Q
Universal determination of microsatellite instability using BAT26 as a single marker in an Argentine colorectal cancer cohort.,/pubmed/29128931,"González ML, Causada-Calo N, Santino JP, Dominguez-Valentin M, Ferro FA, Sammartino I, Kalfayan PG, Verzura MA, Piñero TA, Cajal AR, Pavicic W, Vaccaro C.",Fam Cancer. 2018 Jul;17(3):395-402. doi: 10.1007/s10689-017-0052-4.,Fam Cancer.  2018,PubMed,citation,PMID:29128931,pubmed,29128931,create date:2017/11/13 | first author:González ML
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.,/pubmed/29128266,"Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.",Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.,Clin Colorectal Cancer.  2018,PubMed,citation,PMID:29128266,pubmed,29128266,create date:2017/11/13 | first author:Chiu JW
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.,/pubmed/29123255,"Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, Arnold D, Koopman M.",Br J Cancer. 2017 Dec 5;117(12):1768-1776. doi: 10.1038/bjc.2017.382. Epub 2017 Nov 9.,Br J Cancer.  2017,PubMed,citation,PMID:29123255 | PMCID:PMC5729483,pubmed,29123255,create date:2017/11/11 | first author:Goey KKH
Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival.,/pubmed/29119016,"Ampollini L, Gnetti L, Goldoni M, Viani L, Faedda E, Campanini N, Caruana P, Crafa P, Negri F, Pucci F, Leonardi F, Ventura L, Balestra V, Braggio C, Bocchialini G, Del Rio P, Silini EM, Carbognani P, Rusca M.",J Thorac Dis. 2017 Oct;9(Suppl 12):S1282-S1290. doi: 10.21037/jtd.2017.07.100.,J Thorac Dis.  2017,PubMed,citation,PMID:29119016 | PMCID:PMC5653500,pubmed,29119016,create date:2017/11/10 | first author:Ampollini L
Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR.,/pubmed/29093617,"Olmedillas-López S, Lévano-Linares DC, Alexandre CLA, Vega-Clemente L, Sánchez EL, Villagrasa A, Ruíz-Tovar J, García-Arranz M, García-Olmo D.",World J Gastroenterol. 2017 Oct 21;23(39):7087-7097. doi: 10.3748/wjg.v23.i39.7087.,World J Gastroenterol.  2017,PubMed,citation,PMID:29093617 | PMCID:PMC5656456,pubmed,29093617,create date:2017/11/03 | first author:Olmedillas-López S
KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.,/pubmed/29085005,"Sun DC, Shi Y, Wang YR, Lv Y, Yan H, Mao H, Wang ZK, Wu ZY, Shi WW, Dai GH.",Sci Rep. 2017 Oct 30;7(1):14368. doi: 10.1038/s41598-017-14669-2.,Sci Rep.  2017,PubMed,citation,PMID:29085005 | PMCID:PMC5662591,pubmed,29085005,create date:2017/11/01 | first author:Sun DC
[Personalized Treatment for Colorectal Carcinomas].,/pubmed/29078210,Stintzing S.,Dtsch Med Wochenschr. 2017 Nov;142(22):1652-1659. doi: 10.1055/s-0043-108467. Epub 2017 Oct 27. German. ,Dtsch Med Wochenschr.  2017,PubMed,citation,PMID:29078210,pubmed,29078210,create date:2017/10/28 | first author:Stintzing S
Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?,/pubmed/29071660,"Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS; BIG-RENAPE Working Group..",Ann Surg Oncol. 2018 Jan;25(1):179-187. doi: 10.1245/s10434-017-6141-7. Epub 2017 Oct 25.,Ann Surg Oncol.  2018,PubMed,citation,PMID:29071660,pubmed,29071660,create date:2017/10/27 | first author:Passot G
Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.,/pubmed/29058260,"Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS.",J Gastrointest Cancer. 2019 Mar;50(1):16-22. doi: 10.1007/s12029-017-0017-8.,J Gastrointest Cancer.  2019,PubMed,citation,PMID:29058260,pubmed,29058260,create date:2017/10/24 | first author:Houts AC
MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.,/pubmed/29048575,"Schneiderova M, Naccarati A, Pardini B, Rosa F, Gaetano CD, Jiraskova K, Opattova A, Levy M, Veskrna K, Veskrnova V, Buchler T, Landi S, Vodicka P, Vymetalkova V.",Mutagenesis. 2017 Oct 17;32(5):533-542. doi: 10.1093/mutage/gex026.,Mutagenesis.  2017,PubMed,citation,PMID:29048575,pubmed,29048575,create date:2017/10/20 | first author:Schneiderova M
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.,/pubmed/29045518,"Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F.",Ann Oncol. 2017 Dec 1;28(12):3009-3014. doi: 10.1093/annonc/mdx546.,Ann Oncol.  2017,PubMed,citation,PMID:29045518,pubmed,29045518,create date:2017/10/19 | first author:Cremolini C
Derivation and basic characterization of colorectal carcinoma primary cell lines.,/pubmed/29042709,"Krbal L, Soukup J, Stanislav J, Hanusova V.",Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Dec;161(4):360-368. doi: 10.5507/bp.2017.040. Epub 2017 Oct 17.,Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.  2017,PubMed,citation,PMID:29042709,pubmed,29042709,create date:2017/10/19 | first author:Krbal L
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.,/pubmed/29037218,"Wang X, Wei Q, Gao J, Li J, Li J, Gong J, Li Y, Shen L.",Chin J Cancer. 2017 Oct 16;36(1):81. doi: 10.1186/s40880-017-0247-y.,Chin J Cancer.  2017,PubMed,citation,PMID:29037218 | PMCID:PMC5644136,pubmed,29037218,create date:2017/10/19 | first author:Wang X
'MCC' protein interacts with E-cadherin and β-catenin strengthening cell-cell adhesion of HCT116 colon cancer cells.,/pubmed/29035389,"Benthani FA, Herrmann D, Tran PN, Pangon L, Lucas MC, Allam AH, Currey N, Al-Sohaily S, Giry-Laterriere M, Warusavitarne J, Timpson P, Kohonen-Corish MRJ.",Oncogene. 2018 Feb 1;37(5):663-672. doi: 10.1038/onc.2017.362. Epub 2017 Oct 16.,Oncogene.  2018,PubMed,citation,PMID:29035389,pubmed,29035389,create date:2017/10/17 | first author:Benthani FA
Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.,/pubmed/29029527,"Ridouane Y, Lopes G, Ku G, Masud H, Haaland B.",Oncotarget. 2017 Aug 11;8(39):66458-66466. doi: 10.18632/oncotarget.20185. eCollection 2017 Sep 12.,Oncotarget.  2017,PubMed,citation,PMID:29029527 | PMCID:PMC5630427,pubmed,29029527,create date:2017/10/17 | first author:Ridouane Y
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.,/pubmed/29024937,"Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.",Br J Cancer. 2017 Dec 5;117(12):1819-1827. doi: 10.1038/bjc.2017.353. Epub 2017 Oct 12. Erratum in: Br J Cancer. 2018 Aug;119(3):387. ,Br J Cancer.  2017,PubMed,citation,PMID:29024937 | PMCID:PMC5729470,pubmed,29024937,create date:2017/10/13 | first author:Lièvre A
Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.,/pubmed/28975237,"Aljehani MA, Morgan JW, Guthrie LA, Jabo B, Ramadan M, Bahjri K, Lum SS, Selleck M, Reeves ME, Garberoglio C, Senthil M.",JAMA Surg. 2018 Jan 1;153(1):60-67. doi: 10.1001/jamasurg.2017.3466.,JAMA Surg.  2018,PubMed,citation,PMID:28975237 | PMCID:PMC5833618,pubmed,28975237,create date:2017/10/05 | first author:Aljehani MA
Uncommon somatic mutations in metastatic NUT midline carcinoma.,/pubmed/28967088,"Cavalieri S, Stathis A, Fabbri A, Sonzogni A, Perrone F, Tamborini E, Pelosi G, de Braud F, Platania M.",Tumori. 2017 Nov 15;103(Suppl. 1):e5-e8. doi: 10.5301/tj.5000685.,Tumori.  2017,PubMed,citation,PMID:28967088,pubmed,28967088,create date:2017/10/03 | first author:Cavalieri S
"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.",/pubmed/28958502,"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.",Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.,Lancet Oncol.  2017,PubMed,citation,PMID:28958502,pubmed,28958502,create date:2017/09/30 | first author:Wu YL
The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.,/pubmed/28928870,"Kim ST, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS.",J Cancer. 2017 Aug 23;8(14):2809-2815. doi: 10.7150/jca.18286. eCollection 2017.,J Cancer.  2017,PubMed,citation,PMID:28928870 | PMCID:PMC5604213,pubmed,28928870,create date:2017/09/21 | first author:Kim ST
Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.,/pubmed/28928376,"Chen LM, Liu PY, Chen YA, Tseng HY, Shen PC, Hwang PA, Hsu HL.",Sci Rep. 2017 Sep 19;7(1):11864. doi: 10.1038/s41598-017-12111-1.,Sci Rep.  2017,PubMed,citation,PMID:28928376 | PMCID:PMC5605496,pubmed,28928376,create date:2017/09/21 | first author:Chen LM
The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection.,/pubmed/28927777,"Poston G, Adam R, Xu J, Byrne B, Esser R, Malik H, Wasan H, Xu J.",Eur J Surg Oncol. 2017 Nov;43(11):2001-2011. doi: 10.1016/j.ejso.2017.07.021. Epub 2017 Aug 10. Review.,Eur J Surg Oncol.  2017,PubMed,citation,PMID:28927777,pubmed,28927777,create date:2017/09/21 | first author:Poston G
"Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype.",/pubmed/28921583,"Jayasekara H, English DR, Haydon A, Hodge AM, Lynch BM, Rosty C, Williamson EJ, Clendenning M, Southey MC, Jenkins MA, Room R, Hopper JL, Milne RL, Buchanan DD, Giles GG, MacInnis RJ.",Int J Cancer. 2018 Jan 15;142(2):238-250. doi: 10.1002/ijc.31049. Epub 2017 Oct 4.,Int J Cancer.  2018,PubMed,citation,PMID:28921583,pubmed,28921583,create date:2017/09/19 | first author:Jayasekara H
miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B.,/pubmed/28915933,"Ma Q, Wang Y, Zhang H, Wang F.",Oncol Res. 2018 Sep 14;26(8):1167-1174. doi: 10.3727/096504017X15051741798389. Epub 2017 Sep 15.,Oncol Res.  2018,PubMed,citation,PMID:28915933,pubmed,28915933,create date:2017/09/17 | first author:Ma Q
"Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer.",/pubmed/28912018,"Bellido F, Sowada N, Mur P, Lázaro C, Pons T, Valdés-Mas R, Pineda M, Aiza G, Iglesias S, Soto JL, Urioste M, Caldés T, Balbín M, Blay P, Rueda D, Durán M, Valencia A, Moreno V, Brunet J, Blanco I, Navarro M, Calin GA, et al.",Gastroenterology. 2018 Jan;154(1):181-194.e20. doi: 10.1053/j.gastro.2017.09.005. Epub 2017 Sep 12.,Gastroenterology.  2018,PubMed,citation,PMID:28912018,pubmed,28912018,create date:2017/09/16 | first author:Bellido F
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.,/pubmed/28911069,"Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M.",Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330.,Ann Oncol.  2017,PubMed,citation,PMID:28911069,pubmed,28911069,create date:2017/09/16 | first author:Thierry AR
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.,/pubmed/28911067,"Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, de Leng WWJ, Strengman E, Ten Tije AJ, Creemers GM, van der Velden A, de Jongh FE, Erdkamp FLG, Tanis BC, Punt CJA, Koopman M.",Ann Oncol. 2017 Sep 1;28(9):2128-2134. doi: 10.1093/annonc/mdx322.,Ann Oncol.  2017,PubMed,citation,PMID:28911067,pubmed,28911067,create date:2017/09/16 | first author:Goey KKH
Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience.,/pubmed/28904173,"Johnson B, Jin Z, Truty MJ, Smoot RL, Nagorney DM, Kendrick ML, Kipp BR, Grothey A.",Oncologist. 2018 Jan;23(1):128-134. doi: 10.1634/theoncologist.2017-0230. Epub 2017 Sep 13.,Oncologist.  2018,PubMed,citation,PMID:28904173 | PMCID:PMC5759813,pubmed,28904173,create date:2017/09/15 | first author:Johnson B
Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.,/pubmed/28885658,"Tang M, Deng Z, Li B, Peng Y, Song M, Liu J.",Int J Biol Markers. 2017 Oct 31;32(4):e421-e427. doi: 10.5301/ijbm.5000295.,Int J Biol Markers.  2017,PubMed,citation,PMID:28885658,pubmed,28885658,create date:2017/09/09 | first author:Tang M
The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis.,/pubmed/28881837,"Cao DD, Xu HL, Xu XM, Ge W.",Oncotarget. 2017 Jul 5;8(32):53631-53641. doi: 10.18632/oncotarget.19022. eCollection 2017 Aug 8.,Oncotarget.  2017,PubMed,citation,PMID:28881837 | PMCID:PMC5581136,pubmed,28881837,create date:2017/09/09 | first author:Cao DD
The prognostic role of microsatellite instability in colorectal cancer patients.,/pubmed/28874631,"Micu BV, Andercou O, Vesa SC, Micu CM, Pop TR, Constantea N.",Ann Ital Chir. 2017;6:425-432.,Ann Ital Chir.  2017,PubMed,citation,PMID:28874631,pubmed,28874631,create date:2017/09/07 | first author:Micu BV
Genotoxic effects of high dose rate X-ray and low dose rate gamma radiation in Apc(Min/+) mice.,/pubmed/28856770,"Graupner A, Eide DM, Brede DA, Ellender M, Lindbo Hansen E, Oughton DH, Bouffler SD, Brunborg G, Olsen AK.",Environ Mol Mutagen. 2017 Oct;58(8):560-569. doi: 10.1002/em.22121. Epub 2017 Aug 30.,Environ Mol Mutagen.  2017,PubMed,citation,PMID:28856770 | PMCID:PMC5656900,pubmed,28856770,create date:2017/09/01 | first author:Graupner A
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.,/pubmed/28853050,"Ketzer S, Schimmel K, Koopman M, Guchelaar HJ.",Clin Pharmacokinet. 2018 Apr;57(4):455-473. doi: 10.1007/s40262-017-0590-9. Review.,Clin Pharmacokinet.  2018,PubMed,citation,PMID:28853050 | PMCID:PMC5856878,pubmed,28853050,create date:2017/08/31 | first author:Ketzer S
P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.,/pubmed/28851987,"Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS.",Sci Rep. 2017 Aug 29;7(1):9711. doi: 10.1038/s41598-017-09859-x.,Sci Rep.  2017,PubMed,citation,PMID:28851987 | PMCID:PMC5575263,pubmed,28851987,create date:2017/08/31 | first author:Gokare P
"Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.",/pubmed/28801584,"Gao XH, Yu GY, Gong HF, Liu LJ, Xu Y, Hao LQ, Liu P, Liu ZH, Bai CG, Zhang W.",Sci Rep. 2017 Aug 11;7(1):7882. doi: 10.1038/s41598-017-08413-z.,Sci Rep.  2017,PubMed,citation,PMID:28801584 | PMCID:PMC5554205,pubmed,28801584,create date:2017/08/13 | first author:Gao XH
Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.,/pubmed/28800074,"Park HJ, Park JB, Lee SJ, Song M.",Int J Mol Sci. 2017 Aug 11;18(8). pii: E1746. doi: 10.3390/ijms18081746.,Int J Mol Sci.  2017,PubMed,citation,PMID:28800074 | PMCID:PMC5578136,pubmed,28800074,create date:2017/08/12 | first author:Park HJ
Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.,/pubmed/28767562,"Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN.",Ann Surg. 2019 May;269(5):917-923. doi: 10.1097/SLA.0000000000002450.,Ann Surg.  2019,PubMed,citation,PMID:28767562,pubmed,28767562,create date:2017/08/03 | first author:Chun YS
"Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of...",/pubmed/28735067,"Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators..",Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20.,Eur J Cancer.  2017,PubMed,citation,PMID:28735067,pubmed,28735067,create date:2017/07/25 | first author:Cascinu S
Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition.,/pubmed/28716088,"Larsson C, Ali MA, Pandzic T, Lindroth AM, He L, Sjöblom T.",BMC Cancer. 2017 Jul 17;17(1):487. doi: 10.1186/s12885-017-3472-5.,BMC Cancer.  2017,PubMed,citation,PMID:28716088 | PMCID:PMC5513093,pubmed,28716088,create date:2017/07/19 | first author:Larsson C
Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.,/pubmed/28712098,"Weinberg BA, Hartley ML, Salem ME.",Oncology (Williston Park). 2017 Jul 15;31(7):539-48. Review.,Oncology (Williston Park).  2017,PubMed,citation,PMID:28712098,pubmed,28712098,create date:2017/07/18 | first author:Weinberg BA
Attenuated adenomatous polyposis of the large bowel: Present and future.,/pubmed/28694653,"Roncucci L, Pedroni M, Mariani F.",World J Gastroenterol. 2017 Jun 21;23(23):4135-4139. doi: 10.3748/wjg.v23.i23.4135.,World J Gastroenterol.  2017,PubMed,citation,PMID:28694653 | PMCID:PMC5483487,pubmed,28694653,create date:2017/07/12 | first author:Roncucci L
A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer.,/pubmed/28685354,"Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, Yamaguchi T, Nishitai R, Manaka D, Kato S, Kadokawa Y, Yamanokuchi S, Kawamura J, Zaima M, Kyogoku T, Kanazawa A, Mori Y, Kanai M, Matsumoto S, Sakai Y.",Ann Surg Oncol. 2017 Nov;24(12):3587-3595. doi: 10.1245/s10434-017-5967-3. Epub 2017 Jul 6.,Ann Surg Oncol.  2017,PubMed,citation,PMID:28685354,pubmed,28685354,create date:2017/07/08 | first author:Hasegawa S
The diagnosis of a metastatic breast tumor from ovarian cancer by the succession of a p53 mutation: a case report.,/pubmed/28662703,"Mori R, Futamura M, Morimitsu K, Saigo C, Miyazaki T, Yoshida K.",World J Surg Oncol. 2017 Jun 29;15(1):117. doi: 10.1186/s12957-017-1185-5.,World J Surg Oncol.  2017,PubMed,citation,PMID:28662703 | PMCID:PMC5492946,pubmed,28662703,create date:2017/07/01 | first author:Mori R
Clinical Case of the Month: A 57-Year-Old Man with an Axillary Mass.,/pubmed/28644156,"Desai P, Myers A, Boulmay B, Lopez FA.",J La State Med Soc. 2017 May-Jun;169(3):78-82. Epub 2017 Jun 23. Review.,J La State Med Soc.  2017,PubMed,citation,PMID:28644156,pubmed,28644156,create date:2017/06/24 | first author:Desai P
DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.,/pubmed/28640387,"Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC.",Cancer. 2017 Oct 1;123(19):3732-3743. doi: 10.1002/cncr.30790. Epub 2017 Jun 22.,Cancer.  2017,PubMed,citation,PMID:28640387 | PMCID:PMC5610604,pubmed,28640387,create date:2017/06/24 | first author:Ricker CN
Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Prognosis in Colorectal Cancers.,/pubmed/28638266,"Lee SH, Yoo HJ, Rim DE, Cui Y, Lee A, Jung ES, Oh ST, Kim JG, Kwon OJ, Kim SY, Jeong SW.",Int J Med Sci. 2017 Apr 9;14(6):515-522. doi: 10.7150/ijms.19368. eCollection 2017.,Int J Med Sci.  2017,PubMed,citation,PMID:28638266 | PMCID:PMC5479119,pubmed,28638266,create date:2017/06/24 | first author:Lee SH
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.,/pubmed/28632865,"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, et al.",JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.,JAMA.  2017,PubMed,citation,PMID:28632865 | PMCID:PMC5545896,pubmed,28632865,create date:2017/06/21 | first author:Venook AP
"The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.",/pubmed/28632725,"Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M.",Br J Cancer. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. Epub 2017 Jun 20.,Br J Cancer.  2017,PubMed,citation,PMID:28632725 | PMCID:PMC5537494,pubmed,28632725,create date:2017/06/21 | first author:Demurtas L
Investigation of patterns of nodal metastases in BRAF mutant lung cancer.,/pubmed/28625649,"McEvoy SH, Halpenny DF, Viteri-Jusué A, Hayes SA, Plodkowski AJ, Riely GJ, Ginsberg MS.",Lung Cancer. 2017 Jun;108:62-65. doi: 10.1016/j.lungcan.2017.02.024. Epub 2017 Mar 1.,Lung Cancer.  2017,PubMed,citation,PMID:28625649 | PMCID:PMC5538145,pubmed,28625649,create date:2017/06/20 | first author:McEvoy SH
Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.,/pubmed/28616688,"Clendenning M, Huang A, Jayasekara H, Lorans M, Preston S, O'Callaghan N, Pope BJ, Macrae FA, Winship IM, Milne RL, Giles GG, English DR, Hopper JL, Win AK, Jenkins MA, Southey MC, Rosty C, Buchanan DD; investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort..",Fam Cancer. 2018 Jan;17(1):91-100. doi: 10.1007/s10689-017-0013-y.,Fam Cancer.  2018,PubMed,citation,PMID:28616688 | PMCID:PMC6129400,pubmed,28616688,create date:2017/06/16 | first author:Clendenning M
Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion.,/pubmed/28612017,"Zervoudakis A, Boucher T, Kemeny NE.",Visc Med. 2017 Mar;33(1):47-53. doi: 10.1159/000454693. Epub 2017 Feb 3. Review.,Visc Med.  2017,PubMed,citation,PMID:28612017 | PMCID:PMC5465659,pubmed,28612017,create date:2017/06/15 | first author:Zervoudakis A
BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis.,/pubmed/28611337,"Li Y, Li W.",Saudi J Gastroenterol. 2017 May-Jun;23(3):144-149. doi: 10.4103/1319-3767.207712. Review.,Saudi J Gastroenterol.  2017,PubMed,citation,PMID:28611337 | PMCID:PMC5470373,pubmed,28611337,create date:2017/06/15 | first author:Li Y
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.,/pubmed/28598398,"Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi A.",Int J Mol Sci. 2017 Jun 9;18(6). pii: E1240. doi: 10.3390/ijms18061240.,Int J Mol Sci.  2017,PubMed,citation,PMID:28598398 | PMCID:PMC5486063,pubmed,28598398,create date:2017/06/10 | first author:Ulivi P
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.,/pubmed/28595259,"Alvi MA, Loughrey MB, Dunne P, McQuaid S, Turkington R, Fuchs MA, McGready C, Bingham V, Pang B, Moore W, Maxwell P, Lawler M, James JA, Murray GI, Wilson RH, Salto-Tellez M.",Br J Cancer. 2017 Jul 11;117(2):203-209. doi: 10.1038/bjc.2017.168. Epub 2017 Jun 8.,Br J Cancer.  2017,PubMed,citation,PMID:28595259 | PMCID:PMC5520517,pubmed,28595259,create date:2017/06/09 | first author:Alvi MA
The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells.,/pubmed/28560069,"Huang TH, Wu SY, Huang YJ, Wei PL, Wu AT, Chao TY.",Am J Cancer Res. 2017 May 1;7(5):1227-1237. eCollection 2017.,Am J Cancer Res.  2017,PubMed,citation,PMID:28560069 | PMCID:PMC5446486,pubmed,28560069,create date:2017/06/01 | first author:Huang TH
[A Case Report on a Successful Resection after FOLFIRI plus Cetuximab Therapy for Unresectable Colorectal Cancer with Multiple Liver Metastases].,/pubmed/28536339,"Kanamori M, Kurumiya Y, Mizuno K, Sekoguchi E, Kobayashi S, Fukami Y, Kiriyama M, Aoyama H, Oiwa T, Miyamura K, Jinno T, Nakashima Y, Mori M.",Gan To Kagaku Ryoho. 2017 May;44(5):417-420. Japanese. ,Gan To Kagaku Ryoho.  2017,PubMed,citation,PMID:28536339,pubmed,28536339,create date:2017/05/26 | first author:Kanamori M
Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.,/pubmed/28531214,"Houlleberghs H, Goverde A, Lusseveld J, Dekker M, Bruno MJ, Menko FH, Mensenkamp AR, Spaander MCW, Wagner A, Hofstra RMW, Te Riele H.",PLoS Genet. 2017 May 22;13(5):e1006765. doi: 10.1371/journal.pgen.1006765. eCollection 2017 May.,PLoS Genet.  2017,PubMed,citation,PMID:28531214 | PMCID:PMC5460888,pubmed,28531214,create date:2017/05/23 | first author:Houlleberghs H
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.,/pubmed/28522584,"Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA.",Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18.,Mol Cancer Ther.  2017,PubMed,citation,PMID:28522584 | PMCID:PMC5587368,pubmed,28522584,create date:2017/05/20 | first author:Simmons JK
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.,/pubmed/28513830,"Lee DW, Han SW, Cha Y, Bae JM, Kim HP, Lyu J, Han H, Kim H, Jang H, Bang D, Huh I, Park T, Won JK, Jeong SY, Park KJ, Kang GH, Kim TY.",Cancer. 2017 Sep 15;123(18):3513-3523. doi: 10.1002/cncr.30760. Epub 2017 May 17.,Cancer.  2017,PubMed,citation,PMID:28513830,pubmed,28513830,create date:2017/05/18 | first author:Lee DW
Future perspectives of circulating tumor DNA in colorectal cancer.,/pubmed/28488528,"Nadal C, Winder T, Gerger A, Tougeron D.",Tumour Biol. 2017 May;39(5):1010428317705749. doi: 10.1177/1010428317705749. Review.,Tumour Biol.  2017,PubMed,citation,PMID:28488528,pubmed,28488528,create date:2017/05/11 | first author:Nadal C
(Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.,/pubmed/28486044,"Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A.",J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.,J Clin Oncol.  2017,PubMed,citation,PMID:28486044 | PMCID:PMC5549454,pubmed,28486044,create date:2017/05/10 | first author:Jones JC
Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma.,/pubmed/28476018,"Vakiani E, Shah RH, Berger MF, Makohon-Moore AP, Reiter JG, Ostrovnaya I, Attiyeh MA, Cercek A, Shia J, Iacobuzio-Donahue CA, Solit DB, Weiser MR.",Oncotarget. 2017 Jun 27;8(26):42487-42494. doi: 10.18632/oncotarget.17200.,Oncotarget.  2017,PubMed,citation,PMID:28476018 | PMCID:PMC5522082,pubmed,28476018,create date:2017/05/06 | first author:Vakiani E
"[Molecular Pathology of Colorectal Cancer, Microsatellite Instability - the Detection, the Relationship to the Pathophysiology and Prognosis].",/pubmed/28471193,"Brychtová V, Šefr R, Hrstka R, Vídeňská P, Bencsiková B, Hanáková B, Zdražilová Dubská L, Nenutil R, Budinská E.",Klin Onkol. Spring 2017;30(Supplementum1):153-155. Czech. ,Klin Onkol.  Spri,PubMed,citation,PMID:28471193,pubmed,28471193,create date:2017/05/05 | first author:Brychtová V
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.,/pubmed/28449055,"Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M.",Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119.,Ann Oncol.  2017,PubMed,citation,PMID:28449055 | PMCID:PMC5834073,pubmed,28449055,create date:2017/04/28 | first author:Boeckx N
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.,/pubmed/28446505,"Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R.",Clin Cancer Res. 2017 Aug 15;23(16):4753-4760. doi: 10.1158/1078-0432.CCR-17-0400. Epub 2017 Apr 26.,Clin Cancer Res.  2017,PubMed,citation,PMID:28446505 | PMCID:PMC5788017,pubmed,28446505,create date:2017/04/28 | first author:Cercek A
Selective eradication of cancer cells by delivery of adenovirus-based toxins.,/pubmed/28445136,"Shapira S, Shapira A, Kazanov D, Hevroni G, Kraus S, Arber N.",Oncotarget. 2017 Jun 13;8(24):38581-38591. doi: 10.18632/oncotarget.16934.,Oncotarget.  2017,PubMed,citation,PMID:28445136 | PMCID:PMC5503555,pubmed,28445136,create date:2017/04/27 | first author:Shapira S
Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?,/pubmed/28432610,"Arora SP, Ketchum NS, Michalek J, Gelfond J, Mahalingam D.",J Gastrointest Cancer. 2018 Sep;49(3):283-287. doi: 10.1007/s12029-017-9948-3.,J Gastrointest Cancer.  2018,PubMed,citation,PMID:28432610,pubmed,28432610,create date:2017/04/23 | first author:Arora SP
Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.,/pubmed/28429715,"Liddell C, Droy-Dupré L, Métairie S, Airaud F, Volteau C, Bezieau S, Laboisse CL, Mosnier JF.",Mod Pathol. 2017 Aug;30(8):1177-1189. doi: 10.1038/modpathol.2017.18. Epub 2017 Apr 21.,Mod Pathol.  2017,PubMed,citation,PMID:28429715,pubmed,28429715,create date:2017/04/22 | first author:Liddell C
Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival.,/pubmed/28422723,"Lee CT, Huang YC, Hung LY, Chow NH, Su PF, Ho CL, Tsai HW, Chen YL, Lin SC, Lin BW, Lin PC, Lee JC.",Oncotarget. 2017 May 23;8(21):35165-35175. doi: 10.18632/oncotarget.16815.,Oncotarget.  2017,PubMed,citation,PMID:28422723 | PMCID:PMC5471043,pubmed,28422723,create date:2017/04/20 | first author:Lee CT
Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer.,/pubmed/28418176,"Tsai MH, Pan CH, Peng CL, Shieh MJ.",Adv Healthc Mater. 2017 Jul;6(13). doi: 10.1002/adhm.201700111. Epub 2017 Apr 18.,Adv Healthc Mater.  2017,PubMed,citation,PMID:28418176,pubmed,28418176,create date:2017/04/19 | first author:Tsai MH
The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients.,/pubmed/28416767,"Peng J, Huang D, Poston G, Ma X, Wang R, Sheng W, Zhou X, Zhu X, Cai S.",Oncotarget. 2017 Jul 25;8(30):49076-49083. doi: 10.18632/oncotarget.16176.,Oncotarget.  2017,PubMed,citation,PMID:28416767 | PMCID:PMC5564750,pubmed,28416767,create date:2017/04/19 | first author:Peng J
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.,/pubmed/28407110,"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F.",Ann Oncol. 2017 Aug 1;28(8):1713-1729. doi: 10.1093/annonc/mdx175.,Ann Oncol.  2017,PubMed,citation,PMID:28407110 | PMCID:PMC6246616,pubmed,28407110,create date:2017/04/14 | first author:Arnold D
"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.",/pubmed/28404093,"Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; et al.",Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.,Lancet Gastroenterol Hepatol.  2016,PubMed,citation,PMID:28404093,pubmed,28404093,create date:2017/04/14 | first author:Domingo E
REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.,/pubmed/28392022,"Costa T, Nuñez J, Felismino T, Boente L, Mello C.",Clin Colorectal Cancer. 2017 Dec;16(4):316-323. doi: 10.1016/j.clcc.2017.03.002. Epub 2017 Mar 16.,Clin Colorectal Cancer.  2017,PubMed,citation,PMID:28392022,pubmed,28392022,create date:2017/04/11 | first author:Costa T
DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer.,/pubmed/28378457,"Takane K, Akagi K, Fukuyo M, Yagi K, Takayama T, Kaneda A.",Cancer Med. 2017 May;6(5):1023-1035. doi: 10.1002/cam4.1061. Epub 2017 Apr 4.,Cancer Med.  2017,PubMed,citation,PMID:28378457 | PMCID:PMC5430106,pubmed,28378457,create date:2017/04/06 | first author:Takane K
Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?,/pubmed/28344745,"Veen T, Søreide K.",World J Gastrointest Oncol. 2017 Mar 15;9(3):98-104. doi: 10.4251/wjgo.v9.i3.98.,World J Gastrointest Oncol.  2017,PubMed,citation,PMID:28344745 | PMCID:PMC5348630,pubmed,28344745,create date:2017/03/28 | first author:Veen T
Genetic Alzheimer Disease and Sporadic Dementia With Lewy Bodies: A Comorbidity Presenting as Primary Progressive Aphasia.,/pubmed/28323683,"Picková T, Matěj R, Bezdicek O, Keller J, van der Zee J, Van Broeckhoven C, Cséfalvay Z, Rusina R.",Cogn Behav Neurol. 2017 Mar;30(1):23-29. doi: 10.1097/WNN.0000000000000116.,Cogn Behav Neurol.  2017,PubMed,citation,PMID:28323683,pubmed,28323683,create date:2017/03/23 | first author:Picková T
How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?,/pubmed/28299879,"Au L, Turner N, Wong HL, Field K, Lee B, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, Gibbs P.",Asia Pac J Clin Oncol. 2018 Apr;14(2):e167-e174. doi: 10.1111/ajco.12671. Epub 2017 Mar 16.,Asia Pac J Clin Oncol.  2018,PubMed,citation,PMID:28299879,pubmed,28299879,create date:2017/03/17 | first author:Au L
The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer.,/pubmed/28293327,"Savio AJ, Mrkonjic M, Lemire M, Gallinger S, Knight JA, Bapat B.",Clin Epigenetics. 2017 Mar 9;9:26. doi: 10.1186/s13148-017-0326-6. eCollection 2017.,Clin Epigenetics.  2017,PubMed,citation,PMID:28293327 | PMCID:PMC5345264,pubmed,28293327,create date:2017/03/16 | first author:Savio AJ
Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.,/pubmed/28278514,"Bae JM, Kim JH, Kwak Y, Lee DW, Cha Y, Wen X, Lee TH, Cho NY, Jeong SY, Park KJ, Han SW, Lee HS, Kim TY, Kang GH.",Br J Cancer. 2017 Apr 11;116(8):1012-1020. doi: 10.1038/bjc.2017.52. Epub 2017 Mar 9.,Br J Cancer.  2017,PubMed,citation,PMID:28278514 | PMCID:PMC5396110,pubmed,28278514,create date:2017/03/10 | first author:Bae JM
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.,/pubmed/28275039,"Lee MS, Menter DG, Kopetz S.",J Natl Compr Canc Netw. 2017 Mar;15(3):411-419. Review.,J Natl Compr Canc Netw.  2017,PubMed,citation,PMID:28275039,pubmed,28275039,create date:2017/03/10 | first author:Lee MS
Gastric tumours in FAP.,/pubmed/28271232,"Walton SJ, Frayling IM, Clark SK, Latchford A.",Fam Cancer. 2017 Jul;16(3):363-369. doi: 10.1007/s10689-017-9966-0.,Fam Cancer.  2017,PubMed,citation,PMID:28271232,pubmed,28271232,create date:2017/03/09 | first author:Walton SJ
Clinical outcomes of gastric polyps and neoplasms in patients with familial adenomatous polyposis.,/pubmed/28271094,"Nakamura K, Nonaka S, Nakajima T, Yachida T, Abe S, Sakamoto T, Suzuki H, Yoshinaga S, Oda I, Matsuda T, Sekine S, Kanemitsu Y, Katai H, Saito Y, Hirota S.",Endosc Int Open. 2017 Mar;5(3):E137-E145. doi: 10.1055/s-0042-119809.,Endosc Int Open.  2017,PubMed,citation,PMID:28271094 | PMCID:PMC5339024,pubmed,28271094,create date:2017/03/09 | first author:Nakamura K
Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.,/pubmed/28249812,"Mehta RS, Song M, Nishihara R, Drew DA, Wu K, Qian ZR, Fung TT, Hamada T, Masugi Y, da Silva A, Shi Y, Li W, Gu M, Willett WC, Fuchs CS, Giovannucci EL, Ogino S, Chan AT.",Gastroenterology. 2017 Jun;152(8):1944-1953.e1. doi: 10.1053/j.gastro.2017.02.015. Epub 2017 Feb 27.,Gastroenterology.  2017,PubMed,citation,PMID:28249812 | PMCID:PMC5447483,pubmed,28249812,create date:2017/03/03 | first author:Mehta RS
Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.,/pubmed/28246485,"Soliman ML, Tiwari A, Zhao Q.",World J Gastroenterol. 2017 Feb 14;23(6):1106-1112. doi: 10.3748/wjg.v23.i6.1106.,World J Gastroenterol.  2017,PubMed,citation,PMID:28246485 | PMCID:PMC5311100,pubmed,28246485,create date:2017/03/02 | first author:Soliman ML
[Does the sidedness determine the first line treatment of irresectable metastatic colorectal cancer?],/pubmed/28245681,"Kullmann T, Sipőcz I, Pintér T.",Orv Hetil. 2017 Mar;158(9):340-344. doi: 10.1556/650.2017.30682. Hungarian. ,Orv Hetil.  2017,PubMed,citation,PMID:28245681,pubmed,28245681,create date:2017/03/02 | first author:Kullmann T
Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.,/pubmed/28235632,"Shimada Y, Yagi R, Kameyama H, Nagahashi M, Ichikawa H, Tajima Y, Okamura T, Nakano M, Nakano M, Sato Y, Matsuzawa T, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Kawasaki T, Homma KI, Izutsu H, Kodama K, Ring JE, Protopopov A, et al.",Hum Pathol. 2017 Aug;66:1-9. doi: 10.1016/j.humpath.2017.02.004. Epub 2017 Feb 22.,Hum Pathol.  2017,PubMed,citation,PMID:28235632,pubmed,28235632,create date:2017/02/27 | first author:Shimada Y
Transcriptional Mechanism of the β4-Galactosyltransferase 4 Gene in SW480 Human Colon Cancer Cell Line.,/pubmed/28228616,"Sugiyama A, Fukushima N, Sato T.",Biol Pharm Bull. 2017 May 1;40(5):733-737. doi: 10.1248/bpb.b17-00064. Epub 2017 Feb 23.,Biol Pharm Bull.  2017,PubMed,citation,PMID:28228616,pubmed,28228616,create date:2017/02/24 | first author:Sugiyama A
Correlation of p53 Overexpression with the Clinicopathological Prognostic Factors in Colorectal Adenocarcinoma.,/pubmed/28208862,"Akshatha C, Mysorekar V, Arundhathi S, Arul P, Raj A, Shetty S.",J Clin Diagn Res. 2016 Dec;10(12):EC05-EC08. doi: 10.7860/JCDR/2016/22617.9056. Epub 2016 Dec 1.,J Clin Diagn Res.  2016,PubMed,citation,PMID:28208862 | PMCID:PMC5296435,pubmed,28208862,create date:2017/02/18 | first author:Akshatha C
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.,/pubmed/28197787,"Schimanski CC, Staib F, Göhler T, Hebart H, Heike M, Neise M, Rudi J, Geer T, Dingeldein G, Lang C, Ehscheidt P, Flohr T, Josten KM, Karthaus M, Schmittel A, Wierecky J, Boller E, Indorf M, Wörns MA, Galle PR, Moehler M.",J Cancer Res Clin Oncol. 2017 Jun;143(6):1023-1034. doi: 10.1007/s00432-017-2344-3. Epub 2017 Feb 14.,J Cancer Res Clin Oncol.  2017,PubMed,citation,PMID:28197787,pubmed,28197787,create date:2017/02/16 | first author:Schimanski CC
Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.,/pubmed/28196490,"Ma J, Yang QL, Ling Y.",BMC Cancer. 2017 Feb 14;17(1):132. doi: 10.1186/s12885-017-3133-8.,BMC Cancer.  2017,PubMed,citation,PMID:28196490 | PMCID:PMC5310018,pubmed,28196490,create date:2017/02/16 | first author:Ma J
"Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival.",/pubmed/28184012,"Ptashkin RN, Pagan C, Yaeger R, Middha S, Shia J, O'Rourke KP, Berger MF, Wang L, Cimera R, Wang J, Klimstra DS, Saltz L, Ladanyi M, Zehir A, Hechtman JF.",Mol Cancer Res. 2017 Jun;15(6):708-713. doi: 10.1158/1541-7786.MCR-16-0352. Epub 2017 Feb 9.,Mol Cancer Res.  2017,PubMed,citation,PMID:28184012 | PMCID:PMC5588907,pubmed,28184012,create date:2017/02/12 | first author:Ptashkin RN
Correlation between KRAS mutation and (18)F-FDG uptake in stage IV colorectal cancer.,/pubmed/28161825,"Cho A, Jo K, Hwang SH, Lee N, Jung M, Yun M, Hwang HS.",Abdom Radiol (NY). 2017 Jun;42(6):1621-1626. doi: 10.1007/s00261-017-1054-2.,Abdom Radiol (NY).  2017,PubMed,citation,PMID:28161825,pubmed,28161825,create date:2017/02/06 | first author:Cho A
[A Case of Unresectable Advanced Rectal Cancer with a Pancreatic Tumor That Was Successfully Treated with FOLFIRINOX].,/pubmed/28133357,"Yabe N, Murai S, Ozawa H, Yokose T, Oto I, Yoshikawa T, Kitasato K, Shimizu H, Kojima K, Hasegawa H, Kitagawa Y.",Gan To Kagaku Ryoho. 2016 Nov;43(12):2468-2470. Japanese. ,Gan To Kagaku Ryoho.  2016,PubMed,citation,PMID:28133357,pubmed,28133357,create date:2017/01/31 | first author:Yabe N
[A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification].,/pubmed/28133304,"Matsumoto A, Shimada Y, Yagi R, Miura K, Tajima Y, Okamura T, Nakano M, Kameyama H, Nogami H, Maruyama S, Takii Y, Ichikawa H, Sakata J, Kobayashi T, Wakai T.",Gan To Kagaku Ryoho. 2016 Nov;43(12):2307-2309. Japanese. ,Gan To Kagaku Ryoho.  2016,PubMed,citation,PMID:28133304,pubmed,28133304,create date:2017/01/31 | first author:Matsumoto A
[Unresectable Stage IV Sigmoid Colon Cancer with Extended Resection for Primary Tumor - A Case Report].,/pubmed/28133111,"Kimura Y, Suzuki N, Tomochika S, Inoue Y, Tanaka H, Tokuhisa Y, Iida M, Sakamoto K, Takeda S, Ueno T, Yamamoto S, Yoshino S, Hazama S, Nagano H.",Gan To Kagaku Ryoho. 2016 Nov;43(12):1724-1726. Japanese. ,Gan To Kagaku Ryoho.  2016,PubMed,citation,PMID:28133111,pubmed,28133111,create date:2017/01/31 | first author:Kimura Y
Totally laparoscopic anatomical liver resection for centrally located tumors: A single center experience.,/pubmed/28121916,"Kim WJ, Kim KH, Shin MH, Yoon YI, Lee SG.",Medicine (Baltimore). 2017 Jan;96(4):e5560. doi: 10.1097/MD.0000000000005560.,Medicine (Baltimore).  2017,PubMed,citation,PMID:28121916 | PMCID:PMC5287940,pubmed,28121916,create date:2017/01/26 | first author:Kim WJ
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.,/pubmed/28106826,"Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ.",Int J Mol Sci. 2017 Jan 19;18(1). pii: E197. doi: 10.3390/ijms18010197. Review.,Int J Mol Sci.  2017,PubMed,citation,PMID:28106826 | PMCID:PMC5297828,pubmed,28106826,create date:2017/01/21 | first author:Mármol I
[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].,/pubmed/28105616,Chen G.,Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Jan 25;20(1):28-33. Chinese. ,Zhonghua Wei Chang Wai Ke Za Zhi.  2017,PubMed,citation,PMID:28105616,pubmed,28105616,create date:2017/01/21 | first author:Chen G
Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge.,/pubmed/28104820,"Naboush A, Roman CA, Shapira I.",J Investig Med. 2017 Apr;65(4):754-758. doi: 10.1136/jim-2016-000342. Epub 2017 Jan 19. Review.,J Investig Med.  2017,PubMed,citation,PMID:28104820,pubmed,28104820,create date:2017/01/21 | first author:Naboush A
Erythropoietic protoporphyria a clinical and molecular study from Lebanon: Ferrochelatase a potential tumor suppressor gene in colon cancer.,/pubmed/28075030,"Kadara H, Nemer G, Safi R, Rebeiz N, Daou L, Delbani D, Btadini W, Abbas O, Tofaili M, Bitar F, Kibbi AG, Shimomura Y, Kurban M.",Clin Genet. 2017 Nov;92(5):495-502. doi: 10.1111/cge.12968. Epub 2017 Aug 2.,Clin Genet.  2017,PubMed,citation,PMID:28075030,pubmed,28075030,create date:2017/01/12 | first author:Kadara H
"Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.",/pubmed/28072717,"Schaefer T, Satzger I, Gutzmer R.",Medicine (Baltimore). 2017 Jan;96(1):e5753. doi: 10.1097/MD.0000000000005753.,Medicine (Baltimore).  2017,PubMed,citation,PMID:28072717 | PMCID:PMC5228677,pubmed,28072717,create date:2017/01/11 | first author:Schaefer T
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.,/pubmed/28053287,"Bruera G, Russo A, Galvano A, Rizzo S, Ricevuto E.",Oncotarget. 2017 Jun 6;8(23):37875-37883. doi: 10.18632/oncotarget.14333.,Oncotarget.  2017,PubMed,citation,PMID:28053287 | PMCID:PMC5514958,pubmed,28053287,create date:2017/01/06 | first author:Bruera G
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.,/pubmed/28045335,"Vincent MD, Breadner D, Soulieres D, Kerr IG, Sanatani M, Kocha W, Klimo P, MacKenzie MJ, O'Connell A, Whiston F, Malpage AS, Stitt L, Welch SA.",Future Oncol. 2017 Apr;13(9):777-786. doi: 10.2217/fon-2016-0444. Epub 2017 Jan 3.,Future Oncol.  2017,PubMed,citation,PMID:28045335,pubmed,28045335,create date:2017/01/04 | first author:Vincent MD
Detection of Sessile Serrated Adenomas in the Proximal Colon Using Wide-Field Fluorescence Endoscopy.,/pubmed/28012848,"Joshi BP, Dai Z, Gao Z, Lee JH, Ghimire N, Chen J, Prabhu A, Wamsteker EJ, Kwon RS, Elta GH, Stoffel EM, Pant A, Kaltenbach T, Soetikno RM, Appelman HD, Kuick R, Turgeon DK, Wang TD.",Gastroenterology. 2017 Apr;152(5):1002-1013.e9. doi: 10.1053/j.gastro.2016.12.009. Epub 2016 Dec 22.,Gastroenterology.  2017,PubMed,citation,PMID:28012848 | PMCID:PMC5771498,pubmed,28012848,create date:2016/12/26 | first author:Joshi BP
Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.,/pubmed/28008623,"Connell LC, Boucher TM, Chou JF, Capanu M, Maldonado S, Kemeny NE.",J Surg Oncol. 2017 Mar;115(4):480-487. doi: 10.1002/jso.24536. Epub 2016 Dec 23.,J Surg Oncol.  2017,PubMed,citation,PMID:28008623 | PMCID:PMC5400688,pubmed,28008623,create date:2016/12/23 | first author:Connell LC
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.,/pubmed/28006055,"Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.",JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.,JAMA Oncol.  2017,PubMed,citation,PMID:28006055 | PMCID:PMC5498991,pubmed,28006055,create date:2016/12/23 | first author:Sinicrope FA
A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience.,/pubmed/28003766,"Ranieri G, Niccoli Asabella A, Altini C, Fazio V, Caporusso L, Marech I, Vinciarelli G, Macina F, de Ceglia D, Fanelli M, Ammendola M, Rubini G, Gadaleta CD.",Onco Targets Ther. 2016 Dec 12;9:7527-7535. doi: 10.2147/OTT.S112670. eCollection 2016.,Onco Targets Ther.  2016,PubMed,citation,PMID:28003766 | PMCID:PMC5161393,pubmed,28003766,create date:2016/12/23 | first author:Ranieri G
Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases.,/pubmed/27995091,"Passot G, Soubrane O, Giuliante F, Zimmitti G, Goéré D, Yamashita S, Vauthey JN.",Liver Cancer. 2016 Nov;6(1):72-79. Epub 2016 Nov 29. Review.,Liver Cancer.  2016,PubMed,citation,PMID:27995091 | PMCID:PMC5159720,pubmed,27995091,create date:2016/12/21 | first author:Passot G
[Specificities of carcinomas in adolescents and young adults].,/pubmed/27989630,"Fresneau B, Dourthe ME, Jouin A, Laurence V, de Lambert G, Colas C, Coret M, Laprie A, Rebours C, Orbach D, Demoor-Goldschmidt C.",Bull Cancer. 2017 Mar;104(3):267-280. doi: 10.1016/j.bulcan.2016.11.013. Epub 2016 Dec 15. Review. French. ,Bull Cancer.  2017,PubMed,citation,PMID:27989630,pubmed,27989630,create date:2016/12/19 | first author:Fresneau B
Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.,/pubmed/27979806,"Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Nelson HH, Lynch CF, Pengo T, Thibodeau SN, Church TR, Cerhan JR, Anderson KE, Limburg PJ.",Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):622-631. doi: 10.1158/1055-9965.EPI-16-0641. Epub 2016 Dec 15.,Cancer Epidemiol Biomarkers Prev.  2017,PubMed,citation,PMID:27979806 | PMCID:PMC5380516,pubmed,27979806,create date:2016/12/17 | first author:Prizment AE
Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome.,/pubmed/27965933,"Koelzer VH, Steuer K, Gross UC, Zimmermann D, Paasinen-Sohns A, Mertz KD, Cathomas G.",Front Oncol. 2016 Nov 29;6:252. eCollection 2016.,Front Oncol.  2016,PubMed,citation,PMID:27965933 | PMCID:PMC5126084,pubmed,27965933,create date:2016/12/15 | first author:Koelzer VH
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.,/pubmed/27956538,"Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC.",J Natl Compr Canc Netw. 2016 Dec;14(12):1536-1543.,J Natl Compr Canc Netw.  2016,PubMed,citation,PMID:27956538 | PMCID:PMC5551390,pubmed,27956538,create date:2016/12/14 | first author:Atreya CE
[Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].,/pubmed/27928797,"Qiu H, Zhang P, Feng X, Chen T, Sun X, Yu J, Chen Z, Li Y, Tao K, Li G, Zhou Z.",Zhonghua Wei Chang Wai Ke Za Zhi. 2016 Nov 25;19(11):1265-1270. Chinese. ,Zhonghua Wei Chang Wai Ke Za Zhi.  2016,PubMed,citation,PMID:27928797,pubmed,27928797,create date:2016/12/09 | first author:Qiu H
The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers.,/pubmed/27924065,"Mahathre MM, Rida PC, Aneja R.",J Biomed Res. 2016 Nov;30(6):441-451. doi: 10.7555/JBR.30.20150109. Epub 2015 Nov 10. Review.,J Biomed Res.  2016,PubMed,citation,PMID:27924065 | PMCID:PMC5138576,pubmed,27924065,create date:2016/12/08 | first author:Mahathre MM
Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia.,/pubmed/27915339,"Aldiab A, Al Khayal KA, Al Obaid OA, Alsheikh A, Alsaleh K, Shahid M, Alkharji H.",Oncology. 2017;92(2):75-86. doi: 10.1159/000450857. Epub 2016 Dec 3.,Oncology.  2017,PubMed,citation,PMID:27915339,pubmed,27915339,create date:2016/12/05 | first author:Aldiab A
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.,/pubmed/27914130,"Jang MH, Kim S, Hwang DY, Kim WY, Lim SD, Kim WS, Hwang TS, Han HS.",J Korean Med Sci. 2017 Jan;32(1):38-46. doi: 10.3346/jkms.2017.32.1.38.,J Korean Med Sci.  2017,PubMed,citation,PMID:27914130 | PMCID:PMC5143296,pubmed,27914130,create date:2016/12/04 | first author:Jang MH
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.,/pubmed/27907852,"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V.",Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.,Eur J Cancer.  2017,PubMed,citation,PMID:27907852,pubmed,27907852,create date:2016/12/03 | first author:Holch JW
The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition.,/pubmed/27902462,"McAndrew EN, Lepage CC, McManus KJ.",Oncotarget. 2016 Dec 27;7(52):87417-87430. doi: 10.18632/oncotarget.13654.,Oncotarget.  2016,PubMed,citation,PMID:27902462 | PMCID:PMC5349998,pubmed,27902462,create date:2016/12/03 | first author:McAndrew EN
CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway.,/pubmed/27885175,"Rhee YY, Kim KJ, Kang GH.",Gut Liver. 2017 Jan 15;11(1):38-46. doi: 10.5009/gnl15535. Review.,Gut Liver.  2017,PubMed,citation,PMID:27885175 | PMCID:PMC5221859,pubmed,27885175,create date:2016/11/26 | first author:Rhee YY
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).,/pubmed/27881709,"Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR.",Oncologist. 2016 Dec;21(12):1509-1521. Epub 2016 Nov 23.,Oncologist.  2016,PubMed,citation,PMID:27881709 | PMCID:PMC5153338,pubmed,27881709,create date:2016/11/25 | first author:Singh PP
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.,/pubmed/27856123,"Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Nakajima T.",Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6.,Clin Colorectal Cancer.  2017,PubMed,citation,PMID:27856123,pubmed,27856123,create date:2016/11/20 | first author:Sunakawa Y
The evolving role of microsatellite instability in colorectal cancer: A review.,/pubmed/27838401,"Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S.",Cancer Treat Rev. 2016 Dec;51:19-26. doi: 10.1016/j.ctrv.2016.10.005. Epub 2016 Oct 27. Review.,Cancer Treat Rev.  2016,PubMed,citation,PMID:27838401,pubmed,27838401,create date:2016/11/14 | first author:Gelsomino F
Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia.,/pubmed/27837635,"Cavic M, Krivokuca A, Boljevic I, Brotto K, Jovanovic K, Tanic M, Filipovic L, Zec M, Malisic E, Jankovic R, Radulovic S.",J BUON. 2016 Sept-Oct;21(5):1287-1295.,J BUON.  2016,PubMed,citation,PMID:27837635,pubmed,27837635,create date:2016/11/13 | first author:Cavic M
Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer.,/pubmed/27836416,"Ghanipour L, Jirström K, Sundström M, Glimelius B, Birgisson H.",Eur J Surg Oncol. 2017 Feb;43(2):311-321. doi: 10.1016/j.ejso.2016.10.013. Epub 2016 Oct 31.,Eur J Surg Oncol.  2017,PubMed,citation,PMID:27836416,pubmed,27836416,create date:2016/11/12 | first author:Ghanipour L
Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer.,/pubmed/27835889,"Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS.",Oncotarget. 2016 Dec 6;7(49):81778-81790. doi: 10.18632/oncotarget.13207.,Oncotarget.  2016,PubMed,citation,PMID:27835889 | PMCID:PMC5348429,pubmed,27835889,create date:2016/11/12 | first author:Kwak Y
BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.,/pubmed/27815357,"Summers MG, Smith CG, Maughan TS, Kaplan R, Escott-Price V, Cheadle JP.",Clin Cancer Res. 2017 Jun 1;23(11):2742-2749. doi: 10.1158/1078-0432.CCR-16-1541. Epub 2016 Nov 4.,Clin Cancer Res.  2017,PubMed,citation,PMID:27815357,pubmed,27815357,create date:2016/11/07 | first author:Summers MG
No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.,/pubmed/27811854,"Jia M, Jansen L, Walter V, Tagscherer K, Roth W, Herpel E, Kloor M, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M.",Br J Cancer. 2016 Nov 22;115(11):1359-1366. doi: 10.1038/bjc.2016.361. Epub 2016 Nov 3.,Br J Cancer.  2016,PubMed,citation,PMID:27811854 | PMCID:PMC5129826,pubmed,27811854,create date:2016/11/05 | first author:Jia M
Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma.,/pubmed/27476040,"Ahadi M, Andrici J, Sioson L, Sheen A, Clarkson A, Gill AJ.",Hum Pathol. 2016 Nov;57:91-97. doi: 10.1016/j.humpath.2016.07.010. Epub 2016 Jul 27.,Hum Pathol.  2016,PubMed,citation,PMID:27476040,pubmed,27476040,create date:2016/10/25 | first author:Ahadi M
[A Case of Early Anal Canal Cancer with Pagetoid Spread with Different Antitumor Effects of Chemotherapy on Different Metastatic Sites].,/pubmed/27760964,"Yoshimatsu K, Osawa G, Yokomizo H, Yano Y, Okayama S, Sakuma A, Satake M, Yamada Y, Asaka S, Usui T, Yamaguchi K, Shiozawa S, Shimakawa T, Katsube T, Naritaka Y.",Gan To Kagaku Ryoho. 2016 Oct;43(10):1292-1294. Japanese. ,Gan To Kagaku Ryoho.  2016,PubMed,citation,PMID:27760964,pubmed,27760964,create date:2016/10/21 | first author:Yoshimatsu K
Transcription Factor ZBP-89 Drives a Feedforward Loop of β-Catenin Expression in Colorectal Cancer.,/pubmed/27758879,"Essien BE, Sundaresan S, Ocadiz-Ruiz R, Chavis A, Tsao AC, Tessier AJ, Hayes MM, Photenhauer A, Saqui-Salces M, Kang AJ, Shah YM, Győrffy B, Merchant JL.",Cancer Res. 2016 Dec 1;76(23):6877-6887. Epub 2016 Oct 10.,Cancer Res.  2016,PubMed,citation,PMID:27758879 | PMCID:PMC5379474,pubmed,27758879,create date:2016/10/21 | first author:Essien BE
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.,/pubmed/27743922,"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group..",Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12.,Lancet Oncol.  2016,PubMed,citation,PMID:27743922,pubmed,27743922,create date:2016/10/17 | first author:Franko J
Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.,/pubmed/27726953,"Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A.",Clin Colorectal Cancer. 2017 Jun;16(2):124-128. doi: 10.1016/j.clcc.2016.09.003. Epub 2016 Sep 17.,Clin Colorectal Cancer.  2017,PubMed,citation,PMID:27726953,pubmed,27726953,create date:2016/10/12 | first author:Zhang BY
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.,/pubmed/27722750,"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V.",JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742. ,JAMA Oncol.  2017,PubMed,citation,PMID:27722750,pubmed,27722750,create date:2016/10/11 | first author:Tejpar S
6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.,/pubmed/27710830,"Zhao Y, Fan D, Ru B, Cheng KW, Hu S, Zhang J, Li ET, Wang M.",Eur J Cancer. 2016 Nov;68:38-50. doi: 10.1016/j.ejca.2016.09.001. Epub 2016 Oct 4.,Eur J Cancer.  2016,PubMed,citation,PMID:27710830,pubmed,27710830,create date:2016/10/07 | first author:Zhao Y
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.,/pubmed/27698403,"Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.",Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.,Pharmacogenomics J.  2018,PubMed,citation,PMID:27698403 | PMCID:PMC5378677,pubmed,27698403,create date:2016/10/05 | first author:Sebio A
Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.,/pubmed/27672042,"Nakaji Y, Oki E, Nakanishi R, Ando K, Sugiyama M, Nakashima Y, Yamashita N, Saeki H, Oda Y, Maehara Y.",J Cancer Res Clin Oncol. 2017 Jan;143(1):151-160. doi: 10.1007/s00432-016-2275-4. Epub 2016 Sep 26.,J Cancer Res Clin Oncol.  2017,PubMed,citation,PMID:27672042,pubmed,27672042,create date:2016/09/28 | first author:Nakaji Y
Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy.,/pubmed/27670890,"Kinj R, Bondiau PY, François E, Gérard JP, Naghavi AO, Leysalle A, Chamorey E, Evesque L, Padovani B, Ianessi A, Benezery K, Doyen J.",Clin Colorectal Cancer. 2017 Sep;16(3):e211-e220. doi: 10.1016/j.clcc.2016.08.003. Epub 2016 Aug 31.,Clin Colorectal Cancer.  2017,PubMed,citation,PMID:27670890,pubmed,27670890,create date:2016/09/28 | first author:Kinj R
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.,/pubmed/27595400,"Wang Z, Liang L, Yu Y, Wang Y, Zhuang R, Chen Y, Cui Y, Zhou Y, Liu T.",Cell Physiol Biochem. 2016;39(3):1239-46. doi: 10.1159/000447829. Epub 2016 Sep 5.,Cell Physiol Biochem.  2016,PubMed,citation,PMID:27595400,pubmed,27595400,create date:2016/09/07 | first author:Wang Z
Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up.,/pubmed/27591037,"Boss JD, Lieu P, Tewari A.",BMJ Case Rep. 2016 Sep 2;2016. pii: bcr2016216273. doi: 10.1136/bcr-2016-216273.,BMJ Case Rep.  2016,PubMed,citation,PMID:27591037 | PMCID:PMC5020712,pubmed,27591037,create date:2016/09/04 | first author:Boss JD
Gene heterogeneity in metastasis of colorectal cancer to the lung.,/pubmed/27590223,"Hou J, Zhang Y, Zhu Z.",Semin Cell Dev Biol. 2017 Apr;64:58-64. doi: 10.1016/j.semcdb.2016.08.034. Epub 2016 Aug 31. Review.,Semin Cell Dev Biol.  2017,PubMed,citation,PMID:27590223,pubmed,27590223,create date:2016/09/04 | first author:Hou J
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.,/pubmed/27522626,"Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, Narita Y, Todaka A, Ishihara M, Yokota T, Tanaka T, Machida N, Kadowaki S, Fukutomi A, Ura T, Onozawa Y, Ando M, Tajika M, Muro K, Yasui H, Mori K, Taniguchi H.",Clin Colorectal Cancer. 2017 Mar;16(1):51-57. doi: 10.1016/j.clcc.2016.07.005. Epub 2016 Jul 21.,Clin Colorectal Cancer.  2017,PubMed,citation,PMID:27522626,pubmed,27522626,create date:2016/08/16 | first author:Hamauchi S
Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer.,/pubmed/27521480,"Martínez-Cardús A, Moran S, Musulen E, Moutinho C, Manzano JL, Martinez-Balibrea E, Tierno M, Élez E, Landolfi S, Lorden P, Arribas C, Müller F, Bock C, Tabernero J, Esteller M.",Gastroenterology. 2016 Nov;151(5):961-972. doi: 10.1053/j.gastro.2016.08.001. Epub 2016 Aug 10.,Gastroenterology.  2016,PubMed,citation,PMID:27521480,pubmed,27521480,create date:2016/08/16 | first author:Martínez-Cardús A
Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer.,/pubmed/27509333,"Takahashi Y, Sugai T, Habano W, Ishida K, Eizuka M, Otsuka K, Sasaki A, Takayuki Matsumoto, Morikawa T, Unno M, Suzuki H.",Int J Cancer. 2016 Dec 1;139(11):2493-501. doi: 10.1002/ijc.30377. Erratum in: Int J Cancer. 2017 Jan 1;140(1):E1. ,Int J Cancer.  2016,PubMed,citation,PMID:27509333 | PMCID:PMC5096113,pubmed,27509333,create date:2016/08/11 | first author:Takahashi Y
Regorafenib induced severe toxic hepatitis: characterization and discussion.,/pubmed/27500989,"Sacré A, Lanthier N, Dano H, Aydin S, Leggenhager D, Weber A, Dekairelle AF, De Cuyper A, Gala JL, Humblet Y, Sempoux C, Van den Eynde M.",Liver Int. 2016 Nov;36(11):1590-1594. doi: 10.1111/liv.13217. Epub 2016 Sep 6.,Liver Int.  2016,PubMed,citation,PMID:27500989,pubmed,27500989,create date:2016/08/09 | first author:Sacré A
A gene browser of colorectal cancer with literature evidence and pre-computed regulatory information to identify key tumor suppressors and oncogenes.,/pubmed/27477450,"Zhao M, Liu Y, Huang F, Qu H.",Sci Rep. 2016 Aug 1;6:30624. doi: 10.1038/srep30624.,Sci Rep.  2016,PubMed,citation,PMID:27477450 | PMCID:PMC4967895,pubmed,27477450,create date:2016/08/02 | first author:Zhao M
Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.,/pubmed/27466537,"Ploquin A, Zerimech F, Escande F, Adenis A, Giraud C, Gasnault L, Bourgeois V, Desauw C, Hebbar M.",Anticancer Res. 2016 Aug;36(8):4233-6.,Anticancer Res.  2016,PubMed,citation,PMID:27466537,pubmed,27466537,create date:2016/07/29 | first author:Ploquin A
Better survival in right-sided versus left-sided stage I - III colon cancer patients.,/pubmed/27464835,"Warschkow R, Sulz MC, Marti L, Tarantino I, Schmied BM, Cerny T, Güller U.",BMC Cancer. 2016 Jul 28;16:554. doi: 10.1186/s12885-016-2412-0.,BMC Cancer.  2016,PubMed,citation,PMID:27464835 | PMCID:PMC4964057,pubmed,27464835,create date:2016/07/29 | first author:Warschkow R
Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.,/pubmed/27442239,"Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T.",PLoS One. 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751. eCollection 2016.,PLoS One.  2016,PubMed,citation,PMID:27442239 | PMCID:PMC4956101,pubmed,27442239,create date:2016/07/22 | first author:Grande R
MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.,/pubmed/27438990,"Farchoukh L, Kuan SF, Dudley B, Brand R, Nikiforova M, Pai RK.",Am J Surg Pathol. 2016 Oct;40(10):1390-9. doi: 10.1097/PAS.0000000000000695.,Am J Surg Pathol.  2016,PubMed,citation,PMID:27438990,pubmed,27438990,create date:2016/07/21 | first author:Farchoukh L
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.,/pubmed/27435270,"Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C.",Int J Clin Oncol. 2016 Dec;21(6):1091-1101. Epub 2016 Jul 19.,Int J Clin Oncol.  2016,PubMed,citation,PMID:27435270,pubmed,27435270,create date:2016/07/21 | first author:Zhang X
"Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.",/pubmed/27434036,"Pugh SA, Bowers M, Ball A, Falk S, Finch-Jones M, Valle JW, O'Reilly DA, Siriwardena AK, Hornbuckle J, Rees M, Rees C, Iveson T, Hickish T, Maishman T, Stanton L, Dixon E, Corkhill A, Radford M, Garden OJ, Cunningham D, Maughan TS, Bridgewater JA, et al.",Br J Cancer. 2016 Aug 9;115(4):420-4. doi: 10.1038/bjc.2016.208. Epub 2016 Jul 19.,Br J Cancer.  2016,PubMed,citation,PMID:27434036 | PMCID:PMC4985352,pubmed,27434036,create date:2016/07/20 | first author:Pugh SA
Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses.,/pubmed/27430156,"Wu LS, Qian JY, Wang M, Yang H.",Mol Med Rep. 2016 Sep;14(3):2823-31. doi: 10.3892/mmr.2016.5528. Epub 2016 Jul 18.,Mol Med Rep.  2016,PubMed,citation,PMID:27430156,pubmed,27430156,create date:2016/07/20 | first author:Wu LS
SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.,/pubmed/27411517,"Lundberg IV, Edin S, Eklöf V, Öberg Å, Palmqvist R, Wikberg ML.",BMC Cancer. 2016 Jul 13;16:471. doi: 10.1186/s12885-016-2509-5.,BMC Cancer.  2016,PubMed,citation,PMID:27411517 | PMCID:PMC4944515,pubmed,27411517,create date:2016/07/15 | first author:Lundberg IV
"Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.",/pubmed/27398042,"Calcagno F, Lenoble S, Lakkis Z, Nguyen T, Limat S, Borg C, Jary M, Kim S, Nerich V.",Clin Med Insights Oncol. 2016 Jul 4;10:59-66. doi: 10.4137/CMO.S38335. eCollection 2016.,Clin Med Insights Oncol.  2016,PubMed,citation,PMID:27398042 | PMCID:PMC4933532,pubmed,27398042,create date:2016/07/12 | first author:Calcagno F
Mutation spectra of RAS gene family in colorectal cancer.,/pubmed/27394063,"Chang YY, Lin PC, Lin HH, Lin JK, Chen WS, Jiang JK, Yang SH, Liang WY, Chang SC.",Am J Surg. 2016 Sep;212(3):537-544.e3. doi: 10.1016/j.amjsurg.2016.02.013. Epub 2016 May 10.,Am J Surg.  2016,PubMed,citation,PMID:27394063,pubmed,27394063,create date:2016/07/11 | first author:Chang YY
Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.,/pubmed/27391152,"Mima K, Nowak JA, Qian ZR, Cao Y, Song M, Masugi Y, Shi Y, da Silva A, Gu M, Li W, Hamada T, Zhang X, Wu K, Meyerhardt JA, Baba H, Giovannucci EL, Chan AT, Fuchs CS, Ogino S, Nishihara R.",Oncotarget. 2016 Aug 23;7(34):55098-55109. doi: 10.18632/oncotarget.10398.,Oncotarget.  2016,PubMed,citation,PMID:27391152 | PMCID:PMC5342404,pubmed,27391152,create date:2016/07/09 | first author:Mima K
"Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.",/pubmed/27389564,"Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe LM, Etienne PL, Mineur L, Clisant S, Phelip JM, Kramar A, Andre T.",BMC Cancer. 2016 Jul 7;16:412. doi: 10.1186/s12885-016-2440-9. Erratum in: BMC Cancer. 2016 Jul 25;16(1):518. ,BMC Cancer.  2016,PubMed,citation,PMID:27389564 | PMCID:PMC4936193,pubmed,27389564,create date:2016/07/09 | first author:Adenis A
Human Blood Autoantibodies in the Detection of Colorectal Cancer.,/pubmed/27383396,"Negm OH, Hamed MR, Schoen RE, Whelan RL, Steele RJ, Scholefield J, Dilnot EM, Shantha Kumara HM, Robertson JF, Sewell HF.",PLoS One. 2016 Jul 6;11(7):e0156971. doi: 10.1371/journal.pone.0156971. eCollection 2016.,PLoS One.  2016,PubMed,citation,PMID:27383396 | PMCID:PMC4934916,pubmed,27383396,create date:2016/07/08 | first author:Negm OH
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.,/pubmed/27382031,"Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A.",Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5.,Oncologist.  2016,PubMed,citation,PMID:27382031 | PMCID:PMC4978565,pubmed,27382031,create date:2016/07/07 | first author:Moretto R
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.,/pubmed/27354468,"Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.",Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.,Clin Cancer Res.  2017,PubMed,citation,PMID:27354468,pubmed,27354468,create date:2016/06/30 | first author:Barras D
Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.,/pubmed/27352204,"Sasaki K, Margonis GA, Wilson A, Kim Y, Buettner S, Andreatos N, Gani F, Amini N, Spolverato G, Pawlik TM.",Ann Surg Oncol. 2016 Oct;23(11):3736-3743. doi: 10.1245/s10434-016-5361-6. Epub 2016 Jun 28.,Ann Surg Oncol.  2016,PubMed,citation,PMID:27352204,pubmed,27352204,create date:2016/06/29 | first author:Sasaki K
High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis.,/pubmed/27346571,"Watson R, Liu TC, Ruzinova MB.",Hum Pathol. 2016 Oct;56:163-70. doi: 10.1016/j.humpath.2016.06.010. Epub 2016 Jun 23.,Hum Pathol.  2016,PubMed,citation,PMID:27346571,pubmed,27346571,create date:2016/06/28 | first author:Watson R
Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis.,/pubmed/27331015,"Zhou M, Yu P, Hou K, Fu L, Chen Y, Qu J, Qu X, Liu Y, Zhang J.",Meta Gene. 2016 May 9;9:110-9. doi: 10.1016/j.mgene.2016.05.001. eCollection 2016 Sep.,Meta Gene.  2016,PubMed,citation,PMID:27331015 | PMCID:PMC4908286,pubmed,27331015,create date:2016/06/23 | first author:Zhou M
"Colorectal cancer in the young, many questions, few answers.",/pubmed/27326317,"Deen KI, Silva H, Deen R, Chandrasinghe PC.",World J Gastrointest Oncol. 2016 Jun 15;8(6):481-8. doi: 10.4251/wjgo.v8.i6.481. Review.,World J Gastrointest Oncol.  2016,PubMed,citation,PMID:27326317 | PMCID:PMC4909449,pubmed,27326317,create date:2016/06/22 | first author:Deen KI
Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era.,/pubmed/27326246,"Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS.",J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.,J Cancer.  2016,PubMed,citation,PMID:27326246 | PMCID:PMC4911870,pubmed,27326246,create date:2016/06/22 | first author:Kim ST
PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study.,/pubmed/27296289,"Kuramochi H, Nakamura A, Nakajima G, Kaneko Y, Araida T, Yamamoto M, Hayashi K.",BMC Cancer. 2016 Jun 13;16:366. doi: 10.1186/s12885-016-2400-4.,BMC Cancer.  2016,PubMed,citation,PMID:27296289 | PMCID:PMC4906685,pubmed,27296289,create date:2016/06/15 | first author:Kuramochi H
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.,/pubmed/27272216,"Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S.",Br J Cancer. 2016 Jun 14;114(12):1352-61. doi: 10.1038/bjc.2016.87. Epub 2016 Jun 7.,Br J Cancer.  2016,PubMed,citation,PMID:27272216 | PMCID:PMC4984478,pubmed,27272216,create date:2016/06/09 | first author:Lee MS
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.,/pubmed/27261210,"Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N.",Cancer Biol Ther. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048.,Cancer Biol Ther.  2016,PubMed,citation,PMID:27261210 | PMCID:PMC5004691,pubmed,27261210,create date:2016/06/05 | first author:Roma C
"Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.",/pubmed/27248473,"Javier BM, Yaeger R, Wang L, Sanchez-Vega F, Zehir A, Middha S, Sadowska J, Vakiani E, Shia J, Klimstra D, Ladanyi M, Iacobuzio-Donahue CA, Hechtman JF.",Oncotarget. 2016 Aug 9;7(32):50875-50882. doi: 10.18632/oncotarget.9682.,Oncotarget.  2016,PubMed,citation,PMID:27248473 | PMCID:PMC5239443,pubmed,27248473,create date:2016/06/02 | first author:Javier BM
Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.,/pubmed/27244540,"Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM.",Cancer. 2016 Sep 1;122(17):2698-707. doi: 10.1002/cncr.30085. Epub 2016 May 31.,Cancer.  2016,PubMed,citation,PMID:27244540,pubmed,27244540,create date:2016/06/01 | first author:Margonis GA
Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.,/pubmed/27239120,"Minarikova P, Benesova L, Halkova T, Belsanova B, Suchanek S, Cyrany J, Tuckova I, Bures J, Zavoral M, Minarik M.",World J Gastroenterol. 2016 May 28;22(20):4936-45. doi: 10.3748/wjg.v22.i20.4936.,World J Gastroenterol.  2016,PubMed,citation,PMID:27239120 | PMCID:PMC4873886,pubmed,27239120,create date:2016/05/31 | first author:Minarikova P
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.,/pubmed/27221731,"Chen KH, Shao YY, Chen HM, Lin YL, Lin ZZ, Lai MS, Cheng AL, Yeh KH.",BMC Cancer. 2016 May 24;16:327. doi: 10.1186/s12885-016-2358-2.,BMC Cancer.  2016,PubMed,citation,PMID:27221731 | PMCID:PMC4879738,pubmed,27221731,create date:2016/05/26 | first author:Chen KH
[Insights on colorectal carcinoma based on the biological differences between left-sided and right- sided colon cancers].,/pubmed/27188617,Xu JM.,Zhonghua Zhong Liu Za Zhi. 2016 May 23;38(5):397-400. doi: 10.3760/cma.j.issn.0253-3766.2016.05.016. Chinese. ,Zhonghua Zhong Liu Za Zhi.  2016,PubMed,citation,PMID:27188617,pubmed,27188617,create date:2016/05/18 | first author:Xu JM
DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.,/pubmed/27174913,"Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR.",Oncotarget. 2016 Jul 19;7(29):45144-45157. doi: 10.18632/oncotarget.9266.,Oncotarget.  2016,PubMed,citation,PMID:27174913 | PMCID:PMC5216712,pubmed,27174913,create date:2016/05/14 | first author:Wang D
Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.,/pubmed/27167335,"Suraweera N, Mouradov D, Li S, Jorissen RN, Hampson D, Ghosh A, Sengupta N, Thaha M, Ahmed S, Kirwan M, Aleva F, Propper D, Feakins RM, Vulliamy T, Elwood NJ, Tian P, Ward RL, Hawkins NJ, Xu ZZ, Molloy PL, Jones IT, Croxford M, et al.",Oncotarget. 2016 Jun 14;7(24):36474-36488. doi: 10.18632/oncotarget.9015.,Oncotarget.  2016,PubMed,citation,PMID:27167335 | PMCID:PMC5095014,pubmed,27167335,create date:2016/05/12 | first author:Suraweera N
Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.,/pubmed/27146902,"Dallol A, Buhmeida A, Al-Ahwal MS, Al-Maghrabi J, Bajouh O, Al-Khayyat S, Alam R, Abusanad A, Turki R, Elaimi A, Alhadrami HA, Abuzenadah M, Banni H, Al-Qahtani MH, Abuzenadah AM.",J Transl Med. 2016 May 4;14(1):118. doi: 10.1186/s12967-016-0878-9.,J Transl Med.  2016,PubMed,citation,PMID:27146902 | PMCID:PMC4857423,pubmed,27146902,create date:2016/05/06 | first author:Dallol A
Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival.,/pubmed/27131021,"Batur S, Vuralli Bakkaloglu D, Kepil N, Erdamar S.",Bosn J Basic Med Sci. 2016 Nov 10;16(4):254-260. doi: 10.17305/bjbms.2016.1238.,Bosn J Basic Med Sci.  2016,PubMed,citation,PMID:27131021 | PMCID:PMC5136760,pubmed,27131021,create date:2016/05/01 | first author:Batur S
Lack of BRAFV600E mutation in stage I and II of colorectal cancer.,/pubmed/27099668,"Molaei M, Kishani Farahani R, Maftouh M, Taleghani MY, Vahdatinia M, Khatami F, Nazemalhosseini-Mojarad E, Asadzadeh Aghdae H, Aboutorabi A, Zali MR.",Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):94-9.,Gastroenterol Hepatol Bed Bench.  2016,PubMed,citation,PMID:27099668 | PMCID:PMC4833847,pubmed,27099668,create date:2016/04/22 | first author:Molaei M
Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.,/pubmed/27096951,"Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, Morris D, Kelson M, Dolwani S.",PLoS One. 2016 Apr 20;11(4):e0152402. doi: 10.1371/journal.pone.0152402. eCollection 2016. Review.,PLoS One.  2016,PubMed,citation,PMID:27096951 | PMCID:PMC4838306,pubmed,27096951,create date:2016/04/21 | first author:Elwood PC
[Rare hereditary syndromes associated with polyposis and the development of malignant tumors].,/pubmed/27070770,"Kazubskaya TP, Kozlova VM, Filippova MG, Тrofimov EI, Belev NF, Sokolova IN, Tamrazov RI, Pavlovskaya AI, Kondratyeva TT.",Arkh Patol. 2016 Mar-Apr;78(2):10-18. doi: 10.17116/patol201678210-18. Review. Russian. ,Arkh Patol.  2016,PubMed,citation,PMID:27070770,pubmed,27070770,create date:2016/04/14 | first author:Kazubskaya TP
[A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab].,/pubmed/27067860,"Takagi H, Ariake K, Takemura S, Doi T.",Gan To Kagaku Ryoho. 2016 Mar;43(3):377-9. Japanese. ,Gan To Kagaku Ryoho.  2016,PubMed,citation,PMID:27067860,pubmed,27067860,create date:2016/04/14 | first author:Takagi H
Heterogeneity of KRAS Mutation Status in Rectal Cancer.,/pubmed/27064574,"Jo P, König A, Schirmer M, Kitz J, Conradi LC, Azizian A, Bernhardt M, Wolff HA, Grade M, Ghadimi M, Ströbel P, Schildhaus HU, Gaedcke J.",PLoS One. 2016 Apr 11;11(4):e0153278. doi: 10.1371/journal.pone.0153278. eCollection 2016.,PLoS One.  2016,PubMed,citation,PMID:27064574 | PMCID:PMC4827807,pubmed,27064574,create date:2016/04/12 | first author:Jo P
Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.,/pubmed/27061533,"Pantelic A, Markovic M, Pavlovic M, Jancic S.",J BUON. 2016 Jan-Feb;21(1):70-9.,J BUON.  2016,PubMed,citation,PMID:27061533,pubmed,27061533,create date:2016/04/12 | first author:Pantelic A
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.,/pubmed/27034263,"Chen KH, Lin YL, Liau JY, Tsai JH, Tseng LH, Lin LI, Liang JT, Lin BR, Hung JS, Chang YL, Yeh KH, Cheng AL.",Med Oncol. 2016 May;33(5):39. doi: 10.1007/s12032-016-0756-6. Epub 2016 Mar 31.,Med Oncol.  2016,PubMed,citation,PMID:27034263,pubmed,27034263,create date:2016/04/02 | first author:Chen KH
Modeling the Etiology of p53-mutated Cancer Cells.,/pubmed/27022024,"Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG.",J Biol Chem. 2016 May 6;291(19):10131-47. doi: 10.1074/jbc.M116.724781. Epub 2016 Mar 28.,J Biol Chem.  2016,PubMed,citation,PMID:27022024 | PMCID:PMC4858965,pubmed,27022024,create date:2016/03/30 | first author:Perez RE
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.,/pubmed/27009213,"Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R.",Mol Cancer Ther. 2016 Apr;15(4):533-47. doi: 10.1158/1535-7163.MCT-15-0643. Epub 2016 Mar 23. Review.,Mol Cancer Ther.  2016,PubMed,citation,PMID:27009213,pubmed,27009213,create date:2016/03/25 | first author:Turski ML
KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.,/pubmed/27004155,"Loaiza-Bonilla A, Jensen CE, Shroff S, Furth E, Bonilla-Reyes PA, Deik AF, Morrissette J.",Cureus. 2016 Feb 3;8(2):e478. doi: 10.7759/cureus.478.,Cureus.  2016,PubMed,citation,PMID:27004155 | PMCID:PMC4780686,pubmed,27004155,create date:2016/03/24 | first author:Loaiza-Bonilla A
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.,/pubmed/27002945,"Sunakawa Y, Bekaii-Saab T, Stintzing S.",Cancer Treat Rev. 2016 Apr;45:97-104. doi: 10.1016/j.ctrv.2016.03.007. Epub 2016 Mar 14. Review.,Cancer Treat Rev.  2016,PubMed,citation,PMID:27002945,pubmed,27002945,create date:2016/03/24 | first author:Sunakawa Y
Medullary carcinoma in the colorectum: a systematic review and meta-analysis.,/pubmed/27001432,"Pyo JS, Sohn JH, Kang G.",Hum Pathol. 2016 Jul;53:91-6. doi: 10.1016/j.humpath.2016.02.018. Epub 2016 Mar 19. Review.,Hum Pathol.  2016,PubMed,citation,PMID:27001432,pubmed,27001432,create date:2016/03/24 | first author:Pyo JS
Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis.,/pubmed/26963001,"Zong L, Abe M, Ji J, Zhu WG, Yu D.",Clin Transl Gastroenterol. 2016 Mar 10;7:e151. doi: 10.1038/ctg.2016.14.,Clin Transl Gastroenterol.  2016,PubMed,citation,PMID:26963001 | PMCID:PMC4822093,pubmed,26963001,create date:2016/03/11 | first author:Zong L
Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report.,/pubmed/26940557,"Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K.",World J Surg Oncol. 2016 Mar 3;14:63. doi: 10.1186/s12957-016-0818-4.,World J Surg Oncol.  2016,PubMed,citation,PMID:26940557 | PMCID:PMC4778273,pubmed,26940557,create date:2016/03/05 | first author:Goscinski MA
Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy.,/pubmed/26935130,"Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, Chang SC, Teng HW.",Asia Pac J Clin Oncol. 2016 Sep;12(3):207-15. doi: 10.1111/ajco.12469. Epub 2016 Mar 3.,Asia Pac J Clin Oncol.  2016,PubMed,citation,PMID:26935130,pubmed,26935130,create date:2016/03/05 | first author:Lu HJ
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.,/pubmed/26933125,"Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, Lee J, Kim KM, Gill AJ, Wang K, Gowen K, Sun J, Miller VA, Stephens PJ, Ali SM, Ross JS, Safran H.",Clin Cancer Res. 2016 Aug 1;22(15):3831-40. doi: 10.1158/1078-0432.CCR-15-3000. Epub 2016 Mar 1.,Clin Cancer Res.  2016,PubMed,citation,PMID:26933125,pubmed,26933125,create date:2016/03/05 | first author:Yakirevich E
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.,/pubmed/26927284,"Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, Lorenzini P, Ongaro E, Zoratto F, Catalano V, Sarti D, Rulli E, Cremolini C, De Nictolis M, De Maglio G, Falcone A, Fiorentini G, Magnani M.",Pharmacogenomics J. 2017 Jun;17(3):258-264. doi: 10.1038/tpj.2016.13. Epub 2016 Mar 1.,Pharmacogenomics J.  2017,PubMed,citation,PMID:26927284,pubmed,26927284,create date:2016/03/02 | first author:Graziano F
"Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.",/pubmed/26925640,"Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Nagai Y, Taniguchi H, Boku N, Ushijima T, Shimada Y.",Asian Pac J Cancer Prev. 2016;17(2):539-43.,Asian Pac J Cancer Prev.  2016,PubMed,citation,PMID:26925640,pubmed,26925640,create date:2016/03/02 | first author:Sasaki Y
"Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.",/pubmed/26892153,Ramalingam P.,Oncology (Williston Park). 2016 Feb;30(2):166-76. Review.,Oncology (Williston Park).  2016,PubMed,citation,PMID:26892153,pubmed,26892153,create date:2016/02/20 | first author:Ramalingam P
Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.,/pubmed/26883113,"Kim JH, Bae JM, Cho NY, Kang GH.",Oncotarget. 2016 Mar 22;7(12):14095-111. doi: 10.18632/oncotarget.7374.,Oncotarget.  2016,PubMed,citation,PMID:26883113 | PMCID:PMC4924700,pubmed,26883113,create date:2016/02/18 | first author:Kim JH
Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications.,/pubmed/26842924,Papagiorgis PC.,Tumour Biol. 2016 May;37(5):5727-34. doi: 10.1007/s13277-016-4913-5. Epub 2016 Feb 3. Review.,Tumour Biol.  2016,PubMed,citation,PMID:26842924,pubmed,26842924,create date:2016/02/05 | first author:Papagiorgis PC
Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.,/pubmed/26832770,"Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, Perez Mies B, Soslow RA, Lim RS, Viale A, Huberman KH, Palacios JC, Reis-Filho JS, Matias-Guiu X, Weigelt B.",J Natl Cancer Inst. 2016 Feb 1;108(6):djv427. doi: 10.1093/jnci/djv427. Print 2016 Jun.,J Natl Cancer Inst.  2016,PubMed,citation,PMID:26832770 | PMCID:PMC4909128,pubmed,26832770,create date:2016/02/03 | first author:Schultheis AM
Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis.,/pubmed/26824772,"Nitsche U, Stögbauer F, Späth C, Haller B, Wilhelm D, Friess H, Bader FG.",Dig Surg. 2016;33(2):157-63. doi: 10.1159/000443644. Epub 2016 Jan 30.,Dig Surg.  2016,PubMed,citation,PMID:26824772,pubmed,26824772,create date:2016/01/30 | first author:Nitsche U
Molecular dynamics simulation on the low sensitivity of mutants of NEDD-8 activating enzyme for MLN4924 inhibitor as a cancer drug.,/pubmed/26807320,"Rashidieh B, Valizadeh M, Assadollahi V, Ranjbar MM.",Am J Cancer Res. 2015 Oct 15;5(11):3400-6. eCollection 2015.,Am J Cancer Res.  2015,PubMed,citation,PMID:26807320 | PMCID:PMC4697686,pubmed,26807320,create date:2016/01/26 | first author:Rashidieh B
[A Case of Metachronous Multiple Thyroid Papillary Carcinoma with FAP].,/pubmed/26805188,"Tajima Y, Kumamoto K, Yamamoto A, Chika N, Watanabe Y, Matsuzawa T, Ishibashi K, Mochiki E, Iwama T, Akagi K, Ishida H.",Gan To Kagaku Ryoho. 2015 Nov;42(12):1833-5. Japanese. ,Gan To Kagaku Ryoho.  2015,PubMed,citation,PMID:26805188,pubmed,26805188,create date:2016/01/26 | first author:Tajima Y
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.,/pubmed/26804170,"Grassilli E, Pisano F, Cialdella A, Bonomo S, Missaglia C, Cerrito MG, Masiero L, Ianzano L, Giordano F, Cicirelli V, Narloch R, D'Amato F, Noli B, Ferri GL, Leone BE, Stanta G, Bonin S, Helin K, Giovannoni R, Lavitrano M.",Oncogene. 2016 Aug 18;35(33):4368-78. doi: 10.1038/onc.2015.504. Epub 2016 Jan 25.,Oncogene.  2016,PubMed,citation,PMID:26804170 | PMCID:PMC4994017,pubmed,26804170,create date:2016/01/26 | first author:Grassilli E
KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.,/pubmed/26786089,"Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, Hashimoto M, Kokudo N.",Ann Surg Oncol. 2016 Jun;23(6):1890-6. doi: 10.1245/s10434-016-5087-5. Epub 2016 Jan 19.,Ann Surg Oncol.  2016,PubMed,citation,PMID:26786089,pubmed,26786089,create date:2016/01/21 | first author:Shindoh J
Ileocecal adenocarcinoma with overexpression of P53 protein metastasized to the thenar muscle: report of a rare case and review of literature.,/pubmed/26722571,"Yi C, Liu Z, Chu Y, Li S, Liu L, Li J, Yu X.",Int J Clin Exp Pathol. 2015 Oct 1;8(10):13546-51. eCollection 2015.,Int J Clin Exp Pathol.  2015,PubMed,citation,PMID:26722571 | PMCID:PMC4680516,pubmed,26722571,create date:2016/01/02 | first author:Yi C
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?,/pubmed/26714964,"Price TJ, Beeke C, Townsend AR, Lo L, Amitesh R, Padbury R, Roder D, Maddern G, Moore J, Karapetis C.",Mol Diagn Ther. 2016 Feb;20(1):75-82. doi: 10.1007/s40291-015-0179-7.,Mol Diagn Ther.  2016,PubMed,citation,PMID:26714964,pubmed,26714964,create date:2015/12/31 | first author:Price TJ
Methylator phenotype in colorectal cancer: A prognostic factor or not?,/pubmed/26702883,"Gallois C, Laurent-Puig P, Taieb J.",Crit Rev Oncol Hematol. 2016 Mar;99:74-80. doi: 10.1016/j.critrevonc.2015.11.001. Epub 2015 Dec 7. Review.,Crit Rev Oncol Hematol.  2016,PubMed,citation,PMID:26702883,pubmed,26702883,create date:2015/12/26 | first author:Gallois C
"Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer.",/pubmed/26697204,"McAuliffe JC, Qadan M, D'Angelica MI.",J Gastrointest Oncol. 2015 Dec;6(6):699-708. doi: 10.3978/j.issn.2078-6891.2015.081. Review.,J Gastrointest Oncol.  2015,PubMed,citation,PMID:26697204 | PMCID:PMC4671858,pubmed,26697204,create date:2015/12/24 | first author:McAuliffe JC
Impact of somatic mutations on patterns of metastasis in colorectal cancer.,/pubmed/26697197,"Lipsyc M, Yaeger R.",J Gastrointest Oncol. 2015 Dec;6(6):645-9. doi: 10.3978/j.issn.2078-6891.2015.045. Review.,J Gastrointest Oncol.  2015,PubMed,citation,PMID:26697197 | PMCID:PMC4671855,pubmed,26697197,create date:2015/12/24 | first author:Lipsyc M
Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.,/pubmed/26675719,"Ulaganathan VK, Sperl B, Rapp UR, Ullrich A.",Nature. 2015 Dec 24;528(7583):570-4. doi: 10.1038/nature16449. Epub 2015 Dec 16.,Nature.  2015,PubMed,citation,PMID:26675719,pubmed,26675719,create date:2015/12/18 | first author:Ulaganathan VK
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.,/pubmed/26669312,"Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R.",Clin Transl Oncol. 2015 Dec;17(12):972-81. doi: 10.1007/s12094-015-1434-4. Epub 2015 Dec 15.,Clin Transl Oncol.  2015,PubMed,citation,PMID:26669312 | PMCID:PMC4689763,pubmed,26669312,create date:2015/12/17 | first author:Aranda E
Management of resectable colorectal lung metastases.,/pubmed/26659389,"Moorcraft SY, Ladas G, Bowcock A, Chau I.",Clin Exp Metastasis. 2016 Mar;33(3):285-96. doi: 10.1007/s10585-015-9774-6. Epub 2015 Dec 10. Review.,Clin Exp Metastasis.  2016,PubMed,citation,PMID:26659389,pubmed,26659389,create date:2015/12/15 | first author:Moorcraft SY
Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies.,/pubmed/26650777,"Jesinghaus M, Pfarr N, Kloor M, Endris V, Tavernar L, Muckenhuber A, von Knebel Doeberitz M, Penzel R, Weichert W, Stenzinger A.",Genes Chromosomes Cancer. 2016 Mar;55(3):268-77. doi: 10.1002/gcc.22330. Epub 2015 Dec 9.,Genes Chromosomes Cancer.  2016,PubMed,citation,PMID:26650777,pubmed,26650777,create date:2015/12/10 | first author:Jesinghaus M
Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol.,/pubmed/26646696,"Sun G, Cheng YW, Lai L, Huang TC, Wang J, Wu X, Wang Y, Huang Y, Wang J, Zhang K, Hu S, Yang JR, Yen Y.",Oncotarget. 2016 Jan 26;7(4):3857-72. doi: 10.18632/oncotarget.6460.,Oncotarget.  2016,PubMed,citation,PMID:26646696 | PMCID:PMC4826175,pubmed,26646696,create date:2015/12/10 | first author:Sun G
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.,/pubmed/26623049,"Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N.",Mol Clin Oncol. 2015 Sep;3(5):1053-1057. Epub 2015 Jul 9.,Mol Clin Oncol.  2015,PubMed,citation,PMID:26623049 | PMCID:PMC4534836,pubmed,26623049,create date:2015/12/02 | first author:Osumi H
[A Case of Complete Pathological Response in a Patient with Locally Advanced Sigmoid Colon Cancer after FOLFOX IRI Chemotherapy].,/pubmed/26602406,"Goto M, Okitsu H, Yuasa Y, Matsuo Y, Edagawa H, Tani R, Mori O, Kuramoto S, Tomibayashi A, Yamashita M, Fujii Y.",Gan To Kagaku Ryoho. 2015 Nov;42(11):1431-4. Japanese. ,Gan To Kagaku Ryoho.  2015,PubMed,citation,PMID:26602406,pubmed,26602406,create date:2015/11/26 | first author:Goto M
Sirt3 binds to and deacetylates mitochondrial pyruvate carrier 1 to enhance its activity.,/pubmed/26577410,"Liang L, Li Q, Huang L, Li D, Li X.",Biochem Biophys Res Commun. 2015 Dec 25;468(4):807-12. doi: 10.1016/j.bbrc.2015.11.036. Epub 2015 Nov 11.,Biochem Biophys Res Commun.  2015,PubMed,citation,PMID:26577410,pubmed,26577410,create date:2015/11/19 | first author:Liang L
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.,/pubmed/26575603,"Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D, De Maglio G, Fasola G, Calvetti L, Pilotto S, Carbognin L, Fontanini G, Tortora G, Falcone A, Sperduti I, Bria E.",Br J Cancer. 2016 Jan 12;114(1):30-6. doi: 10.1038/bjc.2015.399. Epub 2015 Nov 17.,Br J Cancer.  2016,PubMed,citation,PMID:26575603 | PMCID:PMC4716533,pubmed,26575603,create date:2015/11/18 | first author:Loupakis F
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.,/pubmed/26572750,"Lo L, Patel D, Townsend AR, Price TJ.",Expert Opin Drug Metab Toxicol. 2015;11(12):1907-24. doi: 10.1517/17425255.2015.1112787. Epub 2015 Nov 16. Review.,Expert Opin Drug Metab Toxicol.  2015,PubMed,citation,PMID:26572750,pubmed,26572750,create date:2015/11/18 | first author:Lo L
"Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.",/pubmed/26553611,"El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.",Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.,Cancer Biol Ther.  2015,PubMed,citation,PMID:26553611 | PMCID:PMC4847814,pubmed,26553611,create date:2015/11/11 | first author:El-Deiry WS
A case series of anal melanoma including the results of treatment with imatinib in selected patients.,/pubmed/26546509,"Knowles J, Lynch AC, Warrier SK, Henderson M, Heriot AG.",Colorectal Dis. 2016 Sep;18(9):877-82. doi: 10.1111/codi.13209.,Colorectal Dis.  2016,PubMed,citation,PMID:26546509,pubmed,26546509,create date:2015/11/08 | first author:Knowles J
rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population.,/pubmed/26543374,"Jiang QH, Peng HX, Zhang Y, Tian P, Xi ZL, Chen H.",Onco Targets Ther. 2015 Oct 22;8:3041-5. doi: 10.2147/OTT.S89746. eCollection 2015.,Onco Targets Ther.  2015,PubMed,citation,PMID:26543374 | PMCID:PMC4622418,pubmed,26543374,create date:2015/11/07 | first author:Jiang QH
Comparative analysis of 14-3-3 isoform expression and epigenetic alterations in colorectal cancer.,/pubmed/26518883,"Young GM, Radhakrishnan VM, Centuori SM, Gomes CJ, Martinez JD.",BMC Cancer. 2015 Oct 30;15:826. doi: 10.1186/s12885-015-1856-y.,BMC Cancer.  2015,PubMed,citation,PMID:26518883 | PMCID:PMC4628284,pubmed,26518883,create date:2015/11/01 | first author:Young GM
Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.,/pubmed/26512054,"Levine AJ, Phipps AI, Baron JA, Buchanan DD, Ahnen DJ, Cohen SA, Lindor NM, Newcomb PA, Rosty C, Haile RW, Laird PW, Weisenberger DJ.",Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):68-75. doi: 10.1158/1055-9965.EPI-15-0935. Epub 2015 Oct 28.,Cancer Epidemiol Biomarkers Prev.  2016,PubMed,citation,PMID:26512054 | PMCID:PMC4713308,pubmed,26512054,create date:2015/10/30 | first author:Levine AJ
Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis.,/pubmed/26503472,"Tricarico R, Cortellino S, Riccio A, Jagmohan-Changur S, Van der Klift H, Wijnen J, Turner D, Ventura A, Rovella V, Percesepe A, Lucci-Cordisco E, Radice P, Bertario L, Pedroni M, Ponz de Leon M, Mancuso P, Devarajan K, Cai KQ, Klein-Szanto AJ, Neri G, Møller P, Viel A, et al.",Oncotarget. 2015 Dec 15;6(40):42892-904. doi: 10.18632/oncotarget.5740.,Oncotarget.  2015,PubMed,citation,PMID:26503472 | PMCID:PMC4767479,pubmed,26503472,create date:2015/10/28 | first author:Tricarico R
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.,/pubmed/26496026,"Schafroth C, Galván JA, Centeno I, Koelzer VH, Dawson HE, Sokol L, Rieger G, Berger MD, Hädrich M, Rosenberg R, Nitsche U, Schnüriger B, Langer R, Inderbitzin D, Lugli A, Zlobec I.",Oncotarget. 2015 Dec 8;6(39):41453-63. doi: 10.18632/oncotarget.6162.,Oncotarget.  2015,PubMed,citation,PMID:26496026 | PMCID:PMC4747166,pubmed,26496026,create date:2015/10/27 | first author:Schafroth C
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?,/pubmed/26485756,"Maccaroni E, Bracci R, Giampieri R, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Del Prete M, Scartozzi M, Cascinu S.",Oncotarget. 2015 Nov 17;6(36):38737-48. doi: 10.18632/oncotarget.5395.,Oncotarget.  2015,PubMed,citation,PMID:26485756 | PMCID:PMC4770733,pubmed,26485756,create date:2015/10/21 | first author:Maccaroni E
Radiation promotes colorectal cancer initiation and progression by inducing senescence-associated inflammatory responses.,/pubmed/26477319,"Kim SB, Bozeman RG, Kaisani A, Kim W, Zhang L, Richardson JA, Wright WE, Shay JW.",Oncogene. 2016 Jun 30;35(26):3365-75. doi: 10.1038/onc.2015.395. Epub 2015 Oct 19.,Oncogene.  2016,PubMed,citation,PMID:26477319 | PMCID:PMC4837107,pubmed,26477319,create date:2015/10/20 | first author:Kim SB
Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.,/pubmed/26471487,"Chang SC, Lin PC, Lin JK, Lin CH, Yang SH, Liang WY, Chen WS, Jiang JK.",Ann Surg Oncol. 2016 Mar;23(3):849-55. doi: 10.1245/s10434-015-4899-z. Epub 2015 Oct 15.,Ann Surg Oncol.  2016,PubMed,citation,PMID:26471487,pubmed,26471487,create date:2015/10/17 | first author:Chang SC
"Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",/pubmed/26439693,"Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.",Oncotarget. 2015 Oct 27;6(33):34561-72. doi: 10.18632/oncotarget.5949.,Oncotarget.  2015,PubMed,citation,PMID:26439693 | PMCID:PMC4741473,pubmed,26439693,create date:2015/10/07 | first author:Lieu CH
c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer.,/pubmed/26426996,"Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB, Choe G, Kim WH, Lee HS.",PLoS One. 2015 Oct 1;10(10):e0139727. doi: 10.1371/journal.pone.0139727. eCollection 2015.,PLoS One.  2015,PubMed,citation,PMID:26426996 | PMCID:PMC4591346,pubmed,26426996,create date:2015/10/02 | first author:Lee KS
Prognostic Significance of Nuclear β-Catenin Expression in Patients with Colorectal Cancer from Iran.,/pubmed/26421170,"Nazemalhosseini Mojarad E, Kashfi SM, Mirtalebi H, Almasi S, Chaleshi V, Kishani Farahani R, Tarban P, Molaei M, Zali MR, J K Kuppen P.",Iran Red Crescent Med J. 2015 Jul 22;17(7):e22324. doi: 10.5812/ircmj.22324v2. eCollection 2015 Jul.,Iran Red Crescent Med J.  2015,PubMed,citation,PMID:26421170 | PMCID:PMC4584109,pubmed,26421170,create date:2015/10/01 | first author:Nazemalhosseini Mojarad E
Stool DNA methylation assays in colorectal cancer screening.,/pubmed/26401070,"Kadiyska T, Nossikoff A.",World J Gastroenterol. 2015 Sep 21;21(35):10057-61. doi: 10.3748/wjg.v21.i35.10057. Review.,World J Gastroenterol.  2015,PubMed,citation,PMID:26401070 | PMCID:PMC4572786,pubmed,26401070,create date:2015/09/25 | first author:Kadiyska T
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.,/pubmed/26384309,"Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, et al.",Oncotarget. 2015 Oct 13;6(31):31604-12. doi: 10.18632/oncotarget.5231.,Oncotarget.  2015,PubMed,citation,PMID:26384309 | PMCID:PMC4741627,pubmed,26384309,create date:2015/09/19 | first author:Vincenzi B
A phosphomimetic mutant of RelA/p65 at Ser536 induces apoptosis and senescence: An implication for tumor-suppressive role of Ser536 phosphorylation.,/pubmed/26375985,"Bu Y, Li X, He Y, Huang C, Shen Y, Cao Y, Huang D, Cai C, Wang Y, Wang Z, Liao DF, Cao D.",Int J Cancer. 2016 Mar 1;138(5):1186-98. doi: 10.1002/ijc.29852. Epub 2015 Oct 5.,Int J Cancer.  2016,PubMed,citation,PMID:26375985,pubmed,26375985,create date:2015/09/17 | first author:Bu Y
Frequent activation of the β-catenin gene in sporadic colorectal carcinomas: A mutational & expression analysis.,/pubmed/26373808,"Anwar M, Kochhar R, Singh R, Bhatia A, Vaiphei K, Mahmood A, Mahmood S.",Mol Carcinog. 2016 Nov;55(11):1627-1638. doi: 10.1002/mc.22414. Epub 2015 Sep 16.,Mol Carcinog.  2016,PubMed,citation,PMID:26373808,pubmed,26373808,create date:2015/09/17 | first author:Anwar M
Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway.,/pubmed/26361422,"Bae JM, Kim JH, Rhee YY, Cho NY, Kim TY, Kang GH.",World J Gastroenterol. 2015 Sep 7;21(33):9749-57. doi: 10.3748/wjg.v21.i33.9749.,World J Gastroenterol.  2015,PubMed,citation,PMID:26361422 | PMCID:PMC4562959,pubmed,26361422,create date:2015/09/12 | first author:Bae JM
Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.,/pubmed/26341410,"Vatandoust S, Price TJ, Ullah S, Roy AC, Beeke C, Young JP, Townsend A, Padbury R, Roder D, Karapetis CS.",Clin Colorectal Cancer. 2016 Mar;15(1):32-6. doi: 10.1016/j.clcc.2015.07.005. Epub 2015 Jul 30.,Clin Colorectal Cancer.  2016,PubMed,citation,PMID:26341410,pubmed,26341410,create date:2015/09/06 | first author:Vatandoust S
Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.,/pubmed/26311743,"Heerma van Voss MR, Vesuna F, Trumpi K, Brilliant J, Berlinicke C, de Leng W, Kranenburg O, Offerhaus GJ, Bürger H, van der Wall E, van Diest PJ, Raman V.",Oncotarget. 2015 Sep 29;6(29):28312-26. doi: 10.18632/oncotarget.4873.,Oncotarget.  2015,PubMed,citation,PMID:26311743 | PMCID:PMC4695062,pubmed,26311743,create date:2015/08/28 | first author:Heerma van Voss MR
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.,/pubmed/26305864,"Jorissen RN, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, Xu ZZ, Molloy PL, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, Busam D, Zhao Q, Strausberg RL, Lipton L, Desai J, Gibbs P, Sieber OM.",Br J Cancer. 2015 Sep 15;113(6):979-88. doi: 10.1038/bjc.2015.296. Epub 2015 Aug 25.,Br J Cancer.  2015,PubMed,citation,PMID:26305864 | PMCID:PMC4578087,pubmed,26305864,create date:2015/08/26 | first author:Jorissen RN
Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses.,/pubmed/26231173,"Imperatori A, Rotolo N, Dominioni L, Nardecchia E, Cattoni M, Cimetti L, Riva C, Sessa F, Furlan D.",BMC Cancer. 2015 Aug 1;15:567. doi: 10.1186/s12885-015-1585-2.,BMC Cancer.  2015,PubMed,citation,PMID:26231173 | PMCID:PMC4522059,pubmed,26231173,create date:2015/08/02 | first author:Imperatori A
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].,/pubmed/26228865,"De Divitiis C, Cassata A, Nasti G, Ottaiano A, Nappi A, Barretta ML, Iaffaioli RV.",Recenti Prog Med. 2015 Aug;106(8):e407-13. doi: 10.1701/1960.21312. Italian. ,Recenti Prog Med.  2015,PubMed,citation,PMID:26228865,pubmed,26228865,create date:2015/08/01 | first author:De Divitiis C
Molecular markers and pathway analysis of colorectal carcinoma in the Middle East.,/pubmed/26218848,"Beg S, Siraj AK, Prabhakaran S, Bu R, Al-Rasheed M, Sultana M, Qadri Z, Al-Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, Uddin S, Al-Kuraya KS.",Cancer. 2015 Nov 1;121(21):3799-808. doi: 10.1002/cncr.29580. Epub 2015 Jul 28.,Cancer.  2015,PubMed,citation,PMID:26218848,pubmed,26218848,create date:2015/07/29 | first author:Beg S
Occurrence of colon tumors in a 16-year-old Japanese boy after hematopoietic stem cell transplantation for Diamond Blackfan anemia at age of 4: a case report.,/pubmed/26191323,"Matsuda I, Tsuchida YA, Toyoshima F, Tozawa K, Ikehara H, Ohda Y, Hori K, Ohtsuka Y, Watari J, Miwa H, Hirota S.",Int J Clin Exp Pathol. 2015 May 1;8(5):5938-43. eCollection 2015.,Int J Clin Exp Pathol.  2015,PubMed,citation,PMID:26191323 | PMCID:PMC4503194,pubmed,26191323,create date:2015/07/21 | first author:Matsuda I
Rectal gastrointestinal stromal tumor as an incidental finding in a patient with rectal polyps.,/pubmed/26191322,"Zhou Y, Wu XD, Fan RG, zha WZ, Xu YH, Qing CL, Jia J.",Int J Clin Exp Pathol. 2015 May 1;8(5):5934-7. eCollection 2015.,Int J Clin Exp Pathol.  2015,PubMed,citation,PMID:26191322 | PMCID:PMC4503193,pubmed,26191322,create date:2015/07/21 | first author:Zhou Y
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).,/pubmed/26187617,"Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR; Alliance for Clinical Trials in Oncology..",Clin Cancer Res. 2015 Dec 1;21(23):5294-304. doi: 10.1158/1078-0432.CCR-15-0527. Epub 2015 Jul 17.,Clin Cancer Res.  2015,PubMed,citation,PMID:26187617 | PMCID:PMC4668228,pubmed,26187617,create date:2015/07/19 | first author:Sinicrope FA
"Colorectal Cancer Patient Characteristics, Treatment and Survival in Oman--a Single Center Study.",/pubmed/26163603,"Kumar S, Burney IA, Zahid KF, D Souza PC, Belushi MA, Mufti TD, Meki WA, Furrukh M, Moundhri MS.",Asian Pac J Cancer Prev. 2015;16(12):4853-8.,Asian Pac J Cancer Prev.  2015,PubMed,citation,PMID:26163603,pubmed,26163603,create date:2015/07/15 | first author:Kumar S
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.,/pubmed/26162609,"Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.",Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.,Ann Oncol.  2015,PubMed,citation,PMID:26162609 | PMCID:PMC4551162,pubmed,26162609,create date:2015/07/15 | first author:Sclafani F
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.,/pubmed/26153495,"Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F.",Ann Oncol. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290. Epub 2015 Jul 7.,Ann Oncol.  2015,PubMed,citation,PMID:26153495,pubmed,26153495,create date:2015/07/15 | first author:Cremolini C
Rectal and colon cancer: Not just a different anatomic site.,/pubmed/26145760,"Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA.",Cancer Treat Rev. 2015 Sep;41(8):671-9. doi: 10.1016/j.ctrv.2015.06.007. Epub 2015 Jun 28. Review.,Cancer Treat Rev.  2015,PubMed,citation,PMID:26145760,pubmed,26145760,create date:2015/07/07 | first author:Tamas K
Pulmonary enteric adenocarcinoma.,/pubmed/26139021,"Handa Y, Kai Y, Ikeda T, Mukaida H, Egawa H, Kaneko M.",Gen Thorac Cardiovasc Surg. 2016 Dec;64(12):749-751. Epub 2015 Jul 3.,Gen Thorac Cardiovasc Surg.  2016,PubMed,citation,PMID:26139021,pubmed,26139021,create date:2015/07/04 | first author:Handa Y
Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.,/pubmed/26130118,"Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D.",Circulation. 2015 Sep 1;132(9):834-47. doi: 10.1161/CIRCULATIONAHA.115.014207. Epub 2015 Jun 30.,Circulation.  2015,PubMed,citation,PMID:26130118,pubmed,26130118,create date:2015/07/02 | first author:Perros F
Current controversies in the management of metastatic colorectal cancer.,/pubmed/26113053,"Vera R, Alonso V, Gállego J, González E, Guillén-Ponce C, Pericay C, Rivera F, Safont MJ, Valladares-Ayerbes M.",Cancer Chemother Pharmacol. 2015 Oct;76(4):659-77. doi: 10.1007/s00280-015-2808-6. Epub 2015 Jun 26. Review.,Cancer Chemother Pharmacol.  2015,PubMed,citation,PMID:26113053,pubmed,26113053,create date:2015/06/27 | first author:Vera R
Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review and Meta-Analysis.,/pubmed/26107680,"Ling Y, Yang L, Huang H, Hu X, Zhao C, Huang H, Ying Y.",Medicine (Baltimore). 2015 Jun;94(25):e908. doi: 10.1097/MD.0000000000000908. Review.,Medicine (Baltimore).  2015,PubMed,citation,PMID:26107680 | PMCID:PMC4504590,pubmed,26107680,create date:2015/06/25 | first author:Ling Y
"Relationship between MLH-1, MSH-2, PMS-2,MSH-6 expression and clinicopathological features in colorectal cancer.",/pubmed/26097592,"Karahan B, Argon A, Yıldırım M, Vardar E.",Int J Clin Exp Pathol. 2015 Apr 1;8(4):4044-53. eCollection 2015.,Int J Clin Exp Pathol.  2015,PubMed,citation,PMID:26097592 | PMCID:PMC4466979,pubmed,26097592,create date:2015/06/23 | first author:Karahan B
Locoregional therapy and systemic cetuximab to treat colorectal liver metastases.,/pubmed/26090075,"Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Mugnoz FG, Cantore M, Ricci S, Catalano V, Mambrini A.",World J Gastrointest Oncol. 2015 Jun 15;7(6):47-54. doi: 10.4251/wjgo.v7.i6.47.,World J Gastrointest Oncol.  2015,PubMed,citation,PMID:26090075 | PMCID:PMC4468842,pubmed,26090075,create date:2015/06/20 | first author:Fiorentini G
Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease.,/pubmed/26085809,"Dharmadhikari AV, Szafranski P, Kalinichenko VV, Stankiewicz P.",Curr Genomics. 2015 Apr;16(2):107-16. doi: 10.2174/1389202916666150122223252.,Curr Genomics.  2015,PubMed,citation,PMID:26085809 | PMCID:PMC4467301,pubmed,26085809,create date:2015/06/19 | first author:Dharmadhikari AV
"Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.",/pubmed/26077004,"Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P.",Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11.,Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.  2015,PubMed,citation,PMID:26077004,pubmed,26077004,create date:2015/06/17 | first author:Uvirova M
Different treatment strategies and molecular features between right-sided and left-sided colon cancers.,/pubmed/26074686,"Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, Zhu LZ, Fang XF, Yuan Y.",World J Gastroenterol. 2015 Jun 7;21(21):6470-8. doi: 10.3748/wjg.v21.i21.6470. Review.,World J Gastroenterol.  2015,PubMed,citation,PMID:26074686 | PMCID:PMC4458758,pubmed,26074686,create date:2015/06/16 | first author:Shen H
A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases.,/pubmed/26064730,"Van Bael K, Jansen Y, Seremet T, Engels B, Delvaux G, Neyns B.",Case Rep Oncol Med. 2015;2015:472037. doi: 10.1155/2015/472037. Epub 2015 May 6.,Case Rep Oncol Med.  2015,PubMed,citation,PMID:26064730 | PMCID:PMC4438152,pubmed,26064730,create date:2015/06/13 | first author:Van Bael K
"Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction.",/pubmed/26046131,"Ding Z, Yang HW, Xia TS, Wang B, Ding Q.",Int J Mol Med. 2015 Aug;36(2):473-84. doi: 10.3892/ijmm.2015.2237. Epub 2015 Jun 5.,Int J Mol Med.  2015,PubMed,citation,PMID:26046131,pubmed,26046131,create date:2015/06/06 | first author:Ding Z
"Is Progression-Free Survival the Right End Point in Trials of Patients With Clearly Resectable, Borderline Resectable, and Unresectable Liver-Limited Colorectal Cancer?",/pubmed/26033812,Köhne CH.,J Clin Oncol. 2015 Jul 20;33(21):2406-7. doi: 10.1200/JCO.2014.60.7044. Epub 2015 Jun 1. No abstract available. ,J Clin Oncol.  2015,PubMed,citation,PMID:26033812,pubmed,26033812,create date:2015/06/03 | first author:Köhne CH
Microsatellite instability testing and its role in the management of colorectal cancer.,/pubmed/26031544,"Kawakami H, Zaanan A, Sinicrope FA.",Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2. Review.,Curr Treat Options Oncol.  2015,PubMed,citation,PMID:26031544 | PMCID:PMC4594190,pubmed,26031544,create date:2015/06/03 | first author:Kawakami H
"Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives.",/pubmed/26024321,"Brito H, Martins AC, Lavrado J, Mendes E, Francisco AP, Santos SA, Ohnmacht SA, Kim NS, Rodrigues CM, Moreira R, Neidle S, Borralho PM, Paulo A.",PLoS One. 2015 May 29;10(5):e0126891. doi: 10.1371/journal.pone.0126891. eCollection 2015.,PLoS One.  2015,PubMed,citation,PMID:26024321 | PMCID:PMC4449006,pubmed,26024321,create date:2015/05/30 | first author:Brito H
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.,/pubmed/25994739,"Phipps AI, Ahnen DJ, Cheng I, Newcomb PA, Win AK, Burnett T.",Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1046-51. doi: 10.1158/1055-9965.EPI-15-0204. Epub 2015 May 20.,Cancer Epidemiol Biomarkers Prev.  2015,PubMed,citation,PMID:25994739 | PMCID:PMC4490937,pubmed,25994739,create date:2015/05/23 | first author:Phipps AI
Types of Cancers Prevailing in Pakistan and their Management Evaluation.,/pubmed/25987010,"Tariq A, Majeed I, Khurshid A.",Asian Pac J Cancer Prev. 2015;16(9):3605-16. Review.,Asian Pac J Cancer Prev.  2015,PubMed,citation,PMID:25987010,pubmed,25987010,create date:2015/05/20 | first author:Tariq A
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.,/pubmed/25979833,"Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA.",Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.,Eur J Cancer.  2015,PubMed,citation,PMID:25979833,pubmed,25979833,create date:2015/05/17 | first author:Brulé SY
Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics.,/pubmed/25976417,"Hardikar S, Newcomb PA, Campbell PT, Win AK, Lindor NM, Buchanan DD, Makar KW, Jenkins MA, Potter JD, Phipps AI.",Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1130-7. doi: 10.1158/1055-9965.EPI-15-0039. Epub 2015 May 14.,Cancer Epidemiol Biomarkers Prev.  2015,PubMed,citation,PMID:25976417 | PMCID:PMC4491038,pubmed,25976417,create date:2015/05/16 | first author:Hardikar S
"Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.",/pubmed/25970543,"Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G.",PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015.,PLoS One.  2015,PubMed,citation,PMID:25970543 | PMCID:PMC4430485,pubmed,25970543,create date:2015/05/15 | first author:Pentheroudakis G
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT.,/pubmed/25961455,"Leszczynska KB, Foskolou IP, Abraham AG, Anbalagan S, Tellier C, Haider S, Span PN, O'Neill EE, Buffa FM, Hammond EM.",J Clin Invest. 2015 Jun;125(6):2385-98. doi: 10.1172/JCI80402. Epub 2015 May 11.,J Clin Invest.  2015,PubMed,citation,PMID:25961455 | PMCID:PMC4497762,pubmed,25961455,create date:2015/05/12 | first author:Leszczynska KB
"Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.",/pubmed/25956750,"Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.",BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.,BMC Cancer.  2015,PubMed,citation,PMID:25956750 | PMCID:PMC4445286,pubmed,25956750,create date:2015/05/10 | first author:Pectasides D
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.,/pubmed/25929517,"Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N.",BMC Cancer. 2015 May 1;15:340. doi: 10.1186/s12885-015-1345-3.,BMC Cancer.  2015,PubMed,citation,PMID:25929517 | PMCID:PMC4423107,pubmed,25929517,create date:2015/05/02 | first author:Li W
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.,/pubmed/25920435,"Lan YT, Jen-Kou L, Lin CH, Yang SH, Lin CC, Wang HS, Chen WS, Lin TC, Jiang JK, Chang SC.",J Surg Oncol. 2015 Jun;111(7):905-10. doi: 10.1002/jso.23895.,J Surg Oncol.  2015,PubMed,citation,PMID:25920435,pubmed,25920435,create date:2015/04/30 | first author:Lan YT
Technology Assessment of Molecular Pathology Testing for the Estimation of Prognosis for Common Cancers [Internet].,/pubmed/25905152,"Meleth S, Reeder-Hayes K, Ashok M, Clark R, Funkhouser W, Wines R, Hill C, Shanahan E, McClure E, Burson K, Coker-Schwimmer M, Garge N, Jonas DE.",Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 May 29.,2014,PubMed,citation,PMID:25905152,pubmed,25905152,create date:2015/04/24 | first author:Meleth S
BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.,/pubmed/25900832,"Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L.",Sci Signal. 2015 Apr 21;8(373):ra38. doi: 10.1126/scisignal.2005886.,Sci Signal.  2015,PubMed,citation,PMID:25900832,pubmed,25900832,create date:2015/04/23 | first author:Margalef P
Avoiding restorative proctocolectomy for colorectal cancer in patients with ulcerative colitis based on preoperative diagnosis involving p53 immunostaining: report of a case.,/pubmed/25888857,"Sada H, Shimomura M, Hinoi T, Egi H, Kawaguchi K, Yano T, Niitsu H, Saitou Y, Sawada H, Miguchi M, Adachi T, Ohdan H.",World J Surg Oncol. 2015 Mar 26;13:123. doi: 10.1186/s12957-015-0540-7.,World J Surg Oncol.  2015,PubMed,citation,PMID:25888857 | PMCID:PMC4377048,pubmed,25888857,create date:2015/04/19 | first author:Sada H
Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.,/pubmed/25887718,"Gleeson FC, Kipp BR, Voss JS, Campion MB, Minot DM, Tu ZJ, Klee EW, Graham RP, Lazaridis KN, Henry MR, Levy MJ.",Gastrointest Endosc. 2015 Sep;82(3):550-6.e1. doi: 10.1016/j.gie.2015.01.050. Epub 2015 Apr 14.,Gastrointest Endosc.  2015,PubMed,citation,PMID:25887718,pubmed,25887718,create date:2015/04/19 | first author:Gleeson FC
"A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.",/pubmed/25886136,"Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.",BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.,BMC Cancer.  2015,PubMed,citation,PMID:25886136 | PMCID:PMC4393591,pubmed,25886136,create date:2015/04/18 | first author:Kawazoe A
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.,/pubmed/25864038,"Deng Y, Wang L, Tan S, Kim GP, Dou R, Chen D, Cai Y, Fu X, Wang L, Zhu J, Wang J.",Mol Oncol. 2015 Aug;9(7):1341-7. doi: 10.1016/j.molonc.2015.03.006. Epub 2015 Mar 27.,Mol Oncol.  2015,PubMed,citation,PMID:25864038 | PMCID:PMC5528807,pubmed,25864038,create date:2015/04/13 | first author:Deng Y
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.,/pubmed/25862899,"Sideris M, Adams K, Moorhead J, Diaz-Cano S, Bjarnason I, Papagrigoriadis S.",Anticancer Res. 2015 Apr;35(4):2345-50.,Anticancer Res.  2015,PubMed,citation,PMID:25862899,pubmed,25862899,create date:2015/04/12 | first author:Sideris M
Factors affecting prognosis in metastatic colorectal cancer patients.,/pubmed/25854399,"Eker B, Ozaslan E, Karaca H, Berk V, Bozkurt O, Inanc M, Duran AO, Ozkan M.",Asian Pac J Cancer Prev. 2015;16(7):3015-21.,Asian Pac J Cancer Prev.  2015,PubMed,citation,PMID:25854399,pubmed,25854399,create date:2015/04/10 | first author:Eker B
"KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines.",/pubmed/25853628,"Lavrado J, Brito H, Borralho PM, Ohnmacht SA, Kim NS, Leitão C, Pisco S, Gunaratnam M, Rodrigues CM, Moreira R, Neidle S, Paulo A.",Sci Rep. 2015 Apr 8;5:9696. doi: 10.1038/srep09696.,Sci Rep.  2015,PubMed,citation,PMID:25853628 | PMCID:PMC5382548,pubmed,25853628,create date:2015/04/09 | first author:Lavrado J
Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.,/pubmed/25844824,"Charlton ME, Karlitz JJ, Schlichting JA, Chen VW, Lynch CF.",Am J Clin Oncol. 2017 Oct;40(5):498-506. doi: 10.1097/COC.0000000000000191.,Am J Clin Oncol.  2017,PubMed,citation,PMID:25844824 | PMCID:PMC4591083,pubmed,25844824,create date:2015/04/07 | first author:Charlton ME
Selected case from the Arkadi M. Rywlin International Pathology Slide Club: carcinoma of the transverse colon in a young girl.,/pubmed/25844680,"Galliani CA, Sanchez IC, D'Errico MM, Bisceglia M.",Adv Anat Pathol. 2015 May;22(3):217-24. doi: 10.1097/PAP.0000000000000068.,Adv Anat Pathol.  2015,PubMed,citation,PMID:25844680,pubmed,25844680,create date:2015/04/07 | first author:Galliani CA
EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression.,/pubmed/25836926,"Carethers JM, Koi M, Tseng-Rogenski SS.",Genes (Basel). 2015 Mar 31;6(2):185-205. doi: 10.3390/genes6020185. Review.,Genes (Basel).  2015,PubMed,citation,PMID:25836926 | PMCID:PMC4488660,pubmed,25836926,create date:2015/04/04 | first author:Carethers JM
KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.,/pubmed/25835782,"de Macêdo MP, de Melo FM, Lisboa BC, Andrade LD, de Souza Begnami MD, Junior SA, Ribeiro HS, Soares FA, Carraro DM, da Cunha IW.",Exp Mol Pathol. 2015 Jun;98(3):563-7. doi: 10.1016/j.yexmp.2015.03.038. Epub 2015 Mar 31.,Exp Mol Pathol.  2015,PubMed,citation,PMID:25835782,pubmed,25835782,create date:2015/04/04 | first author:de Macêdo MP
Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.,/pubmed/25809746,"Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes CE.",J Thromb Haemost. 2015 Jun;13(6):998-1003. doi: 10.1111/jth.12910. Epub 2015 Apr 23.,J Thromb Haemost.  2015,PubMed,citation,PMID:25809746,pubmed,25809746,create date:2015/03/27 | first author:Ades S
Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial.,/pubmed/25750322,"McGregor MJ, Fadhil W, Wharton R, Yanagisawa Y, Presz M, Pritchard A, Womack C, Dutton S, Kerr RS, Kerr DJ, Johnstone EC, Ilyas M.",Anticancer Res. 2015 Mar;35(3):1641-5.,Anticancer Res.  2015,PubMed,citation,PMID:25750322,pubmed,25750322,create date:2015/03/10 | first author:McGregor MJ
[A successful multimodality therapy for a case of recurrent rectal cancer with KRAS mutation].,/pubmed/25743147,"Watanabe A, Inada R, Nagasaka T, Yagi T, Matsumoto H, Toshima T, Mori Y, Kondo Y, Kishimoto H, Fujiwara T.",Gan To Kagaku Ryoho. 2015 Feb;42(2):237-9. Japanese. ,Gan To Kagaku Ryoho.  2015,PubMed,citation,PMID:25743147,pubmed,25743147,create date:2015/03/07 | first author:Watanabe A
Primary tumor location as a prognostic factor in metastatic colorectal cancer.,/pubmed/25713148,"Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.",J Natl Cancer Inst. 2015 Feb 24;107(3). pii: dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar.,J Natl Cancer Inst.  2015,PubMed,citation,PMID:25713148 | PMCID:PMC4565528,pubmed,25713148,create date:2015/02/26 | first author:Loupakis F
BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series.,/pubmed/25710585,"Boulagnon C, Dudez O, Beaudoux O, Dalstein V, Kianmanesh R, Bouché O, Diebold MD.",Appl Immunohistochem Mol Morphol. 2016 Feb;24(2):88-96. doi: 10.1097/PAI.0000000000000157.,Appl Immunohistochem Mol Morphol.  2016,PubMed,citation,PMID:25710585,pubmed,25710585,create date:2015/02/25 | first author:Boulagnon C
"Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.",/pubmed/25686118,"Foltran L, De Maglio G, Pella N, Ermacora P, Aprile G, Masiero E, Giovannoni M, Iaiza E, Cardellino GG, Lutrino SE, Mazzer M, Giangreco M, Pisa FE, Pizzolitto S, Fasola G.",Future Oncol. 2015;11(4):629-40. doi: 10.2217/fon.14.279.,Future Oncol.  2015,PubMed,citation,PMID:25686118,pubmed,25686118,create date:2015/02/17 | first author:Foltran L
KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.,/pubmed/25663779,"Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY.",World J Gastroenterol. 2015 Feb 7;21(5):1595-605. doi: 10.3748/wjg.v21.i5.1595.,World J Gastroenterol.  2015,PubMed,citation,PMID:25663779 | PMCID:PMC4316102,pubmed,25663779,create date:2015/02/11 | first author:Ye JX
Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.,/pubmed/25663765,"Bae JM, Lee TH, Cho NY, Kim TY, Kang GH.",World J Gastroenterol. 2015 Feb 7;21(5):1457-67. doi: 10.3748/wjg.v21.i5.1457.,World J Gastroenterol.  2015,PubMed,citation,PMID:25663765 | PMCID:PMC4316088,pubmed,25663765,create date:2015/02/11 | first author:Bae JM
Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.,/pubmed/25632202,"Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K.",World J Gastroenterol. 2015 Jan 28;21(4):1275-83. doi: 10.3748/wjg.v21.i4.1275.,World J Gastroenterol.  2015,PubMed,citation,PMID:25632202 | PMCID:PMC4306173,pubmed,25632202,create date:2015/01/30 | first author:Kadowaki S
Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.,/pubmed/25624727,"Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C.",World J Gastroenterol. 2015 Jan 21;21(3):926-34. doi: 10.3748/wjg.v21.i3.926.,World J Gastroenterol.  2015,PubMed,citation,PMID:25624727 | PMCID:PMC4299346,pubmed,25624727,create date:2015/01/28 | first author:Korphaisarn K
Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner.,/pubmed/25617735,"Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z, Qian W.",Biochem Biophys Res Commun. 2015 Feb 20;457(4):681-7. doi: 10.1016/j.bbrc.2015.01.048. Epub 2015 Jan 21.,Biochem Biophys Res Commun.  2015,PubMed,citation,PMID:25617735,pubmed,25617735,create date:2015/01/27 | first author:Qin A
TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.,/pubmed/25608838,"Spindler KL, Christensen IJ, Nielsen HJ, Jakobsen A, Brünner N.",Tumour Biol. 2015 Jun;36(6):4301-8. doi: 10.1007/s13277-015-3069-z. Epub 2015 Jan 23.,Tumour Biol.  2015,PubMed,citation,PMID:25608838,pubmed,25608838,create date:2015/01/23 | first author:Spindler KL
Traditional serrated adenomas (TSAs) admixed with other serrated (so-called precursor) polyps and conventional adenomas: a frequent occurrence.,/pubmed/25589791,"Chetty R, Hafezi-Bakhtiari S, Serra S, Colling R, Wang LM.",J Clin Pathol. 2015 Apr;68(4):270-3. doi: 10.1136/jclinpath-2014-202827. Epub 2015 Jan 14.,J Clin Pathol.  2015,PubMed,citation,PMID:25589791,pubmed,25589791,create date:2015/01/16 | first author:Chetty R
Management of colorectal cancer.,/pubmed/25580262,Stintzing S.,F1000Prime Rep. 2014 Nov 4;6:108. doi: 10.12703/P6-108. eCollection 2014. Review.,F1000Prime Rep.  2014,PubMed,citation,PMID:25580262 | PMCID:PMC4229728,pubmed,25580262,create date:2015/01/13 | first author:Stintzing S
CD44-SLC1A2 fusion transcripts in primary colorectal cancer.,/pubmed/25576211,"Shinmura K, Kato H, Igarashi H, Inoue Y, Nakamura S, Du C, Kurachi K, Nakamura T, Ogawa H, Tanahashi M, Niwa H, Sugimura H.",Pathol Oncol Res. 2015 Jul;21(3):759-64. doi: 10.1007/s12253-014-9887-2. Epub 2015 Jan 10.,Pathol Oncol Res.  2015,PubMed,citation,PMID:25576211,pubmed,25576211,create date:2015/01/13 | first author:Shinmura K
Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors.,/pubmed/25576161,"Veganzones S, Maestro ML, Rafael S, de la Orden V, Vidaurreta M, Mediero B, Espantaleón M, Cerdán J, Díaz-Rubio E.",Tumour Biol. 2015 May;36(5):3853-61. doi: 10.1007/s13277-014-3027-1. Epub 2015 Jan 10.,Tumour Biol.  2015,PubMed,citation,PMID:25576161,pubmed,25576161,create date:2015/01/13 | first author:Veganzones S
"Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.",/pubmed/25572811,"Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Lonati V, Ghilardi M, Barni S.",Med Oncol. 2015 Feb;32(2):456. doi: 10.1007/s12032-014-0456-z. Epub 2015 Jan 9. Review.,Med Oncol.  2015,PubMed,citation,PMID:25572811,pubmed,25572811,create date:2015/01/13 | first author:Petrelli F
Medullary colorectal carcinoma revisited: a clinical and pathological study of 102 cases.,/pubmed/25572685,"Knox RD, Luey N, Sioson L, Kedziora A, Clarkson A, Watson N, Toon CW, Cussigh C, Pincott S, Pillinger S, Salama Y, Evans J, Percy J, Schnitzler M, Engel A, Gill AJ.",Ann Surg Oncol. 2015 Sep;22(9):2988-96. doi: 10.1245/s10434-014-4355-5. Epub 2015 Jan 9.,Ann Surg Oncol.  2015,PubMed,citation,PMID:25572685,pubmed,25572685,create date:2015/01/13 | first author:Knox RD
How does the serrated polyp pathway alter CRC screening and surveillance?,/pubmed/25556584,Kahi CJ.,Dig Dis Sci. 2015 Mar;60(3):773-80. doi: 10.1007/s10620-014-3449-z. Epub 2015 Jan 4. Review.,Dig Dis Sci.  2015,PubMed,citation,PMID:25556584,pubmed,25556584,create date:2015/01/06 | first author:Kahi CJ
ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.,/pubmed/25534115,"Shi Y, Han Y, Xie F, Wang A, Feng X, Li N, Guo H, Chen D.",J Cell Mol Med. 2015 Mar;19(3):535-43. doi: 10.1111/jcmm.12435. Epub 2014 Dec 23.,J Cell Mol Med.  2015,PubMed,citation,PMID:25534115 | PMCID:PMC4369811,pubmed,25534115,create date:2014/12/24 | first author:Shi Y
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.,/pubmed/25532759,"Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ.",Pharmacogenomics J. 2015 Aug;15(4):354-62. doi: 10.1038/tpj.2014.73. Epub 2014 Dec 23.,Pharmacogenomics J.  2015,PubMed,citation,PMID:25532759 | PMCID:PMC4478287,pubmed,25532759,create date:2014/12/24 | first author:Maus MK
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.,/pubmed/25491172,"Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N.",Cancer. 2015 Apr 15;121(8):1195-203. doi: 10.1002/cncr.29196. Epub 2014 Dec 9.,Cancer.  2015,PubMed,citation,PMID:25491172 | PMCID:PMC4523078,pubmed,25491172,create date:2014/12/11 | first author:Yaeger R
"Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon.",/pubmed/25477374,"Pekow J, Meckel K, Dougherty U, Butun F, Mustafi R, Lim J, Crofton C, Chen X, Joseph L, Bissonnette M.",Am J Physiol Gastrointest Liver Physiol. 2015 Feb 1;308(3):G179-87. doi: 10.1152/ajpgi.00208.2014. Epub 2014 Dec 4.,Am J Physiol Gastrointest Liver Physiol.  2015,PubMed,citation,PMID:25477374 | PMCID:PMC4312953,pubmed,25477374,create date:2014/12/06 | first author:Pekow J
Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis.,/pubmed/25437589,"Toiyama Y, Inoue Y, Kitajima T, Okigami M, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Mohri Y, Kusunoki M.",Int Surg. 2014 Nov-Dec;99(6):795-801. doi: 10.9738/INTSURG-D-13-00125.1.,Int Surg.  2014,PubMed,citation,PMID:25437589 | PMCID:PMC4254242,pubmed,25437589,create date:2014/12/02 | first author:Toiyama Y
Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.,/pubmed/28548075,"Della Corte CM, Fasano M, Papaccio F, Ciardiello F, Morgillo F.",Biomedicines. 2014 Nov 25;2(4):345-358. doi: 10.3390/biomedicines2040345. Review.,Biomedicines.  2014,PubMed,citation,PMID:28548075 | PMCID:PMC5344276,pubmed,28548075,create date:2014/11/25 | first author:Della Corte CM
The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?,/pubmed/25400031,"Lien K, Berry S, Ko YJ, Chan KK.",Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):81-100. doi: 10.1586/14737167.2015.982100. Epub 2014 Nov 17. Review.,Expert Rev Pharmacoecon Outcomes Res.  2015,PubMed,citation,PMID:25400031,pubmed,25400031,create date:2014/11/18 | first author:Lien K
"Integrative genomic analyses of a novel cytokine, interleukin-34 and its potential role in cancer prediction.",/pubmed/25395235,"Wang B, Xu W, Tan M, Xiao Y, Yang H, Xia TS.",Int J Mol Med. 2015 Jan;35(1):92-102. doi: 10.3892/ijmm.2014.2001. Epub 2014 Nov 12.,Int J Mol Med.  2015,PubMed,citation,PMID:25395235 | PMCID:PMC4249750,pubmed,25395235,create date:2014/11/15 | first author:Wang B
Update on the role of imaging in management of metastatic colorectal cancer.,/pubmed/25384292,"Tirumani SH, Kim KW, Nishino M, Howard SA, Krajewski KM, Jagannathan JP, Cleary JM, Ramaiya NH, Shinagare AB.",Radiographics. 2014 Nov-Dec;34(7):1908-28. doi: 10.1148/rg.347130090. Review.,Radiographics.  2014,PubMed,citation,PMID:25384292 | PMCID:PMC4386871,pubmed,25384292,create date:2014/11/11 | first author:Tirumani SH
Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study.,/pubmed/25379857,"Viganò L, Russolillo N, Ferrero A, De Rosa G, Ferreri E, Forchino F, Sperti E, Capussotti L.",Ann Surg. 2014 Nov;260(5):878-84; discussion 884-5. doi: 10.1097/SLA.0000000000000981.,Ann Surg.  2014,PubMed,citation,PMID:25379857,pubmed,25379857,create date:2014/11/08 | first author:Viganò L
microRNA-338-3p functions as a tumor suppressor in human non‑small‑cell lung carcinoma and targets Ras-related protein 14.,/pubmed/25374067,"Sun J, Feng X, Gao S, Xiao Z.",Mol Med Rep. 2015 Feb;11(2):1400-6. doi: 10.3892/mmr.2014.2880. Epub 2014 Nov 6.,Mol Med Rep.  2015,PubMed,citation,PMID:25374067,pubmed,25374067,create date:2014/11/07 | first author:Sun J
Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer.,/pubmed/25366420,"Szmida E, Karpiński P, Leszczynski P, Sedziak T, Kielan W, Ostasiewicz P, Sasiadek MM.",J Appl Genet. 2015 May;56(2):185-92. doi: 10.1007/s13353-014-0253-6. Epub 2014 Nov 1.,J Appl Genet.  2015,PubMed,citation,PMID:25366420 | PMCID:PMC4412553,pubmed,25366420,create date:2014/11/05 | first author:Szmida E
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.,/pubmed/25361982,"Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.",Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.,Ann Oncol.  2015,PubMed,citation,PMID:25361982,pubmed,25361982,create date:2014/11/02 | first author:Klingbiel D
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.,/pubmed/25359494,"Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R.",FASEB J. 2015 Feb;29(2):464-76. doi: 10.1096/fj.14-262303. Epub 2014 Oct 30.,FASEB J.  2015,PubMed,citation,PMID:25359494,pubmed,25359494,create date:2014/11/02 | first author:Alamo P
Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA.,/pubmed/25342468,"Kuwano Y, Nishida K, Kajita K, Satake Y, Akaike Y, Fujita K, Kano S, Masuda K, Rokutan K.",Cell Death Differ. 2015 May;22(5):815-25. doi: 10.1038/cdd.2014.176. Epub 2014 Oct 24.,Cell Death Differ.  2015,PubMed,citation,PMID:25342468 | PMCID:PMC4392078,pubmed,25342468,create date:2014/10/25 | first author:Kuwano Y
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.,/pubmed/25337237,"Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.",Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.,Int J Clin Exp Pathol.  2014,PubMed,citation,PMID:25337237 | PMCID:PMC4203208,pubmed,25337237,create date:2014/10/23 | first author:Kleist B
CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer.,/pubmed/25326260,"Rosenthal MH, Kim KW, Fuchs CS, Meyerhardt JA, Ramaiya NH.",Abdom Imaging. 2015 Jun;40(5):1170-6. doi: 10.1007/s00261-014-0272-0.,Abdom Imaging.  2015,PubMed,citation,PMID:25326260 | PMCID:PMC4402111,pubmed,25326260,create date:2014/10/19 | first author:Rosenthal MH
Cdx1 and Cdx2 function as tumor suppressors.,/pubmed/25320087,"Hryniuk A, Grainger S, Savory JG, Lohnes D.",J Biol Chem. 2014 Nov 28;289(48):33343-54. doi: 10.1074/jbc.M114.583823. Epub 2014 Oct 15.,J Biol Chem.  2014,PubMed,citation,PMID:25320087 | PMCID:PMC4246091,pubmed,25320087,create date:2014/10/17 | first author:Hryniuk A
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.,/pubmed/25305506,"Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.",Gastroenterology. 2015 Jan;148(1):88-99. doi: 10.1053/j.gastro.2014.09.041. Epub 2014 Oct 8.,Gastroenterology.  2015,PubMed,citation,PMID:25305506 | PMCID:PMC4274188,pubmed,25305506,create date:2014/10/12 | first author:Sinicrope FA
[Proctocolectomy with ileoanal anastomoses and desmoid tumor treated with resection. One case of familial adenomatous polyposis].,/pubmed/25301135,"Villalón-López JS, Souto-del Bosque R, Méndez-Sashida PG.",Rev Med Inst Mex Seguro Soc. 2014 Sep-Oct;52(5):594-7. Spanish. ,Rev Med Inst Mex Seguro Soc.  2014,PubMed,citation,PMID:25301135,pubmed,25301135,create date:2014/10/11 | first author:Villalón-López JS
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.,/pubmed/25294886,"Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J; PETACC-8 Study Investigators..",Ann Oncol. 2014 Dec;25(12):2378-85. doi: 10.1093/annonc/mdu464. Epub 2014 Oct 6. Erratum in: Ann Oncol. 2015 Apr;26(4):822-5. ,Ann Oncol.  2014,PubMed,citation,PMID:25294886,pubmed,25294886,create date:2014/10/09 | first author:Blons H
Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment.,/pubmed/25275049,"Vanacker L, Smeets D, Hoorens A, Teugels E, Algaba R, Dehou MF, De Becker A, Lambrechts D, De Greve J.",Anticancer Res. 2014 Oct;34(10):5517-21.,Anticancer Res.  2014,PubMed,citation,PMID:25275049,pubmed,25275049,create date:2014/10/03 | first author:Vanacker L
Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.,/pubmed/26842186,"Veldore VH, Rao MR, Prabhudesai SA, Tejaswi R, Kakara S, Pattanayak S, Krishnamoorthy N, Tejaswini BN, Hazarika D, Gangoli A, Rahman SM, Dixit J, Naik R, Diwakar RB, Satheesh CT, Shashidhara HP, Patil S, Gopinath KS, Kumar BS.",Indian J Cancer. 2014 Oct-Dec;51(4):531-7. doi: 10.4103/0019-509X.175371.,Indian J Cancer.  2014,PubMed,citation,PMID:26842186,pubmed,26842186,create date:2014/10/01 | first author:Veldore VH
"Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.",/pubmed/25261368,"Ress AL, Stiegelbauer V, Schwarzenbacher D, Deutsch A, Perakis S, Ling H, Ivan C, Calin GA, Rinner B, Gerger A, Pichler M.",Oncotarget. 2014 Sep 30;5(18):8492-502.,Oncotarget.  2014,PubMed,citation,PMID:25261368 | PMCID:PMC4226699,pubmed,25261368,create date:2014/09/28 | first author:Ress AL
PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis.,/pubmed/25260023,"Shan L, Li M, Ma J, Zhang H.",PLoS One. 2014 Sep 26;9(9):e107926. doi: 10.1371/journal.pone.0107926. eCollection 2014. Review.,PLoS One.  2014,PubMed,citation,PMID:25260023 | PMCID:PMC4178055,pubmed,25260023,create date:2014/09/27 | first author:Shan L
MicroRNA-31 expression in colorectal serrated pathway progression.,/pubmed/25232271,"Aoki H, Nosho K, Igarashi H, Ito M, Mitsuhashi K, Naito T, Yamamoto E, Tanuma T, Nomura M, Maguchi H, Shinohara T, Suzuki H, Yamamoto H, Shinomura Y.",World J Gastroenterol. 2014 Sep 14;20(34):12346-9. doi: 10.3748/wjg.v20.i34.12346.,World J Gastroenterol.  2014,PubMed,citation,PMID:25232271 | PMCID:PMC4161822,pubmed,25232271,create date:2014/09/19 | first author:Aoki H
Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection.,/pubmed/25221563,Mansour H.,Front Genet. 2014 Aug 27;5:182. doi: 10.3389/fgene.2014.00182. eCollection 2014. Review.,Front Genet.  2014,PubMed,citation,PMID:25221563 | PMCID:PMC4145725,pubmed,25221563,create date:2014/09/16 | first author:Mansour H
[Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population].,/pubmed/25216999,"Cabrera-Mendoza F, Gainza-Lagunes S, Castañeda-Andrade I, Castro-Zárate A.",Rev Gastroenterol Mex. 2014 Jul-Sep;79(3):166-70. doi: 10.1016/j.rgmx.2014.07.002. Epub 2014 Sep 10. Spanish. ,Rev Gastroenterol Mex.  2014,PubMed,citation,PMID:25216999,pubmed,25216999,create date:2014/09/14 | first author:Cabrera-Mendoza F
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.,/pubmed/25183481,"Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S.",Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348.,Clin Cancer Res.  2014,PubMed,citation,PMID:25183481 | PMCID:PMC4155520,pubmed,25183481,create date:2014/09/04 | first author:Saridaki Z
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.,/pubmed/25164765,"Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF.",Genome Biol. 2014 Aug 28;15(8):454. doi: 10.1186/s13059-014-0454-7.,Genome Biol.  2014,PubMed,citation,PMID:25164765 | PMCID:PMC4189196,pubmed,25164765,create date:2014/08/29 | first author:Brannon AR
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.,/pubmed/25155157,"Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong YC, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI.",Cancer. 2014 Dec 15;120(24):3965-71. doi: 10.1002/cncr.28954. Epub 2014 Aug 25.,Cancer.  2014,PubMed,citation,PMID:25155157 | PMCID:PMC4574496,pubmed,25155157,create date:2014/08/27 | first author:Kemeny NE
[Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as first-line treatment-a case report].,/pubmed/25131880,"Harada K, Hatanaka K, Kinoshita K, Kawamoto Y, Yamato H, Ogawa K, Yamamoto Y, Naruse H.",Gan To Kagaku Ryoho. 2014 Jul;41(7):897-900. Japanese. ,Gan To Kagaku Ryoho.  2014,PubMed,citation,PMID:25131880,pubmed,25131880,create date:2014/08/19 | first author:Harada K
Morphologic and molecular characterization of traditional serrated adenomas of the distal colon and rectum.,/pubmed/25127095,"Wiland HO 4th, Shadrach B, Allende D, Carver P, Goldblum JR, Liu X, Patil DT, Rybicki LA, Pai RK.",Am J Surg Pathol. 2014 Sep;38(9):1290-7. doi: 10.1097/PAS.0000000000000253.,Am J Surg Pathol.  2014,PubMed,citation,PMID:25127095,pubmed,25127095,create date:2014/08/16 | first author:Wiland HO 4th
The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.,/pubmed/25126956,"Olsen J, Espersen ML, Jess P, Kirkeby LT, Troelsen JT.",Surg Oncol. 2014 Sep;23(3):167-76. doi: 10.1016/j.suronc.2014.07.003. Epub 2014 Jul 17. Review.,Surg Oncol.  2014,PubMed,citation,PMID:25126956,pubmed,25126956,create date:2014/08/16 | first author:Olsen J
Recurrence patterns after resection of liver metastases from colorectal cancer.,/pubmed/25103010,Sorbye H.,Recent Results Cancer Res. 2014;203:243-52. doi: 10.1007/978-3-319-08060-4_17. Review.,Recent Results Cancer Res.  2014,PubMed,citation,PMID:25103010,pubmed,25103010,create date:2014/08/12 | first author:Sorbye H
Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells.,/pubmed/25102912,"Horinaka M, Yoshida T, Tomosugi M, Yasuda S, Sowa Y, Sakai T.",Sci Rep. 2014 Aug 8;4:6000. doi: 10.1038/srep06000.,Sci Rep.  2014,PubMed,citation,PMID:25102912 | PMCID:PMC4126006,pubmed,25102912,create date:2014/08/12 | first author:Horinaka M
"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.",/pubmed/25088940,"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, et al.",Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.,Lancet Oncol.  2014,PubMed,citation,PMID:25088940,pubmed,25088940,create date:2014/08/05 | first author:Heinemann V
"Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study.",/pubmed/25083765,"Kirzin S, Marisa L, Guimbaud R, De Reynies A, Legrain M, Laurent-Puig P, Cordelier P, Pradère B, Bonnet D, Meggetto F, Portier G, Brousset P, Selves J.",PLoS One. 2014 Aug 1;9(8):e103159. doi: 10.1371/journal.pone.0103159. eCollection 2014.,PLoS One.  2014,PubMed,citation,PMID:25083765 | PMCID:PMC4118858,pubmed,25083765,create date:2014/08/02 | first author:Kirzin S
KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas.,/pubmed/25083299,"Baskin Y, Dagdeviren YK, Calibasi G, Canda AE, Sarioglu S, Ellidokuz H, Oztop I.",J Gastrointest Oncol. 2014 Aug;5(4):265-9. doi: 10.3978/j.issn.2078-6891.2014.038.,J Gastrointest Oncol.  2014,PubMed,citation,PMID:25083299 | PMCID:PMC4110495,pubmed,25083299,create date:2014/08/02 | first author:Baskin Y
Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population.,/pubmed/25069446,"Maqbool R, Ismail R, Hussain M.",Microrna. 2014;2(3):219-24.,Microrna.  2014,PubMed,citation,PMID:25069446,pubmed,25069446,create date:2014/07/30 | first author:Maqbool R
Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing.,/pubmed/25066378,"Xie T, Cho YB, Wang K, Huang D, Hong HK, Choi YL, Ko YH, Nam DH, Jin J, Yang H, Fernandez J, Deng S, Rejto PA, Lee WY, Mao M.",Genomics. 2014 Oct;104(4):234-41. doi: 10.1016/j.ygeno.2014.07.012. Epub 2014 Jul 25.,Genomics.  2014,PubMed,citation,PMID:25066378,pubmed,25066378,create date:2014/07/30 | first author:Xie T
"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.",/pubmed/25057166,"Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S.",Ann Oncol. 2014 Oct;25(10):1995-2001. doi: 10.1093/annonc/mdu275. Epub 2014 Jul 23.,Ann Oncol.  2014,PubMed,citation,PMID:25057166,pubmed,25057166,create date:2014/07/25 | first author:Missiaglia E
Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients.,/pubmed/25032217,"Er TK, Chen CC, Bujanda L, Herreros-Villanueva M.",Biomed Res Int. 2014;2014:591867. doi: 10.1155/2014/591867. Epub 2014 Jun 18. Review.,Biomed Res Int.  2014,PubMed,citation,PMID:25032217 | PMCID:PMC4086227,pubmed,25032217,create date:2014/07/18 | first author:Er TK
"Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk.",/pubmed/25025473,"Su HX, Zhou HH, Wang MY, Cheng J, Zhang SC, Hui F, Chen XZ, Liu SH, Liu QJ, Zhu ZJ, Hu QR, Wu Y, Ji SR.",PLoS One. 2014 Jul 15;9(7):e102418. doi: 10.1371/journal.pone.0102418. eCollection 2014.,PLoS One.  2014,PubMed,citation,PMID:25025473 | PMCID:PMC4099363,pubmed,25025473,create date:2014/07/16 | first author:Su HX
"Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.",/pubmed/25009008,"Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E.",Ann Oncol. 2014 Oct;25(10):2008-14. doi: 10.1093/annonc/mdu252. Epub 2014 Jul 9.,Ann Oncol.  2014,PubMed,citation,PMID:25009008 | PMCID:PMC4176451,pubmed,25009008,create date:2014/07/11 | first author:Morris VK
A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.,/pubmed/25005754,"Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS.",Mol Cancer. 2014 Jul 8;13:168. doi: 10.1186/1476-4598-13-168.,Mol Cancer.  2014,PubMed,citation,PMID:25005754 | PMCID:PMC4109832,pubmed,25005754,create date:2014/07/10 | first author:Siraj AK
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.,/pubmed/25002720,"Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C; Aide et Recherche en Cancérologie Digestive Foundation..",J Clin Oncol. 2014 Sep 20;32(27):2975-84.,J Clin Oncol.  2014,PubMed,citation,PMID:25002720 | PMCID:PMC4809210,pubmed,25002720,create date:2014/07/09 | first author:Lieu CH
Polyposis syndromes in children and adolescents: a case series data analysis.,/pubmed/24999926,"Cohen S, Gorodnichenco A, Weiss B, Lerner A, Ben-Tov A, Yaron A, Reif S.",Eur J Gastroenterol Hepatol. 2014 Sep;26(9):972-7. doi: 10.1097/MEG.0000000000000143.,Eur J Gastroenterol Hepatol.  2014,PubMed,citation,PMID:24999926,pubmed,24999926,create date:2014/07/08 | first author:Cohen S
Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding.,/pubmed/24962990,"Agyeman A, Jha BK, Mazumdar T, Houghton JA.",Oncotarget. 2014 Jun 30;5(12):4492-503.,Oncotarget.  2014,PubMed,citation,PMID:24962990 | PMCID:PMC4147340,pubmed,24962990,create date:2014/06/26 | first author:Agyeman A
Efficacy of cetuximab in metastatic colon cancer - case report.,/pubmed/24956345,"Grigorean VT, Ciuhu AN, Rahnea Nita G, Strambu V, Straja DN, Popescu M, Sandu AM, Rahnea Nita RA.",Chirurgia (Bucur). 2014 May-Jun;109(3):383-9.,Chirurgia (Bucur).  2014,PubMed,citation,PMID:24956345,pubmed,24956345,create date:2014/06/24 | first author:Grigorean VT
Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma.,/pubmed/24949429,"Huang S, Zhong X, Gao J, Song R, Wu H, Zi S, Yang S, Du P, Cui L, Yang C, Li Z.",Biomed Res Int. 2014;2014:256723. doi: 10.1155/2014/256723. Epub 2014 May 14.,Biomed Res Int.  2014,PubMed,citation,PMID:24949429 | PMCID:PMC4053147,pubmed,24949429,create date:2014/06/21 | first author:Huang S
"Synchronous colorectal cancer: clinical, pathological and molecular implications.",/pubmed/24944471,"Lam AK, Chan SS, Leung M.",World J Gastroenterol. 2014 Jun 14;20(22):6815-20. doi: 10.3748/wjg.v20.i22.6815. Review.,World J Gastroenterol.  2014,PubMed,citation,PMID:24944471 | PMCID:PMC4051920,pubmed,24944471,create date:2014/06/20 | first author:Lam AK
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling.,/pubmed/24930890,"Ormanns S, Neumann J, Horst D, Kirchner T, Jung A.",Oncotarget. 2014 May 30;5(10):2999-3011.,Oncotarget.  2014,PubMed,citation,PMID:24930890 | PMCID:PMC4102786,pubmed,24930890,create date:2014/06/17 | first author:Ormanns S
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.,/pubmed/24928944,"Chen M, Nowak DG, Trotman LC.",Clin Cancer Res. 2014 Jun 15;20(12):3057-63. doi: 10.1158/1078-0432.CCR-12-3680.,Clin Cancer Res.  2014,PubMed,citation,PMID:24928944 | PMCID:PMC4058638,pubmed,24928944,create date:2014/06/15 | first author:Chen M
"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.",/pubmed/24928083,"Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators..",Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.,Lancet Oncol.  2014,PubMed,citation,PMID:24928083,pubmed,24928083,create date:2014/06/15 | first author:Taieb J
"Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.",/pubmed/24925349,"Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR; Alliance for Clinical Trials in Oncology..",J Natl Cancer Inst. 2014 Jun 12;106(7). pii: dju106. doi: 10.1093/jnci/dju106. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2014 Jul;106(7). doi:10.1093/jnci/dju228. ,J Natl Cancer Inst.  2014,PubMed,citation,PMID:24925349 | PMCID:PMC4110470,pubmed,24925349,create date:2014/06/14 | first author:Gonsalves WI
Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency.,/pubmed/24925223,"Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, DeSilva K, Gill AJ.",Hum Pathol. 2014 Aug;45(8):1697-703. doi: 10.1016/j.humpath.2014.04.009. Epub 2014 Apr 24.,Hum Pathol.  2014,PubMed,citation,PMID:24925223,pubmed,24925223,create date:2014/06/14 | first author:Chou A
TP53 mutations in advanced colorectal cancer: the dark side of the moon.,/pubmed/24924261,"Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F.",Oncology. 2014;86(5-6):289-94. doi: 10.1159/000360088. Epub 2014 Jun 7.,Oncology.  2014,PubMed,citation,PMID:24924261,pubmed,24924261,create date:2014/06/14 | first author:Pietrantonio F
BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.,/pubmed/24921639,"Bledsoe JR, Kamionek M, Mino-Kenudson M.",Am J Surg Pathol. 2014 Oct;38(10):1418-28. doi: 10.1097/PAS.0000000000000263.,Am J Surg Pathol.  2014,PubMed,citation,PMID:24921639 | PMCID:PMC4167743,pubmed,24921639,create date:2014/06/13 | first author:Bledsoe JR
Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.,/pubmed/24909058,"Kim JH, Rhee YY, Kim KJ, Cho NY, Lee HS, Kang GH.",APMIS. 2014 Dec;122(12):1187-95. doi: 10.1111/apm.12284. Epub 2014 Jun 7.,APMIS.  2014,PubMed,citation,PMID:24909058,pubmed,24909058,create date:2014/06/10 | first author:Kim JH
Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.,/pubmed/24890702,"Langevin SM, Christensen BC.",Cancer Med. 2014 Oct;3(5):1385-95. doi: 10.1002/cam4.279. Epub 2014 Jun 2. Review.,Cancer Med.  2014,PubMed,citation,PMID:24890702 | PMCID:PMC4302689,pubmed,24890702,create date:2014/06/04 | first author:Langevin SM
Four individually druggable MET hotspots mediate HGF-driven tumor progression.,/pubmed/24865428,"Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P.",J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27.,J Clin Invest.  2014,PubMed,citation,PMID:24865428 | PMCID:PMC4071368,pubmed,24865428,create date:2014/05/29 | first author:Basilico C
Prognostic implication of mucinous histology in resected colorectal cancer liver metastases.,/pubmed/24856126,"Lupinacci RM, Mello ES, Coelho FF, Kruger JA, Perini MV, Pinheiro RS, Fonseca GM, Cecconello I, Herman P.",Surgery. 2014 Jun;155(6):1062-8. doi: 10.1016/j.surg.2014.01.011. Epub 2014 Feb 5.,Surgery.  2014,PubMed,citation,PMID:24856126,pubmed,24856126,create date:2014/05/27 | first author:Lupinacci RM
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.,/pubmed/24816724,"von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP.",J Cancer Res Clin Oncol. 2014 Sep;140(9):1607-14. doi: 10.1007/s00432-014-1678-3. Epub 2014 May 10.,J Cancer Res Clin Oncol.  2014,PubMed,citation,PMID:24816724 | PMCID:PMC4131148,pubmed,24816724,create date:2014/05/13 | first author:von Einem JC
Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.,/pubmed/24807215,"Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, Yuan W, Ha C, Gilbert HN, Reeder J, Pau G, Stinson J, Stern HM, et al.",Nat Commun. 2014 May 8;5:3830. doi: 10.1038/ncomms4830.,Nat Commun.  2014,PubMed,citation,PMID:24807215 | PMCID:PMC4024760,pubmed,24807215,create date:2014/05/09 | first author:Liu J
Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.,/pubmed/24806883,"Ogura T, Kakuta M, Yatsuoka T, Nishimura Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y, Akagi K.",Oncol Rep. 2014 Jul;32(1):50-6. doi: 10.3892/or.2014.3165. Epub 2014 May 6.,Oncol Rep.  2014,PubMed,citation,PMID:24806883,pubmed,24806883,create date:2014/05/09 | first author:Ogura T
Personalised cancer medicine.,/pubmed/24789362,"Jackson SE, Chester JD.",Int J Cancer. 2015 Jul 15;137(2):262-6. doi: 10.1002/ijc.28940. Epub 2014 May 12. Review.,Int J Cancer.  2015,PubMed,citation,PMID:24789362,pubmed,24789362,create date:2014/05/03 | first author:Jackson SE
Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.,/pubmed/24764661,"Kim JH, Kang GH.",World J Gastroenterol. 2014 Apr 21;20(15):4230-43. doi: 10.3748/wjg.v20.i15.4230. Review.,World J Gastroenterol.  2014,PubMed,citation,PMID:24764661 | PMCID:PMC3989959,pubmed,24764661,create date:2014/04/26 | first author:Kim JH
BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer.,/pubmed/24759670,"Lee SH, Ahn BK, Baek SU, Chang HK.",Gastroenterol Rep (Oxf). 2013 Jul;1(1):70-4. doi: 10.1093/gastro/got004. Epub 2013 Apr 5.,Gastroenterol Rep (Oxf).  2013,PubMed,citation,PMID:24759670 | PMCID:PMC3941443,pubmed,24759670,create date:2014/04/25 | first author:Lee SH
Vemurafenib.,/pubmed/24756795,"Garbe C, Abusaif S, Eigentler TK.",Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Review.,Recent Results Cancer Res.  2014,PubMed,citation,PMID:24756795,pubmed,24756795,create date:2014/04/24 | first author:Garbe C
"MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.",/pubmed/24752710,"Ito M, Mitsuhashi K, Igarashi H, Nosho K, Naito T, Yoshii S, Takahashi H, Fujita M, Sukawa Y, Yamamoto E, Takahashi T, Adachi Y, Nojima M, Sasaki Y, Tokino T, Baba Y, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y.",Int J Cancer. 2014 Dec 1;135(11):2507-15. doi: 10.1002/ijc.28920. Epub 2014 Apr 30.,Int J Cancer.  2014,PubMed,citation,PMID:24752710,pubmed,24752710,create date:2014/04/23 | first author:Ito M
[A case of curatively resected sigmoid colon cancer after mFOLFOX6 plus panitumumab neoadjuvant chemotherapy].,/pubmed/24743293,"Yoshikawa K, Kuwata H, Nakahata Y.",Gan To Kagaku Ryoho. 2014 Mar;41(3):399-401. Japanese. ,Gan To Kagaku Ryoho.  2014,PubMed,citation,PMID:24743293,pubmed,24743293,create date:2014/04/20 | first author:Yoshikawa K
[Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].,/pubmed/24742565,"Zhang X, Wang Y, Gao N, Wang J.",Zhonghua Bing Li Xue Za Zhi. 2014 Feb;43(2):77-82. Chinese. ,Zhonghua Bing Li Xue Za Zhi.  2014,PubMed,citation,PMID:24742565,pubmed,24742565,create date:2014/04/20 | first author:Zhang X
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.,/pubmed/24737664,"Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB.",Cancer. 2014 Aug 1;120(15):2316-24. doi: 10.1002/cncr.28729. Epub 2014 Apr 15.,Cancer.  2014,PubMed,citation,PMID:24737664 | PMCID:PMC4928876,pubmed,24737664,create date:2014/04/17 | first author:Yaeger R
Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients.,/pubmed/24729378,"Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, Brenner H, Hoffmeister M, Kloor M.",Int J Cancer. 2014 Nov 15;135(10):2387-96. doi: 10.1002/ijc.28891. Epub 2014 Apr 28.,Int J Cancer.  2014,PubMed,citation,PMID:24729378,pubmed,24729378,create date:2014/04/15 | first author:Dihlmann S
Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).,/pubmed/24727325,"Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB.",Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11.,Clin Cancer Res.  2014,PubMed,citation,PMID:24727325 | PMCID:PMC4084689,pubmed,24727325,create date:2014/04/15 | first author:Sha D
Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer.,/pubmed/24691426,"Watson MM, Berg M, Søreide K.",Br J Cancer. 2014 Aug 26;111(5):823-7. doi: 10.1038/bjc.2014.167. Epub 2014 Apr 1. Review.,Br J Cancer.  2014,PubMed,citation,PMID:24691426 | PMCID:PMC4150258,pubmed,24691426,create date:2014/04/03 | first author:Watson MM
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).,/pubmed/24687927,"Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology..",Clin Cancer Res. 2014 Jun 1;20(11):3033-43. doi: 10.1158/1078-0432.CCR-13-3140. Epub 2014 Mar 31.,Clin Cancer Res.  2014,PubMed,citation,PMID:24687927 | PMCID:PMC4040326,pubmed,24687927,create date:2014/04/02 | first author:Yoon HH
Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.,/pubmed/24675495,"Zahrani A, Kandil M, Badar T, Abdelsalam M, Al-Faiar A, Ismail A.",Tumori. 2014 Jan-Feb;100(1):75-9. doi: 10.1700/1430.15819.,Tumori.  2014,PubMed,citation,PMID:24675495,pubmed,24675495,create date:2014/03/29 | first author:Zahrani A
DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.,/pubmed/24674026,"Loh M, Liem N, Vaithilingam A, Lim PL, Sapari NS, Elahi E, Mok ZY, Cheng CL, Yan B, Pang B, Salto-Tellez M, Yong WP, Iacopetta B, Soong R.",BMC Gastroenterol. 2014 Mar 28;14:55. doi: 10.1186/1471-230X-14-55.,BMC Gastroenterol.  2014,PubMed,citation,PMID:24674026 | PMCID:PMC3986689,pubmed,24674026,create date:2014/03/29 | first author:Loh M
"Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab.",/pubmed/24649163,"Tanaka T, Ichikawa K, Maruoka T, Tomita S, Ueda H, Yamaguchi T, Shida Y, Kato H, Nagata H, Kubota K, Akimoto N, Sakamoto C, Imura J, Arita M, Tanaka H, Okamoto Y, Igarashi Y, Fujimori T.",Mol Clin Oncol. 2013 Mar;1(2):291-296. Epub 2013 Jan 10.,Mol Clin Oncol.  2013,PubMed,citation,PMID:24649163 | PMCID:PMC3915678,pubmed,24649163,create date:2014/03/22 | first author:Tanaka T
Detection and characterization of oncogene mutations in preneoplastic and early neoplastic lesions.,/pubmed/24623243,Minamoto T.,Methods Mol Biol. 2014;1105:381-98. doi: 10.1007/978-1-62703-739-6_29.,Methods Mol Biol.  2014,PubMed,citation,PMID:24623243,pubmed,24623243,create date:2014/03/14 | first author:Minamoto T
Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.,/pubmed/24614151,"Adams JA, Post KM, Bilbo SA, Wang X, Sen JD, Cornwell AJ, Malek AJ, Cheng L.",Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):231-5. doi: 10.1097/PDM.0b013e3182a127f9.,Appl Immunohistochem Mol Morphol.  2014,PubMed,citation,PMID:24614151,pubmed,24614151,create date:2014/03/13 | first author:Adams JA
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.,/pubmed/24594804,"Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q, Fu WL.",PLoS One. 2014 Mar 3;9(3):e90607. doi: 10.1371/journal.pone.0090607. eCollection 2014. Review.,PLoS One.  2014,PubMed,citation,PMID:24594804 | PMCID:PMC3940924,pubmed,24594804,create date:2014/03/07 | first author:Chen D
Molecular and immunohistochemical profile of a basaloid (cloacogenic) carcinoma of the sigmoid colon: possible predictive value for clinical outcomes.,/pubmed/24584270,"Gurzu S, Szentirmay Z, Bara T, Bara T Jr, Iurcsuk O, Jung I.",Eur J Gastroenterol Hepatol. 2014 May;26(5):570-3. doi: 10.1097/MEG.0000000000000064.,Eur J Gastroenterol Hepatol.  2014,PubMed,citation,PMID:24584270,pubmed,24584270,create date:2014/03/04 | first author:Gurzu S
Prevalence and molecular characterisation of the sessile serrated adenoma in a subset of the Chinese population.,/pubmed/24570042,"Qiu Y, Fu X, Zhang W, Xu Y, Xiao L, Chen X, Shi L, Zhou X, Xia G, Peng Y, Deng M.",J Clin Pathol. 2014 Jun;67(6):491-8. doi: 10.1136/jclinpath-2013-202092. Epub 2014 Feb 25.,J Clin Pathol.  2014,PubMed,citation,PMID:24570042,pubmed,24570042,create date:2014/02/27 | first author:Qiu Y
Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction.,/pubmed/24535227,"Wang M, Wei X, Shi L, Chen B, Zhao G, Yang H.",Int J Mol Med. 2014 Apr;33(4):1019-26. doi: 10.3892/ijmm.2014.1649. Epub 2014 Feb 10.,Int J Mol Med.  2014,PubMed,citation,PMID:24535227,pubmed,24535227,create date:2014/02/19 | first author:Wang M
Trefoil factor 1 gene alternations and expression in colorectal carcinomas.,/pubmed/24503794,"Huang YG, Li YF, Pan BL, Wang LP, Zhang Y, Lee WH, Zhang Y.",Tumori. 2013 Nov-Dec;99(6):702-7. doi: 10.1700/1390.15459.,Tumori.  2013,PubMed,citation,PMID:24503794,pubmed,24503794,create date:2014/02/08 | first author:Huang YG
SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.,/pubmed/24503755,"Agaimy A, Rau TT, Hartmann A, Stoehr R.",Am J Surg Pathol. 2014 Jul;38(7):910-20. doi: 10.1097/PAS.0000000000000173. Review.,Am J Surg Pathol.  2014,PubMed,citation,PMID:24503755,pubmed,24503755,create date:2014/02/08 | first author:Agaimy A
Mutational analysis and clinical correlation of metastatic colorectal cancer.,/pubmed/24500602,"Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.",Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.,Cancer.  2014,PubMed,citation,PMID:24500602 | PMCID:PMC4327902,pubmed,24500602,create date:2014/02/07 | first author:Russo AL
"Mucinous differentiation in colorectal cancer: molecular, histological and clinical aspects.",/pubmed/24494463,"Debunne H, Ceelen W.",Acta Chir Belg. 2013 Nov-Dec;113(6):385-90. Review.,Acta Chir Belg.  2013,PubMed,citation,PMID:24494463,pubmed,24494463,create date:2014/02/06 | first author:Debunne H
Risk of desmoid tumours after open and laparoscopic colectomy in patients with familial adenomatous polyposis.,/pubmed/24493089,"Vitellaro M, Sala P, Signoroni S, Radice P, Fortuzzi S, Civelli EM, Ballardini G, Kleiman DA, Morrissey KP, Bertario L.",Br J Surg. 2014 Apr;101(5):558-65. doi: 10.1002/bjs.9411. Epub 2014 Feb 3.,Br J Surg.  2014,PubMed,citation,PMID:24493089,pubmed,24493089,create date:2014/02/05 | first author:Vitellaro M
A case of diffuse infiltrating gastrointestinal stromal tumor of sigmoid colon with perforation.,/pubmed/24471968,"Yamashita D, Usami Y, Toyosawa S, Hirota S, Imai Y.",Pathol Int. 2014 Jan;64(1):34-8. doi: 10.1111/pin.12124.,Pathol Int.  2014,PubMed,citation,PMID:24471968,pubmed,24471968,create date:2014/01/30 | first author:Yamashita D
Ezrin expression and cell survival regulation in colorectal cancer.,/pubmed/24462708,"Leiphrakpam PD, Rajput A, Mathiesen M, Agarwal E, Lazenby AJ, Are C, Brattain MG, Chowdhury S.",Cell Signal. 2014 May;26(5):868-79. doi: 10.1016/j.cellsig.2014.01.014. Epub 2014 Jan 22.,Cell Signal.  2014,PubMed,citation,PMID:24462708 | PMCID:PMC3974425,pubmed,24462708,create date:2014/01/28 | first author:Leiphrakpam PD
Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.,/pubmed/24440976,"Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CF, Sandler RS, Keku TO.",Cancer Biomark. 2013;13(5):359-66. doi: 10.3233/CBM-130366.,Cancer Biomark.  2013,PubMed,citation,PMID:24440976 | PMCID:PMC4589188,pubmed,24440976,create date:2014/01/21 | first author:Kang M
[A case of rectal endocrine cell carcinoma treated by laparoscopic assisted intersphincteric resection after neoadjuvant chemotherapy].,/pubmed/24394001,"Wakatsuki K, Yoshioka S, Shiobara M, Kataoka M, Arai S, Tonooka T, Miyazawa K, Oeda Y.",Gan To Kagaku Ryoho. 2013 Nov;40(12):2026-8. Japanese. ,Gan To Kagaku Ryoho.  2013,PubMed,citation,PMID:24394001,pubmed,24394001,create date:2014/01/08 | first author:Wakatsuki K
"Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.",/pubmed/24382590,"Cajuso T, Hänninen UA, Kondelin J, Gylfe AE, Tanskanen T, Katainen R, Pitkänen E, Ristolainen H, Kaasinen E, Taipale M, Taipale J, Böhm J, Renkonen-Sinisalo L, Mecklin JP, Järvinen H, Tuupanen S, Kilpivaara O, Vahteristo P.",Int J Cancer. 2014 Aug 1;135(3):611-23. doi: 10.1002/ijc.28705. Epub 2014 Jan 13.,Int J Cancer.  2014,PubMed,citation,PMID:24382590,pubmed,24382590,create date:2014/01/03 | first author:Cajuso T
FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.,/pubmed/24370353,"Douillard JY, Zemelka T, Fountzilas G, Barone C, Schlichting M, Heighway J, Eggleton SP, Srimuninnimit V.",Clin Colorectal Cancer. 2014 Mar;13(1):14-26.e1. doi: 10.1016/j.clcc.2013.11.009. Epub 2013 Nov 16.,Clin Colorectal Cancer.  2014,PubMed,citation,PMID:24370353,pubmed,24370353,create date:2013/12/29 | first author:Douillard JY
"BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.",/pubmed/24367680,"Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J.",PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013.,PLoS One.  2013,PubMed,citation,PMID:24367680 | PMCID:PMC3867547,pubmed,24367680,create date:2013/12/25 | first author:Saridaki Z
Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation.,/pubmed/24348051,"Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P, Romiti A, Barucca V, Giannini G, Bianchi L, Tomao S.",Onco Targets Ther. 2013 Nov 29;6:1761-9. doi: 10.2147/OTT.S43828. eCollection 2013.,Onco Targets Ther.  2013,PubMed,citation,PMID:24348051 | PMCID:PMC3848929,pubmed,24348051,create date:2013/12/19 | first author:Rossi L
"Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.",/pubmed/24339949,"Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y.",PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.,PLoS One.  2013,PubMed,citation,PMID:24339949 | PMCID:PMC3858242,pubmed,24339949,create date:2013/12/18 | first author:Shen Y
[Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].,/pubmed/24332053,"Bai YQ, Liu XJ, Wang Y, Ge FJ, Zhao CH, Fu YL, Lin L, Xu JM.",Zhonghua Zhong Liu Za Zhi. 2013 Sep;35(9):666-71. Chinese. ,Zhonghua Zhong Liu Za Zhi.  2013,PubMed,citation,PMID:24332053,pubmed,24332053,create date:2013/12/18 | first author:Bai YQ
BRAF inhibitors in cancer therapy.,/pubmed/24325952,"Hertzman Johansson C, Egyhazi Brage S.",Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8. Review.,Pharmacol Ther.  2014,PubMed,citation,PMID:24325952,pubmed,24325952,create date:2013/12/12 | first author:Hertzman Johansson C
Metachronous serrated neoplasia is uncommon after right colectomy in patients with methylator colon cancers with a high degree of microsatellite instability.,/pubmed/24316944,"Messick CA, Kravochuck S, Church JM, Kalady MF.",Dis Colon Rectum. 2014 Jan;57(1):39-46. doi: 10.1097/01.dcr.0000437690.18709.76.,Dis Colon Rectum.  2014,PubMed,citation,PMID:24316944,pubmed,24316944,create date:2013/12/10 | first author:Messick CA
Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis.,/pubmed/24308539,"Lee H, Flaherty P, Ji HP.",BMC Med Genomics. 2013 Dec 5;6:54. doi: 10.1186/1755-8794-6-54.,BMC Med Genomics.  2013,PubMed,citation,PMID:24308539 | PMCID:PMC3907018,pubmed,24308539,create date:2013/12/07 | first author:Lee H
"Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.",/pubmed/24307987,"Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.",Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.,Biomed Res Int.  2013,PubMed,citation,PMID:24307987 | PMCID:PMC3838846,pubmed,24307987,create date:2013/12/07 | first author:Bruera G
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF.,/pubmed/24298448,"Thiel A, Ristimäki A.",Front Oncol. 2013 Nov 15;3:281. doi: 10.3389/fonc.2013.00281. Review.,Front Oncol.  2013,PubMed,citation,PMID:24298448 | PMCID:PMC3828559,pubmed,24298448,create date:2013/12/04 | first author:Thiel A
"EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.",/pubmed/24281417,"Schweiger T, Hegedüs B, Nikolowsky C, Hegedüs Z, Szirtes I, Mair R, Birner P, Döme B, Lang G, Klepetko W, Ankersmit HJ, Hoetzenecker K.",Ann Surg Oncol. 2014 Mar;21(3):946-54. doi: 10.1245/s10434-013-3386-7. Epub 2013 Nov 27.,Ann Surg Oncol.  2014,PubMed,citation,PMID:24281417,pubmed,24281417,create date:2013/11/28 | first author:Schweiger T
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].,/pubmed/24273914,"Badora A, Kaleta B, Nowara E, Sikora-Jopek M, Budryk M, Smok-Ragankiewicz A.",Ginekol Pol. 2013 Oct;84(10):892-6. Polish. ,Ginekol Pol.  2013,PubMed,citation,PMID:24273914,pubmed,24273914,create date:2013/11/28 | first author:Badora A
"Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.",/pubmed/24242331,"Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, Yamamoto E, Kurokawa S, Adachi Y, Takahashi H, Okuda H, Kusumi T, Hosokawa M, Fujita M, Hasegawa T, Okita K, Hirata K, Suzuki H, et al.",Carcinogenesis. 2014 Apr;35(4):776-83. doi: 10.1093/carcin/bgt374. Epub 2013 Nov 15.,Carcinogenesis.  2014,PubMed,citation,PMID:24242331,pubmed,24242331,create date:2013/11/19 | first author:Nosho K
"Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study.",/pubmed/24196786,"Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, Thirot-Bidault A, Sobhani I, Malka D, Lecomte T, Locher C, Bonnetain F, Laurent-Puig P.",Br J Cancer. 2013 Dec 10;109(12):3057-66. doi: 10.1038/bjc.2013.677. Epub 2013 Nov 5.,Br J Cancer.  2013,PubMed,citation,PMID:24196786 | PMCID:PMC3859950,pubmed,24196786,create date:2013/11/08 | first author:Aparicio T
A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.,/pubmed/24170545,"Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG.",Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29.,Clin Cancer Res.  2013,PubMed,citation,PMID:24170545,pubmed,24170545,create date:2013/10/31 | first author:Puig I
Brain metastases from colorectal cancer: main clinical factors conditioning outcome.,/pubmed/24158623,"Magni E, Santoro L, Ravenda PS, Leonardi MC, Bonomo G, Monfardini L, Nolè F, Zampino MG.",Int J Colorectal Dis. 2014 Feb;29(2):201-8. doi: 10.1007/s00384-013-1781-y. Epub 2013 Oct 26.,Int J Colorectal Dis.  2014,PubMed,citation,PMID:24158623,pubmed,24158623,create date:2013/10/26 | first author:Magni E
"The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury.",/pubmed/24146755,"Gordon M, El-Kalla M, Zhao Y, Fiteih Y, Law J, Volodko N, Anwar-Mohamed A, El-Kadi AO, Liu L, Odenbach J, Thiesen A, Onyskiw C, Ghazaleh HA, Park J, Lee SB, Yu VC, Fernandez-Patron C, Alexander RT, Wine E, Baksh S.","PLoS One. 2013 Oct 16;8(10):e75483. doi: 10.1371/journal.pone.0075483. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/0ed852a0-eb39-4a28-986f-81f28d870747. Mohamed, Anwar [corrected to Anwar-Mohamed, Anwar].  PLoS One. 2015;10(2):e0118034.  PLoS One. 2015;10(6):e0131150. ",PLoS One.  2013,PubMed,citation,PMID:24146755 | PMCID:PMC3797720,pubmed,24146755,create date:2013/10/23 | first author:Gordon M
Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report.,/pubmed/24137455,"Mekata E, Endo Y, Sonoda H, Shimizu T, Kawai Y, Umeda T, Shiomi H, Naka S, Kubota Y, Murata S, Yamamoto H, Abe H, Tani T.",Oncol Lett. 2013 Oct;6(4):1011-1014. Epub 2013 Jul 19.,Oncol Lett.  2013,PubMed,citation,PMID:24137455 | PMCID:PMC3796414,pubmed,24137455,create date:2013/10/19 | first author:Mekata E
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.,/pubmed/24112392,"Clancy C, Burke JP, Kalady MF, Coffey JC.",Colorectal Dis. 2013 Dec;15(12):e711-8. doi: 10.1111/codi.12427. Review.,Colorectal Dis.  2013,PubMed,citation,PMID:24112392,pubmed,24112392,create date:2013/10/12 | first author:Clancy C
"Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis.",/pubmed/24097228,"Salk JJ, Bansal A, Lai LA, Crispin DA, Ussakli CH, Horwitz MS, Bronner MP, Brentnall TA, Loeb LA, Rabinovitch PS, Risques RA.",Inflamm Bowel Dis. 2013 Nov;19(12):2593-602. doi: 10.1097/MIB.0b013e3182a87640.,Inflamm Bowel Dis.  2013,PubMed,citation,PMID:24097228 | PMCID:PMC3885330,pubmed,24097228,create date:2013/10/08 | first author:Salk JJ
KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability.,/pubmed/24078161,"Aissi S, Buisine MP, Zerimech F, Kourda N, Moussa A, Manai M, Porchet N.",Mol Biol Rep. 2013 Nov;40(11):6107-12.,Mol Biol Rep.  2013,PubMed,citation,PMID:24078161,pubmed,24078161,create date:2013/10/01 | first author:Aissi S
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.,/pubmed/24073892,"Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M.",BMC Cancer. 2013 Sep 27;13:439. doi: 10.1186/1471-2407-13-439.,BMC Cancer.  2013,PubMed,citation,PMID:24073892 | PMCID:PMC3849526,pubmed,24073892,create date:2013/10/01 | first author:Popovici V
Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma.,/pubmed/29147353,"Ribeiro KB, Ribeiro KB, Feres O, da Rocha JJR, Rapatoni L, Garcia SB, Silva AR, da Silva Castro Perdona G, de Souza HCC, Santillan SIG, de Oliveira HF, da Cunha Tirapelli DP, Peria FM.",World J Oncol. 2013 Oct;4(4-5):179-187. doi: 10.4021/wjon719w. Epub 2013 Sep 27.,World J Oncol.  2013,PubMed,citation,PMID:29147353 | PMCID:PMC5649925,pubmed,29147353,create date:2013/10/01 | first author:Ribeiro KB
"Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.",/pubmed/24061861,"Garre P, Martín L, Bando I, Tosar A, Llovet P, Sanz J, Romero A, de la Hoya M, Díaz-Rubio E, Caldés T.",Fam Cancer. 2014 Mar;13(1):109-19. doi: 10.1007/s10689-013-9683-2.,Fam Cancer.  2014,PubMed,citation,PMID:24061861,pubmed,24061861,create date:2013/09/26 | first author:Garre P
Clinical significance of microsatellite instability in colorectal cancer.,/pubmed/24048684,"Kloor M, Staffa L, Ahadova A, von Knebel Doeberitz M.",Langenbecks Arch Surg. 2014 Jan;399(1):23-31. doi: 10.1007/s00423-013-1112-3. Epub 2013 Sep 19. Review.,Langenbecks Arch Surg.  2014,PubMed,citation,PMID:24048684,pubmed,24048684,create date:2013/09/21 | first author:Kloor M
"Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.",/pubmed/24025523,"Kim JH, Rhee YY, Bae JM, Cho NY, Kang GH.",Am J Surg Pathol. 2013 Oct;37(10):1532-41. doi: 10.1097/PAS.0b013e31829ab1c1.,Am J Surg Pathol.  2013,PubMed,citation,PMID:24025523,pubmed,24025523,create date:2013/09/13 | first author:Kim JH
"KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.",/pubmed/24022727,"Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G.",J Clin Pathol. 2014 Jan;67(1):1-9. doi: 10.1136/jclinpath-2013-201835. Epub 2013 Sep 10. Review.,J Clin Pathol.  2014,PubMed,citation,PMID:24022727,pubmed,24022727,create date:2013/09/12 | first author:Malapelle U
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.,/pubmed/24019539,"Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.",J Clin Oncol. 2013 Oct 10;31(29):3664-72. doi: 10.1200/JCO.2013.48.9591. Epub 2013 Sep 9.,J Clin Oncol.  2013,PubMed,citation,PMID:24019539 | PMCID:PMC3789216,pubmed,24019539,create date:2013/09/11 | first author:Sinicrope FA
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.,/pubmed/24006244,"Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.",J Gastrointest Cancer. 2014 Mar;45(1):34-9. doi: 10.1007/s12029-013-9546-y.,J Gastrointest Cancer.  2014,PubMed,citation,PMID:24006244 | PMCID:PMC4361942,pubmed,24006244,create date:2013/09/06 | first author:Russo AL
K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011.,/pubmed/23999847,"Ruiz-Candelaria Y, Miranda-Diaz C, Hunter-Mellado RF.",Int J Biol Markers. 2013 Dec 17;28(4):e393-7. doi: 10.5301/JBM.5000043.,Int J Biol Markers.  2013,PubMed,citation,PMID:23999847 | PMCID:PMC4042672,pubmed,23999847,create date:2013/09/04 | first author:Ruiz-Candelaria Y
[Consideration of therapy for colorectal cancer with synchronous unresectable liver metastasis].,/pubmed/23980038,"Zhu DX, Ren L, Xu JM.",Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Aug;16(8):718-20. Chinese. ,Zhonghua Wei Chang Wai Ke Za Zhi.  2013,PubMed,citation,PMID:23980038,pubmed,23980038,create date:2013/08/28 | first author:Zhu DX
Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.,/pubmed/23979710,"Berg M, Guriby M, Nordgård O, Nedrebø BS, Ahlquist TC, Smaaland R, Oltedal S, Søreide JA, Kørner H, Lothe RA, Søreide K.",Mol Med. 2013 Sep 10;19:286-93. doi: 10.2119/molmed.2013.00049.,Mol Med.  2013,PubMed,citation,PMID:23979710 | PMCID:PMC4344456,pubmed,23979710,create date:2013/08/28 | first author:Berg M
The role of KCNQ1 in mouse and human gastrointestinal cancers.,/pubmed/23975432,"Than BL, Goos JA, Sarver AL, O'Sullivan MG, Rod A, Starr TK, Fijneman RJ, Meijer GA, Zhao L, Zhang Y, Largaespada DA, Scott PM, Cormier RT.",Oncogene. 2014 Jul 17;33(29):3861-8. doi: 10.1038/onc.2013.350. Epub 2013 Aug 26.,Oncogene.  2014,PubMed,citation,PMID:23975432 | PMCID:PMC3935979,pubmed,23975432,create date:2013/08/27 | first author:Than BL
A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.,/pubmed/23975373,"Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, Xu GH, Gao LB.",Tumour Biol. 2014 Jan;35(1):831-5. doi: 10.1007/s13277-013-1114-3. Epub 2013 Aug 24.,Tumour Biol.  2014,PubMed,citation,PMID:23975373,pubmed,23975373,create date:2013/08/27 | first author:Pan XM
Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.,/pubmed/23954140,"Chen SF, Kasajima A, Yazdani S, Chan MS, Wang L, He YY, Gao HW, Sasano H.",Hum Pathol. 2013 Oct;44(10):2199-203. doi: 10.1016/j.humpath.2013.04.025. Epub 2013 Aug 16.,Hum Pathol.  2013,PubMed,citation,PMID:23954140,pubmed,23954140,create date:2013/08/21 | first author:Chen SF
Targeted re-sequencing identified rs3106189 at the 5' UTR of TAPBP and rs1052918 at the 3' UTR of TCF3 to be associated with the overall survival of colorectal cancer patients.,/pubmed/23940558,"Shao J, Lou X, Wang J, Zhang J, Chen C, Hua D, Mo F, Han X, Zheng S, Lin B.",PLoS One. 2013 Aug 5;8(8):e70307. doi: 10.1371/journal.pone.0070307. Print 2013.,PLoS One.  2013,PubMed,citation,PMID:23940558 | PMCID:PMC3734069,pubmed,23940558,create date:2013/08/14 | first author:Shao J
Identification of APC gene mutations in jejunal carcinomas from a patient with familial adenomatous polyposis.,/pubmed/23906606,"Ishida H, Kumamoto K, Amano K, Ishibashi K, Iwama T, Higashi M, Tamaru J.",Jpn J Clin Oncol. 2013 Sep;43(9):929-34. doi: 10.1093/jjco/hyt104. Epub 2013 Aug 1.,Jpn J Clin Oncol.  2013,PubMed,citation,PMID:23906606,pubmed,23906606,create date:2013/08/03 | first author:Ishida H
Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.,/pubmed/23900220,"Bae JM, Kim JH, Cho NY, Kim TY, Kang GH.",Br J Cancer. 2013 Aug 20;109(4):1004-12. doi: 10.1038/bjc.2013.430. Epub 2013 Jul 30.,Br J Cancer.  2013,PubMed,citation,PMID:23900220 | PMCID:PMC3749584,pubmed,23900220,create date:2013/08/01 | first author:Bae JM
Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.,/pubmed/23887157,"Hu H, Chang DT, Nikiforova MN, Kuan SF, Pai RK.",Am J Surg Pathol. 2013 Nov;37(11):1660-70. doi: 10.1097/PAS.0b013e31829623b8.,Am J Surg Pathol.  2013,PubMed,citation,PMID:23887157,pubmed,23887157,create date:2013/07/28 | first author:Hu H
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.,/pubmed/23868516,"Leone F, Artale S, Marino D, Cagnazzo C, Cascinu S, Pinto C, Fornarini G, Tampellini M, Di Fabio F, Sartore-Bianchi A, De Carlis L, Pugliese R, Capussotti L, Gioeni L, Siena S, Aglietta M.",Cancer. 2013 Oct 1;119(19):3429-35. doi: 10.1002/cncr.28223. Epub 2013 Jul 18.,Cancer.  2013,PubMed,citation,PMID:23868516,pubmed,23868516,create date:2013/07/23 | first author:Leone F
Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.,/pubmed/23832066,"Netzel BC, Grebe SK.",Clin Chim Acta. 2013 Oct 21;425:1-2. doi: 10.1016/j.cca.2013.06.025. Epub 2013 Jul 4.,Clin Chim Acta.  2013,PubMed,citation,PMID:23832066,pubmed,23832066,create date:2013/07/09 | first author:Netzel BC
Targeting cancer with a bi-functional peptide: in vitro and in vivo results.,/pubmed/23812212,"Meschenmoser K, Kim Y, Franken S, Nowak M, Feldmann G, Bendas G, Wolfgarten M, Messmer D, Schmidt-Wolf IG.",In Vivo. 2013 Jul-Aug;27(4):431-42.,In Vivo.  2013,PubMed,citation,PMID:23812212,pubmed,23812212,create date:2013/07/03 | first author:Meschenmoser K
Panitumumab in metastatic colorectal cancer.,/pubmed/23802848,"Hocking CM, Townsend AR, Price TJ.",Expert Rev Anticancer Ther. 2013 Jul;13(7):781-93. doi: 10.1586/14737140.2013.811064. Epub 2013 Jun 26. Review.,Expert Rev Anticancer Ther.  2013,PubMed,citation,PMID:23802848,pubmed,23802848,create date:2013/06/28 | first author:Hocking CM
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.,/pubmed/23785428,"Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, Hopper JL, Giles GG, Williamson EJ, English DR, Buchanan DD.",PLoS One. 2013 Jun 13;8(6):e65479. doi: 10.1371/journal.pone.0065479. Print 2013.,PLoS One.  2013,PubMed,citation,PMID:23785428 | PMCID:PMC3681782,pubmed,23785428,create date:2013/06/21 | first author:Rosty C
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.,/pubmed/23773459,"Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.",Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.,Clin Colorectal Cancer.  2013,PubMed,citation,PMID:23773459 | PMCID:PMC4090139,pubmed,23773459,create date:2013/06/19 | first author:Cushman-Vokoun AM
Carcinogenesis of PIK3CA.,/pubmed/23768168,"German S, Aslam HM, Saleem S, Raees A, Anum T, Alvi AA, Haseeb A.",Hered Cancer Clin Pract. 2013 Jun 15;11(1):5. doi: 10.1186/1897-4287-11-5.,Hered Cancer Clin Pract.  2013,PubMed,citation,PMID:23768168 | PMCID:PMC3702456,pubmed,23768168,create date:2013/06/19 | first author:German S
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.,/pubmed/23741067,"Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP.",Clin Cancer Res. 2013 Aug 1;19(15):4104-13. doi: 10.1158/1078-0432.CCR-12-2581. Epub 2013 Jun 5.,Clin Cancer Res.  2013,PubMed,citation,PMID:23741067 | PMCID:PMC3732482,pubmed,23741067,create date:2013/06/07 | first author:Smith CG
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.,/pubmed/23728594,"Phipps AI, Makar KW, Newcomb PA.",Int J Colorectal Dis. 2013 Dec;28(12):1637-42. doi: 10.1007/s00384-013-1715-8. Epub 2013 Jun 1.,Int J Colorectal Dis.  2013,PubMed,citation,PMID:23728594 | PMCID:PMC3830592,pubmed,23728594,create date:2013/06/04 | first author:Phipps AI
Practical genetics of colorectal cancer.,/pubmed/25841492,"Lynch HT, Shaw TG.",Chin Clin Oncol. 2013 Jun;2(2):12. doi: 10.3978/j.issn.2304-3865.2013.03.04.,Chin Clin Oncol.  2013,PubMed,citation,PMID:25841492,pubmed,25841492,create date:2013/06/01 | first author:Lynch HT
Right drug for the right patient": hurdles and the path forward in colorectal cancer.,/pubmed/23714474,Kopetz S.,Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e115. Review.,Am Soc Clin Oncol Educ Book.  2013,PubMed,citation,PMID:23714474,pubmed,23714474,create date:2013/05/30 | first author:Kopetz S
Control of the human osteopontin promoter by ERRα in colorectal cancer.,/pubmed/23680656,"Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC.",Am J Pathol. 2013 Jul;183(1):266-76. doi: 10.1016/j.ajpath.2013.03.021. Epub 2013 May 13.,Am J Pathol.  2013,PubMed,citation,PMID:23680656,pubmed,23680656,create date:2013/05/18 | first author:Boudjadi S
Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century.,/pubmed/23680455,"Saeidnia S, Abdollahi M.",Toxicol Appl Pharmacol. 2013 Aug 15;271(1):49-63. doi: 10.1016/j.taap.2013.05.004. Epub 2013 May 13. Review.,Toxicol Appl Pharmacol.  2013,PubMed,citation,PMID:23680455,pubmed,23680455,create date:2013/05/18 | first author:Saeidnia S
MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion.,/pubmed/23666757,"Yu G, Li H, Wang X, Wu T, Zhu J, Huang S, Wan Y, Tang J.",Mol Cell Biochem. 2013 Aug;380(1-2):239-47. doi: 10.1007/s11010-013-1679-6. Epub 2013 May 12.,Mol Cell Biochem.  2013,PubMed,citation,PMID:23666757,pubmed,23666757,create date:2013/05/15 | first author:Yu G
"The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.",/pubmed/23640097,"Ouerhani S, Bougatef K, Soltani I, Elgaaied AB, Abbes S, Menif S.",Mol Biol Rep. 2013 Jun;40(6):4109-14. doi: 10.1007/s11033-013-2512-8. Epub 2013 May 3.,Mol Biol Rep.  2013,PubMed,citation,PMID:23640097,pubmed,23640097,create date:2013/05/04 | first author:Ouerhani S
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.,/pubmed/23633456,"Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Busam D, Zhao Q, et al.",Clin Cancer Res. 2013 Jun 15;19(12):3285-96. doi: 10.1158/1078-0432.CCR-12-3614. Epub 2013 Apr 30.,Clin Cancer Res.  2013,PubMed,citation,PMID:23633456,pubmed,23633456,create date:2013/05/02 | first author:Day FL
Clinicopathological relevance of BRAF mutations in human cancer.,/pubmed/23594689,"Pakneshan S, Salajegheh A, Smith RA, Lam AK.",Pathology. 2013 Jun;45(4):346-56. doi: 10.1097/PAT.0b013e328360b61d. Review.,Pathology.  2013,PubMed,citation,PMID:23594689,pubmed,23594689,create date:2013/04/19 | first author:Pakneshan S
Successful outcome after laparoscopic surgery for sporadic colonic desmoid tumor with β-catenin mutation: a case report.,/pubmed/23575352,"Gunji S, Kawada K, Kawada M, Hasegawa S, Sakai Y.",J Med Case Rep. 2013 Apr 10;7:100. doi: 10.1186/1752-1947-7-100.,J Med Case Rep.  2013,PubMed,citation,PMID:23575352 | PMCID:PMC3637375,pubmed,23575352,create date:2013/04/12 | first author:Gunji S
Novel DNA variants and mutation frequencies of hMLH1 and hMSH2 genes in colorectal cancer in the Northeast China population.,/pubmed/23573243,"Hu F, Li D, Wang Y, Yao X, Zhang W, Liang J, Lin C, Ren J, Zhu L, Wu Z, Li S, Li Y, Zhao X, Cui B, Dong X, Tian S, Zhao Y.",PLoS One. 2013;8(4):e60233. doi: 10.1371/journal.pone.0060233. Epub 2013 Apr 3.,PLoS One.  2013,PubMed,citation,PMID:23573243 | PMCID:PMC3616036,pubmed,23573243,create date:2013/04/11 | first author:Hu F
"High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.",/pubmed/23548132,"Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.",BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.,BMC Cancer.  2013,PubMed,citation,PMID:23548132 | PMCID:PMC3623853,pubmed,23548132,create date:2013/04/04 | first author:Guedes JG
Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.,/pubmed/23538047,"Miglio U, Mezzapelle R, Paganotti A, Allegrini S, Veggiani C, Antona J, Gentilli S, Monga G, Alabiso O, Boldorini R.",Pathol Res Pract. 2013 Apr;209(4):233-6. doi: 10.1016/j.prp.2013.02.006. Epub 2013 Mar 5.,Pathol Res Pract.  2013,PubMed,citation,PMID:23538047,pubmed,23538047,create date:2013/03/30 | first author:Miglio U
KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.,/pubmed/23511557,"Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA.",Br J Cancer. 2013 Apr 30;108(8):1757-64. doi: 10.1038/bjc.2013.118. Epub 2013 Mar 19.,Br J Cancer.  2013,PubMed,citation,PMID:23511557 | PMCID:PMC3668469,pubmed,23511557,create date:2013/03/21 | first author:Phipps AI
MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer.,/pubmed/23437304,"Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK, Sung JJ, Yu J.",PLoS One. 2013;8(2):e57036. doi: 10.1371/journal.pone.0057036. Epub 2013 Feb 21.,PLoS One.  2013,PubMed,citation,PMID:23437304 | PMCID:PMC3578802,pubmed,23437304,create date:2013/02/26 | first author:Wu CW
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?,/pubmed/23429431,Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group..,Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.,Genet Med.  2013,PubMed,citation,PMID:23429431,pubmed,23429431,create date:2013/02/23 | first author:Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Right-sided rhabdoid colorectal tumors might be related to the serrated pathway.,/pubmed/23425390,"Pancione M, Remo A, Sabatino L, Zanella C, Votino C, Fucci A, Di Blasi A, Lepore G, Daniele B, Fenizia F, Molinari E, Normanno N, Manfrin E, Vendraminelli R, Colantuoni V.",Diagn Pathol. 2013 Feb 20;8:31. doi: 10.1186/1746-1596-8-31.,Diagn Pathol.  2013,PubMed,citation,PMID:23425390 | PMCID:PMC3640919,pubmed,23425390,create date:2013/02/22 | first author:Pancione M
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.,/pubmed/23422094,"Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S.",Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518. Epub 2013 Feb 19.,Clin Cancer Res.  2013,PubMed,citation,PMID:23422094,pubmed,23422094,create date:2013/02/21 | first author:Amatu A
Two initiation sites of early detection of colon cancer revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of the tumor cells.,/pubmed/23357054,"Amsterdam A, Shezen E, Raanan C, Schreiber L, Slilat Y, Fabrikant Y, Melzer E, Seger R.",Acta Histochem. 2013 Jul;115(6):569-76. doi: 10.1016/j.acthis.2012.12.006. Epub 2013 Jan 26.,Acta Histochem.  2013,PubMed,citation,PMID:23357054,pubmed,23357054,create date:2013/01/30 | first author:Amsterdam A
Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.,/pubmed/23348904,"Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD.",Mod Pathol. 2013 Jun;26(6):825-34. doi: 10.1038/modpathol.2012.240. Epub 2013 Jan 25.,Mod Pathol.  2013,PubMed,citation,PMID:23348904,pubmed,23348904,create date:2013/01/26 | first author:Rosty C
Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.,/pubmed/23341177,"Bae JM, Kim JH, Kang GH.",Histol Histopathol. 2013 May;28(5):585-95. doi: 10.14670/HH-28.585. Epub 2013 Jan 23. Review.,Histol Histopathol.  2013,PubMed,citation,PMID:23341177,pubmed,23341177,create date:2013/01/24 | first author:Bae JM
The serrated pathway to colorectal carcinoma: current concepts and challenges.,/pubmed/23339363,"Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V.",Histopathology. 2013 Feb;62(3):367-86. doi: 10.1111/his.12055. Review.,Histopathology.  2013,PubMed,citation,PMID:23339363,pubmed,23339363,create date:2013/01/24 | first author:Bettington M
Desmoid tumour biology in patients with familial adenomatous polyposis coli.,/pubmed/23334997,"Schiessling S, Kihm M, Ganschow P, Kadmon G, Büchler MW, Kadmon M.",Br J Surg. 2013 Apr;100(5):694-703. doi: 10.1002/bjs.9053. Epub 2013 Jan 18.,Br J Surg.  2013,PubMed,citation,PMID:23334997,pubmed,23334997,create date:2013/01/22 | first author:Schiessling S
Splice site mutations in mismatch repair genes and risk of cancer in the general population.,/pubmed/23329266,"Thomsen M, Nordestgaard BG, Tybjærg-Hansen A, Bojesen SE.",Fam Cancer. 2013 Sep;12(3):567-72. doi: 10.1007/s10689-013-9601-7.,Fam Cancer.  2013,PubMed,citation,PMID:23329266,pubmed,23329266,create date:2013/01/19 | first author:Thomsen M
[Molecular and genetic features of gastrointestinal stromal tumors (GIST)].,/pubmed/23307090,"Buleje S J, Yábar B A, Guevara-Fujita M, Fujita R.",Rev Gastroenterol Peru. 2012 Oct-Dec;32(4):394-9. Review. Spanish. ,Rev Gastroenterol Peru.  2012,PubMed,citation,PMID:23307090,pubmed,23307090,create date:2013/01/12 | first author:Buleje S J
"Cancer in Māori: lessons from prostate, colorectal and gastric cancer and progress in hereditary stomach cancer in New Zealand.",/pubmed/23279256,"Blair V, Kahokehr A, Sammour T.",ANZ J Surg. 2013 Jan;83(1-2):42-8. doi: 10.1111/ans.12042. Epub 2012 Dec 20.,ANZ J Surg.  2013,PubMed,citation,PMID:23279256,pubmed,23279256,create date:2013/01/03 | first author:Blair V
[Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].,/pubmed/25026750,"Jedrzychowska A, Dołegowska B.",Ann Acad Med Stetin. 2013;59(2):48-53. Polish. ,Ann Acad Med Stetin.  2013,PubMed,citation,PMID:25026750,pubmed,25026750,create date:2013/01/01 | first author:Jedrzychowska A
Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer.,/pubmed/23271133,"Mokarram P, Zamani M, Kavousipour S, Naghibalhossaini F, Irajie C, Moradi Sarabi M, Hosseini SV.",Mol Biol Rep. 2013 May;40(5):3851-7. doi: 10.1007/s11033-012-2465-3. Epub 2012 Dec 28.,Mol Biol Rep.  2013,PubMed,citation,PMID:23271133,pubmed,23271133,create date:2012/12/29 | first author:Mokarram P
Effector CD4 and CD8 T cells and their role in the tumor microenvironment.,/pubmed/23242673,"Hadrup S, Donia M, Thor Straten P.",Cancer Microenviron. 2013 Aug;6(2):123-33. doi: 10.1007/s12307-012-0127-6. Epub 2012 Dec 16.,Cancer Microenviron.  2013,PubMed,citation,PMID:23242673 | PMCID:PMC3717059,pubmed,23242673,create date:2012/12/18 | first author:Hadrup S
Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.,/pubmed/23188063,"Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y, Maehara Y.",Int J Clin Oncol. 2013 Dec;18(6):1042-8. doi: 10.1007/s10147-012-0501-x. Epub 2012 Nov 29.,Int J Clin Oncol.  2013,PubMed,citation,PMID:23188063,pubmed,23188063,create date:2012/11/29 | first author:Nakanishi R
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.,/pubmed/23167843,"Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH.",BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534.,BMC Cancer.  2012,PubMed,citation,PMID:23167843 | PMCID:PMC3526507,pubmed,23167843,create date:2012/11/22 | first author:Kjersem JB
Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.,/pubmed/23165447,"Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson I.",J Pathol. 2013 Feb;229(3):441-8. doi: 10.1002/path.4139.,J Pathol.  2013,PubMed,citation,PMID:23165447 | PMCID:PMC3588155,pubmed,23165447,create date:2012/11/21 | first author:Domingo E
[Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].,/pubmed/23157828,"Wang Q, Zhong M, Lü YL, Yuan J, Wei LX.",Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):603-6. doi: 10.3760/cma.j.issn.0529-5807.2012.09.007. Chinese. ,Zhonghua Bing Li Xue Za Zhi.  2012,PubMed,citation,PMID:23157828,pubmed,23157828,create date:2012/11/20 | first author:Wang Q
[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].,/pubmed/23157823,"Gao J, Sun ZW, Li YY, Shen L.",Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):579-83. doi: 10.3760/cma.j.issn.0529-5807.2012.09.002. Chinese. ,Zhonghua Bing Li Xue Za Zhi.  2012,PubMed,citation,PMID:23157823,pubmed,23157823,create date:2012/11/20 | first author:Gao J
Lessons from the hepatoblastoma-familial polyposis connection.,/pubmed/23116752,"Moore SW, Tshifularo N, Grobbelaar J.",S Afr Med J. 2012 Sep 10;102(11 Pt 2):888-9. doi: 10.7196/samj.6138.,S Afr Med J.  2012,PubMed,citation,PMID:23116752,pubmed,23116752,create date:2012/11/03 | first author:Moore SW
Recurrent desmoids determine outcome in patients with Gardner syndrome: a cohort study of three generations of an APC mutation-positive family across 30 years.,/pubmed/23114473,"Turina M, Pavlik CM, Heinimann K, Behrensmeier F, Simmen HP.",Int J Colorectal Dis. 2013 Jun;28(6):865-72. doi: 10.1007/s00384-012-1600-x. Epub 2012 Nov 1.,Int J Colorectal Dis.  2013,PubMed,citation,PMID:23114473,pubmed,23114473,create date:2012/11/02 | first author:Turina M
CDX2 is an amplified lineage-survival oncogene in colorectal cancer.,/pubmed/23112155,"Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR.",Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3196-205. doi: 10.1073/pnas.1206004109. Epub 2012 Oct 29.,Proc Natl Acad Sci U S A.  2012,PubMed,citation,PMID:23112155 | PMCID:PMC3503165,pubmed,23112155,create date:2012/11/01 | first author:Salari K
Phosphorylation of p68 RNA helicase by p38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin.,/pubmed/23110695,"Dey H, Liu ZR.",BMC Cell Biol. 2012 Oct 31;13:27. doi: 10.1186/1471-2121-13-27.,BMC Cell Biol.  2012,PubMed,citation,PMID:23110695 | PMCID:PMC3519718,pubmed,23110695,create date:2012/11/01 | first author:Dey H
[A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI(5-FU/LV/irinotecan)therapy].,/pubmed/23064076,"Yoshida R, Matsuura T, Hijikawa K, Yanagida H, Kitade H, Takada H, Kwon AH.",Gan To Kagaku Ryoho. 2012 Oct;39(10):1575-7. Japanese. ,Gan To Kagaku Ryoho.  2012,PubMed,citation,PMID:23064076,pubmed,23064076,create date:2012/10/16 | first author:Yoshida R
[Two cases of metastatic colorectal cancer in wild-type K-RAS effectively treated by panitumumab].,/pubmed/23064074,"Ishiyama Y, Kotake M, Matsunaga M, Kitamura H, Yamamoto M, Inaki N, Kurokawa M, Bando H, Yamada T.",Gan To Kagaku Ryoho. 2012 Oct;39(10):1567-70. Japanese. ,Gan To Kagaku Ryoho.  2012,PubMed,citation,PMID:23064074,pubmed,23064074,create date:2012/10/16 | first author:Ishiyama Y
An intrapelvic extraintestinal gastrointestinal stromal tumor of undetermined origin: diagnosis by prostate needle biopsy.,/pubmed/23057997,"Takahashi RH, Matsubayashi J, Yokotsuka M, Tachibana M, Kusama H, Nagao T.",Pathol Res Pract. 2012 Dec 15;208(12):736-40. doi: 10.1016/j.prp.2012.09.003. Epub 2012 Oct 9.,Pathol Res Pract.  2012,PubMed,citation,PMID:23057997,pubmed,23057997,create date:2012/10/13 | first author:Takahashi RH
The spectrum of urological malignancy in Lynch syndrome.,/pubmed/23054215,"Barrow PJ, Ingham S, O'Hara C, Green K, McIntyre I, Lalloo F, Hill J, Evans DG.",Fam Cancer. 2013 Mar;12(1):57-63. doi: 10.1007/s10689-012-9573-z.,Fam Cancer.  2013,PubMed,citation,PMID:23054215,pubmed,23054215,create date:2012/10/12 | first author:Barrow PJ
A LIN28B polymorphism predicts for colon cancer survival.,/pubmed/23052130,"Ye Y, Madison B, Wu X, Rustgi AK.",Cancer Biol Ther. 2012 Dec;13(14):1390-5. doi: 10.4161/cbt.22336. Epub 2012 Oct 10.,Cancer Biol Ther.  2012,PubMed,citation,PMID:23052130 | PMCID:PMC3542229,pubmed,23052130,create date:2012/10/12 | first author:Ye Y
Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.,/pubmed/23033949,Efferth T.,Curr Med Chem. 2012;19(33):5735-44. Review.,Curr Med Chem.  2012,PubMed,citation,PMID:23033949,pubmed,23033949,create date:2012/10/05 | first author:Efferth T
"Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.",/pubmed/23017669,Foxtrot Collaborative Group.,Lancet Oncol. 2012 Nov;13(11):1152-60. doi: 10.1016/S1470-2045(12)70348-0. Epub 2012 Sep 25.,Lancet Oncol.  2012,PubMed,citation,PMID:23017669 | PMCID:PMC3488188,pubmed,23017669,create date:2012/09/29 | first author:Foxtrot Collaborative Group
"The prognostic value of the immunohistochemical aspects of tumor suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-67 in resected colorectal carcinoma.",/pubmed/22990545,"Ghiţă C, Vîlcea ID, Dumitrescu M, Vîlcea AM, Mirea CS, Aşchie M, Vasilescu F.",Rom J Morphol Embryol. 2012;53(3):549-56.,Rom J Morphol Embryol.  2012,PubMed,citation,PMID:22990545,pubmed,22990545,create date:2012/09/20 | first author:Ghiţă C
"Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome.",/pubmed/22965402,"Latchford AR, Neale K, Phillips RK, Clark SK.",Dis Colon Rectum. 2012 Oct;55(10):1038-43. doi: 10.1097/DCR.0b013e31826278b3.,Dis Colon Rectum.  2012,PubMed,citation,PMID:22965402,pubmed,22965402,create date:2012/09/12 | first author:Latchford AR
"Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.",/pubmed/22936063,"Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V.",Mod Pathol. 2013 Feb;26(2):302-13. doi: 10.1038/modpathol.2012.150. Epub 2012 Aug 31.,Mod Pathol.  2013,PubMed,citation,PMID:22936063,pubmed,22936063,create date:2012/09/01 | first author:Voutsina A
K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.,/pubmed/22909976,"Stec R, Bodnar L, Charkiewicz R, Korniluk J, Rokita M, Smoter M, Ciechowicz M, Chyczewski L, Nikliński J, Kozłowski W, Szczylik C.",Cancer Biol Ther. 2012 Nov;13(13):1235-43. doi: 10.4161/cbt.21813. Epub 2012 Aug 22.,Cancer Biol Ther.  2012,PubMed,citation,PMID:22909976 | PMCID:PMC3493430,pubmed,22909976,create date:2012/08/23 | first author:Stec R
BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.,/pubmed/22899730,"Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, Baron JA, Ahnen DJ, Win AK, Potter JD, Newcomb PA.",Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1792-8. doi: 10.1158/1055-9965.EPI-12-0674. Epub 2012 Aug 16.,Cancer Epidemiol Biomarkers Prev.  2012,PubMed,citation,PMID:22899730 | PMCID:PMC3467328,pubmed,22899730,create date:2012/08/18 | first author:Phipps AI
"Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.",/pubmed/22898351,"Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H, Roessner A, Krüger S.",Pathol Res Pract. 2012 Oct 15;208(10):592-7. doi: 10.1016/j.prp.2012.07.003. Epub 2012 Aug 13.,Pathol Res Pract.  2012,PubMed,citation,PMID:22898351,pubmed,22898351,create date:2012/08/18 | first author:Benedix F
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.,/pubmed/22883484,"Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, Shariat SF, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR.",Eur Urol. 2013 Feb;63(2):379-85. doi: 10.1016/j.eururo.2012.07.047. Epub 2012 Aug 2.,Eur Urol.  2013,PubMed,citation,PMID:22883484,pubmed,22883484,create date:2012/08/14 | first author:Skeldon SC
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer.,/pubmed/22876814,"Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee JO, Bang SM, Park KU, Kim DW, Kang SB, Kim JS, Lee JS, Lee KW.",BMC Cancer. 2012 Aug 9;12:347. doi: 10.1186/1471-2407-12-347.,BMC Cancer.  2012,PubMed,citation,PMID:22876814 | PMCID:PMC3488475,pubmed,22876814,create date:2012/08/11 | first author:Kim MJ
Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.,/pubmed/22872705,"Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, Sparano L, De Stefano A, Carlomagno C, Maiello FM, Vita G, Nappi O, Troncone G.",J Clin Pathol. 2012 Oct;65(10):940-4. Epub 2012 Aug 7.,J Clin Pathol.  2012,PubMed,citation,PMID:22872705 | PMCID:PMC3461636,pubmed,22872705,create date:2012/08/09 | first author:Malapelle U
Generation of a selectively cytotoxic fusion protein against p53 mutated cancers.,/pubmed/22862878,"Kousparou CA, Yiacoumi E, Deonarain MP, Epenetos AA.",BMC Cancer. 2012 Aug 3;12:338. doi: 10.1186/1471-2407-12-338.,BMC Cancer.  2012,PubMed,citation,PMID:22862878 | PMCID:PMC3503689,pubmed,22862878,create date:2012/08/07 | first author:Kousparou CA
Genetic testing by cancer site: colon (nonpolyposis syndromes).,/pubmed/22846734,Senter L.,Cancer J. 2012 Jul-Aug;18(4):334-7. doi: 10.1097/PPO.0b013e31826094b2. Review.,Cancer J.  2012,PubMed,citation,PMID:22846734,pubmed,22846734,create date:2012/08/01 | first author:Senter L
Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome.,/pubmed/22766992,"Takahashi M, Furukawa Y, Shimodaira H, Sakayori M, Moriya T, Moriya Y, Nakamura Y, Ishioka C.",Fam Cancer. 2012 Dec;11(4):559-64. doi: 10.1007/s10689-012-9547-1.,Fam Cancer.  2012,PubMed,citation,PMID:22766992,pubmed,22766992,create date:2012/07/07 | first author:Takahashi M
Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer.,/pubmed/22689960,"Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E, Cui L, McFaline JL, Mobley M, Ge Z, Taghizadeh K, Wishnok JS, Wogan GN, Fox JG, Tannenbaum SR, Dedon PC.",Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1820-9. doi: 10.1073/pnas.1207829109. Epub 2012 Jun 11.,Proc Natl Acad Sci U S A.  2012,PubMed,citation,PMID:22689960 | PMCID:PMC3390855,pubmed,22689960,create date:2012/06/13 | first author:Mangerich A
(125)I-Labeled mouse anti-human carbonic anhydrase IX monoclonal antibody.,/pubmed/22675743,Shan L.,2012 May 3 [updated 2012 May 30]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.,Molecular Imaging and Contrast Agent Database (MICAD).  2004,PubMed,citation,PMID:22675743,pubmed,22675743,create date:2012/06/08 | first author:Shan L
Is colorectal surveillance indicated in patients with PTEN mutations?,/pubmed/22672595,"Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Colas C, Möller P, Hes FJ, Hodgson SV, Olderode-Berends MJ, Aretz S, Heinimann K, Gomez Garcia EB, Douglas F, Spigelman A, Timshel S, Lindor NM, Vasen HF.",Colorectal Dis. 2012 Sep;14(9):e562-6. doi: 10.1111/j.1463-1318.2012.03121.x.,Colorectal Dis.  2012,PubMed,citation,PMID:22672595,pubmed,22672595,create date:2012/06/08 | first author:Nieuwenhuis MH
Myeloid sarcoma and adenocarcinoma of the large bowel as collision tumors: a case report.,/pubmed/22648549,"Rocca BJ, Ambrosio MR, Gozzetti A, Bocchia M, Leoncini L, Lazzi S.",Histol Histopathol. 2012 Jul;27(7):941-7. doi: 10.14670/HH-27.941.,Histol Histopathol.  2012,PubMed,citation,PMID:22648549,pubmed,22648549,create date:2012/06/01 | first author:Rocca BJ
Human POLB gene is mutated in high percentage of colorectal tumors.,/pubmed/22577134,"Donigan KA, Sun KW, Nemec AA, Murphy DL, Cong X, Northrup V, Zelterman D, Sweasy JB.",J Biol Chem. 2012 Jul 6;287(28):23830-9. doi: 10.1074/jbc.M111.324947. Epub 2012 May 10.,J Biol Chem.  2012,PubMed,citation,PMID:22577134 | PMCID:PMC3390656,pubmed,22577134,create date:2012/05/12 | first author:Donigan KA
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.,/pubmed/22540151,"Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J.",J Eur Acad Dermatol Venereol. 2013 Jan;27(1):11-8. doi: 10.1111/j.1468-3083.2012.04546.x. Epub 2012 Apr 28. Review.,J Eur Acad Dermatol Venereol.  2013,PubMed,citation,PMID:22540151,pubmed,22540151,create date:2012/05/01 | first author:Manousaridis I
Reduced telomere length in colorectal carcinomas.,/pubmed/22524803,"Feng TB, Cai LM, Qian KQ, Qi CJ.",Asian Pac J Cancer Prev. 2012;13(2):443-6.,Asian Pac J Cancer Prev.  2012,PubMed,citation,PMID:22524803,pubmed,22524803,create date:2012/04/25 | first author:Feng TB
"Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.",/pubmed/22481281,"Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK.",Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.,Mod Pathol.  2012,PubMed,citation,PMID:22481281,pubmed,22481281,create date:2012/04/07 | first author:Chang DT
Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.,/pubmed/22444159,"Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E.",J Exp Clin Cancer Res. 2012 Mar 23;31:26. doi: 10.1186/1756-9966-31-26.,J Exp Clin Cancer Res.  2012,PubMed,citation,PMID:22444159 | PMCID:PMC3325875,pubmed,22444159,create date:2012/03/27 | first author:Shojaei F
Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.,/pubmed/22409860,"Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, Yamamoto M, Hayashi K.",BMC Cancer. 2012 Mar 13;12:88. doi: 10.1186/1471-2407-12-88.,BMC Cancer.  2012,PubMed,citation,PMID:22409860 | PMCID:PMC3317853,pubmed,22409860,create date:2012/03/14 | first author:Kuramochi H
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.,/pubmed/22385512,"Ballestrero A, Garuti A, Cirmena G, Rocco I, Palermo C, Nencioni A, Scabini S, Zoppoli G, Parodi S, Patrone F.",Curr Cancer Drug Targets. 2012 May;12(4):316-28. Review.,Curr Cancer Drug Targets.  2012,PubMed,citation,PMID:22385512,pubmed,22385512,create date:2012/03/06 | first author:Ballestrero A
Villin expression is frequently lost in poorly differentiated colon cancer.,/pubmed/22349300,"Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM.",Am J Pathol. 2012 Apr;180(4):1509-21. doi: 10.1016/j.ajpath.2012.01.006. Epub 2012 Feb 18.,Am J Pathol.  2012,PubMed,citation,PMID:22349300 | PMCID:PMC5426554,pubmed,22349300,create date:2012/02/22 | first author:Arango D
Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.,/pubmed/22337533,"Limburg PJ, Limsui D, Vierkant RA, Tillmans LS, Wang AH, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR.",Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):681-4. doi: 10.1158/1055-9965.EPI-11-1168. Epub 2012 Feb 15.,Cancer Epidemiol Biomarkers Prev.  2012,PubMed,citation,PMID:22337533 | PMCID:PMC3584684,pubmed,22337533,create date:2012/02/18 | first author:Limburg PJ
"BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.",/pubmed/22314188,"Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.",Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.,Am J Surg Pathol.  2012,PubMed,citation,PMID:22314188 | PMCID:PMC6362986,pubmed,22314188,create date:2012/02/09 | first author:Pai RK
Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome.,/pubmed/22287689,"Klarskov L, Holck S, Bernstein I, Nilbert M.",J Clin Pathol. 2012 Apr;65(4):352-6. doi: 10.1136/jclinpath-2011-200535. Epub 2012 Jan 28.,J Clin Pathol.  2012,PubMed,citation,PMID:22287689,pubmed,22287689,create date:2012/01/31 | first author:Klarskov L
"Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.",/pubmed/22287190,"García-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno D D, Pagán-Gómez I, Rodríguez-Braun E, Pérez-Guillermo M.",Int J Cancer. 2012 Oct 15;131(8):1790-9. doi: 10.1002/ijc.27454. Epub 2012 Mar 14.,Int J Cancer.  2012,PubMed,citation,PMID:22287190,pubmed,22287190,create date:2012/01/31 | first author:García-Solano J
Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary.,/pubmed/22280844,"Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C.",Clin Colorectal Cancer. 2012 Sep;11(3):191-4. doi: 10.1016/j.clcc.2011.12.003. Epub 2012 Jan 26.,Clin Colorectal Cancer.  2012,PubMed,citation,PMID:22280844,pubmed,22280844,create date:2012/01/28 | first author:Garrett CR
Sunitinib therapy for melanoma patients with KIT mutations.,/pubmed/22261812,"Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC.",Clin Cancer Res. 2012 Mar 1;18(5):1457-63. doi: 10.1158/1078-0432.CCR-11-1987. Epub 2012 Jan 18.,Clin Cancer Res.  2012,PubMed,citation,PMID:22261812,pubmed,22261812,create date:2012/01/21 | first author:Minor DR
[The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response].,/pubmed/22257237,"Nemecek R, Vyzula R.",Klin Onkol. 2011;24(6):465-9. Czech. ,Klin Onkol.  2011,PubMed,citation,PMID:22257237,pubmed,22257237,create date:2012/01/20 | first author:Nemecek R
Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.,/pubmed/22228162,"Bae JM, Cho NY, Kim TY, Kang GH.",Dis Colon Rectum. 2012 Feb;55(2):181-90. doi: 10.1097/DCR.0b013e31823c46ce.,Dis Colon Rectum.  2012,PubMed,citation,PMID:22228162,pubmed,22228162,create date:2012/01/10 | first author:Bae JM
BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.,/pubmed/22228154,"Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM.",Dis Colon Rectum. 2012 Feb;55(2):128-33. doi: 10.1097/DCR.0b013e31823c08b3.,Dis Colon Rectum.  2012,PubMed,citation,PMID:22228154,pubmed,22228154,create date:2012/01/10 | first author:Kalady MF
Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.,/pubmed/24451733,"Venook AP, Bendell JC, Warren RS.",Am Soc Clin Oncol Educ Book. 2012:193-200. doi: 10.14694/EdBook_AM.2012.32.193.,Am Soc Clin Oncol Educ Book.  2012,PubMed,citation,PMID:24451733,pubmed,24451733,create date:2012/01/01 | first author:Venook AP
"Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer.",/pubmed/22199994,"Poole EM, Curtin K, Hsu L, Kulmacz RJ, Duggan DJ, Makar KW, Xiao L, Carlson CS, Slattery ML, Caan BJ, Potter JD, Ulrich CM.",Int J Mol Epidemiol Genet. 2011;2(4):300-15. Epub 2011 Dec 3.,Int J Mol Epidemiol Genet.  2011,PubMed,citation,PMID:22199994 | PMCID:PMC3244110,pubmed,22199994,create date:2011/12/27 | first author:Poole EM
"Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).",/pubmed/22199312,"Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J.",Anticancer Res. 2011 Dec;31(12):4439-43.,Anticancer Res.  2011,PubMed,citation,PMID:22199312,pubmed,22199312,create date:2011/12/27 | first author:Wöll E
Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates.,/pubmed/22198259,"Berger BM, Ahlquist DA.",Pathology. 2012 Feb;44(2):80-8. doi: 10.1097/PAT.0b013e3283502fdf. Review.,Pathology.  2012,PubMed,citation,PMID:22198259,pubmed,22198259,create date:2011/12/27 | first author:Berger BM
"Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma.",/pubmed/22157687,"Ha SY, Lee SM, Lee EJ, Kang SY, Jang KT, Park CK, Kim JY, Kim YH, Chang DK, Kim KM.",Pathology. 2012 Jan;44(1):18-23. doi: 10.1097/PAT.0b013e32834d7bbf.,Pathology.  2012,PubMed,citation,PMID:22157687,pubmed,22157687,create date:2011/12/14 | first author:Ha SY
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.,/pubmed/22114137,"Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI.",Clin Cancer Res. 2012 Jan 15;18(2):350-9. doi: 10.1158/1078-0432.CCR-11-1397. Epub 2011 Nov 23.,Clin Cancer Res.  2012,PubMed,citation,PMID:22114137 | PMCID:PMC3272273,pubmed,22114137,create date:2011/11/25 | first author:Sylvester BE
"Two initiation sites of early detection of colon cancer, revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of tumor cells.",/pubmed/22108866,"Amsterdam A, Shezen E, Raanan C, Schreiber L, Slilat Y, Fabrikant Y, Melzer E, Seger R.",Int J Oncol. 2012 Mar;40(3):782-8. doi: 10.3892/ijo.2011.1268. Epub 2011 Nov 22. Retraction in: Int J Oncol. 2012 Nov;41(5):1887. ,Int J Oncol.  2012,PubMed,citation,PMID:22108866,pubmed,22108866,create date:2011/11/24 | first author:Amsterdam A
"Expression of p16INK4a, alone or combined with p53, is predictive of better prognosis in colorectal adenocarcinoma in Tunisian patients.",/pubmed/22095233,"Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, Khabir A, Amouri A, Frikha F, Ellouz S, Frikha M, Sellami-Boudawara T, Mokdad-Gargouri R.",Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):562-8. doi: 10.1097/PAI.0b013e3182143380.,Appl Immunohistochem Mol Morphol.  2011,PubMed,citation,PMID:22095233,pubmed,22095233,create date:2011/11/19 | first author:Miladi-Abdennadher I
Tumour genetics and genomics to personalise cancer treatment.,/pubmed/22065002,"Voon PJ, Kong HL.",Ann Acad Med Singapore. 2011 Aug;40(8):362-8. Review.,Ann Acad Med Singapore.  2011,PubMed,citation,PMID:22065002,pubmed,22065002,create date:2011/11/09 | first author:Voon PJ
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis.,/pubmed/22057237,"March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, van der Weyden L, Berns A, Gadiot J, Uren A, Kemp R, Arends MJ, Wessels LF, Winton DJ, Adams DJ.",Nat Genet. 2011 Nov 6;43(12):1202-9. doi: 10.1038/ng.990.,Nat Genet.  2011,PubMed,citation,PMID:22057237 | PMCID:PMC3233530,pubmed,22057237,create date:2011/11/08 | first author:March HN
Role of ancillary studies in fine-needle aspiration from selected tumors.,/pubmed/22045615,"Schmitt F, Barroca H.",Cancer Cytopathol. 2012 Jun 25;120(3):145-60. doi: 10.1002/cncy.20197. Epub 2011 Nov 1. Review.,Cancer Cytopathol.  2012,PubMed,citation,PMID:22045615,pubmed,22045615,create date:2011/11/03 | first author:Schmitt F
BRAF mutations in advanced cancers: clinical characteristics and outcomes.,/pubmed/22039425,"El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R.",PLoS One. 2011;6(10):e25806. doi: 10.1371/journal.pone.0025806. Epub 2011 Oct 19.,PLoS One.  2011,PubMed,citation,PMID:22039425 | PMCID:PMC3198456,pubmed,22039425,create date:2011/11/01 | first author:El-Osta H
A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.,/pubmed/21994416,"Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M.",Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12.,Clin Cancer Res.  2011,PubMed,citation,PMID:21994416 | PMCID:PMC5919188,pubmed,21994416,create date:2011/10/14 | first author:Smits KM
"Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study.",/pubmed/21904137,"Nieuwenhuis MH, Lefevre JH, Bülow S, Järvinen H, Bertario L, Kernéis S, Parc Y, Vasen HF.",Dis Colon Rectum. 2011 Oct;54(10):1229-34. doi: 10.1097/DCR.0b013e318227e4e8.,Dis Colon Rectum.  2011,PubMed,citation,PMID:21904137,pubmed,21904137,create date:2011/09/10 | first author:Nieuwenhuis MH
[Hereditary nonpolyposis colorectal cancer: analysis of a case and review of management].,/pubmed/21894727,"Cubas Castillo R, Ballarino EA, Neirot P, Grasso RL.",Acta Gastroenterol Latinoam. 2011 Jun;41(2):137-41. Review. Spanish. ,Acta Gastroenterol Latinoam.  2011,PubMed,citation,PMID:21894727,pubmed,21894727,create date:2011/09/08 | first author:Cubas Castillo R
[Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report].,/pubmed/23126058,"Sentija K, Bolanca IK, Simon SK, Kukura V, Skrtić A, Gasparov S.",Acta Med Croatica. 2011 Sep;65 Suppl 1:229-34. Croatian. ,Acta Med Croatica.  2011,PubMed,citation,PMID:23126058,pubmed,23126058,create date:2011/09/01 | first author:Sentija K
[Multimodal therapy for colon cancer: state of the art].,/pubmed/21863510,"Weber T, Link KH.",Zentralbl Chir. 2011 Aug;136(4):325-33. doi: 10.1055/s-0031-1271562. Epub 2011 Aug 23. Review. German. ,Zentralbl Chir.  2011,PubMed,citation,PMID:21863510,pubmed,21863510,create date:2011/08/25 | first author:Weber T
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.,/pubmed/21835826,"Rai K, Fujiwara K, Tsushima M, Kudo K, Mizuta M, Matsuo K, Yonei T, Yamadori I, Kiura K, Sato T.",Jpn J Clin Oncol. 2011 Sep;41(9):1138-41. doi: 10.1093/jjco/hyr113. Epub 2011 Aug 10.,Jpn J Clin Oncol.  2011,PubMed,citation,PMID:21835826,pubmed,21835826,create date:2011/08/13 | first author:Rai K
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.,/pubmed/21827707,"Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, Kang GH.",BMC Cancer. 2011 Aug 10;11:344. doi: 10.1186/1471-2407-11-344.,BMC Cancer.  2011,PubMed,citation,PMID:21827707 | PMCID:PMC3162585,pubmed,21827707,create date:2011/08/11 | first author:Min BH
Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.,/pubmed/21825899,"Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Shibuya H, Eshima K.",Dis Colon Rectum. 2011 Sep;54(9):1170-8. doi: 10.1097/DCR.0b013e31821d37a3.,Dis Colon Rectum.  2011,PubMed,citation,PMID:21825899,pubmed,21825899,create date:2011/08/10 | first author:Watanabe T
4-O-methylhonokiol inhibits colon tumor growth via p21-mediated suppression of NF-κB activity.,/pubmed/21820300,"Oh JH, Ban JO, Cho MC, Jo M, Jung JK, Ahn B, Yoon DY, Han SB, Hong JT.",J Nutr Biochem. 2012 Jul;23(7):706-15. doi: 10.1016/j.jnutbio.2011.03.013. Epub 2011 Aug 4.,J Nutr Biochem.  2012,PubMed,citation,PMID:21820300,pubmed,21820300,create date:2011/08/09 | first author:Oh JH
The impact of folate status on the efficacy of colorectal cancer treatment.,/pubmed/21787267,"Porcelli L, Assaraf YG, Azzariti A, Paradiso A, Jansen G, Peters GJ.",Curr Drug Metab. 2011 Dec;12(10):975-84. Review.,Curr Drug Metab.  2011,PubMed,citation,PMID:21787267,pubmed,21787267,create date:2011/07/27 | first author:Porcelli L
FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.,/pubmed/21772113,"Mizota A, Shitara K, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Muro K.",Gan To Kagaku Ryoho. 2011 Jul;38(7):1205-8.,Gan To Kagaku Ryoho.  2011,PubMed,citation,PMID:21772113,pubmed,21772113,create date:2011/07/21 | first author:Mizota A
Two functional S100A4 monomers are necessary for regulating nonmuscle myosin-IIA and HCT116 cell invasion.,/pubmed/21721535,"House RP, Pozzuto M, Patel P, Dulyaninova NG, Li ZH, Zencheck WD, Vitolo MI, Weber DJ, Bresnick AR.",Biochemistry. 2011 Aug 16;50(32):6920-32. doi: 10.1021/bi200498q. Epub 2011 Jul 13.,Biochemistry.  2011,PubMed,citation,PMID:21721535 | PMCID:PMC3227520,pubmed,21721535,create date:2011/07/05 | first author:House RP
The Drosophila Netrin receptor frazzled/DCC functions as an invasive tumor suppressor.,/pubmed/21672235,"VanZomeren-Dohm A, Sarro J, Flannery E, Duman-Scheel M.",BMC Dev Biol. 2011 Jun 14;11:41. doi: 10.1186/1471-213X-11-41.,BMC Dev Biol.  2011,PubMed,citation,PMID:21672235 | PMCID:PMC3144007,pubmed,21672235,create date:2011/06/16 | first author:VanZomeren-Dohm A
"Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.",/pubmed/21660972,"Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.",J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.,J Pathol.  2011,PubMed,citation,PMID:21660972,pubmed,21660972,create date:2011/06/11 | first author:Zlobec I
Microsatellite instability in the management of colorectal cancer.,/pubmed/21651356,"Pino MS, Chung DC.",Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):385-99. doi: 10.1586/egh.11.25. Review.,Expert Rev Gastroenterol Hepatol.  2011,PubMed,citation,PMID:21651356,pubmed,21651356,create date:2011/06/10 | first author:Pino MS
Colonic polyposis and neoplasia in Cowden syndrome.,/pubmed/21628613,"Stanich PP, Owens VL, Sweetser S, Khambatta S, Smyrk TC, Richardson RL, Goetz MP, Patnaik MM.",Mayo Clin Proc. 2011 Jun;86(6):489-92. doi: 10.4065/mcp.2010.0816.,Mayo Clin Proc.  2011,PubMed,citation,PMID:21628613 | PMCID:PMC3104908,pubmed,21628613,create date:2011/06/02 | first author:Stanich PP
Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.,/pubmed/21618350,"Sanchez JA, Dejulius KL, Bronner M, Church JM, Kalady MF.",Inflamm Bowel Dis. 2011 Sep;17(9):1966-70. doi: 10.1002/ibd.21526. Epub 2011 May 25.,Inflamm Bowel Dis.  2011,PubMed,citation,PMID:21618350,pubmed,21618350,create date:2011/05/28 | first author:Sanchez JA
"Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma.",/pubmed/21616717,"Kelemen LE, Köbel M.",Lancet Oncol. 2011 Oct;12(11):1071-80. doi: 10.1016/S1470-2045(11)70058-4. Epub 2011 May 25. Review.,Lancet Oncol.  2011,PubMed,citation,PMID:21616717,pubmed,21616717,create date:2011/05/28 | first author:Kelemen LE
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.,/pubmed/21597022,"Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.","J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added]. ",J Natl Cancer Inst.  2011,PubMed,citation,PMID:21597022 | PMCID:PMC3110173,pubmed,21597022,create date:2011/05/21 | first author:Sinicrope FA
"p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.",/pubmed/21557216,"Bond CE, Umapathy A, Ramsnes I, Greco SA, Zhen Zhao Z, Mallitt KA, Buttenshaw RL, Montgomery GW, Leggett BA, Whitehall VL.",Int J Cancer. 2012 Apr 1;130(7):1567-76. doi: 10.1002/ijc.26175. Epub 2011 Aug 3.,Int J Cancer.  2012,PubMed,citation,PMID:21557216,pubmed,21557216,create date:2011/05/11 | first author:Bond CE
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population.,/pubmed/21553007,"Liou JM, Wu MS, Shun CT, Chiu HM, Chen MJ, Chen CC, Wang HP, Lin JT, Liang JT.",Int J Colorectal Dis. 2011 Nov;26(11):1387-95. doi: 10.1007/s00384-011-1229-1. Epub 2011 May 7.,Int J Colorectal Dis.  2011,PubMed,citation,PMID:21553007,pubmed,21553007,create date:2011/05/10 | first author:Liou JM
Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors.,/pubmed/21547915,"Sjo OH, Berg M, Merok MA, Kolberg M, Svindland A, Lothe RA, Nesbakken A.",J Surg Oncol. 2011 Dec;104(7):792-7. doi: 10.1002/jso.21959. Epub 2011 May 5.,J Surg Oncol.  2011,PubMed,citation,PMID:21547915,pubmed,21547915,create date:2011/05/07 | first author:Sjo OH
Colonic metastasis from primary lung adenocarcinoma: case report and review of the literature.,/pubmed/21516483,"Xue XY, Zhou M, Fu WF, Pan YG, Zhao J.",Med Oncol. 2012 Jun;29(2):644-7. doi: 10.1007/s12032-011-9954-4. Epub 2011 Apr 24. Review.,Med Oncol.  2012,PubMed,citation,PMID:21516483,pubmed,21516483,create date:2011/04/26 | first author:Xue XY
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.,/pubmed/21516079,"Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.",Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.,Mod Pathol.  2011,PubMed,citation,PMID:21516079,pubmed,21516079,create date:2011/04/26 | first author:Lamy A
DNA methylation predicts recurrence from resected stage III proximal colon cancer.,/pubmed/21509761,"Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK, Issa JP.",Cancer. 2011 May 1;117(9):1847-54. doi: 10.1002/cncr.25737. Epub 2010 Nov 18.,Cancer.  2011,PubMed,citation,PMID:21509761 | PMCID:PMC3117123,pubmed,21509761,create date:2011/04/22 | first author:Ahn JB
Oncosuppressor methylation: a possible key role in colon metastatic progression.,/pubmed/21506124,"Tommasi S, Pinto R, Petriella D, Pilato B, Lacalamita R, Santini D, Zito F, Colucci G, Paradiso A, Silvestris N.",J Cell Physiol. 2011 Jul;226(7):1934-9. doi: 10.1002/jcp.22524.,J Cell Physiol.  2011,PubMed,citation,PMID:21506124,pubmed,21506124,create date:2011/04/21 | first author:Tommasi S
DNA repair gene polymorphisms and tobacco smoking in the risk for colorectal adenomas.,/pubmed/21504893,"Gao Y, Hayes RB, Huang WY, Caporaso NE, Burdette L, Yeager M, Chanock SJ, Berndt SI.",Carcinogenesis. 2011 Jun;32(6):882-7. doi: 10.1093/carcin/bgr071. Epub 2011 Apr 18.,Carcinogenesis.  2011,PubMed,citation,PMID:21504893 | PMCID:PMC3106441,pubmed,21504893,create date:2011/04/21 | first author:Gao Y
Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium.,/pubmed/21490395,"Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, Morrisey EE.",J Clin Invest. 2011 May;121(5):1935-45. doi: 10.1172/JCI44871. Epub 2011 Apr 1.,J Clin Invest.  2011,PubMed,citation,PMID:21490395 | PMCID:PMC3083778,pubmed,21490395,create date:2011/04/15 | first author:Pacheco-Pinedo EC
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.,/pubmed/21456008,"Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J.",Cancer. 2011 Oct 15;117(20):4623-32. doi: 10.1002/cncr.26086. Epub 2011 Mar 31.,Cancer.  2011,PubMed,citation,PMID:21456008 | PMCID:PMC4257471,pubmed,21456008,create date:2011/04/02 | first author:Tran B
A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers.,/pubmed/21455990,"Silver A, Sengupta N, Propper D, Wilson P, Hagemann T, Patel A, Parker A, Ghosh A, Feakins R, Dorudi S, Suraweera N.",Int J Cancer. 2012 Mar 1;130(5):1082-92. doi: 10.1002/ijc.26104. Epub 2011 Aug 3.,Int J Cancer.  2012,PubMed,citation,PMID:21455990,pubmed,21455990,create date:2011/04/02 | first author:Silver A
"Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.",/pubmed/21383284,"Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P.",J Clin Oncol. 2011 Apr 1;29(10):1261-70. doi: 10.1200/JCO.2010.30.1366. Epub 2011 Mar 7. Erratum in: J Clin Oncol. 2011 Jul 20;29(21):2949. ,J Clin Oncol.  2011,PubMed,citation,PMID:21383284,pubmed,21383284,create date:2011/03/09 | first author:Hutchins G
Functional characterization of human cancer-derived TRKB mutations.,/pubmed/21379385,"Geiger TR, Song JY, Rosado A, Peeper DS.",PLoS One. 2011 Feb 17;6(2):e16871. doi: 10.1371/journal.pone.0016871.,PLoS One.  2011,PubMed,citation,PMID:21379385 | PMCID:PMC3040757,pubmed,21379385,create date:2011/03/08 | first author:Geiger TR
The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.,/pubmed/21356164,"Yarom N, Jonker DJ.",Discov Med. 2011 Feb;11(57):95-105. Review.,Discov Med.  2011,PubMed,citation,PMID:21356164,pubmed,21356164,create date:2011/03/02 | first author:Yarom N
The cetuximab experience: developing predictive biomarkers in oncology.,/pubmed/29783412,"Harbison CT, Horak CE, Khambata-Ford S.",Per Med. 2011 Mar;8(2):149-159. doi: 10.2217/pme.10.78.,Per Med.  2011,PubMed,citation,PMID:29783412,pubmed,29783412,create date:2011/03/01 | first author:Harbison CT
A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation.,/pubmed/21315413,"Pancione M, Di Blasi A, Sabatino L, Fucci A, Dalena AM, Palombi N, Carotenuto P, Aquino G, Daniele B, Normanno N, Colantuoni V.",Hum Pathol. 2011 Jul;42(7):1047-52. doi: 10.1016/j.humpath.2010.10.016. Epub 2011 Feb 11.,Hum Pathol.  2011,PubMed,citation,PMID:21315413,pubmed,21315413,create date:2011/02/15 | first author:Pancione M
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.,/pubmed/21285991,"Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y.",Br J Cancer. 2011 Mar 1;104(5):856-62. doi: 10.1038/bjc.2011.19. Epub 2011 Feb 1.,Br J Cancer.  2011,PubMed,citation,PMID:21285991 | PMCID:PMC3048210,pubmed,21285991,create date:2011/02/03 | first author:Yokota T
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.,/pubmed/21170361,"Jürchott K, Kuban RJ, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kiełbasa SM, Ungethüm U, Lund P, Knösel T, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperling S, Sers C, Royer HD, Herzel H, Schäfer R.",PLoS Genet. 2010 Dec 2;6(12):e1001231. doi: 10.1371/journal.pgen.1001231.,PLoS Genet.  2010,PubMed,citation,PMID:21170361 | PMCID:PMC2996331,pubmed,21170361,create date:2010/12/21 | first author:Jürchott K
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.,/pubmed/21163770,László L.,Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.,Magy Onkol.  2010,PubMed,citation,PMID:21163770,pubmed,21163770,create date:2010/12/18 | first author:László L
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].,/pubmed/21163071,"Guo GF, Xia LP, Qiu HJ, Xu RH, Zhang B, Jiang WQ, Zhou FF, Wang F.",Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):777-81. Chinese. ,Zhonghua Zhong Liu Za Zhi.  2010,PubMed,citation,PMID:21163071,pubmed,21163071,create date:2010/12/18 | first author:Guo GF
Influence of A9 region mutation in EphB2 gene in the prognosis of patients with colorectal adenocarcinoma.,/pubmed/21161727,"Vidaurreta M, Rafael S, Veganzones S, de la Orden V, Fernández C, Gómez-Casaseca R, Cerdán J, Maestro M.",Ann Surg Oncol. 2011 May;18(5):1501-5. doi: 10.1245/s10434-010-1448-7. Epub 2010 Dec 16.,Ann Surg Oncol.  2011,PubMed,citation,PMID:21161727,pubmed,21161727,create date:2010/12/17 | first author:Vidaurreta M
"[Palliative chemotherapy for colorectal cancer--current state, significance, trends].",/pubmed/21154211,"Stübs P, Habermann P, Wex C, Mohren M, Zierau K, Lippert H, Fahlke J.",Zentralbl Chir. 2010 Dec;135(6):535-40. doi: 10.1055/s-0030-1262701. Epub 2010 Dec 13. Review. German. ,Zentralbl Chir.  2010,PubMed,citation,PMID:21154211,pubmed,21154211,create date:2010/12/15 | first author:Stübs P
Carcinosarcoma on ascending colon found by bowel perforation: a case report.,/pubmed/21152142,"Shim HJ, Hong YK, Kim SJ, Choi YJ, Kang JG.",J Korean Soc Coloproctol. 2010 Oct;26(5):368-72. doi: 10.3393/jksc.2010.26.5.368. Epub 2010 Oct 31.,J Korean Soc Coloproctol.  2010,PubMed,citation,PMID:21152142 | PMCID:PMC2998018,pubmed,21152142,create date:2010/12/15 | first author:Shim HJ
Improving detection of colorectal cancer.,/pubmed/21141248,"Orbell J, West NJ.","Practitioner. 2010 Oct;254(1733):17-21, 2-3. Review.",Practitioner.  2010,PubMed,citation,PMID:21141248,pubmed,21141248,create date:2010/12/15 | first author:Orbell J
Microsatellite instability in colorectal cancer.,/pubmed/21114775,"Iacopetta B, Grieu F, Amanuel B.",Asia Pac J Clin Oncol. 2010 Dec;6(4):260-9. doi: 10.1111/j.1743-7563.2010.01335.x. Epub 2010 Oct 26. Review.,Asia Pac J Clin Oncol.  2010,PubMed,citation,PMID:21114775,pubmed,21114775,create date:2010/12/01 | first author:Iacopetta B
KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.,/pubmed/22811812,"Sharma N, Saifo M, Tamaskar IR, Bhuvaneswari R, Mashtare T, Fakih M.",J Gastrointest Oncol. 2010 Dec;1(2):90-6. doi: 10.3978/j.issn.2078-6891.2010.022.,J Gastrointest Oncol.  2010,PubMed,citation,PMID:22811812 | PMCID:PMC3397582,pubmed,22811812,create date:2010/12/01 | first author:Sharma N
Kras in metastatic colorectal cancer.,/pubmed/21104470,"Wicki A, Herrmann R, Christofori G.",Swiss Med Wkly. 2010 Nov 19;140:w13112. doi: 10.4414/smw.2010.13112. eCollection 2010. Review.,Swiss Med Wkly.  2010,PubMed,citation,PMID:21104470,pubmed,21104470,create date:2010/11/26 | first author:Wicki A
Rapid development of colorectal neoplasia in patients with Lynch syndrome.,/pubmed/21070872,"Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA, Cruz-Correa M, Giardiello FM.",Clin Gastroenterol Hepatol. 2011 Apr;9(4):340-3. doi: 10.1016/j.cgh.2010.10.033. Epub 2010 Nov 9.,Clin Gastroenterol Hepatol.  2011,PubMed,citation,PMID:21070872 | PMCID:PMC3073674,pubmed,21070872,create date:2010/11/13 | first author:Edelstein DL
"The cohesin-interacting protein, precocious dissociation of sisters 5A/sister chromatid cohesion protein 112, is up-regulated in human astrocytic tumors.",/pubmed/21069257,"Hagemann C, Weigelin B, Schommer S, Schulze M, Al-Jomah N, Anacker J, Gerngras S, Kühnel S, Kessler AF, Polat B, Ernestus RI, Patel R, Vince GH.",Int J Mol Med. 2011 Jan;27(1):39-51. doi: 10.3892/ijmm.2010.551. Epub 2010 Nov 8.,Int J Mol Med.  2011,PubMed,citation,PMID:21069257,pubmed,21069257,create date:2010/11/12 | first author:Hagemann C
High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.,/pubmed/21052001,"De Miglio MR, Mura A, Uras MG, Manca A, Contini M, Murgia L, Zinellu A, Sotgia S, Carru C, Massarelli G, Cossu-Rocca P.",Diagn Mol Pathol. 2010 Dec;19(4):201-8. doi: 10.1097/PDM.0b013e3181db67d5.,Diagn Mol Pathol.  2010,PubMed,citation,PMID:21052001,pubmed,21052001,create date:2010/11/06 | first author:De Miglio MR
Review of biomarkers in colorectal cancer.,/pubmed/21040359,"Newton KF, Newman W, Hill J.",Colorectal Dis. 2012 Jan;14(1):3-17. doi: 10.1111/j.1463-1318.2010.02439.x. Review.,Colorectal Dis.  2012,PubMed,citation,PMID:21040359,pubmed,21040359,create date:2010/11/03 | first author:Newton KF
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.,/pubmed/20972872,"Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.",Cancer Chemother Pharmacol. 2011 Aug;68(2):317-23. doi: 10.1007/s00280-010-1496-5. Epub 2010 Oct 24.,Cancer Chemother Pharmacol.  2011,PubMed,citation,PMID:20972872,pubmed,20972872,create date:2010/10/26 | first author:Chang MH
Colorectal gastrointestinal stromal tumor.,/pubmed/20967481,Amato A.,Tech Coloproctol. 2010 Nov;14 Suppl 1:S91-5. doi: 10.1007/s10151-010-0631-y.,Tech Coloproctol.  2010,PubMed,citation,PMID:20967481,pubmed,20967481,create date:2010/10/23 | first author:Amato A
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.,/pubmed/20926454,"Fantini M, Gianni L, Tassinari D, Nicoletti S, Possenti C, Drudi F, Sintini M, Bagli L, Tamburini E, Ravaioli A.",J Oncol Pharm Pract. 2011 Sep;17(3):288-91. doi: 10.1177/1078155210374891. Epub 2010 Oct 6. Review.,J Oncol Pharm Pract.  2011,PubMed,citation,PMID:20926454,pubmed,20926454,create date:2010/10/12 | first author:Fantini M
A proposal for the annotation of recurrent colorectal cancer: the 'Sheffield classification'.,/pubmed/20883522,"Majeed AW, Shorthouse AJ, Blakeborough A, Bird NC.",Colorectal Dis. 2011 Nov;13(11):1273-9. doi: 10.1111/j.1463-1318.2010.02437.x.,Colorectal Dis.  2011,PubMed,citation,PMID:20883522,pubmed,20883522,create date:2010/10/05 | first author:Majeed AW
A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome.,/pubmed/20878717,"Boonstra PS, Gruber SB, Raymond VM, Huang SC, Timshel S, Nilbert M, Mukherjee B.",Genet Epidemiol. 2010 Nov;34(7):756-68. doi: 10.1002/gepi.20534. Review.,Genet Epidemiol.  2010,PubMed,citation,PMID:20878717 | PMCID:PMC3894615,pubmed,20878717,create date:2010/09/30 | first author:Boonstra PS
NRAS mutations are rare in colorectal cancer.,/pubmed/20736745,"Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S.",Diagn Mol Pathol. 2010 Sep;19(3):157-63. doi: 10.1097/PDM.0b013e3181c93fd1.,Diagn Mol Pathol.  2010,PubMed,citation,PMID:20736745 | PMCID:PMC2929976,pubmed,20736745,create date:2010/08/26 | first author:Irahara N
An intronic mutation in MLH1 associated with familial colon and breast cancer.,/pubmed/20717847,"Bianchi F, Raponi M, Piva F, Viel A, Bearzi I, Galizia E, Bracci R, Belvederesi L, Loretelli C, Brugiati C, Corradini F, Baralle D, Cellerino R.",Fam Cancer. 2011 Mar;10(1):27-35. doi: 10.1007/s10689-010-9371-4.,Fam Cancer.  2011,PubMed,citation,PMID:20717847 | PMCID:PMC3036834,pubmed,20717847,create date:2010/08/19 | first author:Bianchi F
Analysis of β-catenin alterations in colon tumors: a novel exon 3 mutation.,/pubmed/20717765,"Akisik E, Buğra D, Yamaner S, Dalay N.",Tumour Biol. 2011 Feb;32(1):71-6. doi: 10.1007/s13277-010-0099-4. Epub 2010 Aug 18.,Tumour Biol.  2011,PubMed,citation,PMID:20717765,pubmed,20717765,create date:2010/08/19 | first author:Akisik E
Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay.,/pubmed/20703819,"Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, Zeng Z, Rosenberg S, Shia J, Barany F, Paty PB.",Ann Surg Oncol. 2010 Dec;17(12):3370-8. doi: 10.1245/s10434-010-1147-4. Epub 2010 Aug 12.,Ann Surg Oncol.  2010,PubMed,citation,PMID:20703819 | PMCID:PMC3269820,pubmed,20703819,create date:2010/08/13 | first author:Esemuede I
Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations.,/pubmed/20673328,"Bavi P, Prabhakaran SE, Abubaker J, Qadri Z, George T, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Uddin S, Al-Kuraya KS.",Mol Cancer. 2010 Jul 30;9:203. doi: 10.1186/1476-4598-9-203.,Mol Cancer.  2010,PubMed,citation,PMID:20673328 | PMCID:PMC2922191,pubmed,20673328,create date:2010/08/03 | first author:Bavi P
"Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.",/pubmed/20664940,"Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A.",Int J Oncol. 2010 Sep;37(3):707-18.,Int J Oncol.  2010,PubMed,citation,PMID:20664940,pubmed,20664940,create date:2010/07/29 | first author:Minoo P
Cy5.5 conjugated anti-epidermal growth factor receptor monoclonal antibody.,/pubmed/20641853,Chopra A.,2007 Oct 18 [updated 2007 Nov 1]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.,Molecular Imaging and Contrast Agent Database (MICAD).  2004,PubMed,citation,PMID:20641853,pubmed,20641853,create date:2010/07/22 | first author:Chopra A
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.,/pubmed/20635392,"Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.",Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555.,Int J Cancer.  2011,PubMed,citation,PMID:20635392,pubmed,20635392,create date:2010/07/17 | first author:Tie J
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.,/pubmed/20603437,"Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.",Ann Oncol. 2011 Jan;22(1):104-9. doi: 10.1093/annonc/mdq315. Epub 2010 Jul 5.,Ann Oncol.  2011,PubMed,citation,PMID:20603437,pubmed,20603437,create date:2010/07/07 | first author:Zhang W
EGFR expression variance in paired colorectal cancer primary and metastatic tumors.,/pubmed/20595818,"Yarom N, Marginean C, Moyana T, Gorn-Hondermann I, Birnboim HC, Marginean H, Auer RC, Vickers M, Asmis TR, Maroun J, Jonker D.",Cancer Biol Ther. 2010 Sep 1;10(5):416-21. Epub 2010 Sep 8.,Cancer Biol Ther.  2010,PubMed,citation,PMID:20595818,pubmed,20595818,create date:2010/07/03 | first author:Yarom N
Candidate driver genes in focal chromosomal aberrations of stage II colon cancer.,/pubmed/20593488,"Brosens RP, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N, Flens M, Meijer GA, Ylstra B.",J Pathol. 2010 Aug;221(4):411-24. doi: 10.1002/path.2724.,J Pathol.  2010,PubMed,citation,PMID:20593488,pubmed,20593488,create date:2010/07/02 | first author:Brosens RP
Juvenile polyps: recurrence in patients with multiple and solitary polyps.,/pubmed/20580940,"Fox VL, Perros S, Jiang H, Goldsmith JD.",Clin Gastroenterol Hepatol. 2010 Sep;8(9):795-9. doi: 10.1016/j.cgh.2010.05.010. Epub 2010 May 23.,Clin Gastroenterol Hepatol.  2010,PubMed,citation,PMID:20580940,pubmed,20580940,create date:2010/06/29 | first author:Fox VL
Mucosal melanomas: a case-based review of the literature.,/pubmed/20571149,"Seetharamu N, Ott PA, Pavlick AC.",Oncologist. 2010;15(7):772-81. doi: 10.1634/theoncologist.2010-0067. Epub 2010 Jun 22. Review.,Oncologist.  2010,PubMed,citation,PMID:20571149 | PMCID:PMC3228004,pubmed,20571149,create date:2010/06/24 | first author:Seetharamu N
Genetic alterations and expression pattern of CEACAM1 in colorectal adenomas and cancers.,/pubmed/20524097,"Song JH, Cao Z, Yoon JH, Nam SW, Kim SY, Lee JY, Park WS.",Pathol Oncol Res. 2011 Mar;17(1):67-74. doi: 10.1007/s12253-010-9282-6. Epub 2010 Jun 4.,Pathol Oncol Res.  2011,PubMed,citation,PMID:20524097,pubmed,20524097,create date:2010/06/05 | first author:Song JH
Focal adhesion kinase and p53 signal transduction pathways in cancer.,/pubmed/20515733,"Golubovskaya VM, Cance W.",Front Biosci (Landmark Ed). 2010 Jun 1;15:901-12. Review.,Front Biosci (Landmark Ed).  2010,PubMed,citation,PMID:20515733 | PMCID:PMC3136041,pubmed,20515733,create date:2010/06/03 | first author:Golubovskaya VM
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.,/pubmed/20504250,"Balboa E, Duran G, Lamas MJ, Gomez-Caamaño A, Celeiro-Muñoz C, Lopez R, Carracedo A, Barros F.",Pharmacogenomics. 2010 Jun;11(6):747-61. doi: 10.2217/pgs.10.51.,Pharmacogenomics.  2010,PubMed,citation,PMID:20504250,pubmed,20504250,create date:2010/05/28 | first author:Balboa E
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.,/pubmed/20501503,"Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, van den Brule AJ.",Ann Oncol. 2010 Dec;21(12):2396-402. doi: 10.1093/annonc/mdq258. Epub 2010 May 25.,Ann Oncol.  2010,PubMed,citation,PMID:20501503,pubmed,20501503,create date:2010/05/27 | first author:Fariña-Sarasqueta A
[Specific treatment situations in metastatic colorectal cancer].,/pubmed/20431307,"Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P.",Onkologie. 2010;33 Suppl 4:8-18. doi: 10.1159/000308447. Epub 2010 Apr 23. Review. German. ,Onkologie.  2010,PubMed,citation,PMID:20431307,pubmed,20431307,create date:2010/05/07 | first author:Arnold D
"Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.",/pubmed/20401611,"Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M.",Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48. doi: 10.1007/s00280-010-1327-8. Epub 2010 Apr 17.,Cancer Chemother Pharmacol.  2011,PubMed,citation,PMID:20401611,pubmed,20401611,create date:2010/04/20 | first author:Lévi F
KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.,/pubmed/20305537,"Kim KM, Lee EJ, Kim YH, Chang DK, Odze RD.",Am J Surg Pathol. 2010 May;34(5):667-75. doi: 10.1097/PAS.0b013e3181d40cb2.,Am J Surg Pathol.  2010,PubMed,citation,PMID:20305537,pubmed,20305537,create date:2010/03/23 | first author:Kim KM
Is BRAF mutation associated with interval colorectal cancers?,/pubmed/20300843,"Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M.",Dig Dis Sci. 2010 Aug;55(8):2352-6. doi: 10.1007/s10620-010-1182-9. Epub 2010 Mar 19.,Dig Dis Sci.  2010,PubMed,citation,PMID:20300843,pubmed,20300843,create date:2010/03/20 | first author:Shaukat A
Induction of p53-independent apoptosis by a novel synthetic hexahydrocannabinol analog is mediated via Sp1-dependent NSAID-activated gene-1 in colon cancer cells.,/pubmed/20230799,"Thapa D, Babu D, Park MA, Kwak MK, Lee YR, Kim JM, Kwon TK, Kim JA.",Biochem Pharmacol. 2010 Jul 1;80(1):62-71. doi: 10.1016/j.bcp.2010.03.008. Epub 2010 Mar 15.,Biochem Pharmacol.  2010,PubMed,citation,PMID:20230799,pubmed,20230799,create date:2010/03/17 | first author:Thapa D
Characterization of functional domains necessary for mutant p53 gain of function.,/pubmed/20212049,"Yan W, Chen X.",J Biol Chem. 2010 May 7;285(19):14229-38. doi: 10.1074/jbc.M109.097253. Epub 2010 Mar 8.,J Biol Chem.  2010,PubMed,citation,PMID:20212049 | PMCID:PMC2863234,pubmed,20212049,create date:2010/03/10 | first author:Yan W
Prognostic relevance of MLH1 and MSH2 mutations in hereditary non-polyposis colorectal cancer patients.,/pubmed/20210238,"Russo A, Sala P, Alberici P, Gazzoli I, Radice P, Montefusco C, Torrini M, Mareni C, Fornasarig M, Santarosa M, Viel A, Benatti P, Pedroni M, de Leon MP, Lucci-Cordisco E, Genuardi M, Messerini L, Stigliano V, Cama A, Curia MC, de Lellis L, Signoroni S, et al.","Tumori. 2009 Nov-Dec;95(6):731-8. Erratum in: Tumori. 2010 Jan-Feb;96(1):183. Pedroni, Maurizio [corrected to Pedroni, Monica]. ",Tumori.  2009,PubMed,citation,PMID:20210238,pubmed,20210238,create date:2010/03/10 | first author:Russo A
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.,/pubmed/20189054,"Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y.",Cancer Treat Rev. 2010 Feb;36 Suppl 1:S11-4. doi: 10.1016/S0305-7372(10)70002-5.,Cancer Treat Rev.  2010,PubMed,citation,PMID:20189054,pubmed,20189054,create date:2010/03/10 | first author:Seront E
3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway.,/pubmed/20197379,"Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A.",Mol Cancer Res. 2010 Mar;8(3):421-32. doi: 10.1158/1541-7786.MCR-09-0179. Epub 2010 Mar 2.,Mol Cancer Res.  2010,PubMed,citation,PMID:20197379,pubmed,20197379,create date:2010/03/04 | first author:Lu Z
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.,/pubmed/20177422,"Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M.",Pharmacogenomics J. 2010 Oct;10(5):458-64. doi: 10.1038/tpj.2010.9. Epub 2010 Feb 23.,Pharmacogenomics J.  2010,PubMed,citation,PMID:20177422,pubmed,20177422,create date:2010/02/24 | first author:Graziano F
A new conditional Apc-mutant mouse model for colorectal cancer.,/pubmed/20176656,"Robanus-Maandag EC, Koelink PJ, Breukel C, Salvatori DC, Jagmohan-Changur SC, Bosch CA, Verspaget HW, Devilee P, Fodde R, Smits R.",Carcinogenesis. 2010 May;31(5):946-52. doi: 10.1093/carcin/bgq046. Epub 2010 Feb 22.,Carcinogenesis.  2010,PubMed,citation,PMID:20176656,pubmed,20176656,create date:2010/02/24 | first author:Robanus-Maandag EC
KRAS mutation screening in colorectal cancer: From paper to practice.,/pubmed/20100685,Fakih MM.,Clin Colorectal Cancer. 2010 Jan;9(1):22-30. doi: 10.3816/CCC.2010.n.003. Review.,Clin Colorectal Cancer.  2010,PubMed,citation,PMID:20100685,pubmed,20100685,create date:2010/01/27 | first author:Fakih MM
Hereditary cancer predisposition syndromes and preimplantation genetic diagnosis: where are we now?,/pubmed/19785065,"Konstantopoulou I, Pertesi M, Fostira F, Grivas A, Yannoukakos D.",J BUON. 2009 Sep;14 Suppl 1:S187-92. Review.,J BUON.  2009,PubMed,citation,PMID:19785065,pubmed,19785065,create date:2010/01/27 | first author:Konstantopoulou I
MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo.,/pubmed/20094071,"Vidic S, Markelc B, Sersa G, Coer A, Kamensek U, Tevz G, Kranjc S, Cemazar M.",Cancer Gene Ther. 2010 Jun;17(6):409-19. doi: 10.1038/cgt.2009.87. Epub 2010 Jan 22.,Cancer Gene Ther.  2010,PubMed,citation,PMID:20094071,pubmed,20094071,create date:2010/01/23 | first author:Vidic S
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.,/pubmed/20086114,"Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE.",Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19.,Cancer Epidemiol Biomarkers Prev.  2010,PubMed,citation,PMID:20086114 | PMCID:PMC2846615,pubmed,20086114,create date:2010/01/21 | first author:Chung CH
KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.,/pubmed/20049644,"Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, François E, Saint-Paul MC, Pedeutour F.",Ann Surg Oncol. 2010 May;17(5):1429-34. doi: 10.1245/s10434-009-0864-z. Epub 2010 Jan 5.,Ann Surg Oncol.  2010,PubMed,citation,PMID:20049644,pubmed,20049644,create date:2010/01/06 | first author:Italiano A
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.,/pubmed/23074403,Medical Advisory Secretariat..,Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.,Ont Health Technol Assess Ser.  2010,PubMed,citation,PMID:23074403 | PMCID:PMC3377508,pubmed,23074403,create date:2010/01/01 | first author:Medical Advisory Secretariat.
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.,/pubmed/23074402,Medical Advisory Secretariat..,Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.,Ont Health Technol Assess Ser.  2010,PubMed,citation,PMID:23074402 | PMCID:PMC3377519,pubmed,23074402,create date:2010/01/01 | first author:Medical Advisory Secretariat.
[A case of liver metastasis treated by cetuximab monotherapy with partial response].,/pubmed/20037354,"Murata K, Ide Y, Nagase H, Mukai R, Okada K, Ota H, Maruyama K, Yokouchi H, Hayashi M, Tanaka S, Oka A, Kinuta M.",Gan To Kagaku Ryoho. 2009 Nov;36(12):2155-7. Japanese. ,Gan To Kagaku Ryoho.  2009,PubMed,citation,PMID:20037354,pubmed,20037354,create date:2009/12/29 | first author:Murata K
[Clinical and pathological analysis of 8 hereditary nonpolyposis colorectal cancer pedigrees].,/pubmed/20034885,"Wang Y, Yang L, Ding YQ, Tong J.",Nan Fang Yi Ke Da Xue Xue Bao. 2009 Dec;29(12):2397-400. Chinese. ,Nan Fang Yi Ke Da Xue Xue Bao.  2009,PubMed,citation,PMID:20034885,pubmed,20034885,create date:2009/12/26 | first author:Wang Y
"Mutational analysis of CASP10 gene in colon, breast, lung and hepatocellular carcinomas.",/pubmed/20025484,"Oh JE, Kim MS, Ahn CH, Kim SS, Han JY, Lee SH, Yoo NJ.",Pathology. 2010 Jan;42(1):73-6. doi: 10.3109/00313020903434371.,Pathology.  2010,PubMed,citation,PMID:20025484,pubmed,20025484,create date:2009/12/23 | first author:Oh JE
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.,/pubmed/20015382,"Menigatti M, Cattaneo E, Sabates-Bellver J, Ilinsky VV, Went P, Buffoli F, Marquez VE, Jiricny J, Marra G.",Mol Cancer. 2009 Dec 16;8:124. doi: 10.1186/1476-4598-8-124.,Mol Cancer.  2009,PubMed,citation,PMID:20015382 | PMCID:PMC2801661,pubmed,20015382,create date:2009/12/18 | first author:Menigatti M
"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.",/pubmed/20008640,"Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F.",J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14.,J Clin Oncol.  2010,PubMed,citation,PMID:20008640,pubmed,20008640,create date:2009/12/17 | first author:Roth AD
"The prognostic value of p73 overexpression in colorectal carcinoma: a clinicopathologic, immunohistochemical, and statistical study of 204 patients.",/pubmed/19956069,"Toumi AA, El Hadj Oel A, Ben Mahmoud LK, Ben Hmida Ael M, Chaar I, Gharbi L, Mzabi S, Bouraoui S.",Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):128-36. doi: 10.1097/PAI.0b013e3181bcb2da.,Appl Immunohistochem Mol Morphol.  2010,PubMed,citation,PMID:19956069,pubmed,19956069,create date:2009/12/04 | first author:Toumi AA
[Serrated pathway of colorectal carcinogenesis].,/pubmed/19921196,Baretton GB.,Pathologe. 2010 Feb;31(1):9-15. doi: 10.1007/s00292-009-1239-8. Review. German. ,Pathologe.  2010,PubMed,citation,PMID:19921196,pubmed,19921196,create date:2009/11/19 | first author:Baretton GB
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.,/pubmed/19911194,"Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH.",Virchows Arch. 2009 Dec;455(6):485-94. doi: 10.1007/s00428-009-0857-0. Epub 2009 Nov 13.,Virchows Arch.  2009,PubMed,citation,PMID:19911194,pubmed,19911194,create date:2009/11/17 | first author:Kim JH
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.,/pubmed/19908233,"Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A.",Int J Cancer. 2010 Jul 15;127(2):367-80. doi: 10.1002/ijc.25042.,Int J Cancer.  2010,PubMed,citation,PMID:19908233,pubmed,19908233,create date:2009/11/13 | first author:Zlobec I
p53 Regulates LIF expression in human medulloblastoma cells.,/pubmed/19907922,"Baxter EW, Milner J.",J Neurooncol. 2010 May;97(3):373-82. doi: 10.1007/s11060-009-0043-x. Epub 2009 Nov 12.,J Neurooncol.  2010,PubMed,citation,PMID:19907922,pubmed,19907922,create date:2009/11/13 | first author:Baxter EW
Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?,/pubmed/19903790,"Myers AP, Meyerhardt JA, Cantley LC.",Clin Cancer Res. 2009 Nov 15;15(22):6748-50. doi: 10.1158/1078-0432.CCR-09-2305. Epub 2009 Nov 10.,Clin Cancer Res.  2009,PubMed,citation,PMID:19903790 | PMCID:PMC3400141,pubmed,19903790,create date:2009/11/12 | first author:Myers AP
PIK3CA mutations predict local recurrences in rectal cancer patients.,/pubmed/19903786,"He Y, Van't Veer LJ, Mikolajewska-Hanclich I, van Velthuysen ML, Zeestraten EC, Nagtegaal ID, van de Velde CJ, Marijnen CA.",Clin Cancer Res. 2009 Nov 15;15(22):6956-62. doi: 10.1158/1078-0432.CCR-09-1165. Epub 2009 Nov 10.,Clin Cancer Res.  2009,PubMed,citation,PMID:19903786,pubmed,19903786,create date:2009/11/12 | first author:He Y
Colorectal cancer due to deficiency in DNA mismatch repair function: a review.,/pubmed/19851131,"Bellizzi AM, Frankel WL.",Adv Anat Pathol. 2009 Nov;16(6):405-17. doi: 10.1097/PAP.0b013e3181bb6bdc. Review.,Adv Anat Pathol.  2009,PubMed,citation,PMID:19851131,pubmed,19851131,create date:2009/10/24 | first author:Bellizzi AM
What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?,/pubmed/19833054,"Al-Salama HM, Johnstone EC, Kerr DJ.",Discov Med. 2009 Oct;8(42):104-7.,Discov Med.  2009,PubMed,citation,PMID:19833054,pubmed,19833054,create date:2009/10/17 | first author:Al-Salama HM
Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.,/pubmed/19824059,"Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.",J Pathol. 2009 Dec;219(4):435-45. doi: 10.1002/path.2625.,J Pathol.  2009,PubMed,citation,PMID:19824059,pubmed,19824059,create date:2009/10/14 | first author:Abubaker J
Technique of right hemihepatectomy preserving ventral right anterior section guided by area of hepatic venous drainage.,/pubmed/19744462,"Tanaka K, Matsumoto C, Takakura H, Matsuo K, Nagano Y, Endo I, Togo S, Shimada H, Bourquain H, Peitgen HO.",Surgery. 2010 Mar;147(3):450-8. doi: 10.1016/j.surg.2009.04.020.,Surgery.  2010,PubMed,citation,PMID:19744462,pubmed,19744462,create date:2009/09/12 | first author:Tanaka K
[Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].,/pubmed/19717258,"Rougier P, Mitry E.",Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):672-80. doi: 10.1016/j.gcb.2009.07.019. Epub 2009 Aug 29. French. ,Gastroenterol Clin Biol.  2009,PubMed,citation,PMID:19717258,pubmed,19717258,create date:2009/09/01 | first author:Rougier P
Colorectal cancer in Iran: immunohistochemical profiles of four mismatch repair proteins.,/pubmed/19707776,"Molaei M, Mansoori BK, Ghiasi S, Khatami F, Attarian H, Zali M.",Int J Colorectal Dis. 2010 Jan;25(1):63-9. doi: 10.1007/s00384-009-0784-1. Epub 2009 Aug 26.,Int J Colorectal Dis.  2010,PubMed,citation,PMID:19707776,pubmed,19707776,create date:2009/08/27 | first author:Molaei M
Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2.,/pubmed/19669161,"Betz B, Theiss S, Aktas M, Konermann C, Goecke TO, Möslein G, Schaal H, Royer-Pokora B.",J Cancer Res Clin Oncol. 2010 Jan;136(1):123-34. doi: 10.1007/s00432-009-0643-z.,J Cancer Res Clin Oncol.  2010,PubMed,citation,PMID:19669161,pubmed,19669161,create date:2009/08/12 | first author:Betz B
Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location.,/pubmed/19648886,"Wei YC, Li CF, Yu SC, Chou FF, Fang FM, Eng HL, Uen YH, Tian YF, Wu JM, Li SH, Huang WW, Li WM, Huang HY.",Mod Pathol. 2009 Oct;22(10):1351-60. doi: 10.1038/modpathol.2009.107. Epub 2009 Jul 31.,Mod Pathol.  2009,PubMed,citation,PMID:19648886,pubmed,19648886,create date:2009/08/04 | first author:Wei YC
Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.,/pubmed/19581844,"Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM.",Dis Colon Rectum. 2009 Jun;52(6):1039-45. doi: 10.1007/DCR.0b013e31819edbd4.,Dis Colon Rectum.  2009,PubMed,citation,PMID:19581844,pubmed,19581844,create date:2009/07/08 | first author:Kalady MF
Value of the identification of microsatellite instability in colorectal cancer.,/pubmed/19574205,"Barrasa Shaw A, López-Guerrero JA, Calatrava Fons A, García-Casado Z, Alapont Olavarrieta V, Campos Máñez J, Vázquez Albaladejo C.",Clin Transl Oncol. 2009 Jul;11(7):465-9.,Clin Transl Oncol.  2009,PubMed,citation,PMID:19574205,pubmed,19574205,create date:2009/07/04 | first author:Barrasa Shaw A
[Palliative treatment for colorectal cancer].,/pubmed/19546597,"Hegewisch-Becker S, Vanhoefer U, Kubicka S, Pech M, Moehler M, Riess H, Hartmann JT, Malek N, Rödel C, Arnold D.",Onkologie. 2009;32 Suppl 2:13-6. doi: 10.1159/000213484. Epub 2009 Jun 22. Review. German. ,Onkologie.  2009,PubMed,citation,PMID:19546597,pubmed,19546597,create date:2009/06/27 | first author:Hegewisch-Becker S
Diplopia as the first symptom of an aggressive metastatic rectal stromal tumor.,/pubmed/19521122,"Barrière J, Thariat J, Vandenbos F, Bondiau PY, Peyrottes I, Peyrade F.",Onkologie. 2009 Jun;32(6):345-7. doi: 10.1159/000215712. Epub 2009 May 14.,Onkologie.  2009,PubMed,citation,PMID:19521122,pubmed,19521122,create date:2009/06/13 | first author:Barrière J
A parametric model for analyzing anticipation in genetically predisposed families.,/pubmed/19492984,"Larsen K, Petersen J, Bernstein I, Nilbert M.",Stat Appl Genet Mol Biol. 2009;8:Article26. doi: 10.2202/1544-6115.1424. Epub 2009 Jun 2.,Stat Appl Genet Mol Biol.  2009,PubMed,citation,PMID:19492984,pubmed,19492984,create date:2009/06/06 | first author:Larsen K
Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.,/pubmed/19450179,"Lin JE, Li P, Pitari GM, Schulz S, Waldman SA.",Future Oncol. 2009 May;5(4):509-22. doi: 10.2217/fon.09.14. Review.,Future Oncol.  2009,PubMed,citation,PMID:19450179 | PMCID:PMC2749695,pubmed,19450179,create date:2009/05/20 | first author:Lin JE
Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.,/pubmed/19443869,"Carcangiu ML, Radice P, Casalini P, Bertario L, Merola M, Sala P.",Int J Surg Pathol. 2010 Feb;18(1):21-6. doi: 10.1177/1066896909332117. Epub 2009 May 14.,Int J Surg Pathol.  2010,PubMed,citation,PMID:19443869,pubmed,19443869,create date:2009/05/16 | first author:Carcangiu ML
[Frequency and clinicopathological associations of K-ras mutations in Venezuelan patients with colo-rectal cancer].,/pubmed/19418727,"Estrada P, Rojas-Atencio A, Zabala W, Borjas L, Soca L, Urdaneta K, Alvarez-Nava F, Cañizales J, Rojas J, Soto M.",Invest Clin. 2009 Mar;50(1):55-63. Spanish. ,Invest Clin.  2009,PubMed,citation,PMID:19418727,pubmed,19418727,create date:2009/05/08 | first author:Estrada P
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.,/pubmed/19337429,"Hoda D, Simon GR, Garrett CR.",Ther Clin Risk Manag. 2008 Dec;4(6):1221-7.,Ther Clin Risk Manag.  2008,PubMed,citation,PMID:19337429 | PMCID:PMC2643103,pubmed,19337429,create date:2009/04/02 | first author:Hoda D
Role of cancer microenvironment in metastasis: focus on colon cancer.,/pubmed/19308686,"Gout S, Huot J.",Cancer Microenviron. 2008 Dec;1(1):69-83. doi: 10.1007/s12307-008-0007-2. Epub 2008 Mar 14.,Cancer Microenviron.  2008,PubMed,citation,PMID:19308686 | PMCID:PMC2654352,pubmed,19308686,create date:2009/03/25 | first author:Gout S
Colorectal cancer in Nigeria: 40 years on. A review.,/pubmed/19267725,"Irabor D, Adedeji OA.",Eur J Cancer Care (Engl). 2009 Mar;18(2):110-5. doi: 10.1111/j.1365-2354.2008.00982.x. Review.,Eur J Cancer Care (Engl).  2009,PubMed,citation,PMID:19267725,pubmed,19267725,create date:2009/03/10 | first author:Irabor D
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.,/pubmed/19223544,"Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.",Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.,Cancer Res.  2009,PubMed,citation,PMID:19223544,pubmed,19223544,create date:2009/02/19 | first author:Sartore-Bianchi A
The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.,/pubmed/20130434,"Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E, Colucci G.",Oncology. 2009;77 Suppl 1:69-74. doi: 10.1159/000258498. Epub 2010 Feb 2. Review.,Oncology.  2009,PubMed,citation,PMID:20130434,pubmed,20130434,create date:2009/01/01 | first author:Silvestris N
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).,/pubmed/19110398,"Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A.",Eur J Surg Oncol. 2009 Jul;35(7):739-45. doi: 10.1016/j.ejso.2008.11.005. Epub 2008 Dec 24.,Eur J Surg Oncol.  2009,PubMed,citation,PMID:19110398,pubmed,19110398,create date:2008/12/27 | first author:Fiore M
First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent.,/pubmed/19101405,Lenz HJ.,Cancer Treat Rev. 2008;34 Suppl 2:S3-7. doi: 10.1016/S0305-7372(08)70002-1.,Cancer Treat Rev.  2008,PubMed,citation,PMID:19101405,pubmed,19101405,create date:2008/12/23 | first author:Lenz HJ
"Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.",/pubmed/19047896,"Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, Chen YT.",Am J Surg Pathol. 2009 Apr;33(4):572-82. doi: 10.1097/PAS.0b013e31818afd6b.,Am J Surg Pathol.  2009,PubMed,citation,PMID:19047896,pubmed,19047896,create date:2008/12/03 | first author:Yantiss RK
p53 expression in colorectal carcinoma in relation to histopathological features in Ugandan patients.,/pubmed/20589130,"Rambau PF, Odida M, Wabinga H.",Afr Health Sci. 2008 Dec;8(4):234-8.,Afr Health Sci.  2008,PubMed,citation,PMID:20589130 | PMCID:PMC2887007,pubmed,20589130,create date:2008/12/01 | first author:Rambau PF
A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts.,/pubmed/19039682,"Sjursen W, Bjørnevoll I, Engebretsen LF, Fjelland K, Halvorsen T, Myrvold HE.",Fam Cancer. 2009;8(3):179-86. doi: 10.1007/s10689-008-9225-5. Epub 2008 Nov 28.,Fam Cancer.  2009,PubMed,citation,PMID:19039682,pubmed,19039682,create date:2008/11/29 | first author:Sjursen W
Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.,/pubmed/18974136,"Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T, Sakai T.",Cancer Res. 2008 Nov 1;68(21):8918-27. doi: 10.1158/0008-5472.CAN-08-1120.,Cancer Res.  2008,PubMed,citation,PMID:18974136,pubmed,18974136,create date:2008/11/01 | first author:Taniguchi H
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.,/pubmed/18922929,"Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F.",Cancer Res. 2008 Oct 15;68(20):8541-6. doi: 10.1158/0008-5472.CAN-08-1171.,Cancer Res.  2008,PubMed,citation,PMID:18922929,pubmed,18922929,create date:2008/10/17 | first author:Barault L
"Clinico-Pathological and Prognostic Significance of p53, Bcl-2 and Her-2/neu Protein Markers in Colorectal Cancer Using Tissue Microarray.",/pubmed/18839030,"Ismail HM, El-Baradie M, Moneer M, Khorshid O, Touny A.",J Egypt Natl Canc Inst. 2007 Mar;19(1):3-14.,J Egypt Natl Canc Inst.  2007,PubMed,citation,PMID:18839030,pubmed,18839030,create date:2008/10/08 | first author:Ismail HM
CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.,/pubmed/18834226,"Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.",Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.,Arch Pathol Lab Med.  2008,PubMed,citation,PMID:18834226,pubmed,18834226,create date:2008/10/07 | first author:Lee S
Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon.,/pubmed/18832169,"Kucherlapati MH, Yang K, Fan K, Kuraguchi M, Sonkin D, Rosulek A, Lipkin M, Bronson RT, Aronow BJ, Kucherlapati R.",Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15493-8. doi: 10.1073/pnas.0802933105. Epub 2008 Oct 1.,Proc Natl Acad Sci U S A.  2008,PubMed,citation,PMID:18832169 | PMCID:PMC2563082,pubmed,18832169,create date:2008/10/04 | first author:Kucherlapati MH
Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients.,/pubmed/18803843,"Stigliano V, Assisi D, Cosimelli M, Palmirotta R, Giannarelli D, Mottolese M, Mete LS, Mancini R, Casale V.",J Exp Clin Cancer Res. 2008 Sep 19;27:39. doi: 10.1186/1756-9966-27-39.,J Exp Clin Cancer Res.  2008,PubMed,citation,PMID:18803843 | PMCID:PMC2559820,pubmed,18803843,create date:2008/09/23 | first author:Stigliano V
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.,/pubmed/18794099,"Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S.",Clin Cancer Res. 2008 Sep 15;14(18):5869-76. doi: 10.1158/1078-0432.CCR-08-0449.,Clin Cancer Res.  2008,PubMed,citation,PMID:18794099,pubmed,18794099,create date:2008/09/17 | first author:Personeni N
Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells.,/pubmed/18760266,"Liu HF, Hsiao PW, Chao JI.",Chem Biol Interact. 2008 Oct 22;176(1):48-57. doi: 10.1016/j.cbi.2008.07.012. Epub 2008 Aug 8.,Chem Biol Interact.  2008,PubMed,citation,PMID:18760266,pubmed,18760266,create date:2008/09/02 | first author:Liu HF
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.,/pubmed/18757341,"Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S.",J Clin Oncol. 2008 Sep 1;26(25):4217-9. doi: 10.1200/JCO.2008.18.7286. No abstract available. ,J Clin Oncol.  2008,PubMed,citation,PMID:18757341,pubmed,18757341,create date:2008/09/02 | first author:Artale S
KIT codon 558 insertions in gastrointestinal stromal tumors. Analysis of 17 rare KIT mutants.,/pubmed/18715619,"Lasota J, Kuban W, Wardelmann E, Debiec-Rychter M, Merkelbach-Bruse S, Sciot R, Rys J, Steigen SE, Iwanik K, Holden JA, Jerzak Vel Dobosz A, Schildhaus HU, Miettinen M.",Hum Pathol. 2008 Dec;39(12):1728-36. doi: 10.1016/j.humpath.2008.05.011. Epub 2008 Aug 20.,Hum Pathol.  2008,PubMed,citation,PMID:18715619,pubmed,18715619,create date:2008/08/22 | first author:Lasota J
Hereditary ovarian cancer.,/pubmed/18656380,"Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G.",Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44. doi: 10.1016/j.critrevonc.2008.06.003. Epub 2008 Jul 24. Review.,Crit Rev Oncol Hematol.  2009,PubMed,citation,PMID:18656380,pubmed,18656380,create date:2008/07/29 | first author:Russo A
Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of beta-catenin and chromosomal instability.,/pubmed/18632876,"Pizzi S, Azzoni C, Tamburini E, Bottarelli L, Campanini N, D'Adda T, Fellegara G, Luong TV, Pasquali C, Rossi G, Delle Fave G, Camisa R, Bordi C, Rindi G.",Endocr Relat Cancer. 2008 Dec;15(4):1013-24. doi: 10.1677/ERC-07-0230. Epub 2008 Jul 16.,Endocr Relat Cancer.  2008,PubMed,citation,PMID:18632876,pubmed,18632876,create date:2008/07/18 | first author:Pizzi S
Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II.,/pubmed/18619647,"Ohta M, Sugimoto T, Seto M, Mohri D, Asaoka Y, Tada M, Tanaka Y, Yamaji Y, Kanai F, Kawabe T, Omata M.",Hum Pathol. 2008 Sep;39(9):1301-8. doi: 10.1016/j.humpath.2008.02.005. Epub 2008 Jul 11.,Hum Pathol.  2008,PubMed,citation,PMID:18619647,pubmed,18619647,create date:2008/07/16 | first author:Ohta M
Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2.,/pubmed/18612159,"Liljegren A, Barker G, Elliott F, Bertario L, Bisgaard ML, Eccles D, Evans G, Macrae F, Maher E, Lindblom A, Rotstein S, Nilsson B, Mecklin JP, Möslein G, Jass J, Fodde R, Mathers J, Burn J, Bishop DT.",J Clin Oncol. 2008 Jul 10;26(20):3434-9. doi: 10.1200/JCO.2007.13.2795.,J Clin Oncol.  2008,PubMed,citation,PMID:18612159 | PMCID:PMC2645083,pubmed,18612159,create date:2008/07/10 | first author:Liljegren A
Risk factors for development of desmoid tumours in familial adenomatous polyposis.,/pubmed/18581438,"Lefevre JH, Parc Y, Kernéis S, Goasguen N, Benis M, Parc R, Tiret E.",Br J Surg. 2008 Sep;95(9):1136-9. doi: 10.1002/bjs.6241.,Br J Surg.  2008,PubMed,citation,PMID:18581438,pubmed,18581438,create date:2008/06/27 | first author:Lefevre JH
P53 expression in synchronous colorectal cancer.,/pubmed/18521459,"Yalcinkaya U, Ozturk E, Ozgur T, Yerci O, Yilmazlar T.",Saudi Med J. 2008 Jun;29(6):826-31.,Saudi Med J.  2008,PubMed,citation,PMID:18521459,pubmed,18521459,create date:2008/06/04 | first author:Yalcinkaya U
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.,/pubmed/18519771,"French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN.",Clin Cancer Res. 2008 Jun 1;14(11):3408-15. doi: 10.1158/1078-0432.CCR-07-1489.,Clin Cancer Res.  2008,PubMed,citation,PMID:18519771 | PMCID:PMC2674786,pubmed,18519771,create date:2008/06/04 | first author:French AJ
"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.",/pubmed/18495536,"Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH.",Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Erratum in: Lancet Oncol. 2008 Jul;9(7):613. ,Lancet Oncol.  2008,PubMed,citation,PMID:18495536,pubmed,18495536,create date:2008/05/23 | first author:Park BH
Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics.,/pubmed/18486467,"Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH, Kim YS.",Eur J Cancer. 2008 Jun;44(9):1290-301. doi: 10.1016/j.ejca.2008.03.014. Epub 2008 May 15.,Eur J Cancer.  2008,PubMed,citation,PMID:18486467,pubmed,18486467,create date:2008/05/20 | first author:Deng G
Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours.,/pubmed/18387968,"Kohler EM, Derungs A, Daum G, Behrens J, Schneikert J.",Hum Mol Genet. 2008 Jul 1;17(13):1978-87. doi: 10.1093/hmg/ddn095. Epub 2008 Apr 2.,Hum Mol Genet.  2008,PubMed,citation,PMID:18387968,pubmed,18387968,create date:2008/04/05 | first author:Kohler EM
High-resolution genotyping of chromosome 8 in colon adenocarcinomas reveals recurrent break point but no gene mutation in the 8p21 region.,/pubmed/18382363,"Mourra N, Zeitoun G, Portier G, Blanche H, Tubacher E, Gressin L, Flejou JF, Tiret E, Thomas G, Olschwang S.",Diagn Mol Pathol. 2008 Jun;17(2):90-3. doi: 10.1097/PDM.0b013e31815bb5eb.,Diagn Mol Pathol.  2008,PubMed,citation,PMID:18382363,pubmed,18382363,create date:2008/04/03 | first author:Mourra N
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene.,/pubmed/18372920,"Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y.",Oncogene. 2008 Jul 17;27(31):4373-9. doi: 10.1038/onc.2008.72. Epub 2008 Mar 31.,Oncogene.  2008,PubMed,citation,PMID:18372920,pubmed,18372920,create date:2008/04/01 | first author:Lu Z
Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.,/pubmed/18365395,"Zhou M, Zhu Y, Wang L, Wang Y, Fu S, Min Z.",Clin Transpl. 2006:395-8.,Clin Transpl.  2006,PubMed,citation,PMID:18365395,pubmed,18365395,create date:2008/03/28 | first author:Zhou M
Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8.,/pubmed/18322661,"Vidaurreta M, Maestro ML, Sanz-Casla MT, Rafael S, Veganzones S, de la Orden V, Cerdán J, Arroyo M, Torres A.",Int J Colorectal Dis. 2008 Jun;23(6):581-6. doi: 10.1007/s00384-008-0454-8. Epub 2008 Mar 6.,Int J Colorectal Dis.  2008,PubMed,citation,PMID:18322661,pubmed,18322661,create date:2008/03/07 | first author:Vidaurreta M
A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene.,/pubmed/18307025,"Izawa N, Matsumoto S, Manabe J, Tanizawa T, Hoshi M, Shigemitsu T, Machinami R, Kanda H, Takeuchi K, Miki Y, Arai M, Shirahama S, Kawaguchi N.",Int J Clin Oncol. 2008 Feb;13(1):78-82. doi: 10.1007/s10147-007-0692-8. Epub 2008 Feb 29.,Int J Clin Oncol.  2008,PubMed,citation,PMID:18307025,pubmed,18307025,create date:2008/03/01 | first author:Izawa N
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.,/pubmed/18297281,"Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN.",Cancer Immunol Immunother. 2008 Sep;57(9):1413-20. doi: 10.1007/s00262-008-0477-6. Epub 2008 Feb 23.,Cancer Immunol Immunother.  2008,PubMed,citation,PMID:18297281,pubmed,18297281,create date:2008/02/26 | first author:Toubaji A
Protective versus promotional effects of white tea and caffeine on PhIP-induced tumorigenesis and beta-catenin expression in the rat.,/pubmed/18283038,"Wang R, Dashwood WM, Löhr CV, Fischer KA, Pereira CB, Louderback M, Nakagama H, Bailey GS, Williams DE, Dashwood RH.",Carcinogenesis. 2008 Apr;29(4):834-9. doi: 10.1093/carcin/bgn051. Epub 2008 Feb 17.,Carcinogenesis.  2008,PubMed,citation,PMID:18283038 | PMCID:PMC2796682,pubmed,18283038,create date:2008/02/20 | first author:Wang R
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers.,/pubmed/18281249,"Cybulski C, Masojc B, Oszutowska D, Jaworowska E, Grodzki T, Waloszczyk P, Serwatowski P, Pankowski J, Huzarski T, Byrski T, Górski B, Jakubowska A, Debniak T, Wokolorczyk D, Gronwald J, Tarnowska C, Serrano-Fernández P, Lubinski J, Narod SA.",Carcinogenesis. 2008 Apr;29(4):762-5. doi: 10.1093/carcin/bgn044. Epub 2008 Feb 14.,Carcinogenesis.  2008,PubMed,citation,PMID:18281249,pubmed,18281249,create date:2008/02/19 | first author:Cybulski C
Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX.,/pubmed/18273838,"Alsop AE, Taylor K, Zhang J, Gabra H, Paige AJ, Edwards PA.",Genes Chromosomes Cancer. 2008 May;47(5):437-47. doi: 10.1002/gcc.20548.,Genes Chromosomes Cancer.  2008,PubMed,citation,PMID:18273838,pubmed,18273838,create date:2008/02/15 | first author:Alsop AE
The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.,/pubmed/18241079,"Ferracin M, Gafà R, Miotto E, Veronese A, Pultrone C, Sabbioni S, Lanza G, Negrini M.",J Pathol. 2008 Apr;214(5):594-602. doi: 10.1002/path.2318.,J Pathol.  2008,PubMed,citation,PMID:18241079,pubmed,18241079,create date:2008/02/05 | first author:Ferracin M
Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis.,/pubmed/18237870,"Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A, Nagengast FM, Kleibeuker JH, Mathus-Vliegen EM, Dekker E, Dees J, Wijnen J, Vasen HF.",Clin Gastroenterol Hepatol. 2008 Feb;6(2):215-9. doi: 10.1016/j.cgh.2007.11.011.,Clin Gastroenterol Hepatol.  2008,PubMed,citation,PMID:18237870,pubmed,18237870,create date:2008/02/02 | first author:Nieuwenhuis MH
"Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.",/pubmed/18224685,"Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lièvre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F.",Int J Cancer. 2008 May 15;122(10):2255-9. doi: 10.1002/ijc.23388.,Int J Cancer.  2008,PubMed,citation,PMID:18224685,pubmed,18224685,create date:2008/01/29 | first author:Barault L
CT colonography in cancer detection: methods and results.,/pubmed/18215973,"Schima W, Mang T.",Cancer Imaging. 2004 Apr 6;4 Spec No A:S33-41. doi: 10.1102/1470-7330.2004.0014.,Cancer Imaging.  2004,PubMed,citation,PMID:18215973 | PMCID:PMC1435345,pubmed,18215973,create date:2008/01/25 | first author:Schima W
Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers.,/pubmed/18208804,"Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M.",Am J Clin Pathol. 2008 Feb;129(2):238-44. doi: 10.1309/0PP5GDRTXUDVKAWJ.,Am J Clin Pathol.  2008,PubMed,citation,PMID:18208804,pubmed,18208804,create date:2008/01/23 | first author:Halvarsson B
Dual positive and negative regulation of wingless signaling by adenomatous polyposis coli.,/pubmed/18202290,"Takacs CM, Baird JR, Hughes EG, Kent SS, Benchabane H, Paik R, Ahmed Y.",Science. 2008 Jan 18;319(5861):333-6. doi: 10.1126/science.1151232.,Science.  2008,PubMed,citation,PMID:18202290,pubmed,18202290,create date:2008/01/19 | first author:Takacs CM
Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.,/pubmed/18199160,"Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.",Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.,Pathol Int.  2008,PubMed,citation,PMID:18199160,pubmed,18199160,create date:2008/01/18 | first author:Lee S
Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents in colon cancer cells.,/pubmed/18162445,"Abdel-Rahman WM, Knuutila S, Peltomäki P, Harrison DJ, Bader SA.",DNA Repair (Amst). 2008 Feb 1;7(2):321-8. Epub 2007 Dec 26.,DNA Repair (Amst).  2008,PubMed,citation,PMID:18162445,pubmed,18162445,create date:2007/12/29 | first author:Abdel-Rahman WM
Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis.,/pubmed/18155426,"Iaquinto G, Fornasarig M, Quaia M, Giardullo N, D'Onofrio V, Iaquinto S, Di Bella S, Cannizzaro R.",Gastrointest Endosc. 2008 Jan;67(1):61-7.,Gastrointest Endosc.  2008,PubMed,citation,PMID:18155426,pubmed,18155426,create date:2007/12/25 | first author:Iaquinto G
Investigation of miRNA biology by bioinformatic tools and impact of miRNAs in colorectal cancer--regulatory relationship of c-Myc and p53 with miRNAs.,/pubmed/18079974,"Xi Y, Edwards JR, Ju J.",Cancer Inform. 2007 May 31;3:245-53.,Cancer Inform.  2007,PubMed,citation,PMID:18079974 | PMCID:PMC2133370,pubmed,18079974,create date:2007/12/15 | first author:Xi Y
p38MAPK delta controls c-Myb degradation in response to stress.,/pubmed/18006338,"Pani E, Ferrari S.",Blood Cells Mol Dis. 2008 May-Jun;40(3):388-94. Epub 2007 Nov 19.,Blood Cells Mol Dis.  2008,PubMed,citation,PMID:18006338,pubmed,18006338,create date:2007/11/17 | first author:Pani E
Biological stoichiometry in human cancer.,/pubmed/17925876,"Elser JJ, Kyle MM, Smith MS, Nagy JD.",PLoS One. 2007 Oct 10;2(10):e1028.,PLoS One.  2007,PubMed,citation,PMID:17925876 | PMCID:PMC2000353,pubmed,17925876,create date:2007/10/11 | first author:Elser JJ
Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome.,/pubmed/17919485,"Mecklin JP, Aarnio M, Läärä E, Kairaluoma MV, Pylvänäinen K, Peltomäki P, Aaltonen LA, Järvinen HJ.",Gastroenterology. 2007 Oct;133(4):1093-8. Epub 2007 Aug 14.,Gastroenterology.  2007,PubMed,citation,PMID:17919485,pubmed,17919485,create date:2007/10/09 | first author:Mecklin JP
Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis.,/pubmed/17855511,"Hashimoto Y, Parsons M, Adams JC.",Mol Biol Cell. 2007 Nov;18(11):4591-602. Epub 2007 Sep 12.,Mol Biol Cell.  2007,PubMed,citation,PMID:17855511 | PMCID:PMC2043557,pubmed,17855511,create date:2007/09/15 | first author:Hashimoto Y
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.,/pubmed/17850658,"Chand M, Moore PJ, Clarke AD, Nash GF, Hickisk T.",World J Surg Oncol. 2007 Sep 12;5:102.,World J Surg Oncol.  2007,PubMed,citation,PMID:17850658 | PMCID:PMC2075500,pubmed,17850658,create date:2007/09/14 | first author:Chand M
RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.,/pubmed/17828469,"Clark JC, Thomas DM, Choong PF, Dass CR.",Cancer Metastasis Rev. 2007 Dec;26(3-4):675-83. Review.,Cancer Metastasis Rev.  2007,PubMed,citation,PMID:17828469,pubmed,17828469,create date:2007/09/11 | first author:Clark JC
Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex.,/pubmed/17687193,"Notarnicola M, Altomare DF, Calvani M, Orlando A, Bifulco M, D'Attoma B, Caruso MG.",Oncology. 2006;71(5-6):327-32. Epub 2007 Aug 8.,Oncology.  2006,PubMed,citation,PMID:17687193,pubmed,17687193,create date:2007/08/10 | first author:Notarnicola M
Understanding Lynch syndrome: implications for nursing.,/pubmed/17623626,"Bannon E, Coleman EA.",Clin J Oncol Nurs. 2007 Jun;11(3):423-7. Review.,Clin J Oncol Nurs.  2007,PubMed,citation,PMID:17623626,pubmed,17623626,create date:2007/07/12 | first author:Bannon E
"Somatic mutations of BECN1, an autophagy-related gene, in human cancers.",/pubmed/17550384,"Lee JW, Jeong EG, Lee SH, Yoo NJ, Lee SH.",APMIS. 2007 Jun;115(6):750-6.,APMIS.  2007,PubMed,citation,PMID:17550384,pubmed,17550384,create date:2007/06/07 | first author:Lee JW
CYP2S1 gene polymorphisms in a Korean population.,/pubmed/17529885,"Jang YJ, Cha EY, Kim WY, Park SW, Shon JH, Lee SS, Shin JG.",Ther Drug Monit. 2007 Jun;29(3):292-8.,Ther Drug Monit.  2007,PubMed,citation,PMID:17529885,pubmed,17529885,create date:2007/05/29 | first author:Jang YJ
"Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.",/pubmed/17410283,"Akkiprik M, Ataizi-Celikel C, Düşünceli F, Sönmez O, Gulluoglu BM, Sav A, Ozer A.","J Gastrointestin Liver Dis. 2007 Mar;16(1):11-7. Erratum in: J Gastrointestin Liver Dis. 2007 Dec;16(4):486. Ataizi-Celikel, Ciddem [corrected to Ataizi-Celikel, Cigdem]; Güllüoglu, Bahadýr M [corrected to Gulluoglu, Bahadir M]; Sav, Aydým [corrected to Sav, Aydin]. ",J Gastrointestin Liver Dis.  2007,PubMed,citation,PMID:17410283,pubmed,17410283,create date:2007/04/06 | first author:Akkiprik M
Analysis of RIN1 gene expression in colorectal cancer.,/pubmed/17390061,"Senda K, Goi T, Hirono Y, Katayama K, Yamaguchi A.",Oncol Rep. 2007 May;17(5):1171-5.,Oncol Rep.  2007,PubMed,citation,PMID:17390061,pubmed,17390061,create date:2007/03/29 | first author:Senda K
Loss of Smad4 expression predicts liver metastasis in human colorectal cancer.,/pubmed/17390050,"Losi L, Bouzourene H, Benhattar J.",Oncol Rep. 2007 May;17(5):1095-9.,Oncol Rep.  2007,PubMed,citation,PMID:17390050,pubmed,17390050,create date:2007/03/29 | first author:Losi L
The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression.,/pubmed/17387143,"Baran AA, Silverman KA, Zeskand J, Koratkar R, Palmer A, McCullen K, Curran WJ Jr, Edmonston TB, Siracusa LD, Buchberg AM.",Genome Res. 2007 May;17(5):566-76. Epub 2007 Mar 26.,Genome Res.  2007,PubMed,citation,PMID:17387143 | PMCID:PMC1855180,pubmed,17387143,create date:2007/03/28 | first author:Baran AA
Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis.,/pubmed/17368237,"Nieuwenhuis MH, Mathus-Vliegen LM, Slors FJ, Griffioen G, Nagengast FM, Schouten WR, Kleibeuker JH, Vasen HF.",Clin Gastroenterol Hepatol. 2007 Mar;5(3):374-8.,Clin Gastroenterol Hepatol.  2007,PubMed,citation,PMID:17368237,pubmed,17368237,create date:2007/03/21 | first author:Nieuwenhuis MH
Prevention and early detection of colorectal cancer--new horizons.,/pubmed/17302195,Rennert G.,Recent Results Cancer Res. 2007;174:179-87. Review.,Recent Results Cancer Res.  2007,PubMed,citation,PMID:17302195,pubmed,17302195,create date:2007/02/17 | first author:Rennert G
Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.,/pubmed/17273769,"Kouhara J, Yoshida T, Nakata S, Horinaka M, Wakada M, Ueda Y, Yamagishi H, Sakai T.",Int J Oncol. 2007 Mar;30(3):679-87.,Int J Oncol.  2007,PubMed,citation,PMID:17273769,pubmed,17273769,create date:2007/02/03 | first author:Kouhara J
Ubiquitination regulates PTEN nuclear import and tumor suppression.,/pubmed/17218261,"Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP.",Cell. 2007 Jan 12;128(1):141-56.,Cell.  2007,PubMed,citation,PMID:17218261 | PMCID:PMC1855245,pubmed,17218261,create date:2007/01/16 | first author:Trotman LC
Expression of p53 in colorectal carcinoma: correlation with clinicopathologic features.,/pubmed/17198452,"Ghavam-Nasiri MR, Rezaei E, Ghafarzadegan K, Seilanian-Toosi M, Malekifard H.",Arch Iran Med. 2007 Jan;10(1):38-42.,Arch Iran Med.  2007,PubMed,citation,PMID:17198452,pubmed,17198452,create date:2007/01/03 | first author:Ghavam-Nasiri MR
Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis.,/pubmed/17192888,"Valanzano R, Ficari F, Curia MC, Aceto G, Veschi S, Cama A, Battista P, Tonelli F.",J Surg Oncol. 2007 Jan 1;95(1):28-33.,J Surg Oncol.  2007,PubMed,citation,PMID:17192888,pubmed,17192888,create date:2006/12/29 | first author:Valanzano R
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.,/pubmed/17145525,Hochster HS.,Semin Oncol. 2006 Oct;33(5 Suppl 10):S8-14. Review.,Semin Oncol.  2006,PubMed,citation,PMID:17145525,pubmed,17145525,create date:2006/12/06 | first author:Hochster HS
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer.,/pubmed/17101323,"Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH.",Gastroenterology. 2006 Nov;131(5):1486-500. Epub 2006 Aug 22.,Gastroenterology.  2006,PubMed,citation,PMID:17101323,pubmed,17101323,create date:2006/11/15 | first author:Stein U
GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation.,/pubmed/17087981,"Felix R, Bodmer W, Fearnhead NS, van der Merwe L, Goldberg P, Ramesar RS.",Mutat Res. 2006 Dec 1;602(1-2):175-81.,Mutat Res.  2006,PubMed,citation,PMID:17087981,pubmed,17087981,create date:2006/11/08 | first author:Felix R
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.,/pubmed/17046731,"Morel A, Boisdron-Celle M, Fey L, Lainé-Cessac P, Gamelin E.",Clin Biochem. 2007 Jan;40(1-2):11-7. Epub 2006 Sep 1.,Clin Biochem.  2007,PubMed,citation,PMID:17046731,pubmed,17046731,create date:2006/10/19 | first author:Morel A
The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome.,/pubmed/17039271,"Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, Green RC.",Fam Cancer. 2007;6(1):1-12.,Fam Cancer.  2007,PubMed,citation,PMID:17039271,pubmed,17039271,create date:2006/10/14 | first author:Stuckless S
Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.,/pubmed/17013898,"Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, Jeong SY, Park JG.",Int J Cancer. 2007 Jan 1;120(1):7-12.,Int J Cancer.  2007,PubMed,citation,PMID:17013898,pubmed,17013898,create date:2006/10/03 | first author:Park HW
Current ideas in desmoid tumours.,/pubmed/16998673,"Sturt NJ, Clark SK.",Fam Cancer. 2006;5(3):275-85; discussion 287-8. Review.,Fam Cancer.  2006,PubMed,citation,PMID:16998673,pubmed,16998673,create date:2006/09/26 | first author:Sturt NJ
Role of nucleotide excision repair deficiency in intestinal tumorigenesis in multiple intestinal neoplasia (Min) mice.,/pubmed/16962818,"Steffensen IL, Schut HA, Nesland JM, Tanaka K, Alexander J.",Mutat Res. 2006 Dec 10;611(1-2):71-82. Epub 2006 Sep 8.,Mutat Res.  2006,PubMed,citation,PMID:16962818,pubmed,16962818,create date:2006/09/12 | first author:Steffensen IL
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.,/pubmed/16951157,"Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, Moreno V, Esteller M, Capellà G, Ribas M, Peinado MA.",Cancer Res. 2006 Sep 1;66(17):8462-9468.,Cancer Res.  2006,PubMed,citation,PMID:16951157,pubmed,16951157,create date:2006/09/05 | first author:Rodriguez J
Adequacy of colonoscopic biopsy specimens for molecular analysis: a comparative study with colectomy tissue.,/pubmed/16932072,"Zauber NP, Sabbath-Solitare M, Marotta S, Perera LP, Bishop DT.",Diagn Mol Pathol. 2006 Sep;15(3):162-8.,Diagn Mol Pathol.  2006,PubMed,citation,PMID:16932072,pubmed,16932072,create date:2006/08/26 | first author:Zauber NP
Do MSI-L sporadic colorectal tumors develop through "mild mutator pathway"?,/pubmed/16891863,"Oliart S, Martínez-Santos C, Moreno-Azcoita M, Cerquella C, Nejda N, Daimiel L, Iglesias D, Fernández-Peralta AM, González-Aguilera JJ.",Am J Clin Oncol. 2006 Aug;29(4):364-70.,Am J Clin Oncol.  2006,PubMed,citation,PMID:16891863,pubmed,16891863,create date:2006/08/08 | first author:Oliart S
The evolving role of cetuximab in non-small cell lung cancer.,/pubmed/16857823,Lilenbaum RC.,Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4432s-4435s. Review.,Clin Cancer Res.  2006,PubMed,citation,PMID:16857823,pubmed,16857823,create date:2006/07/22 | first author:Lilenbaum RC
Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.,/pubmed/16728434,"Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ.",Carcinogenesis. 2006 Dec;27(12):2371-82. Epub 2006 May 25.,Carcinogenesis.  2006,PubMed,citation,PMID:16728434,pubmed,16728434,create date:2006/05/27 | first author:Bos CL
DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset.,/pubmed/16702365,"Jones JS, Amos CI, Pande M, Gu X, Chen J, Campos IM, Wei Q, Rodriguez-Bigas M, Lynch PM, Frazier ML.",Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):886-91.,Cancer Epidemiol Biomarkers Prev.  2006,PubMed,citation,PMID:16702365,pubmed,16702365,create date:2006/05/17 | first author:Jones JS
Immunohistochemistry detects mismatch repair gene defects in colorectal cancer.,/pubmed/16684085,"Hameed F, Goldberg PA, Hall P, Algar U, van Wijk R, Ramesar R.",Colorectal Dis. 2006 Jun;8(5):411-7.,Colorectal Dis.  2006,PubMed,citation,PMID:16684085,pubmed,16684085,create date:2006/05/11 | first author:Hameed F
Novel findings in Swedish patients with MYH-associated polyposis: mutation detection and clinical characterization.,/pubmed/16616356,"Kanter-Smoler G, Björk J, Fritzell K, Engwall Y, Hallberg B, Karlsson G, Grönberg H, Karlsson P, Wallgren A, Wahlström J, Hultcrantz R, Nordling M.",Clin Gastroenterol Hepatol. 2006 Apr;4(4):499-506.,Clin Gastroenterol Hepatol.  2006,PubMed,citation,PMID:16616356,pubmed,16616356,create date:2006/04/18 | first author:Kanter-Smoler G
Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan.,/pubmed/16569251,"Chen SP, Tsai ST, Jao SW, Huang YL, Chao YC, Chen YL, Wu CC, Lin SZ, Harn HJ.",BMC Cancer. 2006 Mar 29;6:83.,BMC Cancer.  2006,PubMed,citation,PMID:16569251 | PMCID:PMC1488868,pubmed,16569251,create date:2006/03/30 | first author:Chen SP
Microsatellite instability in colorectal cancer.,/pubmed/16555243,"Söreide K, Janssen EA, Söiland H, Körner H, Baak JP.",Br J Surg. 2006 Apr;93(4):395-406. Review.,Br J Surg.  2006,PubMed,citation,PMID:16555243,pubmed,16555243,create date:2006/03/24 | first author:Söreide K
[Morphological characteristics of stromal gastrointestinal tumors].,/pubmed/16544528,"Anurova OA, Snigur PV, Filippova NA, Sel'chuk VIu.",Arkh Patol. 2006 Jan-Feb;68(1):10-3. Russian. ,Arkh Patol.  2006,PubMed,citation,PMID:16544528,pubmed,16544528,create date:2006/03/21 | first author:Anurova OA
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.,/pubmed/16524972,"Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, et al.",Ann Oncol. 2006 May;17(5):842-7. Epub 2006 Mar 8.,Ann Oncol.  2006,PubMed,citation,PMID:16524972,pubmed,16524972,create date:2006/03/10 | first author:Iacopetta B
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.,/pubmed/16508634,"Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G.",Br J Cancer. 2006 Mar 27;94(6):792-7.,Br J Cancer.  2006,PubMed,citation,PMID:16508634 | PMCID:PMC2361373,pubmed,16508634,create date:2006/03/02 | first author:Vincenzi B
[Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10].,/pubmed/16440771,"Sakai R, Kanamori H, Ishigatsubo Y.",Rinsho Ketsueki. 2005 Oct;46(10):1105-8. Japanese. ,Rinsho Ketsueki.  2005,PubMed,citation,PMID:16440771,pubmed,16440771,create date:2006/01/31 | first author:Sakai R
"[Gastrointestinal stromal tumors (GIST). Clinical characteristics, diagnosis, and therapy in five cases].",/pubmed/16418817,"Ludolph T, Schweitzer A, Bremer A, Schulz U, Glasbrenner B.",Med Klin (Munich). 2006 Jan 15;101(1):69-74. German. ,Med Klin (Munich).  2006,PubMed,citation,PMID:16418817,pubmed,16418817,create date:2006/01/19 | first author:Ludolph T
T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma.,/pubmed/16391798,"Bueter M, Gasser M, Schramm N, Lebedeva T, Tocco G, Gerstlauer C, Grimm M, Nichiporuk E, Thalheimer A, Thiede A, Meyer D, Benichou G, Waaga-Gasser AM.",Int J Oncol. 2006 Feb;28(2):431-8.,Int J Oncol.  2006,PubMed,citation,PMID:16391798,pubmed,16391798,create date:2006/01/05 | first author:Bueter M
[EGFR expression in colorectal cancer and role in tumorigenesis].,/pubmed/16387663,"Penault-Llorca F, Bibeau F, Arnould L, Bralet MP, Rochaix P, Sabourin JC.",Bull Cancer. 2005 Aug;92(Spec no):S5-11. Review. French. ,Bull Cancer.  2005,PubMed,citation,PMID:16387663,pubmed,16387663,create date:2006/01/03 | first author:Penault-Llorca F
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.,/pubmed/16369438,Friedenson B.,MedGenMed. 2005 Jun 29;7(2):60.,MedGenMed.  2005,PubMed,citation,PMID:16369438 | PMCID:PMC1681605,pubmed,16369438,create date:2005/12/22 | first author:Friedenson B
Detection of stool DNA mutations before and after treatment of colorectal neoplasia.,/pubmed/16342248,"Syngal S, Stoffel E, Chung D, Willett C, Schoetz D, Schroy P, Jagadeesh D, Morel K, Ross M.",Cancer. 2006 Jan 15;106(2):277-83.,Cancer.  2006,PubMed,citation,PMID:16342248,pubmed,16342248,create date:2005/12/13 | first author:Syngal S
Microsatellite instability and colorectal cancer prognosis.,/pubmed/16322293,"Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G.",Clin Cancer Res. 2005 Dec 1;11(23):8332-40. Erratum in: Clin Cancer Res. 2006 Jun 15;12(12):3868-9. ,Clin Cancer Res.  2005,PubMed,citation,PMID:16322293,pubmed,16322293,create date:2005/12/03 | first author:Benatti P
Molecular pathological subclassification of mucinous adenocarcinoma of the colorectum.,/pubmed/16287491,"Li D, Semba S, Wu M, Yokozaki H.",Pathol Int. 2005 Dec;55(12):766-74.,Pathol Int.  2005,PubMed,citation,PMID:16287491,pubmed,16287491,create date:2005/11/17 | first author:Li D
Surveillance colonoscopy in individuals at risk for hereditary nonpolyposis colorectal cancer: an evidence-based review.,/pubmed/16284887,"Johnson PM, Gallinger S, McLeod RS.",Dis Colon Rectum. 2006 Jan;49(1):80-93; discussion 94-5.,Dis Colon Rectum.  2006,PubMed,citation,PMID:16284887,pubmed,16284887,create date:2005/11/15 | first author:Johnson PM
[Detection mutations in the DNA mismatch repair genes of hMLH1 and hMSH2 genes in Colombian families with suspicion of hereditary non-polyposis colorectal carcinoma (Lynch syndrome)].,/pubmed/16276679,"Gómez A, Salguero G, García H, Aristizábal F, Gutiérrez O, Angel LA, Padrón J, Martínez C, Martínez H, Malaver O, Barvo R, Giraldo A.",Biomedica. 2005 Sep;25(3):315-24. Spanish. ,Biomedica.  2005,PubMed,citation,PMID:16276679,pubmed,16276679,create date:2005/11/10 | first author:Gómez A
History and molecular genetics of Lynch syndrome in family G: a century later.,/pubmed/16264161,"Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, Lynch HT.",JAMA. 2005 Nov 2;294(17):2195-202.,JAMA.  2005,PubMed,citation,PMID:16264161,pubmed,16264161,create date:2005/11/03 | first author:Douglas JA
"[Gastrointestinal stromal tumor (GIST) with jejunum localisation, unusual source of digestive bleeding. Considerations about two cases].",/pubmed/16238204,"Paşalega M, Meşină C, Vîlcea D, Cheie M, Vasile I.",Chirurgia (Bucur). 2005 Jul-Aug;100(4):385-90. Romanian. ,Chirurgia (Bucur).  2005,PubMed,citation,PMID:16238204,pubmed,16238204,create date:2005/10/22 | first author:Paşalega M
Relationship between genetic alterations and prognosis in sporadic colorectal cancer.,/pubmed/16231316,"Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW.",Int J Cancer. 2006 Apr 1;118(7):1721-7.,Int J Cancer.  2006,PubMed,citation,PMID:16231316,pubmed,16231316,create date:2005/10/19 | first author:Chang SC
Tumor promotion by caspase-resistant retinoblastoma protein.,/pubmed/16227443,"Borges HL, Bird J, Wasson K, Cardiff RD, Varki N, Eckmann L, Wang JY.",Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15587-92. Epub 2005 Oct 14.,Proc Natl Acad Sci U S A.  2005,PubMed,citation,PMID:16227443 | PMCID:PMC1255734,pubmed,16227443,create date:2005/10/18 | first author:Borges HL
"The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.",/pubmed/16172461,"Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group..",J Clin Oncol. 2005 Oct 20;23(30):7518-28. Epub 2005 Sep 19. Review.,J Clin Oncol.  2005,PubMed,citation,PMID:16172461,pubmed,16172461,create date:2005/09/21 | first author:Russo A
Molecular dynamics of a food carcinogen-DNA adduct in a replicative DNA polymerase suggest hindered nucleotide incorporation and extension.,/pubmed/16167826,"Zhang L, Shapiro R, Broyde S.",Chem Res Toxicol. 2005 Sep;18(9):1347-63.,Chem Res Toxicol.  2005,PubMed,citation,PMID:16167826,pubmed,16167826,create date:2005/09/20 | first author:Zhang L
Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.,/pubmed/16166455,"Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N.",Clin Cancer Res. 2005 Sep 15;11(18):6738-44.,Clin Cancer Res.  2005,PubMed,citation,PMID:16166455,pubmed,16166455,create date:2005/09/17 | first author:Lev-Ari S
"Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.",/pubmed/16143123,"Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML.",Gastroenterology. 2005 Sep;129(3):837-45.,Gastroenterology.  2005,PubMed,citation,PMID:16143123,pubmed,16143123,create date:2005/09/07 | first author:Samowitz WS
Hereditary ovarian cancer.,/pubmed/16112002,"Prat J, Ribé A, Gallardo A.",Hum Pathol. 2005 Aug;36(8):861-70. Review.,Hum Pathol.  2005,PubMed,citation,PMID:16112002,pubmed,16112002,create date:2005/08/23 | first author:Prat J
Nitrative DNA damage in inflammation and its possible role in carcinogenesis.,/pubmed/16099698,"Sawa T, Ohshima H.",Nitric Oxide. 2006 Mar;14(2):91-100. Epub 2005 Aug 15. Review.,Nitric Oxide.  2006,PubMed,citation,PMID:16099698,pubmed,16099698,create date:2005/08/16 | first author:Sawa T
Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,/pubmed/16083711,"Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lönnqvist KE, Holinski-Feder E, Sutter C, McKinnon W, Duraisamy S, Gerdes AM, Peltomäki P, Kohonen-Ccorish M, Mangold E, Macrae F, Greenblatt M, de la Chapelle A, Nyström M.",Gastroenterology. 2005 Aug;129(2):537-49.,Gastroenterology.  2005,PubMed,citation,PMID:16083711,pubmed,16083711,create date:2005/08/09 | first author:Raevaara TE
Global phosphoproteome of HT-29 human colon adenocarcinoma cells.,/pubmed/16083285,"Kim JE, Tannenbaum SR, White FM.",J Proteome Res. 2005 Jul-Aug;4(4):1339-46.,J Proteome Res.  2005,PubMed,citation,PMID:16083285,pubmed,16083285,create date:2005/08/09 | first author:Kim JE
"Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.",/pubmed/16077965,"Catalano T, Curia MC, Aceto G, Verginelli F, Cascinu S, Cama A, Mariani-Costantini R, Teti D, Battista P.",Oncol Rep. 2005 Sep;14(3):625-31.,Oncol Rep.  2005,PubMed,citation,PMID:16077965,pubmed,16077965,create date:2005/08/04 | first author:Catalano T
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.,/pubmed/16024606,"Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML.",Cancer Res. 2005 Jul 15;65(14):6063-9.,Cancer Res.  2005,PubMed,citation,PMID:16024606,pubmed,16024606,create date:2005/07/19 | first author:Samowitz WS
Stability of colon stem cell methylation after neo-adjuvant therapy in a patient with attenuated familial adenomatous polyposis.,/pubmed/15941485,"Kim JY, Beart RW, Shibata D.",BMC Gastroenterol. 2005 Jun 7;5:19.,BMC Gastroenterol.  2005,PubMed,citation,PMID:15941485 | PMCID:PMC1164411,pubmed,15941485,create date:2005/06/09 | first author:Kim JY
"P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.",/pubmed/15930341,"de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, Porte RJ, Slooff MJ, van Goor H, van den Berg A.",Clin Cancer Res. 2005 Jun 1;11(11):4067-73.,Clin Cancer Res.  2005,PubMed,citation,PMID:15930341,pubmed,15930341,create date:2005/06/03 | first author:de Jong KP
Cancer risks and mortality in heterozygous ATM mutation carriers.,/pubmed/15928302,"Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF.",J Natl Cancer Inst. 2005 Jun 1;97(11):813-22.,J Natl Cancer Inst.  2005,PubMed,citation,PMID:15928302,pubmed,15928302,create date:2005/06/02 | first author:Thompson D
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.,/pubmed/15923428,"Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N.",Ann Oncol. 2005 May;16 Suppl 4:iv44-49. Review.,Ann Oncol.  2005,PubMed,citation,PMID:15923428,pubmed,15923428,create date:2005/06/01 | first author:Russo A
"[Clinical significance of HNPCC, surgical aspects of early recognition].",/pubmed/15907009,"Tanyi M, Kanyári Z, Orosz L, Juhász B, Lukács G, Damjanovich L.",Magy Seb. 2004 Oct;57(5):267-78. Review. Hungarian. ,Magy Seb.  2004,PubMed,citation,PMID:15907009,pubmed,15907009,create date:2005/05/24 | first author:Tanyi M
Gastric cancer: new genetic developments.,/pubmed/15895459,"Lynch HT, Grady W, Suriano G, Huntsman D.",J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133.,J Surg Oncol.  2005,PubMed,citation,PMID:15895459,pubmed,15895459,create date:2005/05/17 | first author:Lynch HT
Fordyce granules and hereditary non-polyposis colorectal cancer syndrome.,/pubmed/15879014,"De Felice C, Parrini S, Chitano G, Gentile M, Dipaola L, Latini G.",Gut. 2005 Sep;54(9):1279-82. Epub 2005 May 6.,Gut.  2005,PubMed,citation,PMID:15879014 | PMCID:PMC1774669,pubmed,15879014,create date:2005/05/10 | first author:De Felice C
The initiation of colon cancer in a chronic inflammatory setting.,/pubmed/15860506,"Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Bronner MP, Brentnall TA.",Carcinogenesis. 2005 Sep;26(9):1513-9. Epub 2005 Apr 28.,Carcinogenesis.  2005,PubMed,citation,PMID:15860506,pubmed,15860506,create date:2005/04/30 | first author:Chen R
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.,/pubmed/15858133,"Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, Schuff-Werner P.",J Clin Pathol. 2005 May;58(5):553-5.,J Clin Pathol.  2005,PubMed,citation,PMID:15858133 | PMCID:PMC1770668,pubmed,15858133,create date:2005/04/29 | first author:Steiner M
"[New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].",/pubmed/15832750,"Catani M, De Milito R, Simi M.",Chir Ital. 2005 Jan-Feb;57(1):127-33. Italian. ,Chir Ital.  2005,PubMed,citation,PMID:15832750,pubmed,15832750,create date:2005/04/19 | first author:Catani M
Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.,/pubmed/15802015,"Thorstensen L, Lind GE, Løvig T, Diep CB, Meling GI, Rognum TO, Lothe RA.",Neoplasia. 2005 Feb;7(2):99-108.,Neoplasia.  2005,PubMed,citation,PMID:15802015 | PMCID:PMC1501125,pubmed,15802015,create date:2005/04/02 | first author:Thorstensen L
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.,/pubmed/15788691,"Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.",Clin Cancer Res. 2005 Mar 15;11(6):2398-407.,Clin Cancer Res.  2005,PubMed,citation,PMID:15788691,pubmed,15788691,create date:2005/03/25 | first author:Mantha AJ
Clinicopathological and molecular genetic analysis of HNPCC in China.,/pubmed/15786548,"Luo DC, Cai Q, Sun MH, Ni YZ, Ni SC, Chen ZJ, Li XY, Tao CW, Zhang XM, Shi DR.",World J Gastroenterol. 2005 Mar 21;11(11):1673-9.,World J Gastroenterol.  2005,PubMed,citation,PMID:15786548 | PMCID:PMC4305952,pubmed,15786548,create date:2005/03/24 | first author:Luo DC
[Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder].,/pubmed/15765304,"Wiedmann M, Schoppmeyer K, Witzigmann H, Hauss J, Mössner J, Caca K.",Z Gastroenterol. 2005 Mar;43(3):305-15. Review. German. ,Z Gastroenterol.  2005,PubMed,citation,PMID:15765304,pubmed,15765304,create date:2005/03/15 | first author:Wiedmann M
Hereditary nonpolyposis colorectal cancer (Lynch syndrome): criteria for identification and management.,/pubmed/15745097,"Kouraklis G, Misiakos EP.",Dig Dis Sci. 2005 Feb;50(2):336-44. Review.,Dig Dis Sci.  2005,PubMed,citation,PMID:15745097,pubmed,15745097,create date:2005/03/05 | first author:Kouraklis G
Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.,/pubmed/15713769,"Casey G, Lindor NM, Papadopoulos N, Thibodeau SN, Moskow J, Steelman S, Buzin CH, Sommer SS, Collins CE, Butz M, Aronson M, Gallinger S, Barker MA, Young JP, Jass JR, Hopper JL, Diep A, Bapat B, Salem M, Seminara D, Haile R; Colon Cancer Family Registry..",JAMA. 2005 Feb 16;293(7):799-809.,JAMA.  2005,PubMed,citation,PMID:15713769 | PMCID:PMC2933041,pubmed,15713769,create date:2005/02/17 | first author:Casey G
The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells.,/pubmed/15677629,"Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet RJ Jr, Mehrotra S, Morimiya A, Badve S, Nakshatri H.",Carcinogenesis. 2005 May;26(5):900-7. Epub 2005 Jan 27.,Carcinogenesis.  2005,PubMed,citation,PMID:15677629,pubmed,15677629,create date:2005/01/29 | first author:Wollmann W
Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis.,/pubmed/15665291,"Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, Furukawa F, Sekimoto G, Watanabe T, Uemura Y, Sakaida N, Yoshioka K, Kamiyama Y, Seki T, Okazaki K.",Cancer Res. 2005 Jan 1;65(1):157-65.,Cancer Res.  2005,PubMed,citation,PMID:15665291,pubmed,15665291,create date:2005/01/25 | first author:Yamagata H
Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.,/pubmed/15657659,"Smyth EF, Sharma A, Sivarajasingham N, Hartley J, Monson JR, Cawkwell L.",Dis Colon Rectum. 2004 Dec;47(12):2086-91; discussion 2091-2.,Dis Colon Rectum.  2004,PubMed,citation,PMID:15657659,pubmed,15657659,create date:2005/01/20 | first author:Smyth EF
Detection of disseminated tumour cells in the liver of colorectal cancer patients.,/pubmed/15642424,"Conzelmann M, Linnemann U, Berger MR.",Eur J Surg Oncol. 2005 Feb;31(1):38-44.,Eur J Surg Oncol.  2005,PubMed,citation,PMID:15642424,pubmed,15642424,create date:2005/01/12 | first author:Conzelmann M
Mutation of FADD gene is rare in human colon and stomach cancers.,/pubmed/15601308,"Soung YH, Lee JW, Kim SY, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.",APMIS. 2004 Sep;112(9):595-7.,APMIS.  2004,PubMed,citation,PMID:15601308,pubmed,15601308,create date:2004/12/17 | first author:Soung YH
Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer.,/pubmed/15574462,"Frigola J, Solé X, Paz MF, Moreno V, Esteller M, Capellà G, Peinado MA.",Hum Mol Genet. 2005 Jan 15;14(2):319-26. Epub 2004 Dec 1.,Hum Mol Genet.  2005,PubMed,citation,PMID:15574462,pubmed,15574462,create date:2004/12/03 | first author:Frigola J
Clinicopathologic features in colorectal cancer patients with microsatellite instability.,/pubmed/15542114,"Raut CP, Pawlik TM, Rodriguez-Bigas MA.",Mutat Res. 2004 Dec 21;568(2):275-82. Review.,Mutat Res.  2004,PubMed,citation,PMID:15542114,pubmed,15542114,create date:2004/11/16 | first author:Raut CP
APC genotype is not a prognostic factor in familial adenomatous polyposis patients with colorectal cancer.,/pubmed/15540296,"Bertario L, Russo A, Sala P, Varesco L, Crucianelli R, Frattini M, Pierotti MA, Radice P; Hereditary Colorectal Tumors Registry..",Dis Colon Rectum. 2004 Oct;47(10):1662-9.,Dis Colon Rectum.  2004,PubMed,citation,PMID:15540296,pubmed,15540296,create date:2004/11/13 | first author:Bertario L
Familial pancreatic carcinoma in Jews.,/pubmed/15516847,"Lynch HT, Deters CA, Lynch JF, Brand RE.",Fam Cancer. 2004;3(3-4):233-40. Review.,Fam Cancer.  2004,PubMed,citation,PMID:15516847,pubmed,15516847,create date:2004/11/02 | first author:Lynch HT
Inflammatory bowel disease in Ashkenazi Jews: implications for familial colorectal cancer.,/pubmed/15516846,"Lynch HT, Brand RE, Locker GY.",Fam Cancer. 2004;3(3-4):229-32. Review.,Fam Cancer.  2004,PubMed,citation,PMID:15516846,pubmed,15516846,create date:2004/11/02 | first author:Lynch HT
Cancer in Jews: introduction and overview.,/pubmed/15516840,"Lynch HT, Rubinstein WS, Locker GY.",Fam Cancer. 2004;3(3-4):177-92. Review.,Fam Cancer.  2004,PubMed,citation,PMID:15516840,pubmed,15516840,create date:2004/11/02 | first author:Lynch HT
Detection and characterization of oncogene mutations in preneoplastic and early neoplastic lesions.,/pubmed/15502229,Minamoto T.,Methods Mol Biol. 2005;291:263-78.,Methods Mol Biol.  2005,PubMed,citation,PMID:15502229,pubmed,15502229,create date:2004/10/27 | first author:Minamoto T
Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer.,/pubmed/15377848,"Tsuji N, Furuse K, Asanuma K, Furuya M, Kondoh K, Kamagata C, Sasaki M, Kobayashi D, Yagihashi A, Takahashi H, Watanabe N.",Breast Cancer Res Treat. 2004 Sep;87(1):23-31.,Breast Cancer Res Treat.  2004,PubMed,citation,PMID:15377848,pubmed,15377848,create date:2004/09/21 | first author:Tsuji N
CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells.,/pubmed/15322075,"Yamaguchi H, Wang HG.",J Biol Chem. 2004 Oct 29;279(44):45495-502. Epub 2004 Aug 18.,J Biol Chem.  2004,PubMed,citation,PMID:15322075,pubmed,15322075,create date:2004/08/24 | first author:Yamaguchi H
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.,/pubmed/15309515,Peek RM Jr.,Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S50-6. Review.,Cancer Chemother Pharmacol.  2004,PubMed,citation,PMID:15309515,pubmed,15309515,create date:2004/08/17 | first author:Peek RM Jr
Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis.,/pubmed/15300576,"Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, Kuwada SK, Neklason DW, Disario JA, Lyon E, Hughes JP, Chey WY, White RL.",Gastroenterology. 2004 Aug;127(2):444-51.,Gastroenterology.  2004,PubMed,citation,PMID:15300576,pubmed,15300576,create date:2004/08/10 | first author:Burt RW
ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background.,/pubmed/15282542,"Fang Y, Tsao CC, Goodman BK, Furumai R, Tirado CA, Abraham RT, Wang XF.",EMBO J. 2004 Aug 4;23(15):3164-74. Epub 2004 Jul 29.,EMBO J.  2004,PubMed,citation,PMID:15282542 | PMCID:PMC514932,pubmed,15282542,create date:2004/07/30 | first author:Fang Y
Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.,/pubmed/15239234,"Nasif WA, El-Emshaty HM, Tabll A, Elmasry SA, Attallah AM, Gad Elhak NA.",Hepatogastroenterology. 2004 Jul-Aug;51(58):1001-6.,Hepatogastroenterology.  2004,PubMed,citation,PMID:15239234,pubmed,15239234,create date:2004/07/09 | first author:Nasif WA
A functional polymorphism (-347 G-->GA) in the E-cadherin gene is associated with colorectal cancer.,/pubmed/15231691,"Shin Y, Kim IJ, Kang HC, Park JH, Park HW, Jang SG, Lee MR, Jeong SY, Chang HJ, Ku JL, Park JG.",Carcinogenesis. 2004 Nov;25(11):2173-6. Epub 2004 Jul 1.,Carcinogenesis.  2004,PubMed,citation,PMID:15231691,pubmed,15231691,create date:2004/07/03 | first author:Shin Y
[Clinical analysis and molecular genetic study of hereditary nonpolyposis colorectal cancer kindreds].,/pubmed/15062061,"Luo DC, Cai Q, Sun MH, Ni YZ, Tao CW, Chen ZJ, Shi DR.",Zhonghua Wai Ke Za Zhi. 2004 Feb 7;42(3):158-62. Chinese. ,Zhonghua Wai Ke Za Zhi.  2004,PubMed,citation,PMID:15062061,pubmed,15062061,create date:2004/04/06 | first author:Luo DC
[Clinical significance of transrectal ultrasound in detecting of rectal cancer margin and deciding of distal surgical incisal edge].,/pubmed/15062016,"Yu B, Li SY, Liang ZJ, Yuan SJ, Wang H, Tian YW.",Zhonghua Wai Ke Za Zhi. 2004 Mar 7;42(5):279-81. Chinese. ,Zhonghua Wai Ke Za Zhi.  2004,PubMed,citation,PMID:15062016,pubmed,15062016,create date:2004/04/06 | first author:Yu B
Inactivating mutations of proapoptotic Bad gene in human colon cancers.,/pubmed/15033904,"Lee JW, Soung YH, Kim SY, Nam SW, Kim CJ, Cho YG, Lee JH, Kim HS, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.",Carcinogenesis. 2004 Aug;25(8):1371-6. Epub 2004 Mar 19.,Carcinogenesis.  2004,PubMed,citation,PMID:15033904,pubmed,15033904,create date:2004/03/23 | first author:Lee JW
Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.,/pubmed/14965154,Hamid O.,J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):52-8. Review.,J Am Pharm Assoc (2003).  2004,PubMed,citation,PMID:14965154,pubmed,14965154,create date:2004/02/18 | first author:Hamid O
Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer.,/pubmed/14760116,"Emterling A, Wallin A, Arbman G, Sun XF.",Ann Oncol. 2004 Feb;15(2):242-6.,Ann Oncol.  2004,PubMed,citation,PMID:14760116,pubmed,14760116,create date:2004/02/05 | first author:Emterling A
Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease.,/pubmed/14752072,"Saurin JC, Gutknecht C, Napoleon B, Chavaillon A, Ecochard R, Scoazec JY, Ponchon T, Chayvialle JA.",J Clin Oncol. 2004 Feb 1;22(3):493-8.,J Clin Oncol.  2004,PubMed,citation,PMID:14752072,pubmed,14752072,create date:2004/01/31 | first author:Saurin JC
Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas.,/pubmed/14639609,"Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, Ohki R, Choi YL, Wada T, Konishi F, Nagai H, Mano H.",Int J Cancer. 2004 Jan 10;108(2):237-42.,Int J Cancer.  2004,PubMed,citation,PMID:14639609,pubmed,14639609,create date:2003/11/26 | first author:Koinuma K
Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer.,/pubmed/14612515,"Risques RA, Moreno V, Ribas M, Marcuello E, Capellà G, Peinado MA.",Cancer Res. 2003 Nov 1;63(21):7206-14.,Cancer Res.  2003,PubMed,citation,PMID:14612515,pubmed,14612515,create date:2003/11/13 | first author:Risques RA
"Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia.",/pubmed/14604438,"Terry MB, Neugut AI, Mansukhani M, Waye J, Harpaz N, Hibshoosh H.",BMC Cancer. 2003 Nov 6;3:29.,BMC Cancer.  2003,PubMed,citation,PMID:14604438 | PMCID:PMC280655,pubmed,14604438,create date:2003/11/08 | first author:Terry MB
"Cadherins, catenins and APC in pleural malignant mesothelioma.",/pubmed/14595746,"Abutaily AS, Collins JE, Roche WR.",J Pathol. 2003 Nov;201(3):355-62.,J Pathol.  2003,PubMed,citation,PMID:14595746,pubmed,14595746,create date:2003/11/05 | first author:Abutaily AS
Familial sarcoma: challenging pedigrees.,/pubmed/14584079,"Lynch HT, Deters CA, Hogg D, Lynch JF, Kinarsky Y, Gatalica Z.",Cancer. 2003 Nov 1;98(9):1947-57.,Cancer.  2003,PubMed,citation,PMID:14584079,pubmed,14584079,create date:2003/10/30 | first author:Lynch HT
Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumors.,/pubmed/14582698,"Okimoto T, Yahata H, Itou H, Shinozaki K, Tanji H, Sakaguchi T, Asahara T.",J Exp Clin Cancer Res. 2003 Sep;22(3):399-406.,J Exp Clin Cancer Res.  2003,PubMed,citation,PMID:14582698,pubmed,14582698,create date:2003/10/30 | first author:Okimoto T
Attenuated familial adenomatous polyposis (AFAP). A review of the literature.,/pubmed/14574166,"Knudsen AL, Bisgaard ML, Bülow S.",Fam Cancer. 2003;2(1):43-55. Review.,Fam Cancer.  2003,PubMed,citation,PMID:14574166,pubmed,14574166,create date:2003/10/24 | first author:Knudsen AL
"Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.",/pubmed/14517842,"Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, Eilers R, Dienes HP, Schirmacher P.",J Pathol. 2003 Oct;201(2):250-9.,J Pathol.  2003,PubMed,citation,PMID:14517842,pubmed,14517842,create date:2003/10/01 | first author:Prange W
High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas.,/pubmed/14508843,"Strazzullo M, Cossu A, Baldinu P, Colombino M, Satta MP, Tanda F, De Bonis ML, Cerase A, D'Urso M, D'Esposito M, Palmieri G.",Cancer. 2003 Oct 1;98(7):1540-6.,Cancer.  2003,PubMed,citation,PMID:14508843,pubmed,14508843,create date:2003/09/26 | first author:Strazzullo M
Mutational analysis of Noxa gene in human cancers.,/pubmed/12969015,"Lee SH, Soung YH, Lee JW, Kim HS, Lee JH, Kim HS, Lee JH, Park JY, Cho YG, Kim CJ, Kim SY, Park WS, Kim SH, Lee JY, Yoo NJ.",APMIS. 2003 Jun;111(6):599-604.,APMIS.  2003,PubMed,citation,PMID:12969015,pubmed,12969015,create date:2003/09/13 | first author:Lee SH
Microsatellite instability and MBD4 mutation in unselected colorectal cancer.,/pubmed/12926109,"Evertson S, Wallin A, Arbman G, Rütten S, Emterling A, Zhang H, Sun XF.",Anticancer Res. 2003 Jul-Aug;23(4):3569-74.,Anticancer Res.  2003,PubMed,citation,PMID:12926109,pubmed,12926109,create date:2003/08/21 | first author:Evertson S
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.,/pubmed/12912934,"Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B.",Clin Cancer Res. 2003 Aug 1;9(8):2898-903.,Clin Cancer Res.  2003,PubMed,citation,PMID:12912934,pubmed,12912934,create date:2003/08/13 | first author:Van Rijnsoever M
Survivin and molecular pathogenesis of colorectal cancer.,/pubmed/12885482,"Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC.",Lancet. 2003 Jul 19;362(9379):205-9.,Lancet.  2003,PubMed,citation,PMID:12885482,pubmed,12885482,create date:2003/07/30 | first author:Kim PJ
Genetic analysis of cancer occurring in the ileocecal valve.,/pubmed/12828072,"Takada M, Horita Y, Okumoto S, Fujimori T, Ku Y, Kuroda Y.",Hepatogastroenterology. 2003 May-Jun;50(51):729-31.,Hepatogastroenterology.  2003,PubMed,citation,PMID:12828072,pubmed,12828072,create date:2003/06/28 | first author:Takada M
"Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.",/pubmed/12817876,"Miettinen M, Lasota J.",Pol J Pathol. 2003;54(1):3-24. Review.,Pol J Pathol.  2003,PubMed,citation,PMID:12817876,pubmed,12817876,create date:2003/06/24 | first author:Miettinen M
Options for screening for colorectal cancer.,/pubmed/12797674,Atkin W.,Scand J Gastroenterol Suppl. 2003;(237):13-6. Review.,Scand J Gastroenterol Suppl.  2003,PubMed,citation,PMID:12797674,pubmed,12797674,create date:2003/06/12 | first author:Atkin W
[Clinicopathological features of typical and non-typical hereditary non-polyposis colorectal cancer and their germline mutation of hMLH1 and hMSH2].,/pubmed/12783672,"Cui L, Jin HY, Meng RG, Yan YD, Wang JS, Liu F, Xu HL, Yu DH.",Zhonghua Wai Ke Za Zhi. 2003 Feb;41(2):112-5. Chinese. ,Zhonghua Wai Ke Za Zhi.  2003,PubMed,citation,PMID:12783672,pubmed,12783672,create date:2003/06/05 | first author:Cui L
Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.,/pubmed/12777192,"Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME.",Clin Colorectal Cancer. 2003 May;3(1):47-53.,Clin Colorectal Cancer.  2003,PubMed,citation,PMID:12777192,pubmed,12777192,create date:2003/06/05 | first author:Tagore KS
Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1.,/pubmed/12727890,"Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavó E, di Pietro M, Marra G, Jiricny J.",EMBO J. 2003 May 1;22(9):2245-54.,EMBO J.  2003,PubMed,citation,PMID:12727890 | PMCID:PMC156088,pubmed,12727890,create date:2003/05/03 | first author:Cejka P
Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis.,/pubmed/12702765,"Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, Bird A, Clarke AR, Frisch SM.",Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5211-6. Epub 2003 Apr 17.,Proc Natl Acad Sci U S A.  2003,PubMed,citation,PMID:12702765 | PMCID:PMC154324,pubmed,12702765,create date:2003/04/19 | first author:Screaton RA
Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer.,/pubmed/12697967,"Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J, Iacopetta B.",Oncology. 2003;64(3):259-65.,Oncology.  2003,PubMed,citation,PMID:12697967,pubmed,12697967,create date:2003/04/17 | first author:Wang C
An early stage small bowel adenocarcinoma with microsatellite instability phenotype in a case of hereditary nonpolyposis colorectal cancer.,/pubmed/12673494,"Furukawa T, Konishi F, Shitoh K, Tsukamoto T, Nagai H.",Int J Colorectal Dis. 2003 May;18(3):267-70. Epub 2003 Feb 7.,Int J Colorectal Dis.  2003,PubMed,citation,PMID:12673494,pubmed,12673494,create date:2003/04/04 | first author:Furukawa T
Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis.,/pubmed/12652573,"Bjørheim J, Gaudernack G, Giercksky KE, Ekstrøm PO.",Electrophoresis. 2003 Jan;24(1-2):63-9.,Electrophoresis.  2003,PubMed,citation,PMID:12652573,pubmed,12652573,create date:2003/03/26 | first author:Bjørheim J
TP53 mutation in colorectal cancer.,/pubmed/12619112,Iacopetta B.,Hum Mutat. 2003 Mar;21(3):271-6. Review.,Hum Mutat.  2003,PubMed,citation,PMID:12619112,pubmed,12619112,create date:2003/03/06 | first author:Iacopetta B
Serrated adenomas and mixed polyposis caused by a splice acceptor deletion in the mouse Smad4 gene.,/pubmed/12557227,"Hohenstein P, Molenaar L, Elsinga J, Morreau H, van der Klift H, Struijk A, Jagmohan-Changur S, Smits R, van Kranen H, van Ommen GJ, Cornelisse C, Devilee P, Fodde R.",Genes Chromosomes Cancer. 2003 Mar;36(3):273-82.,Genes Chromosomes Cancer.  2003,PubMed,citation,PMID:12557227,pubmed,12557227,create date:2003/01/31 | first author:Hohenstein P
Altered expression of the receptor and ligand in the TGF beta signaling pathway in diffusely infiltrating colon carcinoma.,/pubmed/12552954,"Nagayama S, Onodera H, Toguchida J, Imamura M.",Anticancer Res. 2002 Nov-Dec;22(6B):3545-54.,Anticancer Res.  2002,PubMed,citation,PMID:12552954,pubmed,12552954,create date:2003/01/30 | first author:Nagayama S
An evolutionary paradigm for carcinogenesis?,/pubmed/12540682,"Vineis P, Matullo G, Manuguerra M.",J Epidemiol Community Health. 2003 Feb;57(2):89-95. Review.,J Epidemiol Community Health.  2003,PubMed,citation,PMID:12540682 | PMCID:PMC1732384,pubmed,12540682,create date:2003/01/24 | first author:Vineis P
Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.,/pubmed/12528772,"Miettinen M, Majidi M, Lasota J.",Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51. Review.,Eur J Cancer.  2002,PubMed,citation,PMID:12528772,pubmed,12528772,create date:2003/01/17 | first author:Miettinen M
NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells.,/pubmed/12527911,"Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V.",Oncogene. 2003 Jan 9;22(1):90-7.,Oncogene.  2003,PubMed,citation,PMID:12527911,pubmed,12527911,create date:2003/01/16 | first author:Bentires-Alj M
Microsatellite instability in a population of sporadic colorectal cancers: correlation between genetic and pathological profiles.,/pubmed/12502211,"Luceri C, De Filippo C, Guglielmi F, Caderni G, Messerini L, Biggeri A, Mini E, Tonelli F, Cianchi F, Dolara P.",Dig Liver Dis. 2002 Aug;34(8):553-9.,Dig Liver Dis.  2002,PubMed,citation,PMID:12502211,pubmed,12502211,create date:2002/12/28 | first author:Luceri C
A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.,/pubmed/12492501,"Yu JL, Coomber BL, Kerbel RS.",Differentiation. 2002 Dec;70(9-10):599-609. Review.,Differentiation.  2002,PubMed,citation,PMID:12492501,pubmed,12492501,create date:2002/12/21 | first author:Yu JL
[Juvenile polyposis coli. The usefulness of a genetic study and the role of surgical treatment].,/pubmed/12483142,"Tenière P, Songne K, Frebourg T, Moguelet P, Foulatier O, Michot F, Le Pessot F, Le Blanc I, Scotte M.",Gastroenterol Clin Biol. 2002 Nov;26(11):1047-50. French. ,Gastroenterol Clin Biol.  2002,PubMed,citation,PMID:12483142,pubmed,12483142,create date:2002/12/17 | first author:Tenière P
The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells.,/pubmed/12466967,"Zhu GH, Lenzi M, Schwartz EL.",Oncogene. 2002 Dec 5;21(55):8477-85.,Oncogene.  2002,PubMed,citation,PMID:12466967,pubmed,12466967,create date:2002/12/06 | first author:Zhu GH
Butyrate down-regulates CD44 transcription and liver colonisation in a highly metastatic human colon carcinoma cell line.,/pubmed/12439723,"Barshishat M, Levi I, Benharroch D, Schwartz B.",Br J Cancer. 2002 Nov 18;87(11):1314-20.,Br J Cancer.  2002,PubMed,citation,PMID:12439723 | PMCID:PMC2408907,pubmed,12439723,create date:2002/11/20 | first author:Barshishat M
Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.,/pubmed/12427779,"van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B.",Gut. 2002 Dec;51(6):797-802.,Gut.  2002,PubMed,citation,PMID:12427779 | PMCID:PMC1773491,pubmed,12427779,create date:2002/11/13 | first author:van Rijnsoever M
APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status.,/pubmed/12408524,"Løvig T, Meling GI, Diep CB, Thorstensen L, Norheim Andersen S, Lothe RA, Rognum TO.",Scand J Gastroenterol. 2002 Oct;37(10):1184-93.,Scand J Gastroenterol.  2002,PubMed,citation,PMID:12408524,pubmed,12408524,create date:2002/11/01 | first author:Løvig T
"K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China.",/pubmed/12374683,"Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, Shen MC, Deng J, Hsing AW.",Clin Cancer Res. 2002 Oct;8(10):3156-63.,Clin Cancer Res.  2002,PubMed,citation,PMID:12374683,pubmed,12374683,create date:2002/10/11 | first author:Rashid A
Extent of nodal involvement in Stage III colorectal carcinoma: relationship to clinicopathologic variables and genetic alterations.,/pubmed/12352240,"Elsaleh H, Cserni G, Iacopetta B.",Dis Colon Rectum. 2002 Sep;45(9):1218-22.,Dis Colon Rectum.  2002,PubMed,citation,PMID:12352240,pubmed,12352240,create date:2002/09/28 | first author:Elsaleh H
Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer.,/pubmed/12210601,"Geido E, Sciutto A, Rubagotti A, Oliani C, Monaco R, Risio M, Giaretti W.",Cytometry. 2002 Aug 15;50(4):216-24.,Cytometry.  2002,PubMed,citation,PMID:12210601,pubmed,12210601,create date:2002/09/05 | first author:Geido E
Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability.,/pubmed/12210079,"Furlan D, Casati B, Cerutti R, Facco C, Terracciano L, Capella C, Chiaravalli AM.",J Pathol. 2002 Aug;197(5):603-9.,J Pathol.  2002,PubMed,citation,PMID:12210079,pubmed,12210079,create date:2002/09/05 | first author:Furlan D
"A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.",/pubmed/12176785,"Sharma S, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB.",Ann Oncol. 2002 Jul;13(7):1067-71.,Ann Oncol.  2002,PubMed,citation,PMID:12176785,pubmed,12176785,create date:2002/08/15 | first author:Sharma S
Nijmegen breakage syndrome gene (NBS1) is not the tumor suppressor gene at 8q21.3 involved in colorectal carcinoma.,/pubmed/12066197,"Varon R, Gosse-Brun S, Bignon YJ, Sperling K, Uhrhammer N.",Oncol Rep. 2002 Jul-Aug;9(4):709-11.,Oncol Rep.  2002,PubMed,citation,PMID:12066197,pubmed,12066197,create date:2002/06/18 | first author:Varon R
P53 gene mutations: case study of a clinical marker for solid tumors.,/pubmed/12063677,"Liu MC, Gelmann EP.",Semin Oncol. 2002 Jun;29(3):246-57. Review.,Semin Oncol.  2002,PubMed,citation,PMID:12063677,pubmed,12063677,create date:2002/06/14 | first author:Liu MC
[Life without DNA repair].,/pubmed/12013614,Klungland A.,Tidsskr Nor Laegeforen. 2001 Jan 10;121(1):41-9. Norwegian. ,Tidsskr Nor Laegeforen.  2001,PubMed,citation,PMID:12013614,pubmed,12013614,create date:2002/05/17 | first author:Klungland A
Prognostic significance of p53 mutations in colon cancer at the population level.,/pubmed/11992552,"Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML.",Int J Cancer. 2002 Jun 1;99(4):597-602.,Int J Cancer.  2002,PubMed,citation,PMID:11992552,pubmed,11992552,create date:2002/05/07 | first author:Samowitz WS
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.,/pubmed/11984524,"Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R.",Gastroenterology. 2002 May;122(5):1376-87.,Gastroenterology.  2002,PubMed,citation,PMID:11984524,pubmed,11984524,create date:2002/05/02 | first author:Hawkins N
Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study.,/pubmed/11950808,"Groves CJ, Saunders BP, Spigelman AD, Phillips RK.",Gut. 2002 May;50(5):636-41.,Gut.  2002,PubMed,citation,PMID:11950808 | PMCID:PMC1773219,pubmed,11950808,create date:2002/04/16 | first author:Groves CJ
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.,/pubmed/11875499,"LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.",Nat Med. 2002 Mar;8(3):274-81.,Nat Med.  2002,PubMed,citation,PMID:11875499,pubmed,11875499,create date:2002/03/05 | first author:LeBlanc H
Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer.,/pubmed/11854698,"Gervaz P, Cerottini JP, Bouzourene H, Hahnloser D, Doan CL, Benhattar J, Chaubert P, Secic M, Gillet M, Carethers JM.",Surgery. 2002 Feb;131(2):190-7.,Surgery.  2002,PubMed,citation,PMID:11854698,pubmed,11854698,create date:2002/02/21 | first author:Gervaz P
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.,/pubmed/11854519,"Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW, Kollermann J, Speicher MR, Pantel K.",Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2246-51.,Proc Natl Acad Sci U S A.  2002,PubMed,citation,PMID:11854519 | PMCID:PMC122350,pubmed,11854519,create date:2002/02/21 | first author:Solakoglu O
Comparison of clinicopathologic characteristics and genetic alterations between microsatellite instability-positive and microsatellite instability-negative sporadic colorectal carcinomas in patients younger than 40 years old.,/pubmed/11852336,"Suh JH, Lim SD, Kim JC, Hong SH, Kang GH.",Dis Colon Rectum. 2002 Feb;45(2):219-28.,Dis Colon Rectum.  2002,PubMed,citation,PMID:11852336,pubmed,11852336,create date:2002/02/20 | first author:Suh JH
p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma.,/pubmed/11801554,Sun XF.,Clin Cancer Res. 2002 Jan;8(1):165-70.,Clin Cancer Res.  2002,PubMed,citation,PMID:11801554,pubmed,11801554,create date:2002/01/22 | first author:Sun XF
[Clinical significance of a carcinogenesis model of colorectal carcinoma].,/pubmed/11765350,"Spisni R, Faviana P, Pingitore R, Castagna M, Baroncini R, Biondi R, Lagomarsini B, Colizzi C.",Ann Ital Chir. 2001 May-Jun;72(3):323-7. Italian. ,Ann Ital Chir.  2001,PubMed,citation,PMID:11765350,pubmed,11765350,create date:2002/01/05 | first author:Spisni R
Combined molecular and clinical approach for decision making for surgery in HNPCC patients: a report on three cases in two families.,/pubmed/11760904,"Pistorius SR, Nagel M, Kruger S, Plaschke J, Kruppa C, Wehrmann U, Schackert HK, Saeger HD.",Int J Colorectal Dis. 2001 Nov;16(6):402-7.,Int J Colorectal Dis.  2001,PubMed,citation,PMID:11760904,pubmed,11760904,create date:2002/01/05 | first author:Pistorius SR
Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.,/pubmed/11745689,"Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B.",J Pathol. 2001 Dec;195(5):543-8.,J Pathol.  2001,PubMed,citation,PMID:11745689,pubmed,11745689,create date:2001/12/18 | first author:Gnanasampanthan G
Methylation of CpG sites in exon 2 of the bcl-2 gene occurs in colorectal carcinoma.,/pubmed/11724359,"Babidge WJ, Butler LM, Burton MA, Cowled PA.",Anticancer Res. 2001 Jul-Aug;21(4A):2809-14.,Anticancer Res.  2001,PubMed,citation,PMID:11724359,pubmed,11724359,create date:2001/11/29 | first author:Babidge WJ
Phenotypic characteristics of colo-rectal cancer in I1307K APC germline mutation carriers compared with sporadic cases.,/pubmed/11720476,"Figer A, Shtoyerman-Chen R, Tamir A, Geva R, Irmin L, Flex D, Theodor L, Sulkes A, Sadetzki S, Bar-Meir S, Friedman E.",Br J Cancer. 2001 Nov 2;85(9):1368-71.,Br J Cancer.  2001,PubMed,citation,PMID:11720476 | PMCID:PMC2375261,pubmed,11720476,create date:2001/11/27 | first author:Figer A
P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases.,/pubmed/11710597,"Khan ZA, Jonas SK, Feldmann KA, Patel H, Wharton RQ, Tarragona A, Ivison A, Allen-Mersh TG.",J Cancer Res Clin Oncol. 2001 Nov;127(11):675-80.,J Cancer Res Clin Oncol.  2001,PubMed,citation,PMID:11710597,pubmed,11710597,create date:2001/11/17 | first author:Khan ZA
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.,/pubmed/11606375,"Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA.",Cancer Res. 2001 Oct 15;61(20):7426-9.,Cancer Res.  2001,PubMed,citation,PMID:11606375,pubmed,11606375,create date:2001/10/19 | first author:Philp AJ
MSH2 and MLH1 immunodetection and the prognosis of colon cancer.,/pubmed/11604984,"Perrin J, Gouvernet J, Parriaux D, Noguchi T, Giovannini MH, Giovannini M, Delpero JR, Birnbaum D, Monges G.",Int J Oncol. 2001 Nov;19(5):891-5.,Int J Oncol.  2001,PubMed,citation,PMID:11604984,pubmed,11604984,create date:2001/10/18 | first author:Perrin J
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.,/pubmed/11600610,"Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT.",J Clin Oncol. 2001 Oct 15;19(20):4074-80.,J Clin Oncol.  2001,PubMed,citation,PMID:11600610,pubmed,11600610,create date:2001/10/16 | first author:Vasen HF
Mechanisms of oncogenesis in colon versus rectal cancer.,/pubmed/11592095,"Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ, van Krieken JH.",J Pathol. 2001 Sep;195(2):171-8.,J Pathol.  2001,PubMed,citation,PMID:11592095,pubmed,11592095,create date:2001/10/10 | first author:Kapiteijn E
Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma.,/pubmed/11572874,"Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ, Phillips WA.",J Biol Chem. 2001 Nov 30;276(48):45113-9. Epub 2001 Sep 25.,J Biol Chem.  2001,PubMed,citation,PMID:11572874,pubmed,11572874,create date:2001/09/27 | first author:Rockman SP
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.,/pubmed/11555601,"Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Höffken K.",Clin Cancer Res. 2001 Sep;7(9):2832-9.,Clin Cancer Res.  2001,PubMed,citation,PMID:11555601,pubmed,11555601,create date:2001/09/14 | first author:Raida M
"Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.",/pubmed/11535846,"Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Zala GF, Flury R, Seelentag W, Roth J, Meyenberger C, Fried M, Hoppeler T, Spigelman AD, Scott RJ.",Dis Colon Rectum. 2001 Aug;44(8):1090-7; discussion 1097-9.,Dis Colon Rectum.  2001,PubMed,citation,PMID:11535846,pubmed,11535846,create date:2001/09/06 | first author:Guldenschuh I
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.,/pubmed/11535541,"Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML.",Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23.,Cancer Epidemiol Biomarkers Prev.  2001,PubMed,citation,PMID:11535541,pubmed,11535541,create date:2001/09/06 | first author:Samowitz WS
MLH1 and MSH2 protein immunohistochemistry is useful for detection of hereditary non-polyposis colorectal cancer in young patients.,/pubmed/11532035,"Paraf F, Gilquin M, Longy M, Gilbert B, Gorry P, Petit B, Labrousse F.",Histopathology. 2001 Sep;39(3):250-8.,Histopathology.  2001,PubMed,citation,PMID:11532035,pubmed,11532035,create date:2001/09/05 | first author:Paraf F
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.,/pubmed/11531254,"Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, et al.",Br J Cancer. 2001 Sep 1;85(5):692-6.,Br J Cancer.  2001,PubMed,citation,PMID:11531254 | PMCID:PMC2364126,pubmed,11531254,create date:2001/09/05 | first author:Andreyev HJ
Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer.,/pubmed/11494233,"Benatti P, Roncucci L, Ganazzi D, Percesepe A, Di Gregorio C, Pedroni M, Borghi F, Sala E, Scarselli A, Menigatti M, Rossi G, Genuardi M, Viel A, Ponz De Leon M.",Int J Cancer. 2001 Sep 20;95(5):323-8.,Int J Cancer.  2001,PubMed,citation,PMID:11494233,pubmed,11494233,create date:2001/08/09 | first author:Benatti P
p53 mutation in plasma DNA and its prognostic value in breast cancer patients.,/pubmed/11489795,"Shao ZM, Wu J, Shen ZZ, Nguyen M.","Clin Cancer Res. 2001 Aug;7(8):2222-7. Retraction in: Shao ZM, Wu J, Shen ZZ, Nguyen M. Clin Cancer Res. 2002 Sep;8(9):3027. ",Clin Cancer Res.  2001,PubMed,citation,PMID:11489795,pubmed,11489795,create date:2001/08/08 | first author:Shao ZM
Familial adenomatous polyposis: a case report and review of the literature.,/pubmed/11446392,"Beech D, Pontius A, Muni N, Long WP.",J Natl Med Assoc. 2001 Jun;93(6):208-13. Review.,J Natl Med Assoc.  2001,PubMed,citation,PMID:11446392 | PMCID:PMC2594024,pubmed,11446392,create date:2001/07/12 | first author:Beech D
Microsatellite instability.,/pubmed/11435683,Atkin NB.,Cytogenet Cell Genet. 2001;92(3-4):177-81. Review.,Cytogenet Cell Genet.  2001,PubMed,citation,PMID:11435683,pubmed,11435683,create date:2001/07/04 | first author:Atkin NB
Study of P53 protein expression in colorectal cancer.,/pubmed/11374803,"Sulkowska M, Famulski W, Guzińska-Ustymowicz K, Sulkowski S.",Folia Histochem Cytobiol. 2001;39(2):157-8.,Folia Histochem Cytobiol.  2001,PubMed,citation,PMID:11374803,pubmed,11374803,create date:2001/05/26 | first author:Sulkowska M
Caspase-3 activity as a prognostic factor in colorectal carcinoma.,/pubmed/11351040,"Jonges LE, Nagelkerke JF, Ensink NG, van der Velde EA, Tollenaar RA, Fleuren GJ, van de Velde CJ, Morreau H, Kuppen PJ.",Lab Invest. 2001 May;81(5):681-8.,Lab Invest.  2001,PubMed,citation,PMID:11351040,pubmed,11351040,create date:2001/05/15 | first author:Jonges LE
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.,/pubmed/11350904,"Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B.",Clin Cancer Res. 2001 May;7(5):1343-9.,Clin Cancer Res.  2001,PubMed,citation,PMID:11350904,pubmed,11350904,create date:2001/05/15 | first author:Elsaleh H
p53 mutation found to be a significant prognostic indicator in distal colorectal cancer.,/pubmed/11295071,"Okubo R, Masuda H, Nemoto N.",Oncol Rep. 2001 May-Jun;8(3):509-14.,Oncol Rep.  2001,PubMed,citation,PMID:11295071,pubmed,11295071,create date:2001/04/11 | first author:Okubo R
Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.,/pubmed/11289282,"Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC, Belin B.",Dis Colon Rectum. 2001 Mar;44(3):364-72; discussion 372-3.,Dis Colon Rectum.  2001,PubMed,citation,PMID:11289282,pubmed,11289282,create date:2001/04/06 | first author:Gervaz P
Mutations of p53 gene in human colorectal cancer: distinct frameshifts among populations.,/pubmed/11275993,"Tang R, Wang PF, Wang HC, Wang JY, Hsieh LL.",Int J Cancer. 2001 Mar 15;91(6):863-8.,Int J Cancer.  2001,PubMed,citation,PMID:11275993,pubmed,11275993,create date:2001/03/29 | first author:Tang R
Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.,/pubmed/11237496,"Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M.",Eur J Surg Oncol. 2001 Feb;27(1):80-7.,Eur J Surg Oncol.  2001,PubMed,citation,PMID:11237496,pubmed,11237496,create date:2001/03/10 | first author:Petrowsky H
Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer.,/pubmed/11161382,"Hawkins NJ, Tomlinson I, Meagher A, Ward RL.",Br J Cancer. 2001 Jan;84(2):232-6.,Br J Cancer.  2001,PubMed,citation,PMID:11161382 | PMCID:PMC2363701,pubmed,11161382,create date:2001/02/13 | first author:Hawkins NJ
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.,/pubmed/11156646,"Andreyev HJ, Ross PJ, Cunningham D, Clarke PA.",Gut. 2001 Feb;48(2):230-7.,Gut.  2001,PubMed,citation,PMID:11156646 | PMCID:PMC1728205,pubmed,11156646,create date:2001/01/13 | first author:Andreyev HJ
Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.,/pubmed/11118040,"Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG.",Cancer Res. 2000 Dec 1;60(23):6597-600.,Cancer Res.  2000,PubMed,citation,PMID:11118040,pubmed,11118040,create date:2000/12/16 | first author:Bernhard EJ
"Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.",/pubmed/11097226,"Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML.",Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7.,Cancer Epidemiol Biomarkers Prev.  2000,PubMed,citation,PMID:11097226,pubmed,11097226,create date:2000/11/30 | first author:Samowitz WS
Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer.,/pubmed/11073815,"Wielenga VJ, van der Voort R, Taher TE, Smit L, Beuling EA, van Krimpen C, Spaargaren M, Pals ST.",Am J Pathol. 2000 Nov;157(5):1563-73.,Am J Pathol.  2000,PubMed,citation,PMID:11073815 | PMCID:PMC1885727,pubmed,11073815,create date:2000/11/14 | first author:Wielenga VJ
Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.,/pubmed/11051374,"Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker JT.",Am J Gastroenterol. 2000 Oct;95(10):2953-7.,Am J Gastroenterol.  2000,PubMed,citation,PMID:11051374,pubmed,11051374,create date:2000/10/29 | first author:Bleeker WA
"Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.",/pubmed/11044641,"Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B.",Eur J Cancer. 2000 Oct;36(16):2053-60.,Eur J Cancer.  2000,PubMed,citation,PMID:11044641,pubmed,11044641,create date:2000/10/25 | first author:Soong R
"The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer.",/pubmed/10928094,"Pajkos G, Kiss I, Sándor J, Ember I, Kisházi P.",Anticancer Res. 2000 May-Jun;20(3A):1695-701.,Anticancer Res.  2000,PubMed,citation,PMID:10928094,pubmed,10928094,create date:2000/08/06 | first author:Pajkos G
[Familial ovarian cancer].,/pubmed/10921314,"Sekine M, Tanaka K.",Nihon Rinsho. 2000 Jul;58(7):1409-12. Review. Japanese. ,Nihon Rinsho.  2000,PubMed,citation,PMID:10921314,pubmed,10921314,create date:2000/08/02 | first author:Sekine M
[Muir-Torre syndrome and HNPCC: importance of clinical diagnosis and genetic investigation in family members].,/pubmed/10914216,"Strul H, Rozen P, Naiman T, Shomrat R.","Harefuah. 1999 Feb 15;136(4):274-6, 339. Hebrew. ",Harefuah.  1999,PubMed,citation,PMID:10914216,pubmed,10914216,create date:2000/07/29 | first author:Strul H
Racial and ethnic factors in the genetic pathogenesis of colorectal cancer.,/pubmed/10826011,Carethers JM.,J Assoc Acad Minor Phys. 1999;10(3):59-67.,J Assoc Acad Minor Phys.  1999,PubMed,citation,PMID:10826011,pubmed,10826011,create date:2000/05/29 | first author:Carethers JM
Molecular prognostic factors in rectal cancer treated by radiation and surgery.,/pubmed/10789738,"Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garciá-Aguilar J.",Dis Colon Rectum. 2000 Apr;43(4):451-9.,Dis Colon Rectum.  2000,PubMed,citation,PMID:10789738,pubmed,10789738,create date:2000/05/02 | first author:Qiu H
Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer.,/pubmed/10765127,"Speer G, Dworak O, Cseh K, Bori Z, Salamon D, Török I, Winkler G, Vargha P, Nagy Z, Takács I, Kucsera M, Lakatos P.",Oncology. 2000 Apr;58(3):242-7.,Oncology.  2000,PubMed,citation,PMID:10765127,pubmed,10765127,create date:2000/04/15 | first author:Speer G
Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells.,/pubmed/10744679,"Harwood FG, Kasibhatla S, Petak I, Vernes R, Green DR, Houghton JA.",J Biol Chem. 2000 Apr 7;275(14):10023-9.,J Biol Chem.  2000,PubMed,citation,PMID:10744679,pubmed,10744679,create date:2000/04/01 | first author:Harwood FG
A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas.,/pubmed/10718211,"Logullo AF, de Moura RP, Nonogaki S, Kowalski LP, Nagai MA, Simpson AJ.",Diagn Mol Pathol. 2000 Mar;9(1):35-40.,Diagn Mol Pathol.  2000,PubMed,citation,PMID:10718211,pubmed,10718211,create date:2000/03/16 | first author:Logullo AF
Chronic inflammatory bowel disease and cancer.,/pubmed/10690586,"Pohl C, Hombach A, Kruis W.",Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70. Review.,Hepatogastroenterology.  2000,PubMed,citation,PMID:10690586,pubmed,10690586,create date:2000/02/26 | first author:Pohl C
[The Lynch syndrome].,/pubmed/10687268,"Fracasso P, Assisi D, Stigliano V, Casale V.",Clin Ter. 1999 Sep-Oct;150(5):373-8. Review. Italian. ,Clin Ter.  1999,PubMed,citation,PMID:10687268,pubmed,10687268,create date:2000/02/25 | first author:Fracasso P
"p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.",/pubmed/10644941,"Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B.",Oncology. 2000;58(1):52-9.,Oncology.  2000,PubMed,citation,PMID:10644941,pubmed,10644941,create date:2000/01/25 | first author:Elsaleh H
"Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer.",/pubmed/10644313,"Curran B, Lenehan K, Mulcahy H, Tighe O, Bennett MA, Kay EW, O'Donoghue DP, Leader M, Croke DT.",Gut. 2000 Feb;46(2):200-4.,Gut.  2000,PubMed,citation,PMID:10644313 | PMCID:PMC1727803,pubmed,10644313,create date:2000/01/22 | first author:Curran B
[Identification and genetic counseling of people with HNPCC (hereditary nonpolyposis colorectal cancer): old and new research goals].,/pubmed/10637951,"Müller H, Dobbie Z, Heinimann K.",Schweiz Med Wochenschr. 1999 Dec 18;129(50):1978-85. Review. German. ,Schweiz Med Wochenschr.  1999,PubMed,citation,PMID:10637951,pubmed,10637951,create date:2000/01/19 | first author:Müller H
[Registration of hereditary non-polyposis colorectal cancer].,/pubmed/10603753,"Bernstein IT, Bisgaard ML, Myrhøj T.",Ugeskr Laeger. 1999 Nov 8;161(45):6174-8. Danish. ,Ugeskr Laeger.  1999,PubMed,citation,PMID:10603753,pubmed,10603753,create date:1999/12/22 | first author:Bernstein IT
TP53 status and gene amplification in human colorectal carcinomas.,/pubmed/10598144,"Soulié P, Fourme E, Hamelin R, Asselain B, Salmon RJ, Dutrillaux B, Muleris M.",Cancer Genet Cytogenet. 1999 Dec;115(2):118-22.,Cancer Genet Cytogenet.  1999,PubMed,citation,PMID:10598144,pubmed,10598144,create date:1999/12/22 | first author:Soulié P
Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence.,/pubmed/10499618,"Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, Herman JG, Jen J, Sidransky D.",Clin Cancer Res. 1999 Sep;5(9):2450-4.,Clin Cancer Res.  1999,PubMed,citation,PMID:10499618,pubmed,10499618,create date:1999/09/28 | first author:Sanchez-Cespedes M
Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables.,/pubmed/10470121,"Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, Kristjansson AK, Ragnarsson G, Jonasson JG, Egilsson V, Ingvarsson S.",Anticancer Res. 1999 May-Jun;19(3A):1821-6.,Anticancer Res.  1999,PubMed,citation,PMID:10470121,pubmed,10470121,create date:1999/09/02 | first author:Johannsdottir JT
"[Prognostic value of the presence of the mutation of the codons 12, 13 and 61 in K-ras oncogene in colorectal cancer].",/pubmed/10461447,"Pajkos G, Kiss I, Sándor J, Ember I, Kisházi P.",Orv Hetil. 1999 Jul 25;140(30):1673-9. Hungarian. ,Orv Hetil.  1999,PubMed,citation,PMID:10461447,pubmed,10461447,create date:1999/08/26 | first author:Pajkos G
Colorectal cancer in hereditary breast cancer kindreds.,/pubmed/10458128,"Lin KM, Ternent CA, Adams DR, Thorson AG, Blatchford GJ, Christensen MA, Watson P, Lynch HT.",Dis Colon Rectum. 1999 Aug;42(8):1041-5.,Dis Colon Rectum.  1999,PubMed,citation,PMID:10458128,pubmed,10458128,create date:1999/08/24 | first author:Lin KM
p53 point mutation and survival in colorectal cancer patients: effect of disease dissemination and tumour location.,/pubmed/10427130,"Goh HS, Elnatan J, Low CH, Smith DR.",Int J Oncol. 1999 Sep;15(3):491-8.,Int J Oncol.  1999,PubMed,citation,PMID:10427130,pubmed,10427130,create date:1999/07/31 | first author:Goh HS
Screening for colorectal cancer and other GI cancers.,/pubmed/10416884,"Scotiniotis I, Lewis JD, Strom BL.",Curr Opin Oncol. 1999 Jul;11(4):305-11. Review.,Curr Opin Oncol.  1999,PubMed,citation,PMID:10416884,pubmed,10416884,create date:1999/07/23 | first author:Scotiniotis I
Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue.,/pubmed/10408787,"Hayes VM, Bleeker W, Verlind E, Timmer T, Karrenbeld A, Plukker JT, Marx MP, Hofstra RM, Buys CH.",Diagn Mol Pathol. 1999 Mar;8(1):2-10.,Diagn Mol Pathol.  1999,PubMed,citation,PMID:10408787,pubmed,10408787,create date:1999/07/17 | first author:Hayes VM
"Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma.",/pubmed/10404094,"Ko JM, Cheung MH, Kwan MW, Wong CM, Lau KW, Tang CM, Lung ML.",Int J Cancer. 1999 Aug 20;84(4):404-9.,Int J Cancer.  1999,PubMed,citation,PMID:10404094,pubmed,10404094,create date:1999/07/15 | first author:Ko JM
Gene-environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing.,/pubmed/10404064,"Park JG, Park YJ, Wijnen JT, Vasen HF.",Int J Cancer. 1999 Aug 12;82(4):516-9.,Int J Cancer.  1999,PubMed,citation,PMID:10404064,pubmed,10404064,create date:1999/07/15 | first author:Park JG
Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.,/pubmed/10398103,"Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD.",J Pathol. 1999 Mar;187(4):433-8.,J Pathol.  1999,PubMed,citation,PMID:10398103,pubmed,10398103,create date:1999/07/09 | first author:Al-Mulla F
p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations.,/pubmed/10398083,"Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosari S.",J Pathol. 1999 Feb;187(3):302-7.,J Pathol.  1999,PubMed,citation,PMID:10398083,pubmed,10398083,create date:1999/07/09 | first author:Viale G
Mutations of the adenomatous polyposis coli and p53 genes in a child with Turcot's syndrome.,/pubmed/10397462,"Barel D, Cohen IJ, Mor C, Stern S, Shapiro R, Shomrat R, Galanti Y, Legum C, Zaizov R, Avigad S.",Cancer Lett. 1998 Oct 23;132(1-2):119-25.,Cancer Lett.  1998,PubMed,citation,PMID:10397462,pubmed,10397462,create date:1999/07/09 | first author:Barel D
Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects.,/pubmed/10382540,"Bocker T, Rüschoff J, Fishel R.",Biochim Biophys Acta. 1999 May 31;1423(3):O1-O10. Review.,Biochim Biophys Acta.  1999,PubMed,citation,PMID:10382540,pubmed,10382540,create date:1999/06/26 | first author:Bocker T
Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection.,/pubmed/10370632,"Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Chien CT, Wang SM.",Hepatogastroenterology. 1999 Mar-Apr;46(26):883-90.,Hepatogastroenterology.  1999,PubMed,citation,PMID:10370632,pubmed,10370632,create date:1999/06/17 | first author:Liang JT
Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features.,/pubmed/10348818,"Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M.",Gastroenterology. 1999 Jun;116(6):1348-57.,Gastroenterology.  1999,PubMed,citation,PMID:10348818,pubmed,10348818,create date:1999/05/29 | first author:Yamamoto H
Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum.,/pubmed/10339657,"Zhang H, Evertsson S, Sun X.",Int J Oncol. 1999 Jun;14(6):1057-61.,Int J Oncol.  1999,PubMed,citation,PMID:10339657,pubmed,10339657,create date:1999/05/26 | first author:Zhang H
Loss of heterozygosity at the ATM locus in colorectal carcinoma.,/pubmed/10203610,"Uhrhammer N, Bay J, Pernin D, Rio P, Grancho M, Kwiatkowski F, Gosse-Brun S, Daver A, Bignon Y.",Oncol Rep. 1999 May-Jun;6(3):655-8.,Oncol Rep.  1999,PubMed,citation,PMID:10203610,pubmed,10203610,create date:1999/04/16 | first author:Uhrhammer N
"The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumours: tumour development in female SWR mice does not require a K-ras mutational event.",/pubmed/10190570,"Jackson PE, Cooper DP, O'Connor PJ, Povey AC.",Carcinogenesis. 1999 Mar;20(3):509-13.,Carcinogenesis.  1999,PubMed,citation,PMID:10190570,pubmed,10190570,create date:1999/04/06 | first author:Jackson PE
Microsatellite instability and aneuploidy rate in young colorectal-cancer patients do not differ significantly from those in older patients.,/pubmed/10048964,"Yao J, Eu KW, Seow-Choen F, Vijayan V, Cheah PY.",Int J Cancer. 1999 Mar 1;80(5):667-70.,Int J Cancer.  1999,PubMed,citation,PMID:10048964,pubmed,10048964,create date:1999/02/27 | first author:Yao J
Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability.,/pubmed/10022131,"Biden KG, Simms LA, Cummings M, Buttenshaw R, Schoch E, Searle J, Gobe G, Jass JR, Meltzer SJ, Leggett BA, Young J.",Oncogene. 1999 Feb 4;18(5):1245-9.,Oncogene.  1999,PubMed,citation,PMID:10022131,pubmed,10022131,create date:1999/02/18 | first author:Biden KG
Colorectal cancer.,/pubmed/9950460,"Midgley R, Kerr D.",Lancet. 1999 Jan 30;353(9150):391-9. Review.,Lancet.  1999,PubMed,citation,PMID:9950460,pubmed,9950460,create date:1999/02/09 | first author:Midgley R
[Mutation localization as a guide for surgical approach in familial adenomatous polyposis?].,/pubmed/9931913,"Kadmon M, Tandara A, Dupon C, Gebert J, von Knebel-Doeberitz M, Herfarth C.",Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1464-6. German. ,Langenbecks Arch Chir Suppl Kongressbd.  1998,PubMed,citation,PMID:9931913,pubmed,9931913,create date:1999/02/05 | first author:Kadmon M
[Beta-catenin expression and its significance for metastasis in curatively operated rectum carcinoma].,/pubmed/9931888,"Günther K, Brabletz T, Dworak O, Reymond MA, Köckerling F, Ballhausen W, Hohenberger W.",Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1380-2. German. ,Langenbecks Arch Chir Suppl Kongressbd.  1998,PubMed,citation,PMID:9931888,pubmed,9931888,create date:1999/02/05 | first author:Günther K
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.,/pubmed/9823339,"Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S.",Cancer Res. 1998 Nov 15;58(22):5248-57. Review.,Cancer Res.  1998,PubMed,citation,PMID:9823339,pubmed,9823339,create date:1998/11/21 | first author:Boland CR
Second primary tumors in laryngeal cancer: results of long-term follow-up.,/pubmed/9806515,"Narayana A, Vaughan AT, Fisher SG, Reddy SP.",Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):557-62.,Int J Radiat Oncol Biol Phys.  1998,PubMed,citation,PMID:9806515,pubmed,9806515,create date:1998/11/07 | first author:Narayana A
Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer.,/pubmed/9788389,"Günther K, Brabletz T, Kraus C, Dworak O, Reymond MA, Jung A, Hohenberger W, Kirchner T, Köckerling F, Ballhausen WG.",Dis Colon Rectum. 1998 Oct;41(10):1256-61.,Dis Colon Rectum.  1998,PubMed,citation,PMID:9788389,pubmed,9788389,create date:1998/10/27 | first author:Günther K
Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas.,/pubmed/9754757,"Bhatavdekar JM, Patel DD, Chikhlikar PR, Trivedi TI, Gosalia NM, Ghosh N, Shah NG, Vora HH, Suthar TP.",Ann Surg Oncol. 1998 Sep;5(6):495-501.,Ann Surg Oncol.  1998,PubMed,citation,PMID:9754757,pubmed,9754757,create date:1998/10/01 | first author:Bhatavdekar JM
Rare loss-of-function mutation of a death receptor gene in head and neck cancer.,/pubmed/9721851,"Pai SI, Wu GS, Ozören N, Wu L, Jen J, Sidransky D, El-Deiry WS.",Cancer Res. 1998 Aug 15;58(16):3513-8.,Cancer Res.  1998,PubMed,citation,PMID:9721851,pubmed,9721851,create date:1998/08/29 | first author:Pai SI
Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.,/pubmed/9709044,"Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, Tops C, Møller P, Fodde R.",N Engl J Med. 1998 Aug 20;339(8):511-8.,N Engl J Med.  1998,PubMed,citation,PMID:9709044,pubmed,9709044,create date:1998/08/26 | first author:Wijnen JT
Growth dependency of human colon cancer xenograft on organ environment is related with their original clinical stage.,/pubmed/9703939,"Pocard M, Muleris M, Hamelin R, Salmon RJ, Dutrillaux B, Poupon MF.",Anticancer Res. 1998 Jul-Aug;18(4A):2743-7.,Anticancer Res.  1998,PubMed,citation,PMID:9703939,pubmed,9703939,create date:1998/08/15 | first author:Pocard M
Association between H-ras minisatellite and colorectal cancer risk.,/pubmed/9703917,"Gosse-Brun S, Sauvaigo S, Daver A, Larra F, Kwiatkowski F, Bignon YJ, Bernard-Gallon D.",Anticancer Res. 1998 Jul-Aug;18(4A):2611-6.,Anticancer Res.  1998,PubMed,citation,PMID:9703917,pubmed,9703917,create date:1998/08/15 | first author:Gosse-Brun S
Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC.,/pubmed/9669805,"Rodriguez-Bigas MA, Vasen HF, Lynch HT, Watson P, Myrhøj T, Järvinen HJ, Mecklin JP, Macrae F, St John DJ, Bertario L, Fidalgo P, Madlensky L, Rozen P.",Cancer. 1998 Jul 15;83(2):240-4.,Cancer.  1998,PubMed,citation,PMID:9669805,pubmed,9669805,create date:1998/07/21 | first author:Rodriguez-Bigas MA
Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: relationship to clinicopathological features and genetic alterations.,/pubmed/9664904,"Iacopetta BJ, Welch J, Soong R, House AK, Zhou XP, Hamelin R.",J Pathol. 1998 Apr;184(4):390-5.,J Pathol.  1998,PubMed,citation,PMID:9664904,pubmed,9664904,create date:1998/07/17 | first author:Iacopetta BJ
Correlation of macroscopic and histological characteristics in the regional lymph nodes of patients with rectal and sigmoidal adenocarcinoma.,/pubmed/9638420,"Bjelovic M, Kalezic V, Petrovic M, Pesko P, Usaj SK, Marinkovic J, Radovanovic N.",Hepatogastroenterology. 1998 Mar-Apr;45(20):433-8.,Hepatogastroenterology.  1998,PubMed,citation,PMID:9638420,pubmed,9638420,create date:1998/06/25 | first author:Bjelovic M
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.,/pubmed/9586664,"Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA.",J Natl Cancer Inst. 1998 May 6;90(9):675-84.,J Natl Cancer Inst.  1998,PubMed,citation,PMID:9586664,pubmed,9586664,create date:1998/05/20 | first author:Andreyev HJ
TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.,/pubmed/9516972,"Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E.",Clin Cancer Res. 1998 Jan;4(1):203-10.,Clin Cancer Res.  1998,PubMed,citation,PMID:9516972,pubmed,9516972,create date:1998/05/14 | first author:Børresen-Dale AL
Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population.,/pubmed/9559626,"Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT.",Dis Colon Rectum. 1998 Apr;41(4):428-33.,Dis Colon Rectum.  1998,PubMed,citation,PMID:9559626,pubmed,9559626,create date:1998/04/29 | first author:Lin KM
Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent.,/pubmed/9448296,"Andrew SE, McKinnon M, Cheng BS, Francis A, Penney J, Reitmair AH, Mak TW, Jirik FR.",Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1126-30.,Proc Natl Acad Sci U S A.  1998,PubMed,citation,PMID:9448296 | PMCID:PMC18694,pubmed,9448296,create date:1998/03/14 | first author:Andrew SE
"APC genotype, polyp number, and surgical options in familial adenomatous polyposis.",/pubmed/9445111,"Wu JS, Paul P, McGannon EA, Church JM.",Ann Surg. 1998 Jan;227(1):57-62.,Ann Surg.  1998,PubMed,citation,PMID:9445111 | PMCID:PMC1191173,pubmed,9445111,create date:1998/01/28 | first author:Wu JS
Molecular biology of colorectal cancer.,/pubmed/9438104,"Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J.",Curr Probl Cancer. 1997 Sep-Oct;21(5):233-300. Review.,Curr Probl Cancer.  1997,PubMed,citation,PMID:9438104,pubmed,9438104,create date:1998/01/23 | first author:Gryfe R
Critical issues in the evolving management of rectal cancer.,/pubmed/9422268,"Mohiuddin M, Ahmed MM.",Semin Oncol. 1997 Dec;24(6):732-44. Review.,Semin Oncol.  1997,PubMed,citation,PMID:9422268,pubmed,9422268,create date:1998/01/09 | first author:Mohiuddin M
"Common cancers--genetics, origin, prevention, screening: Parts I and II.",/pubmed/9374953,"Schifeling DJ, Horton J, Tafelski TJ.",Dis Mon. 1997 Oct;43(10):681-742. Review.,Dis Mon.  1997,PubMed,citation,PMID:9374953,pubmed,9374953,create date:1997/12/31 | first author:Schifeling DJ
Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.,/pubmed/9377556,"Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW, Kirsch IR.",Cancer Res. 1997 Oct 15;57(20):4478-81.,Cancer Res.  1997,PubMed,citation,PMID:9377556,pubmed,9377556,create date:1997/10/23 | first author:Kitaeva MN
Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases.,/pubmed/9291442,"Chen WS, Chen JY, Liu JM, Lin WC, King KL, Whang-Peng J, Yang WK.",Int J Cancer. 1997 Aug 22;74(4):470-4.,Int J Cancer.  1997,PubMed,citation,PMID:9291442,pubmed,9291442,create date:1997/08/22 | first author:Chen WS
p53 alterations are associated with improved prognosis in distal colonic carcinomas.,/pubmed/9815825,"Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B.",Clin Cancer Res. 1997 Aug;3(8):1405-11.,Clin Cancer Res.  1997,PubMed,citation,PMID:9815825,pubmed,9815825,create date:1997/08/01 | first author:Soong R
Bi-transgenic mice reveal that K-rasVal12 augments a p53-independent apoptosis when small intestinal villus enterocytes reenter the cell cycle.,/pubmed/9214390,"Coopersmith CM, Chandrasekaran C, McNevin MS, Gordon JI.",J Cell Biol. 1997 Jul 14;138(1):167-79.,J Cell Biol.  1997,PubMed,citation,PMID:9214390 | PMCID:PMC2139936,pubmed,9214390,create date:1997/07/14 | first author:Coopersmith CM
Structure and organization of the human TRKA gene encoding a high affinity receptor for nerve growth factor.,/pubmed/9290260,"Indo Y, Mardy S, Tsuruta M, Karim MA, Matsuda I.",Jpn J Hum Genet. 1997 Jun;42(2):343-51.,Jpn J Hum Genet.  1997,PubMed,citation,PMID:9290260,pubmed,9290260,create date:1997/06/01 | first author:Indo Y
Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene.,/pubmed/9092316,"Giardiello FM, Brensinger JD, Luce MC, Petersen GM, Cayouette MC, Krush AJ, Bacon JA, Booker SV, Bufill JA, Hamilton SR.",Ann Intern Med. 1997 Apr 1;126(7):514-9.,Ann Intern Med.  1997,PubMed,citation,PMID:9092316,pubmed,9092316,create date:1997/04/01 | first author:Giardiello FM
Homeosis and intestinal tumours in Cdx2 mutant mice.,/pubmed/9052785,"Chawengsaksophak K, James R, Hammond VE, Köntgen F, Beck F.",Nature. 1997 Mar 6;386(6620):84-7.,Nature.  1997,PubMed,citation,PMID:9052785,pubmed,9052785,create date:1997/03/06 | first author:Chawengsaksophak K
Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers.,/pubmed/9036877,"Jernvall P, Mäkinen M, Karttunen T, Mäkelä J, Vihko P.",Int J Cancer. 1997 Feb 20;74(1):97-101.,Int J Cancer.  1997,PubMed,citation,PMID:9036877,pubmed,9036877,create date:1997/02/20 | first author:Jernvall P
Cloning and characterization of a functional human homolog of Escherichia coli endonuclease III.,/pubmed/8990169,"Aspinwall R, Rothwell DG, Roldan-Arjona T, Anselmino C, Ward CJ, Cheadle JP, Sampson JR, Lindahl T, Harris PC, Hickson ID.",Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):109-14.,Proc Natl Acad Sci U S A.  1997,PubMed,citation,PMID:8990169 | PMCID:PMC19249,pubmed,8990169,create date:1997/01/07 | first author:Aspinwall R
Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention.,/pubmed/9589350,"Wiest JS, Franklin WA, Drabkin H, Gemmill R, Sidransky D, Anderson MW.",J Cell Biochem Suppl. 1997;28-29:64-73. Review.,J Cell Biochem Suppl.  1997,PubMed,citation,PMID:9589350,pubmed,9589350,create date:1997/01/01 | first author:Wiest JS
[P21-ras protein in tumors of the large intestine].,/pubmed/9446408,"Pawłowska-Wakowicz B, Paluszkiewicz P, Karski J, Wojcierowski J.",Wiad Lek. 1997;50 Suppl 1 Pt 1:76-81. Polish. ,Wiad Lek.  1997,PubMed,citation,PMID:9446408,pubmed,9446408,create date:1997/01/01 | first author:Pawłowska-Wakowicz B
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.,/pubmed/9321930,"Gao X, Porter AT, Honn KV.",Adv Exp Med Biol. 1997;407:41-53. Review.,Adv Exp Med Biol.  1997,PubMed,citation,PMID:9321930,pubmed,9321930,create date:1997/01/01 | first author:Gao X
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.,/pubmed/9272128,"Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G.",Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. Review.,Cancer Chemother Pharmacol.  1997,PubMed,citation,PMID:9272128,pubmed,9272128,create date:1997/01/01 | first author:Sikic BI
Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation.,/pubmed/9052405,"el-Mahdani N, Vaillant JC, Guiguet M, Prévot S, Bertrand V, Bernard C, Parc R, Béréziat G, Hermelin B.",Br J Cancer. 1997;75(4):528-36.,Br J Cancer.  1997,PubMed,citation,PMID:9052405 | PMCID:PMC2063311,pubmed,9052405,create date:1997/01/01 | first author:el-Mahdani N
Multiple ependymomas in a patient with Turcot's syndrome.,/pubmed/8950338,"Torres CF, Korones DN, Pilcher W.",Med Pediatr Oncol. 1997 Jan;28(1):59-61.,Med Pediatr Oncol.  1997,PubMed,citation,PMID:8950338,pubmed,8950338,create date:1997/01/01 | first author:Torres CF
Extracolonic features of familial adenomatous polyposis in patients with sporadic colorectal cancer.,/pubmed/8956794,"Dunlop MG, Farrington SM, Bubb VJ, Cunningham C, Wright M, Curtis LJ, Butt ZA, Wright E, Fleck BW, Redhead D, Mitchell R, Rainey JB, Macintyre IM, Carter DC, Wyllie AH.",Br J Cancer. 1996 Dec;74(11):1789-95.,Br J Cancer.  1996,PubMed,citation,PMID:8956794 | PMCID:PMC2077219,pubmed,8956794,create date:1996/12/01 | first author:Dunlop MG
Malignant rhabdoid tumor of the colon. Report of a case with molecular analysis.,/pubmed/8918447,"Marcus VA, Viloria J, Owen D, Tsao MS.",Dis Colon Rectum. 1996 Nov;39(11):1322-6.,Dis Colon Rectum.  1996,PubMed,citation,PMID:8918447,pubmed,8918447,create date:1996/11/01 | first author:Marcus VA
"Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-f]quinoline.",/pubmed/8813112,"Hayashi R, Luk H, Horio D, Dashwood R.",Cancer Res. 1996 Oct 1;56(19):4307-10.,Cancer Res.  1996,PubMed,citation,PMID:8813112,pubmed,8813112,create date:1996/10/01 | first author:Hayashi R
Clinico-pathological features and p53 expression in left-sided sporadic colorectal cancers with and without microsatellite instability.,/pubmed/8869282,"Ilyas M, Tomlinson IP, Novelli MR, Hanby A, Bodmer WF, Talbot IC.",J Pathol. 1996 Aug;179(4):370-5.,J Pathol.  1996,PubMed,citation,PMID:8869282,pubmed,8869282,create date:1996/08/01 | first author:Ilyas M
Point mutation of the c-Ki-ras proto-oncogene and the p53 tumour suppressor gene in distal colonic adenocarcinomas.,/pubmed/21544478,"Smith D, Elnatan J, Yao J, Goh H.",Int J Oncol. 1996 Jun;8(6):1165-9.,Int J Oncol.  1996,PubMed,citation,PMID:21544478,pubmed,21544478,create date:1996/06/01 | first author:Smith D
Chromosome 11q in sporadic colorectal carcinoma: patterns of allele loss and their significance for tumorigenesis.,/pubmed/8707952,"Tomlinson IP, Bodmer WF.",J Clin Pathol. 1996 May;49(5):386-90.,J Clin Pathol.  1996,PubMed,citation,PMID:8707952 | PMCID:PMC500477,pubmed,8707952,create date:1996/05/01 | first author:Tomlinson IP
[Recent progress of molecular oncology and its contribution to clinical gastroenterology].,/pubmed/8920648,"Imai K, Hinoda Y.",Nihon Rinsho. 1996 Apr;54(4):906-10. Review. Japanese. ,Nihon Rinsho.  1996,PubMed,citation,PMID:8920648,pubmed,8920648,create date:1996/04/01 | first author:Imai K
Double cancer in a 74-year-old woman: a case report with genetic findings.,/pubmed/8804161,"Katada F, Murakami K, Uzuki M, Horii A.",Tohoku J Exp Med. 1996 Apr;178(4):437-45.,Tohoku J Exp Med.  1996,PubMed,citation,PMID:8804161,pubmed,8804161,create date:1996/04/01 | first author:Katada F
p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.,/pubmed/8608838,"Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, Poston G.",Eur J Surg Oncol. 1996 Apr;22(2):182-5.,Eur J Surg Oncol.  1996,PubMed,citation,PMID:8608838,pubmed,8608838,create date:1996/04/01 | first author:Brett MC
C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas.,/pubmed/8814697,"Elnatan J, Goh HS, Smith DR.",Eur J Cancer. 1996 Mar;32A(3):491-7.,Eur J Cancer.  1996,PubMed,citation,PMID:8814697,pubmed,8814697,create date:1996/03/01 | first author:Elnatan J
Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer.,/pubmed/8687158,"Kressner U, Lindmark G, Gerdin B, Påhlman L, Glimelius B.",Anticancer Res. 1996 Mar-Apr;16(2):951-7.,Anticancer Res.  1996,PubMed,citation,PMID:8687158,pubmed,8687158,create date:1996/03/01 | first author:Kressner U
"Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma.",/pubmed/8600060,"Sun XF, Carstensen JM, Stål O, Zhang H, Nordenskjöld B.",Int J Cancer. 1996 Feb 20;69(1):5-8.,Int J Cancer.  1996,PubMed,citation,PMID:8600060,pubmed,8600060,create date:1996/02/20 | first author:Sun XF
p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer.,/pubmed/8607033,"Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K.",Semin Oncol. 1996 Feb;23(1):66-77. Review.,Semin Oncol.  1996,PubMed,citation,PMID:8607033,pubmed,8607033,create date:1996/02/01 | first author:Bookstein R
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.,/pubmed/10388011,Piver MS.,Oncologist. 1996;1(5):326-330.,Oncologist.  1996,PubMed,citation,PMID:10388011,pubmed,10388011,create date:1996/01/01 | first author:Piver MS
"1995 Deichmann Lecture--p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment.",/pubmed/8597035,Harris CC.,Toxicol Lett. 1995 Dec;82-83:1-7. Review.,Toxicol Lett.  1995,PubMed,citation,PMID:8597035,pubmed,8597035,create date:1995/12/01 | first author:Harris CC
APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis.,/pubmed/8522331,"van der Luijt RB, Vasen HF, Tops CM, Breukel C, Fodde R, Meera Khan P.",Hum Genet. 1995 Dec;96(6):705-10.,Hum Genet.  1995,PubMed,citation,PMID:8522331,pubmed,8522331,create date:1995/12/01 | first author:van der Luijt RB
Immunohistochemical detection of p53 and the recurrence of rectal adenocarcinoma.,/pubmed/7487716,"Subramaniam P, Sinha SN, Wilkinson S.",Aust N Z J Surg. 1995 Oct;65(10):740-2.,Aust N Z J Surg.  1995,PubMed,citation,PMID:7487716,pubmed,7487716,create date:1995/10/01 | first author:Subramaniam P
An immunohistochemical study of P53 protein on colorectal carcinomas.,/pubmed/9455363,"Pandrea IV, Mihailovici MS, Carasevici E, Székely AM, Reynes M, Târcoveanu E, Dragomir C.",Rev Med Chir Soc Med Nat Iasi. 1995 Jul-Dec;99(3-4):171-8.,Rev Med Chir Soc Med Nat Iasi.  1995,PubMed,citation,PMID:9455363,pubmed,9455363,create date:1995/07/01 | first author:Pandrea IV
Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms.,/pubmed/7743481,"Chadburn A, Cesarman E, Liu YF, Addonizio L, Hsu D, Michler RE, Knowles DM.",Cancer. 1995 Jun 1;75(11):2747-56.,Cancer.  1995,PubMed,citation,PMID:7743481,pubmed,7743481,create date:1995/06/01 | first author:Chadburn A
Microsatellite instability in squamous cell carcinoma of the head and neck.,/pubmed/7734301,"Field JK, Kiaris H, Howard P, Vaughan ED, Spandidos DA, Jones AS.",Br J Cancer. 1995 May;71(5):1065-9.,Br J Cancer.  1995,PubMed,citation,PMID:7734301 | PMCID:PMC2033778,pubmed,7734301,create date:1995/05/01 | first author:Field JK
Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile.,/pubmed/7665246,"Seruca R, Santos NR, David L, Constância M, Barroca H, Carneiro F, Seixas M, Peltomäki P, Lothe R, Sobrinho-Simões M.",Int J Cancer. 1995 Feb 20;64(1):32-6.,Int J Cancer.  1995,PubMed,citation,PMID:7665246,pubmed,7665246,create date:1995/02/20 | first author:Seruca R
Activation and effects of the food-derived heterocyclic amines in extrahepatic tissues.,/pubmed/8844803,"Overvik E, Hellmold H, Branting C, Gustafsson JA.",Princess Takamatsu Symp. 1995;23:123-33. Review.,Princess Takamatsu Symp.  1995,PubMed,citation,PMID:8844803,pubmed,8844803,create date:1995/01/01 | first author:Overvik E
"Early stages of 1,2-dimethylhydrazine-induced colon carcinogenesis suppress immune-regulated ion transport of mouse distal colon.",/pubmed/7954425,"Broaddus RR, Wargovich MJ, Castro GA.",Cancer Res. 1994 Nov 15;54(22):5930-6.,Cancer Res.  1994,PubMed,citation,PMID:7954425,pubmed,7954425,create date:1994/11/15 | first author:Broaddus RR
Characterization of p53 gene mutations in colorectal carcinomas from an Asian population.,/pubmed/7872723,"Shi CY, Phang TW, Ngoi SS, Wee A, Li B, Lin Y, Lee HP, Ong CN.",Anticancer Res. 1994 Nov-Dec;14(6B):2811-6.,Anticancer Res.  1994,PubMed,citation,PMID:7872723,pubmed,7872723,create date:1994/11/01 | first author:Shi CY
Molecular approach to rapid assessment of p53 tumor suppressor mutations in esophageal tumors from stained histological slides.,/pubmed/7520333,"Whetsell LH, Ringer DP, Schaefer FV.",Diagn Mol Pathol. 1994 Jun;3(2):132-41.,Diagn Mol Pathol.  1994,PubMed,citation,PMID:7520333,pubmed,7520333,create date:1994/06/01 | first author:Whetsell LH
Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.,/pubmed/8158699,"Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK.",J Natl Cancer Inst. 1994 May 4;86(9):681-7.,J Natl Cancer Inst.  1994,PubMed,citation,PMID:8158699,pubmed,8158699,create date:1994/05/04 | first author:Bosari S
Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer.,/pubmed/7906810,"Caspari R, Friedl W, Mandl M, Möslein G, Kadmon M, Knapp M, Jacobasch KH, Ecker KW, Kreissler-Haag D, Timmermanns G, et al.",Lancet. 1994 Mar 12;343(8898):629-32. Erratum in: Lancet 1994 Apr 2;343(8901):863. ,Lancet.  1994,PubMed,citation,PMID:7906810,pubmed,7906810,create date:1994/03/12 | first author:Caspari R
Mutation in a splice-donor site of the APC gene in a family with polyposis and late age of colonic cancer death.,/pubmed/8125478,"Varesco L, Gismondi V, Presciuttini S, Groden J, Spirio L, Sala P, Rossetti C, De Benedetti L, Bafico A, Heouaine A, et al.",Hum Genet. 1994 Mar;93(3):281-6.,Hum Genet.  1994,PubMed,citation,PMID:8125478,pubmed,8125478,create date:1994/03/01 | first author:Varesco L
The molecular and cellular basis of human lung cancer.,/pubmed/8166465,Gazdar AF.,Anticancer Res. 1994 Jan-Feb;14(1B):261-7. Review.,Anticancer Res.  1994,PubMed,citation,PMID:8166465,pubmed,8166465,create date:1994/01/01 | first author:Gazdar AF
The pathology of the gastrointestinal endocrine system.,/pubmed/8125073,"Solcia E, Fiocca R, Rindi G, Villani L, Cornaggia M, Capella C.",Endocrinol Metab Clin North Am. 1993 Dec;22(4):795-821. Review.,Endocrinol Metab Clin North Am.  1993,PubMed,citation,PMID:8125073,pubmed,8125073,create date:1993/12/01 | first author:Solcia E
Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry.,/pubmed/8314221,"Joypaul BV, Vojtesek B, Newman EL, Hopwood D, Grant A, Lane DP, Cuschieri A.",Histopathology. 1993 Nov;23(5):465-70.,Histopathology.  1993,PubMed,citation,PMID:8314221,pubmed,8314221,create date:1993/11/01 | first author:Joypaul BV
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.,/pubmed/8253089,"Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR, Sikorska M.",EMBO J. 1993 Sep;12(9):3679-84.,EMBO J.  1993,PubMed,citation,PMID:8253089 | PMCID:PMC413644,pubmed,8253089,create date:1993/09/01 | first author:Oberhammer F
Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis.,/pubmed/8489386,"Finkelstein SD, Sayegh R, Bakker A, Swalsky P.",Arch Surg. 1993 May;128(5):526-31; discussion 531-2.,Arch Surg.  1993,PubMed,citation,PMID:8489386,pubmed,8489386,create date:1993/05/01 | first author:Finkelstein SD
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.,/pubmed/8453635,"Thorlacius S, Börresen AL, Eyfjörd JE.",Cancer Res. 1993 Apr 1;53(7):1637-41.,Cancer Res.  1993,PubMed,citation,PMID:8453635,pubmed,8453635,create date:1993/04/01 | first author:Thorlacius S
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer.,/pubmed/8419262,"Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF, Quirke P.",Gastroenterology. 1993 Jan;104(1):57-64.,Gastroenterology.  1993,PubMed,citation,PMID:8419262,pubmed,8419262,create date:1993/01/01 | first author:Bell SM
Increased p53 protein content of colorectal tumours correlates with poor survival.,/pubmed/1419618,"Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G.",Br J Cancer. 1992 Oct;66(4):758-64.,Br J Cancer.  1992,PubMed,citation,PMID:1419618 | PMCID:PMC1977434,pubmed,1419618,create date:1992/10/01 | first author:Remvikos Y
The molecular biology of lung cancer.,/pubmed/1306309,Gazdar AF.,Tohoku J Exp Med. 1992 Oct;168(2):239-45.,Tohoku J Exp Med.  1992,PubMed,citation,PMID:1306309,pubmed,1306309,create date:1992/10/01 | first author:Gazdar AF
Toxicology and Carcinogenesis Studies of Quercetin (CAS No. 117-39-5) in F344 Rats (Feed Studies).,/pubmed/12621521,National Toxicology Program ..,Natl Toxicol Program Tech Rep Ser. 1992 Sep;409:1-171.,Natl Toxicol Program Tech Rep Ser.  1992,PubMed,citation,PMID:12621521,pubmed,12621521,create date:1992/09/01 | first author:National Toxicology Program .
The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma.,/pubmed/1568571,"Offerhaus GJ, De Feyter EP, Cornelisse CJ, Tersmette KW, Floyd J, Kern SE, Vogelstein B, Hamilton SR.",Gastroenterology. 1992 May;102(5):1612-9.,Gastroenterology.  1992,PubMed,citation,PMID:1568571,pubmed,1568571,create date:1992/05/01 | first author:Offerhaus GJ
Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.,/pubmed/1566048,"Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B.",Science. 1992 Apr 3;256(5053):102-5.,Science.  1992,PubMed,citation,PMID:1566048,pubmed,1566048,create date:1992/04/03 | first author:Sidransky D
The ras gene family in human non-small-cell lung cancer.,/pubmed/1327034,"Slebos RJ, Rodenhuis S.",J Natl Cancer Inst Monogr. 1992;(13):23-9.,J Natl Cancer Inst Monogr.  1992,PubMed,citation,PMID:1327034,pubmed,1327034,create date:1992/01/01 | first author:Slebos RJ
Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas.,/pubmed/1868464,"Campo E, de la Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, Vives J, Cardesa A, Yague J.",Cancer Res. 1991 Aug 15;51(16):4436-42.,Cancer Res.  1991,PubMed,citation,PMID:1868464,pubmed,1868464,create date:1991/08/15 | first author:Campo E
c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis.,/pubmed/1854618,"Bell SM, Kelly SA, Hoyle JA, Lewis FA, Taylor GR, Thompson H, Dixon MF, Quirke P.",Br J Cancer. 1991 Jul;64(1):174-8.,Br J Cancer.  1991,PubMed,citation,PMID:1854618 | PMCID:PMC1977292,pubmed,1854618,create date:1991/07/01 | first author:Bell SM
p53 expression in colorectal tumors.,/pubmed/1707233,"Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC.",Am J Pathol. 1991 Apr;138(4):807-13.,Am J Pathol.  1991,PubMed,citation,PMID:1707233 | PMCID:PMC1886110,pubmed,1707233,create date:1991/04/01 | first author:Purdie CA
Growth factors and oncogenes in human gastrointestinal carcinomas.,/pubmed/2157713,Tahara E.,J Cancer Res Clin Oncol. 1990;116(2):121-31. Review.,J Cancer Res Clin Oncol.  1990,PubMed,citation,PMID:2157713,pubmed,2157713,create date:1990/01/01 | first author:Tahara E
Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected].,/pubmed/2654431,"Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M, Nakamura Y, White R, Vogelstein B, Hamilton SR.",JAMA. 1989 Jun 2;261(21):3099-103. Erratum in: JAMA 1989 Oct 13;262(14):1952. ,JAMA.  1989,PubMed,citation,PMID:2654431,pubmed,2654431,create date:1989/06/02 | first author:Kern SE
NTP Toxicology and Carcinogenesis Studies of 2-Amino-5-Nitrophenol (CAS No. 121-88-0) in F344/N Rats and B6C3F1 Mice (Gavage Studies).,/pubmed/12732902,National Toxicology Program ..,Natl Toxicol Program Tech Rep Ser. 1988 Feb;334:1-158.,Natl Toxicol Program Tech Rep Ser.  1988,PubMed,citation,PMID:12732902,pubmed,12732902,create date:1988/02/01 | first author:National Toxicology Program .
